Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
29000.0 | 2012-05-03 00:00:00 UTC | Barrick Profit Up on Higher Price - Analyst Blog | ABG | https://www.nasdaq.com/articles/barrick-profit-up-on-higher-price-analyst-blog-2012-05-03 | nan | nan | Barrick Gold Corp. 's ( ABX ) adjusted net earnings (excluding one time items) rose 8% to $1.09 per share in the first quarter of 2012 compared with $1.01 in the prior-year quarter. The results came in line with the Zacks Consensus Estimate. Earnings were driven by higher average realized gold price. Profit, as reported, rose roughly 3% year over year to $1.03 billion (or $1.03 a share).
Revenue
Revenues came in at $3,644 million, up 18% from $3,087 million in the year ago quarter, missing the Zacks Consensus Estimate of $3,758 million. The company produced 1.88 million ounces of gold in the quarter versus 1.96 million ounces in the year-ago period.
Copper production in the quarter amounted to 117 million pounds, a 56% jump from the year ago production of 75 million pounds. Total gold cash costs jumped 24.7% to $545 per ounce of gold, while total cash cost for copper increased to $2.08 per pound from $1.25 per pound in the prior-year quarter.
Regional Results
North America: North America region produced 0.89 million ounces of gold at total cash costs of $485 per ounce compared with 0.86 million ounces at total cash costs of $396 per ounce a year ago. Strong performance by Cortez mine due to higher than budgeted grades led to the growth in production.
Production at Goldstrike was, however, hampered by maintenance activities and construction at the autoclaves. For 2012, production for the North America region is expected to be in the range of 3.425-3.60 million ounces at total cash costs of $475-$525 per ounce.
South America : This business region's production in the quarter was 0.45 million ounces at total cash costs of $421 per ounce compared with 0.42 million ounces at cash costs of 340 per ounce. Production from South America in 2012 is expected to be in the range of 1.55-1.7 million ounces at total cash costs of $430-$480 per ounce.
AustraliaPacific: This business region produced 0.43 million ounces in the quarter, compared with 0.46 million ounces in the year-ago quarter. Total cash costs were $748 per ounce in the reported quarter compared with $585 per ounce in the year-ago quarter. Australia Pacific is forecast to produce 1.80-1.95 million ounces at total cash costs of $700-$750 per ounce in 2012.
African Barrick Gold plc. (ABG): Attributable production from ABG in the first quarter of 2012 was 0.11 million ounces at total cash costs of $925 per ounce compared with 0.13 million ounces at total cash costs of $658 per ounce in the prior-year quarter. Barrick Gold expects to produce 0.5-0.535 million ounces at total cash costs of $790-$860 per ounce in 2012.
Dividend
The company declared a 33% hike in its quarterly dividend to 20 cents per share, up from the previous payout of 15 cents. The increase was driven by strong earnings and operating cash flows.
Financial Position
Cash and cash equivalents stood at $2,665 million at the end of March 31, 2012, compared with $2,745 million at the end of March 31, 2011. In the first quarter of 2012, operating cash flows decreased 11.6% to $1,272 million.
Outlook
Barrick Gold maintained its 2012 forecast of 7.3 -7.8 million ounces of gold and 550 -600 million pounds of copper. Total cash costs for 2012 for gold are expected to be in the range of $520-$560 per ounce and net cash costs are expected to be within the band of $400-$450 per ounce. The company expects copper cash costs of $1.90-$2.20 per pound for 2012.
Barrick Gold increased its exploration budget to $450-$490 million from the prior year actual expenditure of $350 million as a result of exploration success in 2011.
The company remains on track to advance construction at Pueblo Viejo and Pascua-Lama, with first production expected in mid-2012 and mid-2013, respectively. The two projects in combination are expected to generate average annual production of 1.5 million ounces with total average annual EBITDA of approximately $2.5 billion in their first full five years.
We currently have a long-term Neutral recommendation on Barrick Gold. The company, which competes with AngloGold Ashanti Ltd. (AU ) and Newmont Mining Corp. ( NEM ), maintains a Zacks #3 Rank, which translates into a short-term (1 to 3 months) Hold rating.
BARRICK GOLD CP (ABX): Free Stock Analysis Report
ANGLOGOLD LTD (AU): Free Stock Analysis Report
NEWMONT MINING (NEM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (ABG): Attributable production from ABG in the first quarter of 2012 was 0.11 million ounces at total cash costs of $925 per ounce compared with 0.13 million ounces at total cash costs of $658 per ounce in the prior-year quarter. Strong performance by Cortez mine due to higher than budgeted grades led to the growth in production. The company remains on track to advance construction at Pueblo Viejo and Pascua-Lama, with first production expected in mid-2012 and mid-2013, respectively. | (ABG): Attributable production from ABG in the first quarter of 2012 was 0.11 million ounces at total cash costs of $925 per ounce compared with 0.13 million ounces at total cash costs of $658 per ounce in the prior-year quarter. Regional Results North America: North America region produced 0.89 million ounces of gold at total cash costs of $485 per ounce compared with 0.86 million ounces at total cash costs of $396 per ounce a year ago. South America : This business region's production in the quarter was 0.45 million ounces at total cash costs of $421 per ounce compared with 0.42 million ounces at cash costs of 340 per ounce. | (ABG): Attributable production from ABG in the first quarter of 2012 was 0.11 million ounces at total cash costs of $925 per ounce compared with 0.13 million ounces at total cash costs of $658 per ounce in the prior-year quarter. Regional Results North America: North America region produced 0.89 million ounces of gold at total cash costs of $485 per ounce compared with 0.86 million ounces at total cash costs of $396 per ounce a year ago. South America : This business region's production in the quarter was 0.45 million ounces at total cash costs of $421 per ounce compared with 0.42 million ounces at cash costs of 340 per ounce. | (ABG): Attributable production from ABG in the first quarter of 2012 was 0.11 million ounces at total cash costs of $925 per ounce compared with 0.13 million ounces at total cash costs of $658 per ounce in the prior-year quarter. Regional Results North America: North America region produced 0.89 million ounces of gold at total cash costs of $485 per ounce compared with 0.86 million ounces at total cash costs of $396 per ounce a year ago. Total cash costs were $748 per ounce in the reported quarter compared with $585 per ounce in the year-ago quarter. |
29001.0 | 2012-03-22 00:00:00 UTC | SIRIUS XM Teams with Asbury (revised) - Analyst Blog | ABG | https://www.nasdaq.com/articles/sirius-xm-teams-with-asbury-revised-analyst-blog-2012-03-22 | nan | nan | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Asbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles.
One of the leading automobile retailer and service provider in the US, Asbury currently has 79 dealers operating in the U.S. Over 4,000 dealerships will participate in this program overall, according to a press release. Thus, we believe that the partnership with Asbury will provide SIRIUS XM the leading edge to expand their market share.
In the last quarter of fiscal 2011, SIRIUS XM added nearly 540,000 customers, which in itself is a record since 2008. So we continue to believe that such strategic partnerships with different car manufacturers and dealers coupled with improving U.S. economic conditions will further increase the company's subscriber base going forward.
In December, 2011, SIRIUS XM launched the advanced version SIRIUS XM 2.0 called "Lynx." Lynx is touted as the next-generation satellite receiver that allows the subscribers to stream content to home audio systems via Bluetooth. It also features high-resolution touch screen support and allows 200 hours of music storage, hence providing more options to the users to access their favorite music anytime and from anywhere. Such an innovative product launch will certainly act as catalyst for growth for the company going forward.
Despite higher programming cost and stiff competition from Pioneer System and other media players like Cumulus Media Inc. ( CMLS ), we believe that the company will perform well mainly based on increased programming line ups and improved ratings.
We maintain our long-term Outperform recommendation for SIRIUS XM. Currently, the company has a Zacks #3 Rank, implying a short-term Hold rating.
Based in New York, SIRIUS XM provides satellite radio services in the U.S. and Canada.
(We are reissuing this article to correct a couple mistakes. The original article, issued March 13, 2012, should no longer be relied upon.)
ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report
CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report
SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Asbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. One of the leading automobile retailer and service provider in the US, Asbury currently has 79 dealers operating in the U.S. Over 4,000 dealerships will participate in this program overall, according to a press release. | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Asbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. Based in New York, SIRIUS XM provides satellite radio services in the U.S. and Canada. | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Asbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. In December, 2011, SIRIUS XM launched the advanced version SIRIUS XM 2.0 called "Lynx." | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Asbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. So we continue to believe that such strategic partnerships with different car manufacturers and dealers coupled with improving U.S. economic conditions will further increase the company's subscriber base going forward. |
29002.0 | 2012-03-13 00:00:00 UTC | SIRIUS XM Teams with Ashbury - Analyst Blog | ABG | https://www.nasdaq.com/articles/sirius-xm-teams-with-ashbury-analyst-blog-2012-03-13 | nan | nan | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Ashbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles.
One of the leading automobile retailer and service provider in the US, Ashbury currently boasts 4,000 dealers operating in the U.S. Thus, we believe that the partnership with Asbury will provide SIRIUS XM the leading edge to expand their market share.
In the last quarter of fiscal 2011,SIRIUS XM added nearly 540,000 customers, which in itself is a record since 2008. So we continue to believe that such strategic partnerships with different car manufacturers and dealers coupled with improving U.S. economic conditions will further increase the company's subscriber base going forward.
In December, 2011, SIRIUS XM launched the advanced version SIRIUS XM 2.0 called "Lynx." Lynx is touted as the next-generation satellite receiver that allows the subscribers to stream content to home audio systems via Bluetooth. It also features high-resolution touch screen support and allows 200 hours of music storage, hence providing more options to the users to access their favorite music anytime and from anywhere. Such an innovative product launch will certainly act as catalyst for growth for the company going forward.
Despite higher programming cost and stiff competition from Pioneer System and other media players like Cumulus Media Inc. ( CMLS ), we believe that the company will perform well mainly based on increased programming line ups and improved ratings.
We maintain our long-term Outperform recommendation for SIRIUS XM. Currently, the company has a Zacks #3 Rank, implying a short-term Hold rating.
Based in New York, SIRIUS XM provides satellite radio services in the U.S. and Canada.
ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report
CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report
SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Ashbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. Thus, we believe that the partnership with Asbury will provide SIRIUS XM the leading edge to expand their market share. | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Ashbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. Based in New York, SIRIUS XM provides satellite radio services in the U.S. and Canada. | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Ashbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. In December, 2011, SIRIUS XM launched the advanced version SIRIUS XM 2.0 called "Lynx." | SIRIUS XM Radio Inc. ( SIRI ) recently announced a strategic partnership with Ashbury Automotive Group ( ABG ) in order to provide radio service to the latter's pre-owned vehicles. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report CUMULUS MEDIA ( CMLS ): Free Stock Analysis Report SIRIUS XM RADIO ( SIRI ): Free Stock Analysis Report To read this article on Zacks.com click here. So we continue to believe that such strategic partnerships with different car manufacturers and dealers coupled with improving U.S. economic conditions will further increase the company's subscriber base going forward. |
29003.0 | 2012-02-28 00:00:00 UTC | Value Stock Picks-Feb.28, 2012 - Zacks Rank Buys | ABG | https://www.nasdaq.com/articles/value-stock-picks-feb28-2012-zacks-rank-buys-2012-02-28 | nan | nan | ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report
OIL STATES INTL ( OIS ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report OIL STATES INTL ( OIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report OIL STATES INTL ( OIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report OIL STATES INTL ( OIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report OIL STATES INTL ( OIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
29004.0 | 2012-02-21 00:00:00 UTC | Zacks Releases Four Powerful ''Buy'' Stocks: Texas Capital Bancshares, Bob Evans Farms, Cintas and Asbury Automotive Group - Press Releases | ABG | https://www.nasdaq.com/articles/zacks-releases-four-powerful-buy-stocks%3A-texas-capital-bancshares-bob-evans-farms-cintas | nan | nan | For Immediate Release
Chicago, IL - February 21, 2012 - Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value.
The four highlighted picks are: Texas Capital Bancshares ( TCBI ), Bob Evans Farms, Inc. ( BOBE ), Cintas Corporation ( CTAS ) and Asbury Automotive Group, Inc. ( ABG ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free. http://at.zacks.com/?id=88
From 1988 through the present - a period that included serious corrections and recessions - the Zacks #1 Rank Stocks have nearly tripled the market with a fully documented average gain of +28% per year.
Here is a summary of today's selected stocks that are now highly rated by Zacks:
Aggressive Growth - Texas Capital Bancshares ( TCBI )
Texas Capital Bancshares has put some big losses behind it and is poised for growth. The stock is a Zacks #1 Rank (Strong Buy).
Zacks Guide to Aggressive Growth Investing (free!) - http://at.zacks.com/?id=4309
Growth & Income - Bob Evans Farms, Inc. ( BOBE )
Estimates have been rising for Bob Evans Farms, Inc. after the company delivered better-than-expected results for the third quarter of its fiscal 2012 on February 14.
Zacks Guide to Growth & Income Investing (free!) - http://at.zacks.com/?id=4310
Momentum - Cintas Corporation ( CTAS )
Cintas does more than just rental work uniforms. Over the years, they have evolved into many diverse segments from document management to fire protection. Even with this variety, just about all of their businesses are dependent on a strong consumer and healthy economy.
Zacks Guide to Momentum Investing (free!): http://at.zacks.com/?id=4311
Value - Asbury Automotive Group, Inc. ( ABG )
Automobile retailers continue to see improvement as the American consumer comes out of its deep freeze. Asbury Automotive Group, Inc. grew earnings by the double digits in 2011 and is expected to again in 2012. This Zacks #1 Rank (Strong Buy) is also a value stock, with a forward P/E of 12.2.
Zacks Guide to Value Investing (free!) - http://at.zacks.com/?id=4312
How to Regularly Access Top Zacks Rank Picks for Free - http://at.zacks.com/?id=7154
Underlying the four free stock picks is a simple truth that first appeared in a Financial Analysts Journal article published in 1979. Leonard Zacks, a Ph.D. from M.I.T. found that "earnings estimate revisions are the most powerful force impacting stock prices." Zacks #1 Rank is awarded to a stock when analysts sharply upgrade their estimates of what the company will earn.
Today, Zacks is promoting its stock recommendations by offering four daily picks free to those who register here: http://at.zacks.com/?id=7155
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.
Then, when changes are discovered, they're applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock-picking system continues to outperform the market by a nearly 3-to-1 margin.
More Free Stock Picks
Each weekday, new Zacks #1 Rank or Zacks #2 Rank stock picks are released on the free email newsletter, Profit from the Pros . Investors are invited to register for their free subscription here: http://at.zacks.com/?id=91
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report
BOB EVANS FARMS ( BOBE ): Free Stock Analysis Report
CINTAS CORP ( CTAS ): Free Stock Analysis Report
TEXAS CAP BCSHS ( TCBI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The four highlighted picks are: Texas Capital Bancshares ( TCBI ), Bob Evans Farms, Inc. ( BOBE ), Cintas Corporation ( CTAS ) and Asbury Automotive Group, Inc. ( ABG ). ): http://at.zacks.com/?id=4311 Value - Asbury Automotive Group, Inc. ( ABG ) Automobile retailers continue to see improvement as the American consumer comes out of its deep freeze. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report BOB EVANS FARMS ( BOBE ): Free Stock Analysis Report CINTAS CORP ( CTAS ): Free Stock Analysis Report TEXAS CAP BCSHS ( TCBI ): Free Stock Analysis Report To read this article on Zacks.com click here. | The four highlighted picks are: Texas Capital Bancshares ( TCBI ), Bob Evans Farms, Inc. ( BOBE ), Cintas Corporation ( CTAS ) and Asbury Automotive Group, Inc. ( ABG ). ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report BOB EVANS FARMS ( BOBE ): Free Stock Analysis Report CINTAS CORP ( CTAS ): Free Stock Analysis Report TEXAS CAP BCSHS ( TCBI ): Free Stock Analysis Report To read this article on Zacks.com click here. ): http://at.zacks.com/?id=4311 Value - Asbury Automotive Group, Inc. ( ABG ) Automobile retailers continue to see improvement as the American consumer comes out of its deep freeze. | ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report BOB EVANS FARMS ( BOBE ): Free Stock Analysis Report CINTAS CORP ( CTAS ): Free Stock Analysis Report TEXAS CAP BCSHS ( TCBI ): Free Stock Analysis Report To read this article on Zacks.com click here. The four highlighted picks are: Texas Capital Bancshares ( TCBI ), Bob Evans Farms, Inc. ( BOBE ), Cintas Corporation ( CTAS ) and Asbury Automotive Group, Inc. ( ABG ). ): http://at.zacks.com/?id=4311 Value - Asbury Automotive Group, Inc. ( ABG ) Automobile retailers continue to see improvement as the American consumer comes out of its deep freeze. | The four highlighted picks are: Texas Capital Bancshares ( TCBI ), Bob Evans Farms, Inc. ( BOBE ), Cintas Corporation ( CTAS ) and Asbury Automotive Group, Inc. ( ABG ). ): http://at.zacks.com/?id=4311 Value - Asbury Automotive Group, Inc. ( ABG ) Automobile retailers continue to see improvement as the American consumer comes out of its deep freeze. ASBURY AUTO GRP ( ABG ): Free Stock Analysis Report BOB EVANS FARMS ( BOBE ): Free Stock Analysis Report CINTAS CORP ( CTAS ): Free Stock Analysis Report TEXAS CAP BCSHS ( TCBI ): Free Stock Analysis Report To read this article on Zacks.com click here. |
29005.0 | 2012-02-21 00:00:00 UTC | Barrick Profit Up on High Price - Analyst Blog | ABG | https://www.nasdaq.com/articles/barrick-profit-up-on-high-price-analyst-blog-2012-02-21 | nan | nan | Barrick Gold Corp. 's ( ABX ) adjusted net earnings rose 15% to $1.17 billion or $1.17 per share in the fourth quarter of 2011 compared with $1.02 billion or $1.02 per share in the prior-year period, missing the Zacks Consensus Estimate of $1.26 per share.
The year-over-year increase in profit was led by higher realized gold prices and increased copper sales volumes. For full-year 2011, adjusted net earnings came in at $4.67 billion or $4.67 per share compared with $3.52 billion or $3.56 per share in 2010.
Revenue
Revenues were $3.8 billion in the quarter compared with $3.0 billion in the year-ago quarter. The company produced 1.81 million ounces of gold in the quarter versus 1.7 million ounces in the year-ago period.
Total gold cash costs amounted to $505 per ounce, up from $440 per ounce in the year-ago quarter. Copper production in the quarter jumped 74.4% to 143 million pounds at total cash costs of $1.99 per pound.
For the full year, revenues came in at $14.3 billion compared with $11.0 billion in 2010. Total gold production in the quarter decreased to 7.68 million ounces from 7.8 million ounces in 2010. Copper production increased by 22.6% to 451 million pounds in 2011.
Regional Results
North America: North America region produced 0.76 million ounces of gold at total cash costs of $498 per ounce compared with 0.69 million ounces at total cash costs of $437 per ounce. Strong performances by Cortez and Goldstrike mines led to the growth in production.
The Cortez property contributed 0.28 million ounces at total cash costs of $331 per ounce for the quarter on higher tonnage from the open pit. Production at Cortez is anticipated to be in the range of 1.20-1.25 million ounces at total cash costs of $300-$350 per ounce in 2012, reflecting higher proportion of underground ounces and lower open pit grades as part of planned mine sequencing.
The Goldstrike operation performed strongly, producing 0.25 million ounces at total cash costs of $570 per ounce in the quarter, primarily due to more underground tons and higher open pit grades than anticipated. Production at Goldstrike is expected to be in the range of 1.25-1.30 million ounces in 2012 as the open pit moves back into a higher ore phase.
For full-year 2012, production for the North America business unit is expected to be in the range of 3.425-3.600 million ounces at total cash costs of $475-$525 per ounce.
South America: This business region performed as expected, with production of 0.45 million ounces at total cash costs of $357 per ounce compared with 0.38 million ounces at cash costs of 251 per ounce. The Veladero mine produced 0.23 million ounces at total cash costs of $355 per ounce in the quarter. The Lagunas Norte operation contributed 0.18 million ounces at total cash costs of $268 per ounce.
Production from South America in 2012 is expected to be in the range of 1.550-1.700 million ounces at total cash costs of $430-$480 per ounce, primarily due to lower grades at Veladero and lower grades and recoveries at Lagunas Norte as anticipated in their mine plans.
AustraliaPacific: This business region produced 0.49 million ounces in the quarter, in line with the year-ago quarter. Total cash costs were $677 per ounce in the reported quarter compared with $602 per ounce in the year-ago quarter.
The Porgera mine produced 0.12 million ounces at total cash costs of $679 per ounce. Australia Pacific is expected to produce 1.800-1.950 million ounces in 2012 at total cash costs of $700-$750 per ounce, primarily reflecting higher power costs for Porgera.
African Barrick Gold plc. ( ABG ): Attributable production from ABG in the fourth quarter of 2011 was 0.12 million ounces at total cash costs of $779 per ounce compared with 0.13 million ounces at total cash costs of $622 per ounce in the prior-year quarter.
Lumwana mine produced 60 million pounds from the Lumwana mine at total cash costs of $2.47 per pound. Lumwana is expected to produce 230-260 million pounds of copper in 2012 at total cash costs of $2.40-$2.75 per pound.
Zaldivar mine in Chile produced 83 million pounds at total cash costs of $1.65 per pound in the fourth quarter and is expected to produce approximately 285-300 million pounds of copper at total cash costs of $1.45-$1.75 per pound in 2012. Barrick's share of 2012 production is expected to be 0.500-0.535 million ounces at total cash costs of $790-$860 per ounce.
Financial Position
Cash and cash equivalents stood at $2.7 billion at the end of December 31, 2011 compared with $4.0 billion at the end of December 31, 2010. The company's debt increased to $13.2 billion at the end of December 31, 2011 compared with $6.6 billion at the end of December 31, 2010.
In the fourth quarter of 2011, operating cash flow increased 41% to $1.22 billion. In 2011, operating cash flow increased 23% to $5.32 billion, setting a record for the company.
Outlook
The company expects 2012 gold production in the range of 7.3-7.8 million ounces on lower than expected grades and production at Cortez and Veladero. Total cash costs are expected to be in the range of $520-$560 per ounce and net cash costs in the range of $400-$450 per ounce for 2012. The cash costs reflect a change in the production mix, smaller amounts of capitalized waste stripping and higher labor and other inflationary costs.
Copper production is expected to be in the range of 550-600 million pounds at total cash costs of $1.90-$2.20 per pound in 2012. The cash costs assume that Lumwana mine will produce for entire 2012. It also takes into account higher sulfuric acid costs in Chile, higher royalties in Zambia and the second half start up of Jabal Sayid.
Capital project expenditures for 2012 are expected to be in the range of $2.60-$2.75 billion primarily related to construction activities at Pueblo Viejo and Pascua-Lama.
Barrick retains a Zacks #3 Rank, which translates into a short-term (1 to 3 months) Hold rating. We have recommended the shares of the company as Neutral for the long-term (more than 6 months). The company faces stiff competition from AngloGold Ashanti Ltd. (AU ) and Newmont Mining Corp. ( NEM ).
BARRICK GOLD CP ( ABX ): Free Stock Analysis Report
ANGLOGOLD LTD ( AU ): Free Stock Analysis Report
NEWMONT MINING ( NEM ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ( ABG ): Attributable production from ABG in the fourth quarter of 2011 was 0.12 million ounces at total cash costs of $779 per ounce compared with 0.13 million ounces at total cash costs of $622 per ounce in the prior-year quarter. Production at Goldstrike is expected to be in the range of 1.25-1.30 million ounces in 2012 as the open pit moves back into a higher ore phase. Production from South America in 2012 is expected to be in the range of 1.550-1.700 million ounces at total cash costs of $430-$480 per ounce, primarily due to lower grades at Veladero and lower grades and recoveries at Lagunas Norte as anticipated in their mine plans. | ( ABG ): Attributable production from ABG in the fourth quarter of 2011 was 0.12 million ounces at total cash costs of $779 per ounce compared with 0.13 million ounces at total cash costs of $622 per ounce in the prior-year quarter. Regional Results North America: North America region produced 0.76 million ounces of gold at total cash costs of $498 per ounce compared with 0.69 million ounces at total cash costs of $437 per ounce. The Goldstrike operation performed strongly, producing 0.25 million ounces at total cash costs of $570 per ounce in the quarter, primarily due to more underground tons and higher open pit grades than anticipated. | ( ABG ): Attributable production from ABG in the fourth quarter of 2011 was 0.12 million ounces at total cash costs of $779 per ounce compared with 0.13 million ounces at total cash costs of $622 per ounce in the prior-year quarter. Regional Results North America: North America region produced 0.76 million ounces of gold at total cash costs of $498 per ounce compared with 0.69 million ounces at total cash costs of $437 per ounce. South America: This business region performed as expected, with production of 0.45 million ounces at total cash costs of $357 per ounce compared with 0.38 million ounces at cash costs of 251 per ounce. | ( ABG ): Attributable production from ABG in the fourth quarter of 2011 was 0.12 million ounces at total cash costs of $779 per ounce compared with 0.13 million ounces at total cash costs of $622 per ounce in the prior-year quarter. Total gold cash costs amounted to $505 per ounce, up from $440 per ounce in the year-ago quarter. Barrick's share of 2012 production is expected to be 0.500-0.535 million ounces at total cash costs of $790-$860 per ounce. |
29006.0 | 2011-08-03 00:00:00 UTC | Investing 101: Stocks Reaching 52-Week Highs on Big Money Inflows | ABG | https://www.nasdaq.com/articles/investing-101-stocks-reaching-52-week-highs-big-money-inflows-2011-08-03 | nan | nan | (List compiled by Becca Lipman)
If you are an investor that likes to go with the trend, this list may offer an interesting starting point for new additions to your portfolio.
To compile this list we looked for companies that satisfied the following characteristics:
- Market Cap above $300 Million
- Trading 0-3% from the 52-Week High
- Experienced positive money flows from institutional investors over the last two quarters
Want to dig deeper into these terms and find out why they are important indicators when analyzing a stock's value? You got it:
Market Capitalization (Market Cap): Market capitalization, commonly referred to as market cap, is the total market value of a company's outstanding shares. It can be thought of as a measure of company's size. It can be calculated by multiplying the number of shares by the current price of the shares. Companies with higher market cap are considered to have more trustworthy information because they have greater histories of profitability and data.
The 52-Week High is the highest price paid for a share of the company in the last 52 weeks (one year).
The 52-Week Low is the lowest price paid for a share of a given stock in the last 52 weeks (one year).
Institutional investors are also known as "big money" investors or managers. They represent big pools of money such as investment banks, pension funds, mutual funds, hedge funds, endowment funds, etc. When they invest in stocks, they can invest hundreds of thousands of dollars or more at one time. These transactions, called "block trades," can have a significant effect on share prices.
Because institutional investors handle such large amounts of money, it is easy enough to assume that the big money managers know what they are doing -- or at the very least know more than the average investor. This is why these investors are also sometimes referred to as "smart money."
If institutional investors start investing in a company, regular investors can assume that some of the most talented analysts and money managers expect the company's share prices to increase over time. The stocks on our list are experiencing significant investment from big money.
Now that you're armed with information, take a look at the list of stocks meeting the above requirements. Use the list as a starting-off point for your own analysis.
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
List sorted by institutional purchases as a % of share float.
1. ZAGG Incorporated (ZAGG): Specialty Retail Industry. Market cap of $394.13M. Current price at $16.48. This stock is trading -2.49% below its 52-week high. On a net basis, institutional investors bought 3.6M shares during the current quarter. This represents 27.27% of the company's 13.20M share float. The stock is a short squeeze candidate, with a short float at 74.33% (equivalent to 5.18 days of average volume). Exhibiting strong upside momentum--currently trading 10.44% above its SMA20, 25.88% above its SMA50, and 73.84% above its SMA200. The stock has had a good month, gaining 25.29%.
2. Peet's Coffee & Tea Inc. (PEET): Processed & Packaged Goods Industry. Market cap of $770.99M. Current price at $62.67. This stock is trading -0.3% below its 52-week high. On a net basis, institutional investors bought 2.3M shares during the current quarter. This represents 18.25% of the company's 12.60M share float. The stock is a short squeeze candidate, with a short float at 25.02% (equivalent to 18.37 days of average volume). The stock has gained 43.43% over the last year.
3. Quality Distribution Inc. (QLTY): Trucking Industry. Market cap of $300.64M. Current price at $13.27. This stock is trading -2.78% below its 52-week high. On a net basis, institutional investors bought 2.5M shares during the current quarter. This represents 16.77% of the company's 14.91M share float. This is a risky stock that is significantly more volatile than the overall market (beta = 2.47). The stock has had a couple of great days, gaining 5.88% over the last week.
4. Asbury Automotive Group, Inc. (ABG): Auto Dealerships Industry. Market cap of $673.55M. Current price at $21.41. This stock is trading -2.68% below its 52-week high. On a net basis, institutional investors bought 2.9M shares during the current quarter. This represents 15.03% of the company's 19.29M share float. This is a risky stock that is significantly more volatile than the overall market (beta = 2.84). The stock is a short squeeze candidate, with a short float at 14.49% (equivalent to 11.33 days of average volume). The stock has had a good month, gaining 11.32%.
5. MarketAxess Holdings Inc. (MKTX): Investment Brokerage Industry. Market cap of $997.50M. Current price at $26.9. This stock is trading -0.37% below its 52-week high. On a net basis, institutional investors bought 4.9M shares during the current quarter. This represents 14.39% of the company's 34.04M share float. The stock has had a couple of great days, gaining 5.38% over the last week.
6. PriceSmart Inc. (PSMT): Discount, Variety Stores Industry. Market cap of $1.74B. Current price at $61.28. This stock is trading -1.59% below its 52-week high. On a net basis, institutional investors bought 2.0M shares during the current quarter. This represents 10.99% of the company's 18.20M share float. The stock is a short squeeze candidate, with a short float at 9.36% (equivalent to 7.92 days of average volume). The stock has had a good month, gaining 10.65%.
7. Cypress Sharpridge Investments, Inc. (CYS): REIT Industry. Market cap of $1.06B. Current price at $12.95. This stock is trading -2.04% below its 52-week high. On a net basis, institutional investors bought 7.0M shares during the current quarter. This represents 8.59% of the company's 81.52M share float. The stock has gained 13.29% over the last year.
8. Heartland Payment Systems, Inc. (HPY): Business Services Industry. Market cap of $844.41M. Current price at $22.5. This stock is trading -2.2% below its 52-week high. On a net basis, institutional investors bought 3.1M shares during the current quarter. This represents 8.24% of the company's 37.63M share float. Exhibiting strong upside momentum--currently trading 10.27% above its SMA20, 13.38% above its SMA50, and 26.96% above its SMA200. The stock has had a couple of great days, gaining 12.42% over the last week.
9. j2 Global Communications, Inc. (JCOM): Internet Software & Services Industry. Market cap of $1.19B. Current price at $30.53. This stock is trading -1.39% below its 52-week high. On a net basis, institutional investors bought 3.2M shares during the current quarter. This represents 7.28% of the company's 43.94M share float. The stock is a short squeeze candidate, with a short float at 10.77% (equivalent to 21.49 days of average volume). It's been a rough couple of days for the stock, losing 7.18% over the last week.
10. Lubrizol Corporation (LZ): Specialty Chemicals Industry. Market cap of $8.65B. Current price at $134.6. This stock is trading -1.15% below its 52-week high. On a net basis, institutional investors bought 3.5M shares during the current quarter. This represents 6.03% of the company's 58.05M share float. The stock has gained 42.63% over the last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Asbury Automotive Group, Inc. (ABG): Auto Dealerships Industry. To compile this list we looked for companies that satisfied the following characteristics: - Market Cap above $300 Million - Trading 0-3% from the 52-Week High - Experienced positive money flows from institutional investors over the last two quarters Want to dig deeper into these terms and find out why they are important indicators when analyzing a stock's value? Companies with higher market cap are considered to have more trustworthy information because they have greater histories of profitability and data. | Asbury Automotive Group, Inc. (ABG): Auto Dealerships Industry. You got it: Market Capitalization (Market Cap): Market capitalization, commonly referred to as market cap, is the total market value of a company's outstanding shares. On a net basis, institutional investors bought 3.6M shares during the current quarter. | Asbury Automotive Group, Inc. (ABG): Auto Dealerships Industry. To compile this list we looked for companies that satisfied the following characteristics: - Market Cap above $300 Million - Trading 0-3% from the 52-Week High - Experienced positive money flows from institutional investors over the last two quarters Want to dig deeper into these terms and find out why they are important indicators when analyzing a stock's value? You got it: Market Capitalization (Market Cap): Market capitalization, commonly referred to as market cap, is the total market value of a company's outstanding shares. | Asbury Automotive Group, Inc. (ABG): Auto Dealerships Industry. To compile this list we looked for companies that satisfied the following characteristics: - Market Cap above $300 Million - Trading 0-3% from the 52-Week High - Experienced positive money flows from institutional investors over the last two quarters Want to dig deeper into these terms and find out why they are important indicators when analyzing a stock's value? If institutional investors start investing in a company, regular investors can assume that some of the most talented analysts and money managers expect the company's share prices to increase over time. |
29007.0 | 2010-10-29 00:00:00 UTC | Nana Sangmuah: African Takeouts on the Menu | ABG | https://www.nasdaq.com/articles/nana-sangmuah-african-takeouts-menu-2010-10-29 | nan | nan | Clarus Securities Analyst Nana Sangmuah was born in Ghana, West Africa-a growing hot spot for gold exploration. He believes several gold juniors operating in West Africa are prime takeover targets and expects merger and acquisition (M&A) activity to heat up as the major gold producers seek to replenish their diminishing project pipelines. In this exclusive interview with The Gold Report, Nana reveals a few juniors on both sides of the Atlantic that could fall prey to larger predators.
The Gold Report: Nana, tell us about your coverage sector.
Nana Sangmuah: My coverage universe consists mainly of the junior golds with market caps under $500 million, but some of those are creeping up in size. An example is Semafo Inc. (TSX:SMF) , which is currently worth about $3 billion. Obviously, the idea is to pick up names with a growth trajectory that could give upside to investors.
Currently, my universe includes some of the little ones like Azumah Resources Ltd. (ASX:AZM) , which has a good growth trajectory, a $175 million market cap, significant exploration upside and a good management team to move it along the path. Other names in our coverage universe include Cluff Gold PLC (TSX:CFG;LSE:CFG) , which is significantly undervalued and poised for a rerating in the near term and developers like Keegan Resources Inc. (TSX:KGN; NYSE.A:KGN) and Perseus Mining Ltd. (TSX:PRU; ASX:PRU) . They are prime takeover candidates in West Africa, which is heating up. We also cover very seasoned, disciplined players in the space like Randgold Resources Ltd. ( GOLD ) , which probably has the best growth trajectory in the universe, and all of that can be fully funded internally with operating cash flow.
TGR: So, you're looking for companies that are on a growth trajectory. How do you arrive at that decision? What's your methodology for finding companies that fit that thesis?
NS: Obviously, you need a sizeable resource. Geology is key, and that plays into the size of the land packages because bigger land packages, potentially, hold bigger resources. And the land package should be on a greenstone belt because that is where we've seen most of the world's recent significant gold discoveries. Once the location and the geology check out, then you ask questions about the management team behind the asset. Does it have the know-how? Has it developed other deposits? Does it have people working with it that could unlock value on the asset? And then you have to make sure the company has the cash to execute the strategy. You can have the best asset but if the balance sheet is not strong enough, there will be a lack of news flow and investors will probably turn their attention to other projects.
TGR: You're from Ghana and West Africa in general has received a lot of attention lately due to Kinross Gold Corp. (TSX:K; NYSE:KGC) acquiring the assets of Red Back Mining. One of these was the Chirano gold mine in Ghana, and the other was the Tasiast Gold Mine in Mauritania. This has people talking about some other companies that could be takeover targets in West Africa. What are majors looking for in takeover targets?
NS: In the takeover category, most majors look for production visibility and exploration upside. One of the guys in my coverage universe fits the bill quite well: Perseus Mining, which is totally cashed up and on track to launch production at the rate of about 220 (Koz.) per year, starting in Q311.
Aside from the fact that Perseus will be graduating into the producer category, it has enormous exploration potential. The company is doing just about the most aggressive drilling in the region on its Central Ashanti Gold Project (formerly the Ayanfuri). Perseus is drilling 30,000 meters a month companywide, which is definitely going to provide a lot of news flow to sustain investor attention during development.
The project was owned by AngloGold Ashanti Ltd. (NYSE:AU; JSE:ANG; ASX:AGG; LSE:AGD) before it was abandoned and Perseus took over. Perseus has since delineated about 5.3 million ounces (Moz.) of gold at Ayanfuri alone. With a companywide global resource of 7.3 Moz., Anglo is one of the largest resource holders in West Africa that's not owned by a major mining company; that makes it a prime takeover candidate. There is going to be a site visit trip for analysts in November to showcase the progress of development, which seems to be going well.
Aside from that, it also has assets in Cote d'Ivoire-mainly the Tengrela Gold Project (1.3 Moz.), which is also on track with a definitive feasibility study in November. That project could sustain head grades of about 3-4 grams per ton (g/t) for the first four years of production at cash costs in the low $300s. The market is not assigning a lot of value to this asset at this stage.
The exploration results from Tengrela show that the whole project is growing with recent new discoveries. There is further exploration upside in Cote d'Ivoire as the company has ground right next to Rangold's Tongon Project (4.6 Moz.), which is starting production in Q4 at the rate of 250,000 oz/year. This is yet to be drilled by the company.
TGR: How much value do you put on ounces in the ground? For instance, if it's an inferred resource, do you ascribe a different value to it than actual reserves?
NS: If it's an actual reserve that could easily make its way into the discounted cash flow (DCF) profile, you would have a discounted cash flow valuation on the reserves. The inferred resources would be valued based on a peer market average for an ounce in the ground, and that is currently creeping up. It's around $100 per ounce now based on my peer comparable tables.
TGR: You recently attended the Denver Gold Forum in September, and apparently there was quite a fierce debate there between Martin Murenbeeld, who's the chief economist with DundeeWealth Inc., and Paul Walker, the CEO of precious metals consulting firm GFMS. Murenbeeld was bullish on gold and Walker was bearish. What side is Clarus on?
NS: Well, we're obviously on the bullish side for the next couple of years and we raised our forecast to $1,300 for 2011 and 2012. But we're reverting it back to $1,000 by 2013.
Now, the reason is that there's no sign of real recovery out there yet. This is probably one of the rare occasions where we've seen a lot of countries fall into recession at the same time, and everybody is mirroring each other in the ways they're trying to get themselves out of this equation. This will likely go on for a while, and I think people will continue to look for alternative places for investment. This will prompt further increases in gold investment demand and physical demand, which traditionally gets stronger in the fourth quarter.
Frankly, the supply side of the equation has not really improved as the number of new discoveries over the last 10 years has kept diminishing. For the next while, I think we can solidly bank on having some strength in the gold price going forward, based on pure fundamentals.
On the other side, if there's a recovery, we will probably have to start rotating out of gold investment and looking elsewhere.
Before that happens, I think inflation is definitely going to be the gatekeeper. If a real recovery comes through, inflation should hit hard, and that would drive gold prices to a higher level before we roll over. I think the logical time frame to get that happening would probably be around the 2013 mark.
TGR: At that point, you think enough gold supply will have come onstream, the global economy will have recovered and that those two things will conspire to lower the gold price. Is that what you're saying?
NS: Supply in itself might not necessarily increase drastically, but as interest rates creep up, I think people will start looking elsewhere for investment alternatives and gold will no longer be the "go-to" choice. People might even start to sell off positions.
TGR: There is a theory that suggests the geology in West Africa is very similar to the geology on the east coast of Brazil because these continents were attached millions of years ago. Do you believe that theory?
NS: It's logical if you look at the plate tectonics that have been in existence for a long period of time. I would highlight, though, that the mineralogy and the grade profile on those zones are quite different. Even within West Africa, you find different grade profiles along different belts.
The prospectivity of eastern Brazil, though, is impressive. Based on my statistics, so far around 90 Moz. has been delineated in that region, with grade profiles of about 2-3 g/t, and there's still more drilling to be done.
Some of the companies that are active in this space will probably be adding to the tally in the next little while, like Rio Novo Gold Inc. (TSX:RN) . It's currently returning about 3-4 g/t rates on the Almas Gold Project, and Rio is about to tap into the Guarantã Gold Project, as well.
TGR: One of those Rio Novo projects is in a greenstone belt that is similar to the greenstone belts of West Africa. Do you see potential for Rio Novo to continue to expand its resources there?
NS: Well, based on the NI 43-101-compliant resources, it would probably be under 1 Moz.; but historical, non 43-101-compliant resources come in about 1.5x higher. And the company's doing a lot of infill drilling. The prospectivity remains. I think it could easily meet and exceed 1 Moz. based on additional targets yet to be chased on the project.
I will be seeing the project in a few weeks to do some level of due diligence. But it's not wholly a matter of growing the resource, which oftentimes becomes the focus for a lot of people. The key is whether a company can get those ounces in the ground into meaningful production. And that's what excites me about the Rio Novo group-the management is really proven. The technical team has built mines operating at a capacity of 55,000 tons per day (tpd), so putting these less-than-10,000 tpd operations into production should prove less of a challenge. And the geological team has actually proven a lot of discoveries in the belt. Technically, I think these people are savvy, and I think the company should probably rerate itself into producer in a very short while.
TGR: You mentioned that you have an upcoming site visit to see Perseus' projects in Africa, and that you've got another Rio Novo project to see in Brazil. You recently visited Colombia for a conference in Medellin and conducted some site visits in the area. Tell us about your trip.
NS: Continental Gold Ltd. ( CNL ) is a company I visited, and I was very impressed by what I saw walking in these adits at the Buriticá project. There's nothing to make you disbelieve that there's gold in those veins. I think the key here is how big the potential resource is going to be, because the dimensions are not well established yet. We should know all these dimensions soon with five drill rigs turning on the property, as the company aims to complete an initial resource in 2011. With a current market cap of around $570 million, the resource is being counted at 5 Moz. Is that a stretch? I believe its strong portfolio of assets covering 160,000 hectares in Colombia gives it huge, untapped exploration potential.
Some of the other assets like Berlin, which has some drills currently turning on it, look much more exciting. Historically, Berlin has produced about 400 Koz. gold in a single lode with a thickness of about 20 meters. That is just about 20% of the whole strike length. The rest of the asset has yet to be tested, but Continental currently has almost $100 million in cash to put into all of these projects. The ability to delineate the resources to back the valuation, and even exceed it, is told there.
Continental has a great management team; and good geologists that have delineated significant resources at other projects are working on this asset, so it's just a matter of time. I always encourage investors to sit tight and watch for results to come out. The results here are typically very high-grade zones that have not really been closed off at depth. There's still huge potential in the initial veins that we've seen at Buriticá. The company has come up with some new samples and there are geophysical anomalies that have yet to be tested, as well. The growth prospects are quite enormous.
TGR: Continental's an interesting story certainly in part due to its management. You've got an Aurelian Resources reunion with Patrick Anderson and Tim Warman on the board, and now Keith McKay as CFO. These guys were all part of Aurelian, which was sold to Kinross for about $1 billion in 2008.
NS: Exactly, that's one of the key points I try to find in these early stage companies. The assets should be prolific, which shakes out on Continental, and management should know what it's doing because it's done it before. Thirdly, it should have the cash to drill these veins aggressively-and Continental has that, as well. It all lines up.
TGR: It sure does. What are some other companies you're following?
NS: It's a broad list. It includes Cluff Gold and its West African assets, which produce about 100 Koz. per year. But Cluff is grossly undervalued because people are discounting the life of the current operations-the Kalsaka mine in Burkina Faso and the Angovia project in Cote d'Ivoire. Based on current drilling information, there could be extensions to these resources that could extend the mine life, but that is not the only key value driver of the stock. The flagship asset is the Baomahun gold project in Sierra Leone; only 25% of a 12 km. strike length has been tested, and 2.5 Moz. has been delineated. Cluff has picked up nine similar prospects along the strike length that have yet to be tested. The company is cash-flow positive and will be chasing some of these zones aggressively.
Cluff is trading at roughly 7x cash flow-quite a huge discount compared to its peers, which trade at around 18x. And even on an in-situ valuation basis, which is often used for early stage junior gold companies, it trades at $55/oz., which is still below companies that have yet to show any production visibility that average about $100/oz. New COO Peter Spivey will take the reins officially in January, and he will continue to guide the turnaround story. There's a lot of upside at these levels. Cluff is pouring gold and is unhedged with great exposure to the gold price right now.
TGR: You mentioned that Cluff's flagship project is in Sierra Leone. I think when a lot of people hear Sierra Leone, they think of jurisdiction risk. What are your thoughts on that?
NS: Well, I think the company's had a challenging past, but that's probably where the opportunity lies. There's stability in the region now. You probably have to add a little bit to your cost estimates because the infrastructure is not great. But in talking with peers and colleagues working in the country, there's little perceived political risk. I mean we are seeing investment demand increase with significant investment made in the country by China. I think Sierra Leone is at ground level in terms of exploiting its natural resources, and that's probably where you're going to get the most upside.
TGR: One company that you mentioned earlier is also exploring in Ghana, and that's Keegan. Tell us about that one.
NS: Keegan has the Esaase gold project in Ghana; within 18 months, it's been able to delineate 3.5 Moz. And I think this resource could easily be pushed closer to 5 Moz. We're expecting an update in Q4, but Keegan is another company that I think should be reaching the radar screens of a lot of people looking to acquire gold assets in West Africa. It's also shown production visibility by completing a preliminary economic study that shows it's capable of reaching production by 2013.
Keegan currently has about $30 million to continue derisking the asset, and one good thing about the project is the underground potential. Most people realize there's potential to dig deep in a greenstone belt. Currently, the company's chasing rich veins to a depth of 2.5 kilometers. A deep intersection on the Esaase project, at about the 400- to 500-meter level, is coming up with grades of about 10 g/t over 24 meters, suggesting this potential is available.
The other aspect to Keegan is its other Ghana asset, the Asumura gold property. This property is close to Newmont's 16 Moz. Ahafo gold operation, which has yet to be fully tested. Keegan has two rigs turning on it, and no analyst on the Street has a valuation on this asset yet. Decent exploration success is going to spike another wave of growth in the stock.
TGR: In March, Barrick Gold Corporation (NYSE:ABX; TSX:ABX) spun out its African assets into African Barrick Gold Plc. ( ABG ) . Is that company looking to expand its project pipeline and production profile in Africa?
NS: Yes, and I think it's just about time because it had some level of production from its mines in Tanzania, but that has not been smooth. I think the company revised guidance downward on that twice this year, and that's had an impact on the stock. People are waiting for African Barrick to tell investors where the growth is going to come from.
I see them as potential acquirers, and that adds to the list of companies who are looking in West Africa. I don't see a significant team of geologists in African Barrick that can start looking at the grassroots projects and build upward. Obviously, if it had those people, it would take a lot more time to get the growth that it is seeking.
TGR: Any parting thoughts on the junior gold sector?
NS: Well, we've seen all kinds of M&A activity. But I think it's going to accelerate because a lot of the majors still have a decline in their production profiles, and few have had much success with exploration. There's only one way to boost your production profile and that is to acquire a junior. I think most of these juniors, particularly those in my coverage universe, are well cashed up. In the next 6-18 months, they will be attacking their assets with a lot more vigor as part of an effort to grow their resource profiles. That would definitely be enticing to a lot of these majors looking to boost their resource and production profiles in those regions.
Clarus Securities Analyst Nana Sangmuah obtained his BSc (Honors) Engineering at the University of Mines and Technology (Tarkwa, Ghana) in 1999. His previous industry experience includes state-owned Prestea Underground Mine in Ghana (currently owned by Golden Star); AngloGold Ashanti's Obuasi and Iduapriem mines (Tarkwa, Ghana) and Goldfields International's Damang gold mine (Tarkwa, Ghana). Nana completed his postgraduate MBA finance degree at University of Toronto, Rotman School of Management in 2004. He has roughly seven years of global mining equity research experience that covers more than 60 mining companies worldwide in the gold, base metals and diamond sectors and has in-depth knowledge of mining projects in West Africa.
Want to read more exclusive Gold Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Expert Insights page.
DISCLOSURE:
1.) Brian Sylvester of The Gold Report conducted this interview. He personally and/or his family own shares of the following companies mentioned in this interview: None.
2.) The following companies mentioned in the interview are sponsors of The Gold Report: Continental.
3.) Nana Sangmuah: I personally and/or my family own shares of the following companies mentioned in this interview: None. I personally and/or my family am paid by the following companies mentioned in this interview: None.
Streetwise - The Gold Report is Copyright © 2010 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.
The GOLD Report does not render general or specificinvestment adviceand does not endorse or recommend the business, products, services or securities of any industry or company mentioned in this report.
From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.
Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.
Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.
Participating companies provide the logos used in The Gold Report. These logos are trademarks and are the property of the individual companies.
Streetwise Reports LLC
P.O. Box 1099
Kenwood, CA 95452
Tel.: (707) 282-5593
Fax: (707) 282-5592
Email: jmallin@streetwisereports.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ( ABG ) . We also cover very seasoned, disciplined players in the space like Randgold Resources Ltd. ( GOLD ) , which probably has the best growth trajectory in the universe, and all of that can be fully funded internally with operating cash flow. TGR: You're from Ghana and West Africa in general has received a lot of attention lately due to Kinross Gold Corp. (TSX:K; NYSE:KGC) acquiring the assets of Red Back Mining. | ( ABG ) . Currently, my universe includes some of the little ones like Azumah Resources Ltd. (ASX:AZM) , which has a good growth trajectory, a $175 million market cap, significant exploration upside and a good management team to move it along the path. Other names in our coverage universe include Cluff Gold PLC (TSX:CFG;LSE:CFG) , which is significantly undervalued and poised for a rerating in the near term and developers like Keegan Resources Inc. (TSX:KGN; NYSE.A:KGN) and Perseus Mining Ltd. (TSX:PRU; ASX:PRU) . | ( ABG ) . He believes several gold juniors operating in West Africa are prime takeover targets and expects merger and acquisition (M&A) activity to heat up as the major gold producers seek to replenish their diminishing project pipelines. We're expecting an update in Q4, but Keegan is another company that I think should be reaching the radar screens of a lot of people looking to acquire gold assets in West Africa. | ( ABG ) . What are some other companies you're following? NS: Keegan has the Esaase gold project in Ghana; within 18 months, it's been able to delineate 3.5 Moz. |
29008.0 | 2010-10-14 00:00:00 UTC | Oil Rises as OPEC Sees Healthy Global Energy Demand, Gold Continues to Rise | ABG | https://www.nasdaq.com/articles/oil-rises-opec-sees-healthy-global-energy-demand-gold-continues-rise-2010-10-14 | nan | nan | Oil prices are on the rise in early morning trade with Saudi Arabia's oil minister Ali an-Naimi stating ahead of the Organization of Petroleum Exporting Countries' latest meeting that global energy demand was very healthy. Many analysts expect OPEC to keep oil output unchanged, even though some countries may call for higher crude prices.
Gold too is up, breaking its own record highs as the dollar fell against major currencies amid expectations of further monetary easy by the Federal Reserve. Still, speculation is growing among some investors that the yellow metal's demand as a safe haven asset may not be sustainable for much longer.
At 0750 ET, Brent crude is up 0.4% at $85.17 a barrel, while light sweet crude is up 0.3% at $83.27 a barrel, and natural gas is down 1.8% at $3.63 a million British thermal units.
Gold is up 0.8% at $1,381.50 an ounce, and silver is 2.2% stronger at $24.46 an ounce, while copper is up 0.3% at $3.83 a pound.
Occidental Petroleum Corp.'s ( OXY ) CEO Ray Irani may step down in May, according to the Wall Street Journal. The financial daily added that Irani will remain chairman until the end of 2014, and face a pay cut as he is succeeded by Stephen Chazen, who is currently Occidental's president.
In Russia, the operator of Exxon Mobil Corp.'s ( XOM ) Sakhalin-1 field is looking to double the project's budget to $100 billion, according to daily Vedomosti. Partners in the project operated by Exxon Neftegas Ltd include OAO Rosneft (ROSN), ONGC Videsh Ltd, and Sakhalin Oil & Gas Development Co.
The Filipino unit of Royal Dutch Shell plc (RDSA) is facing a $567 million lawsuit from the government for tax evasion. The Bureau of Customs said that the company misclassified 52 shipments between 2005 and 2009.
In the mining sector, African Barrick Gold plc ( ABG ) fell by 11% in London trade, its biggest decline since the company listed on the exchange in March, on concerns about gangs infiltrating its mine in Tanzania. Systematic theft by the gang has forced the company to suspend 60 workers and delay production.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the mining sector, African Barrick Gold plc ( ABG ) fell by 11% in London trade, its biggest decline since the company listed on the exchange in March, on concerns about gangs infiltrating its mine in Tanzania. Gold too is up, breaking its own record highs as the dollar fell against major currencies amid expectations of further monetary easy by the Federal Reserve. The financial daily added that Irani will remain chairman until the end of 2014, and face a pay cut as he is succeeded by Stephen Chazen, who is currently Occidental's president. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In the mining sector, African Barrick Gold plc ( ABG ) fell by 11% in London trade, its biggest decline since the company listed on the exchange in March, on concerns about gangs infiltrating its mine in Tanzania. Partners in the project operated by Exxon Neftegas Ltd include OAO Rosneft (ROSN), ONGC Videsh Ltd, and Sakhalin Oil & Gas Development Co. | In the mining sector, African Barrick Gold plc ( ABG ) fell by 11% in London trade, its biggest decline since the company listed on the exchange in March, on concerns about gangs infiltrating its mine in Tanzania. Oil prices are on the rise in early morning trade with Saudi Arabia's oil minister Ali an-Naimi stating ahead of the Organization of Petroleum Exporting Countries' latest meeting that global energy demand was very healthy. Gold too is up, breaking its own record highs as the dollar fell against major currencies amid expectations of further monetary easy by the Federal Reserve. | In the mining sector, African Barrick Gold plc ( ABG ) fell by 11% in London trade, its biggest decline since the company listed on the exchange in March, on concerns about gangs infiltrating its mine in Tanzania. Many analysts expect OPEC to keep oil output unchanged, even though some countries may call for higher crude prices. Gold too is up, breaking its own record highs as the dollar fell against major currencies amid expectations of further monetary easy by the Federal Reserve. |
29009.0 | 2010-07-27 00:00:00 UTC | Oil Gains as Goldman Projects Prices to Rise; Gold Up on Bargain-Hunting | ABG | https://www.nasdaq.com/articles/oil-gains-goldman-projects-prices-rise-gold-bargain-hunting-2010-07-27 | nan | nan | Oil is up slightly in early morning trade, lifted in part by a Goldman Sachs report finding current crude prices too cheap. Investors will be eyeing the release of the latest U.S. crude inventories data, as the American Petroleum Institute will be releasing its weekly numbers later in the day. Analysts broadly expect stockpiles to have declined as Tropical Storm Bonnie disrupted production in the Gulf of Mexico.
Gold is on the rise as bargain-hunters swooped in to take advantage of the yellow metal's decline. The London Metal Exchange reported trading in the first half of the year reaching record levels, with total trading reaching 59.3 million contracts, up 8% from the same period a year ago. The LME will create a global steel contract Wednesday through the merger of its Far East and Mediterranean steel billet futures contracts.
At 0755 ET, Brent crude is up 0.4% at $77.79 a barrel, while light sweet crude is up 0.4% at $79.26 a barrel, and natural gas is up 0.9% at $4.65 a million British thermal units.
Gold is up 0.1% at $1,184.00 an ounce, while silver is up 0.2% at $18.23 an ounce, and copper is up 0.3% at $3.23 a pound.
Goldman reported that crude prices are too low at current levels, given the rebound in U.S. equity prices in particular, and the investment bank expects the balance between supply and demand to tighten in the latter part of this year.
As for BP plc ( BP ), it is up nearly 5% in pre-market trade on the NYSE, even though the oil giant reported a record net loss of $17.2 billion in the second quarter, compared to a $4.39 billion profit during the same period a year ago. The company also announced Monday that Robert Dudley will replace Tony Hayward as CEO on Oct. 1, as the British group continues to struggle with the clean-up and costs due to the Gulf of Mexico spill.
Mining group African Barrick Gold ( ABG ) cut back its production guidance for the fiscal year due to delays in accessing higher grade from its Buzwagi mine in Tanzania. The company expects to produce 750,000 ounces to 800,000 ounces of gold this fiscal year at a cash cost of $500 to $550 an ounce. Previously, the company had projected production of 800,000 to 850,000 ounces.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mining group African Barrick Gold ( ABG ) cut back its production guidance for the fiscal year due to delays in accessing higher grade from its Buzwagi mine in Tanzania. Oil is up slightly in early morning trade, lifted in part by a Goldman Sachs report finding current crude prices too cheap. Analysts broadly expect stockpiles to have declined as Tropical Storm Bonnie disrupted production in the Gulf of Mexico. | Mining group African Barrick Gold ( ABG ) cut back its production guidance for the fiscal year due to delays in accessing higher grade from its Buzwagi mine in Tanzania. The London Metal Exchange reported trading in the first half of the year reaching record levels, with total trading reaching 59.3 million contracts, up 8% from the same period a year ago. The company expects to produce 750,000 ounces to 800,000 ounces of gold this fiscal year at a cash cost of $500 to $550 an ounce. | Mining group African Barrick Gold ( ABG ) cut back its production guidance for the fiscal year due to delays in accessing higher grade from its Buzwagi mine in Tanzania. The London Metal Exchange reported trading in the first half of the year reaching record levels, with total trading reaching 59.3 million contracts, up 8% from the same period a year ago. Goldman reported that crude prices are too low at current levels, given the rebound in U.S. equity prices in particular, and the investment bank expects the balance between supply and demand to tighten in the latter part of this year. | Mining group African Barrick Gold ( ABG ) cut back its production guidance for the fiscal year due to delays in accessing higher grade from its Buzwagi mine in Tanzania. Oil is up slightly in early morning trade, lifted in part by a Goldman Sachs report finding current crude prices too cheap. Investors will be eyeing the release of the latest U.S. crude inventories data, as the American Petroleum Institute will be releasing its weekly numbers later in the day. |
29010.0 | 2010-04-27 00:00:00 UTC | Gold Lower as Dollar Gains, African Barrick Gold Earnings Soar on Higher Output | ABG | https://www.nasdaq.com/articles/gold-lower-dollar-gains-african-barrick-gold-earnings-soar-higher-output-2010-04-27 | nan | nan | Gold is on the decline in morning trade Tuesday as the greenback gained against the euro amid worries about Greece's financial bailout prospects. Continued concerns about Greece and the euro zone in general has led traders to fret about sovereign risk in the euro zone on the one hand, while a stronger dollar decreases investors' appetite for alternative assets including precious metals on the other.
Traders are likely to refrain from shoring up the yellow metal until more details about financial aid to Greece are available, particularly amid worries about credit risk spreading to neighboring countries such as Spain and Portugal. Such concerns are putting a damper on both investment and industrial demand for metals.
At 0805 ET, gold is down 0.2% at $1,151.80 an ounce, while silver is 0.8% weaker at $18.20 an ounce, and copper is down 1.5% at $347.50 a pound.
In earnings news, African Barrick Gold plc ( ABG ) reported first quarter earnings rising to $100 million from $41 million from the same period a year ago. The surge was largely due to production kicking off at its Buzwagi mine that bolstered gold production by 40% to 177,095 ounces as well as higher gold prices.
Newmont Mining Corp. ( NEM ) reported net income nearly tripling to $546 million in the first quarter, compared to $189 million reached during the same period a year ago. Earnings per share reached $1.11 in the latest quarter compared to 40 cents in the previous year, considerably higher than the 79 cents forecast by analysts polled by FactSet Research. Gold output for 2010 is expected to remain unchanged, however, as it expects to produce 5.3 million to 5.5 million ounces with costs applicable to sales between $450 and $480 an ounce.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In earnings news, African Barrick Gold plc ( ABG ) reported first quarter earnings rising to $100 million from $41 million from the same period a year ago. Gold is on the decline in morning trade Tuesday as the greenback gained against the euro amid worries about Greece's financial bailout prospects. Continued concerns about Greece and the euro zone in general has led traders to fret about sovereign risk in the euro zone on the one hand, while a stronger dollar decreases investors' appetite for alternative assets including precious metals on the other. | In earnings news, African Barrick Gold plc ( ABG ) reported first quarter earnings rising to $100 million from $41 million from the same period a year ago. Gold is on the decline in morning trade Tuesday as the greenback gained against the euro amid worries about Greece's financial bailout prospects. Newmont Mining Corp. ( NEM ) reported net income nearly tripling to $546 million in the first quarter, compared to $189 million reached during the same period a year ago. | In earnings news, African Barrick Gold plc ( ABG ) reported first quarter earnings rising to $100 million from $41 million from the same period a year ago. Continued concerns about Greece and the euro zone in general has led traders to fret about sovereign risk in the euro zone on the one hand, while a stronger dollar decreases investors' appetite for alternative assets including precious metals on the other. Gold output for 2010 is expected to remain unchanged, however, as it expects to produce 5.3 million to 5.5 million ounces with costs applicable to sales between $450 and $480 an ounce. | In earnings news, African Barrick Gold plc ( ABG ) reported first quarter earnings rising to $100 million from $41 million from the same period a year ago. At 0805 ET, gold is down 0.2% at $1,151.80 an ounce, while silver is 0.8% weaker at $18.20 an ounce, and copper is down 1.5% at $347.50 a pound. Newmont Mining Corp. ( NEM ) reported net income nearly tripling to $546 million in the first quarter, compared to $189 million reached during the same period a year ago. |
29011.0 | 2010-04-20 00:00:00 UTC | Gold Gains as Inflation Risks Seen | ABG | https://www.nasdaq.com/articles/gold-gains-inflation-risks-seen-2010-04-20 | nan | nan | Gold is on the rise in morning trade, gaining ground as worries about repercussions of the SEC suing Goldman Sachs subsided on the one hand, and expectations of inflation increase on the other.
India, which is a major gold buyer, raised interest rates for the second time this month, and that has boosted the allure of the yellow metal as a hedge against inflation. Many economists expect the Reserve Bank of India to tighten policy again before its next meeting on July 27.
At 0810 ET, gold is up 0.6% at $1,142.20 an ounce, while silver is up 1.2% at $17.95 an ounce, and copper is up 1.2% at $353.85 a pound.
Meanwhile, a 5.0-magnitude earthquake has struck a major gold mining area in Australia. There have not been any reports of major injuries as of yet, but the quake that struck about six miles southwest of the town of Kalgoorlie-Boulder may have affected mines. Over 50 mines operatein Kalgoorie, which is about 370 miles east of Perth.
As for BUK Holdco Ltd. ( BUK ), which is a wholly-owned subsidiary of African Barrick Gold plc. ( ABG ), it has declared a takeover offer for all shares of Tusker Gold Ltd (T66).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ( ABG ), it has declared a takeover offer for all shares of Tusker Gold Ltd (T66). Gold is on the rise in morning trade, gaining ground as worries about repercussions of the SEC suing Goldman Sachs subsided on the one hand, and expectations of inflation increase on the other. India, which is a major gold buyer, raised interest rates for the second time this month, and that has boosted the allure of the yellow metal as a hedge against inflation. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ( ABG ), it has declared a takeover offer for all shares of Tusker Gold Ltd (T66). Meanwhile, a 5.0-magnitude earthquake has struck a major gold mining area in Australia. | ( ABG ), it has declared a takeover offer for all shares of Tusker Gold Ltd (T66). Gold is on the rise in morning trade, gaining ground as worries about repercussions of the SEC suing Goldman Sachs subsided on the one hand, and expectations of inflation increase on the other. India, which is a major gold buyer, raised interest rates for the second time this month, and that has boosted the allure of the yellow metal as a hedge against inflation. | ( ABG ), it has declared a takeover offer for all shares of Tusker Gold Ltd (T66). Gold is on the rise in morning trade, gaining ground as worries about repercussions of the SEC suing Goldman Sachs subsided on the one hand, and expectations of inflation increase on the other. India, which is a major gold buyer, raised interest rates for the second time this month, and that has boosted the allure of the yellow metal as a hedge against inflation. |
29012.0 | 2023-02-08 00:00:00 UTC | BML Investment Partners Increases Position in Arca Biopharma (ABIO) | ABIO | https://www.nasdaq.com/articles/bml-investment-partners-increases-position-in-arca-biopharma-abio | nan | nan | Fintel reports that BML Investment Partners has filed a 13G/A form with the SEC disclosing ownership of 0.86MM shares of Arca Biopharma Inc (ABIO). This represents 5.95% of the company.
In their previous filing dated January 27, 2022 they reported 0.76MM shares and 5.30% of the company, an increase in shares of 12.65% and an increase in total ownership of 0.65% (calculated as current - previous percent ownership).
Fund Sentiment
There are 42 funds or institutions reporting positions in Arca Biopharma. This is a decrease of 0 owner(s) or 0.00%.
Average portfolio weight of all funds dedicated to US:ABIO is 0.0103%, an increase of 58.9420%. Total shares owned by institutions increased in the last three months by 33.29% to 2,481K shares.
What are large shareholders doing?
Newtyn Management holds 500,000 shares representing 3.47% ownership of the company.
Susquehanna International Group, Llp holds 314,213 shares representing 2.18% ownership of the company. In it's prior filing, the firm reported owning 227,917 shares, representing an increase of 27.46%. The firm increased its portfolio allocation in ABIO by 19.05% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 312,166 shares representing 2.17% ownership of the company. In it's prior filing, the firm reported owning 311,254 shares, representing an increase of 0.29%. The firm decreased its portfolio allocation in ABIO by 13.51% over the last quarter.
Geode Capital Management holds 155,870 shares representing 1.08% ownership of the company. In it's prior filing, the firm reported owning 102,911 shares, representing an increase of 33.98%. The firm increased its portfolio allocation in ABIO by 29.84% over the last quarter.
Group One Trading holds 144,284 shares representing 1.00% ownership of the company. In it's prior filing, the firm reported owning 131,501 shares, representing an increase of 8.86%. The firm increased its portfolio allocation in ABIO by 13.93% over the last quarter.
ARCA biopharma Background Information
(This description is provided by the company.)
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that BML Investment Partners has filed a 13G/A form with the SEC disclosing ownership of 0.86MM shares of Arca Biopharma Inc (ABIO). Average portfolio weight of all funds dedicated to US:ABIO is 0.0103%, an increase of 58.9420%. The firm increased its portfolio allocation in ABIO by 19.05% over the last quarter. | Fintel reports that BML Investment Partners has filed a 13G/A form with the SEC disclosing ownership of 0.86MM shares of Arca Biopharma Inc (ABIO). Average portfolio weight of all funds dedicated to US:ABIO is 0.0103%, an increase of 58.9420%. The firm increased its portfolio allocation in ABIO by 19.05% over the last quarter. | Fintel reports that BML Investment Partners has filed a 13G/A form with the SEC disclosing ownership of 0.86MM shares of Arca Biopharma Inc (ABIO). Average portfolio weight of all funds dedicated to US:ABIO is 0.0103%, an increase of 58.9420%. The firm increased its portfolio allocation in ABIO by 19.05% over the last quarter. | Fintel reports that BML Investment Partners has filed a 13G/A form with the SEC disclosing ownership of 0.86MM shares of Arca Biopharma Inc (ABIO). Average portfolio weight of all funds dedicated to US:ABIO is 0.0103%, an increase of 58.9420%. The firm increased its portfolio allocation in ABIO by 19.05% over the last quarter. |
29013.0 | 2022-09-28 00:00:00 UTC | Here's Why We're Watching ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation | ABIO | https://www.nasdaq.com/articles/heres-why-were-watching-arca-biopharmas-nasdaq%3Aabio-cash-burn-situation | nan | nan | There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.
Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.
How Long Is ARCA biopharma's Cash Runway?
A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at June 2022, ARCA biopharma had cash of US$46m and no debt. In the last year, its cash burn was US$17m. Therefore, from June 2022 it had 2.8 years of cash runway. Arguably, that's a prudent and sensible length of runway to have. Depicted below, you can see how its cash holdings have changed over time.
NasdaqCM:ABIO Debt to Equity History September 28th 2022
How Is ARCA biopharma's Cash Burn Changing Over Time?
ARCA biopharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. With the cash burn rate up 20% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. ARCA biopharma makes us a little nervous due to its lack of substantial operating revenue. We prefer most of the stocks on this list of stocks that analysts expect to grow.
Can ARCA biopharma Raise More Cash Easily?
Given its cash burn trajectory, ARCA biopharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.
ARCA biopharma has a market capitalisation of US$30m and burnt through US$17m last year, which is 55% of the company's market value. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising.
How Risky Is ARCA biopharma's Cash Burn Situation?
Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought ARCA biopharma's cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. Separately, we looked at different risks affecting the company and spotted 3 warning signs for ARCA biopharma (of which 2 are significant!) you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History September 28th 2022 How Is ARCA biopharma's Cash Burn Changing Over Time? For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History September 28th 2022 How Is ARCA biopharma's Cash Burn Changing Over Time? Given its cash burn trajectory, ARCA biopharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History September 28th 2022 How Is ARCA biopharma's Cash Burn Changing Over Time? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History September 28th 2022 How Is ARCA biopharma's Cash Burn Changing Over Time? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. |
29014.0 | 2022-05-03 00:00:00 UTC | TCMD Expects 13-15% Revenue Growth In 2022, AXSM On Watch, QURE Awaits Huntington's Trial Data | ABIO | https://www.nasdaq.com/articles/tcmd-expects-13-15-revenue-growth-in-2022-axsm-on-watch-qure-awaits-huntingtons-trial-data | nan | nan | (RTTNews) - The following are some of the biotech companies that reported quarterly earnings and provided business update on Monday.
1. ARCA biopharma Inc. (ABIO) has revealed that it is in the process of evaluating options for creating stockholder value, including potential development of its assets, partnering and other strategic options.
The company is focused on developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.
Cash and cash equivalents totaled $49.1 million as of March 31, 2022.
ABIO closed Monday's trading at $2.37.
2. Addus HomeCare Corp. (ADUS), a provider of home care services, has reported better-than-expected earnings for the first quarter of 2022 while revenue missed analysts' estimate.
Adjusted net income for the first quarter of 2022 improved to $12.34 million or $0.77 per share from $11.91 million or $0.74 per share for the first quarter of 2021. Total revenue for Q1, 2022 was $226.6 million compared to $205 million in the year-earlier quarter.
Wall Street analysts were expecting the company to earn $0.76 per share on revenue of $227.33 million for the quarter.
As of March 31, 2022, cash on hand was $124.8 million and bank debt was $259.9 million.
ADUS closed Monday's trading at $84.31, up 0.04%.
3. Axsome Therapeutics Inc. (AXSM) has a couple of anticipated milestones to achieve in the coming months.
The company has plans to explore its drug candidate AXS-05 in a pivotal Phase 2/3 trial in smoking cessation, and information on the timing of initiation of this study is expected to be provided this year.
AXS-05 is also being explored as a treatment for major depressive disorder, with the FDA decision expected this quarter.
Yesterday, the FDA declined to approve the company's AXS-07, proposed for the acute treatment of migraine, citing chemistry, manufacturing, and controls (CMC) considerations.
AXS-12 and AXS-14 are the other clinical compounds in the company's pipeline.
AXS-12 is under a phase III trial in the treatment of narcolepsy, dubbed SYMPHONY, with topline results anticipated in the first half of 2023.
AXS-14, being developed for the management of fibromyalgia, has successfully completed phase III trial, with NDA submission planned in 2023.
AXSM closed Monday's trading at $34.04, up 7.21%.
4. InMode Ltd. (INMD) reported strong earnings and revenue for the first quarter ended March 31, 2022.
For the first quarter of 2022, the company reported non-GAAP net income of $34.1 million or $0.40 per share on revenue of $85.9 million. This compares with a non-GAAP net income of $29.3 million or $0.34 per share and revenue of $65.5 million in the first quarter of 2021.
Looking ahead to full-year 2022, the company expects revenues between $415 million and $425 million. Non-GAAP income from operations is expected to be between $199 million and $204 million and non-GAAP earnings per share are anticipated to be between $2.06 and $2.11.
Wall Street analysts expect the company to earn $2.08 per share on revenue of $423.28 million.
INMD closed Monday's trading at $25.61, up 1.99%.
5. uniQure N.V. (QURE) has a clinical trial catalyst to watch in the coming months.
The company expects to present one-year safety and biomarker data from the 10-patient lower dose cohort of the U.S. randomized, controlled Phase I/II trial of AMT-130 in Huntington's disease this quarter.
Last month, the company initiated an IND-enabling dose-ranging study of AMT-260, a potential treatment for refractory temporal lobe epilepsy. A Good Laboratory Practices (GLP) toxicity study of AMT-260 in non-human primates is expected to be initiated in the second half of 2022 to support an IND submission in 2023.
The company expects to initiate a GLP toxicology study of AMT-191 in non-human primates in the second half of 2022, which is expected to support an IND submission in 2023. AMT-191 is being developed for the treatment of Fabry disease.
As of March 31, 2022, the company held cash and cash equivalents of $524.9 million.
QURE closed Monday's trading at $15.77, up 5.56%.
6. Semler Scientific Inc. (SMLR) reported lower net income for the three months ended March 31, 2022, as operating expenses increased 41% and revenue improved just 6%.
Net income for the first quarter of 2022 declined to $3.4 million or $0.41 per share from $4.9 million or $0.60 per share in the year-ago quarter. Revenue for the quarter was $14.0 million, an increase of 6% over $13.2 million reported in the year-ago quarter.
Semler Scientific expects revenue to range between $14.2 million and $15.2 million for the second quarter of 2022, and annual revenue to range from $58.0 million to $60.0 million.
Wall Street analysts expect the company to report revenue of $15.84 million for the second quarter and $59.57 million for the full-year of 2022.
The company's cash on hand totaled $38.4 million at March 31, 2022.
SMLR closed Monday's trading at $47.34, up 2.94%.
7. Tactile Systems Technology Inc. (TCMD), a medical technology company, has reported 12% revenue growth for the first quarter ended March 31, 2022, and has reaffirmed its total revenue guidance for full-year 2022.
Non-GAAP net loss for the first quarter of 2022 widened to $8.4 million from $1.5 million in first quarter of 2021. On a per share basis, net loss was $0.78 in the first quarter of 2022 compared to a net loss of $0.12 per share in the first quarter of 2021.
Total revenue in the first quarter of 2022 increased to $48.0 million from $42.8 million in the year-ago comparable quarter.
Looking ahead to full-year 2022, the company continues to expect total revenue in the range of $235.0 million to $240.0 million, up from $208.1 million in 2021, reflecting growth of roughly 13% to 15% year-over-year.
Wall Street analysts expect the company to report revenue in the range of $235.3 million to $237.4 million in 2022.
TCMD closed Monday's trading at $17.91, up 6.10%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc. (ABIO) has revealed that it is in the process of evaluating options for creating stockholder value, including potential development of its assets, partnering and other strategic options. ABIO closed Monday's trading at $2.37. Addus HomeCare Corp. (ADUS), a provider of home care services, has reported better-than-expected earnings for the first quarter of 2022 while revenue missed analysts' estimate. | ARCA biopharma Inc. (ABIO) has revealed that it is in the process of evaluating options for creating stockholder value, including potential development of its assets, partnering and other strategic options. ABIO closed Monday's trading at $2.37. Semler Scientific Inc. (SMLR) reported lower net income for the three months ended March 31, 2022, as operating expenses increased 41% and revenue improved just 6%. | ARCA biopharma Inc. (ABIO) has revealed that it is in the process of evaluating options for creating stockholder value, including potential development of its assets, partnering and other strategic options. ABIO closed Monday's trading at $2.37. For the first quarter of 2022, the company reported non-GAAP net income of $34.1 million or $0.40 per share on revenue of $85.9 million. | ARCA biopharma Inc. (ABIO) has revealed that it is in the process of evaluating options for creating stockholder value, including potential development of its assets, partnering and other strategic options. ABIO closed Monday's trading at $2.37. The company has plans to explore its drug candidate AXS-05 in a pivotal Phase 2/3 trial in smoking cessation, and information on the timing of initiation of this study is expected to be provided this year. |
29015.0 | 2022-04-28 00:00:00 UTC | French renewables firm Albioma confirms takeover deal with KKR | ABIO | https://www.nasdaq.com/articles/french-renewables-firm-albioma-confirms-takeover-deal-with-kkr | nan | nan | Adds detail, shares
April 28 (Reuters) - U.S. buyout firm KKR KKR.N has reached a deal to buy France's Albioma ABIO.PA for 50 euros per share, the renewables power producer said on Thursday, sending its shares up 15% in morning trade.
The stock was trading at 50.30 euros at 0900 GMT.
Albioma said the offer - which includes an additional 84 cent cash dividend - represents a 52% premium to its closing price on March 7, before reports that KKR was in the early stages of discussing a bid sent prices soaring.
"The offer price seems to us rather ungenerous, given the group's fundamentals, the ongoing shift towards 100% renewable and anticipated earnings growth from 2023," said Portzamparc analyst Nicolas Royot.
Midcap Partners, however, called the premium "generous" in light of the group's ongoing exposure to coal which has weighed on its share price.
Albioma's market value after the announcement had risen to around 1.7 billion euros ($1.8 billion).
Albioma operates a hybrid coal thermal plant in Reunion, which it is in the process of converting to 100% biomass using bagasse, forest wood and imported pellets.
It aims to completely stop using coal there by the end of 2023.
"KKR fully supports the group's strategy to approach 100% renewable energy by 2030," Albioma said in a statement, adding that the firm would preserve the company's jobs and corporate identity.
It said state-owned bank and shareholder Bpifrance would be investing alongside KKR.
European countries have been looking increasingly to renewable energy as an escalating economic war following Russia's invasion of Ukraine threatens the region's gas supplies.
($1 = 0.9511 euros)
(Reporting by Sarah Morland; editing by Jacqueline Wong and Jason Neely)
((sarah.morland@thomsonreuters.com; +48 58 769 65 92;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds detail, shares April 28 (Reuters) - U.S. buyout firm KKR KKR.N has reached a deal to buy France's Albioma ABIO.PA for 50 euros per share, the renewables power producer said on Thursday, sending its shares up 15% in morning trade. Albioma operates a hybrid coal thermal plant in Reunion, which it is in the process of converting to 100% biomass using bagasse, forest wood and imported pellets. "KKR fully supports the group's strategy to approach 100% renewable energy by 2030," Albioma said in a statement, adding that the firm would preserve the company's jobs and corporate identity. | Adds detail, shares April 28 (Reuters) - U.S. buyout firm KKR KKR.N has reached a deal to buy France's Albioma ABIO.PA for 50 euros per share, the renewables power producer said on Thursday, sending its shares up 15% in morning trade. Albioma's market value after the announcement had risen to around 1.7 billion euros ($1.8 billion). "KKR fully supports the group's strategy to approach 100% renewable energy by 2030," Albioma said in a statement, adding that the firm would preserve the company's jobs and corporate identity. | Adds detail, shares April 28 (Reuters) - U.S. buyout firm KKR KKR.N has reached a deal to buy France's Albioma ABIO.PA for 50 euros per share, the renewables power producer said on Thursday, sending its shares up 15% in morning trade. Albioma said the offer - which includes an additional 84 cent cash dividend - represents a 52% premium to its closing price on March 7, before reports that KKR was in the early stages of discussing a bid sent prices soaring. "KKR fully supports the group's strategy to approach 100% renewable energy by 2030," Albioma said in a statement, adding that the firm would preserve the company's jobs and corporate identity. | Adds detail, shares April 28 (Reuters) - U.S. buyout firm KKR KKR.N has reached a deal to buy France's Albioma ABIO.PA for 50 euros per share, the renewables power producer said on Thursday, sending its shares up 15% in morning trade. Midcap Partners, however, called the premium "generous" in light of the group's ongoing exposure to coal which has weighed on its share price. Albioma's market value after the announcement had risen to around 1.7 billion euros ($1.8 billion). |
29016.0 | 2022-04-04 00:00:00 UTC | Health Care Sector Update for 04/04/2022: SAGE, USPH, ABIO, SLS | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-04-04-2022%3A-sage-usph-abio-sls | nan | nan | (Corrects to show correct name of Sage's drug candidate in third paragraph.)
Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%.
The Nasdaq Biotechnology index, however, was climbing 2% in late trade.
In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-718 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. Patients saw improvement from baseline levels on several measurements of executive functions and in their learning and memory skills, the company said, adding there were no reports of serious adverse events or deaths linked to the trial.
US Physical Therapy (USPH) rose 4.3% after the outpatient treatment chain announced its $11.5 million purchase of a 70% stake in of Madden and Gilbert Physical Therapy, which operates six clinics in south central Pennsylvania and generates more than $7.5 million in yearly revenue.
Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint.
Sellas Life Sciences Group (SLS) tumbled as much as 40% on Friday to touch a 16-month low after the biopharmaceuticals company priced a $25 million public offering of nearly 4.63 million common shares at $5.40 apiece, or more than 34% under its last closing price. Investors also received an equal number of five-year warrants exercisable at $5.40 a share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-718 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. Patients saw improvement from baseline levels on several measurements of executive functions and in their learning and memory skills, the company said, adding there were no reports of serious adverse events or deaths linked to the trial. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. (Corrects to show correct name of Sage's drug candidate in third paragraph.) Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%. In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-718 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. (Corrects to show correct name of Sage's drug candidate in third paragraph.) Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%. |
29017.0 | 2022-04-01 00:00:00 UTC | Health Care Sector Update for 04/01/2022: SAGE, USPH, ABIO, SLS | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-04-01-2022%3A-sage-usph-abio-sls | nan | nan | Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%.
The Nasdaq Biotechnology index, however, was climbing 2% in late trade.
In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-178 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. Patients saw improvement from baseline levels on several measurements of executive functions and in their learning and memory skills, the company said, adding there were no reports of serious adverse events or deaths linked to the trial.
US Physical Therapy (USPH) rose 4.3% after the outpatient treatment chain announced its $11.5 million purchase of a 70% stake in of Madden and Gilbert Physical Therapy, which operates six clinics in south central Pennsylvania and generates more than $7.5 million in yearly revenue.
Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint.
Sellas Life Sciences Group (SLS) tumbled as much as 40% on Friday to touch a 16-month low after the biopharmaceuticals company priced a $25 million public offering of nearly 4.63 million common shares at $5.40 apiece, or more than 34% under its last closing price. Investors also received an equal number of five-year warrants exercisable at $5.40 a share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-178 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. Patients saw improvement from baseline levels on several measurements of executive functions and in their learning and memory skills, the company said, adding there were no reports of serious adverse events or deaths linked to the trial. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%. In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-178 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%. In company news, Sage Therapeutics (SAGE) added nearly 12% after saying its SAGE-178 drug candidate showed "promising" results during phase II testing in patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease. | Among decliners, ARCA Biopharma (ABIO) was down 4.1%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks added to their midday gains this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.5%. The Nasdaq Biotechnology index, however, was climbing 2% in late trade. |
29018.0 | 2022-04-01 00:00:00 UTC | Health Care Sector Update for 04/01/2022: USPH,ABIO,SLS | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-04-01-2022%3A-usphabiosls | nan | nan | Health care stocks were edging higher this afternoon, with the NYSE Health Care Index rising 0.2% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.1%.
The Nasdaq Biotechnology index, however, was climbing 1.1% in recent trade.
In company news, US Physical Therapy (USPH) rose 3.9% after the outpatient treatment chain announced its $11.5 million purchase of a 70% stake in of Madden and Gilbert Physical Therapy, which operates six clinics in south central Pennsylvania and generates more than $7.5 million in yearly revenue.
ARCA Biopharma (ABIO) was down 5.7%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint.
Sellas Life Sciences Group (SLS) tumbled as much as 40% on Friday to touch a 16-month low after the biopharmaceuticals company priced a $25 million public offering of nearly 4.63 million common shares at $5.40 apiece, or more than 34% under its last closing price. Investors also received an equal number of five-year warrants exercisable at $5.40 a share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA Biopharma (ABIO) was down 5.7%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. In company news, US Physical Therapy (USPH) rose 3.9% after the outpatient treatment chain announced its $11.5 million purchase of a 70% stake in of Madden and Gilbert Physical Therapy, which operates six clinics in south central Pennsylvania and generates more than $7.5 million in yearly revenue. Sellas Life Sciences Group (SLS) tumbled as much as 40% on Friday to touch a 16-month low after the biopharmaceuticals company priced a $25 million public offering of nearly 4.63 million common shares at $5.40 apiece, or more than 34% under its last closing price. | ARCA Biopharma (ABIO) was down 5.7%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks were edging higher this afternoon, with the NYSE Health Care Index rising 0.2% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.1%. In company news, US Physical Therapy (USPH) rose 3.9% after the outpatient treatment chain announced its $11.5 million purchase of a 70% stake in of Madden and Gilbert Physical Therapy, which operates six clinics in south central Pennsylvania and generates more than $7.5 million in yearly revenue. | ARCA Biopharma (ABIO) was down 5.7%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks were edging higher this afternoon, with the NYSE Health Care Index rising 0.2% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.1%. In company news, US Physical Therapy (USPH) rose 3.9% after the outpatient treatment chain announced its $11.5 million purchase of a 70% stake in of Madden and Gilbert Physical Therapy, which operates six clinics in south central Pennsylvania and generates more than $7.5 million in yearly revenue. | ARCA Biopharma (ABIO) was down 5.7%, paring a portion of its more than 23% morning decline, after saying its phase 2b trial evaluating the lower and higher doses of rNAPc2 for the potential treatment of hospitalized COVID-19 patients failed to achieve its primary endpoint. Health care stocks were edging higher this afternoon, with the NYSE Health Care Index rising 0.2% while the SPDR Health Care Select Sector ETF (XLV) was up less than 0.1%. The Nasdaq Biotechnology index, however, was climbing 1.1% in recent trade. |
29019.0 | 2022-01-09 00:00:00 UTC | ARCA biopharma Inc Shares Approach 52-Week Low - Market Mover | ABIO | https://www.nasdaq.com/articles/arca-biopharma-inc-shares-approach-52-week-low-market-mover | nan | nan | ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. The stock is currently down 5.1% year-to-date, down 51.7% over the past 12 months, and down 96.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%.
Trading Activity
Trading volume this week was 1.2% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9.
Technical Indicators
The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
MACD, a trend-following momentum indicator, indicates a downward trend.
The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date beats the peer average by -45.1%
The company's stock price performance over the past 12 months lags the peer average by -1436.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -1436.0% | ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought. | ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -1436.0% This story was produced by the Kwhen Automated News Generator. | ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought. |
29020.0 | 2021-12-30 00:00:00 UTC | ARCA biopharma Inc Shares Close in on 52-Week Low - Market Mover | ABIO | https://www.nasdaq.com/articles/arca-biopharma-inc-shares-close-in-on-52-week-low-market-mover | nan | nan | ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. The stock is currently down 44.4% year-to-date, down 46.4% over the past 12 months, and down 95.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%.
Trading Activity
Trading volume this week was 17.2% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8.
Technical Indicators
The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by -268.9%
The company's stock price performance over the past 12 months lags the peer average by -299.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8. The stock closed below its Bollinger band, indicating it may be oversold. | ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought. | ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -268.9% The company's stock price performance over the past 12 months lags the peer average by -299.0% This story was produced by the Kwhen Automated News Generator. | ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought. |
29021.0 | 2021-10-29 00:00:00 UTC | Health Care Sector Update for 10/29/2021: ABBV, ABIO, ADCT | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-10-29-2021%3A-abbv-abio-adct-2021-10-29 | nan | nan | Health care stocks were muted ahead of the opening bell on Friday. The Health Care SPDR (XLV) was flat while the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower.
AbbVie (ABBV) rose 2.6% after the drug maker reported higher Q3 EPS and revenue and raised its full-year profit guidance.
ARCA biopharma (ABIO) was 12% higher after the Data and Safety Monitoring Committee recommended the completion of the ASPEN-COVID-19 phase 2b clinical trial with no alterations on the trial design.
ADC Therapeutics (ADCT) gained 4.4% on after the European Medicines Agency validated its marketing authorization application for Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma (ABIO) was 12% higher after the Data and Safety Monitoring Committee recommended the completion of the ASPEN-COVID-19 phase 2b clinical trial with no alterations on the trial design. The Health Care SPDR (XLV) was flat while the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower. AbbVie (ABBV) rose 2.6% after the drug maker reported higher Q3 EPS and revenue and raised its full-year profit guidance. | ARCA biopharma (ABIO) was 12% higher after the Data and Safety Monitoring Committee recommended the completion of the ASPEN-COVID-19 phase 2b clinical trial with no alterations on the trial design. Health care stocks were muted ahead of the opening bell on Friday. The Health Care SPDR (XLV) was flat while the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower. | ARCA biopharma (ABIO) was 12% higher after the Data and Safety Monitoring Committee recommended the completion of the ASPEN-COVID-19 phase 2b clinical trial with no alterations on the trial design. The Health Care SPDR (XLV) was flat while the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma (ABIO) was 12% higher after the Data and Safety Monitoring Committee recommended the completion of the ASPEN-COVID-19 phase 2b clinical trial with no alterations on the trial design. Health care stocks were muted ahead of the opening bell on Friday. The Health Care SPDR (XLV) was flat while the iShares NASDAQ Biotechnology Index (IBB) was 0.2% lower. |
29022.0 | 2021-10-29 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday | ABIO | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-friday-2021-10-29 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Good morning, investor! It’s the last day of the trading week and we’re starting it with a dive into the biggest pre-market stock movers for Friday!
Source: f11photo/Shutterstock.com
We’ve got plenty of news moving shares today. That includes multiple earnings reports, business deals, and more.
Let’s jump into those pre-market stock movers below!
Pre-Market Stock Movers: 10 Top Gainers
ARCA biopharma (NASDAQ:ABIO) stock is soaring more than 19% after a committee recommended it continue its Covid-19 treatment trial.
DBV Technologies (NASDAQ:DBVT) shares are increasing over 18% as the penny stock recovers from a dip on Thursday.
BEST (NYSE:BEST) stock is surging more than 14% on news of it selling its business in China.
WiMi Hologram Cloud (NASDAQ:WIMI) shares are gaining over 12% likely due to Facebook’s (NASDAQ:FB) Meta plans.
A10 Networks (NYSE:ATEN) stock is running more than 11% higher after releasing earnings for its third quarter of 2021.
Tailwind Two Acquisition (NYSE:TWNT) shares are rising over 10% after the SPAC announced a merger agreement with Terran Orbital.
Soligenix (NASDAQ:SNGX) stock is climbing more than 10% despite a lack of news this morning.
Entasis Therapeutics (NASDAQ:ETTX) shares are jumping over 10% after announcing it will release its most recent earnings report next week.
Getnet Adquirência (NASDAQ:GET) stock is getting a more than 9% boost on no apparent news.
AdvanSix (NYSE:ASIX) shares are up over 9% with the release of its Q3 2021 earnings report.
7 Top Stocks to Buy On Any Dip If You Get the Chance in Q4
10 Top Losers
Retail Value (NYSE:RVI) stock is plummeting nearly 74% as retail traders eye the stock.
RiverNorth Opportunities Fund, Inc. Rights (NYSE:RIVR) are diving close to 39% during pre-market trading.
ALFI (NASDAQ:ALF) shares are taking a more than 20% beating after a decent rally on Thursday.
Zendesk (NYSE:ZEN) stock is dropping over 19% following the release of its most recent earnings report.
Microvision (NASDAQ:MVIS) shares are falling more than 17% with the release of its Q3 2021 earnings report.
LiveOne (NASDAQ:LVO) stock is decreasing almost 14% after releasing its earnings report for its fiscal second quarter of 2022.
HCW Biologics (NASDAQ:HCWB) shares are retreating over 13% after jumping on FDA news yesterday.
Glimpse Group (NASDAQ:VRAR) stock is slipping more than 12% after a rally yesterday on Frankfurt Stock Exchange listing news.
Western Digital (NASDAQ:WDC) shares are dipping 11% with the release of its fiscal Q1 2022 earnings report.
4D Molecular Therapeutics (NASDAQ:FDMT) stock closes out our pre-market stock movers down over 10% after announcing the pricing of a public offering for its common stock.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pre-Market Stock Movers: 10 Top Gainers ARCA biopharma (NASDAQ:ABIO) stock is soaring more than 19% after a committee recommended it continue its Covid-19 treatment trial. Tailwind Two Acquisition (NYSE:TWNT) shares are rising over 10% after the SPAC announced a merger agreement with Terran Orbital. Entasis Therapeutics (NASDAQ:ETTX) shares are jumping over 10% after announcing it will release its most recent earnings report next week. | Pre-Market Stock Movers: 10 Top Gainers ARCA biopharma (NASDAQ:ABIO) stock is soaring more than 19% after a committee recommended it continue its Covid-19 treatment trial. Entasis Therapeutics (NASDAQ:ETTX) shares are jumping over 10% after announcing it will release its most recent earnings report next week. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. | Pre-Market Stock Movers: 10 Top Gainers ARCA biopharma (NASDAQ:ABIO) stock is soaring more than 19% after a committee recommended it continue its Covid-19 treatment trial. 7 Top Stocks to Buy On Any Dip If You Get the Chance in Q4 10 Top Losers Retail Value (NYSE:RVI) stock is plummeting nearly 74% as retail traders eye the stock. 4D Molecular Therapeutics (NASDAQ:FDMT) stock closes out our pre-market stock movers down over 10% after announcing the pricing of a public offering for its common stock. | Pre-Market Stock Movers: 10 Top Gainers ARCA biopharma (NASDAQ:ABIO) stock is soaring more than 19% after a committee recommended it continue its Covid-19 treatment trial. Entasis Therapeutics (NASDAQ:ETTX) shares are jumping over 10% after announcing it will release its most recent earnings report next week. AdvanSix (NYSE:ASIX) shares are up over 9% with the release of its Q3 2021 earnings report. |
29023.0 | 2021-10-29 00:00:00 UTC | Pre-market Movers: RVI, ABIO, ALF, ZEN, DBVT… | ABIO | https://www.nasdaq.com/articles/pre-market-movers%3A-rvi-abio-alf-zen-dbvt...-2021-10-29 | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT).
In the Green
ARCA biopharma, Inc. (ABIO) is up over 23% at $3.23 DBV Technologies S.A. (DBVT) is up over 19% at $3.66 WiMi Hologram Cloud Inc. (WIMI) is up over 16% at $5.08 Vyant Bio, Inc. (VYNT) is up over 12% at $2.45 Tailwind Two Acquisition Corp. (TWNT) is up over 11% at $11.04 Exela Technologies, Inc. (XELA) is up over 10% at $2.00 Getnet Adquirência e Serviços para Meios de Pagamento S.A. (GET) is up over 9% at $1.84 United States Steel Corporation (X) is up over 7% at $25.23 Marpai, Inc. (MRAI) is up over 7% at $6.10 Soligenix, Inc. (SNGX) is up over 7% at $1.06
In the Red
Retail Value Inc. (RVI) is down over 73% at $7.16 Alfi, Inc. (ALF) is down over 21% at $4.47 Zendesk, Inc. (ZEN) is down over 19% at $96.28 MicroVision, Inc. (MVIS) is down over 17% at $7.46 The Glimpse Group, Inc. (VRAR) is down over 13% at $12.64 Western Digital Corporation (WDC) is down over 11% at $50.80 HCW Biologics Inc. (HCWB) is down over 11% at $4.20 Rafael Holdings, Inc. (RFL) is down over 10% at $7.25 Valneva SE (VALN) is down over 8% at $41.39 Pulmatrix, Inc. (PULM) is down over 8% at $0.91 KemPharm, Inc. (KMPH) is down over 4% at $9.55
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green ARCA biopharma, Inc. (ABIO) is up over 23% at $3.23 DBV Technologies S.A. (DBVT) is up over 19% at $3.66 WiMi Hologram Cloud Inc. (WIMI) is up over 16% at $5.08 Vyant Bio, Inc. (VYNT) is up over 12% at $2.45 Tailwind Two Acquisition Corp. (TWNT) is up over 11% at $11.04 Exela Technologies, Inc. (XELA) is up over 10% at $2.00 Getnet Adquirência e Serviços para Meios de Pagamento S.A. (GET) is up over 9% at $1.84 United States Steel Corporation (X) is up over 7% at $25.23 Marpai, Inc. (MRAI) is up over 7% at $6.10 Soligenix, Inc. (SNGX) is up over 7% at $1.06 In the Red Retail Value Inc. (RVI) is down over 73% at $7.16 Alfi, Inc. (ALF) is down over 21% at $4.47 Zendesk, Inc. (ZEN) is down over 19% at $96.28 MicroVision, Inc. (MVIS) is down over 17% at $7.46 The Glimpse Group, Inc. (VRAR) is down over 13% at $12.64 Western Digital Corporation (WDC) is down over 11% at $50.80 HCW Biologics Inc. (HCWB) is down over 11% at $4.20 Rafael Holdings, Inc. (RFL) is down over 10% at $7.25 Valneva SE (VALN) is down over 8% at $41.39 Pulmatrix, Inc. (PULM) is down over 8% at $0.91 KemPharm, Inc. (KMPH) is down over 4% at $9.55 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT). | In the Green ARCA biopharma, Inc. (ABIO) is up over 23% at $3.23 DBV Technologies S.A. (DBVT) is up over 19% at $3.66 WiMi Hologram Cloud Inc. (WIMI) is up over 16% at $5.08 Vyant Bio, Inc. (VYNT) is up over 12% at $2.45 Tailwind Two Acquisition Corp. (TWNT) is up over 11% at $11.04 Exela Technologies, Inc. (XELA) is up over 10% at $2.00 Getnet Adquirência e Serviços para Meios de Pagamento S.A. (GET) is up over 9% at $1.84 United States Steel Corporation (X) is up over 7% at $25.23 Marpai, Inc. (MRAI) is up over 7% at $6.10 Soligenix, Inc. (SNGX) is up over 7% at $1.06 In the Red Retail Value Inc. (RVI) is down over 73% at $7.16 Alfi, Inc. (ALF) is down over 21% at $4.47 Zendesk, Inc. (ZEN) is down over 19% at $96.28 MicroVision, Inc. (MVIS) is down over 17% at $7.46 The Glimpse Group, Inc. (VRAR) is down over 13% at $12.64 Western Digital Corporation (WDC) is down over 11% at $50.80 HCW Biologics Inc. (HCWB) is down over 11% at $4.20 Rafael Holdings, Inc. (RFL) is down over 10% at $7.25 Valneva SE (VALN) is down over 8% at $41.39 Pulmatrix, Inc. (PULM) is down over 8% at $0.91 KemPharm, Inc. (KMPH) is down over 4% at $9.55 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT). | In the Green ARCA biopharma, Inc. (ABIO) is up over 23% at $3.23 DBV Technologies S.A. (DBVT) is up over 19% at $3.66 WiMi Hologram Cloud Inc. (WIMI) is up over 16% at $5.08 Vyant Bio, Inc. (VYNT) is up over 12% at $2.45 Tailwind Two Acquisition Corp. (TWNT) is up over 11% at $11.04 Exela Technologies, Inc. (XELA) is up over 10% at $2.00 Getnet Adquirência e Serviços para Meios de Pagamento S.A. (GET) is up over 9% at $1.84 United States Steel Corporation (X) is up over 7% at $25.23 Marpai, Inc. (MRAI) is up over 7% at $6.10 Soligenix, Inc. (SNGX) is up over 7% at $1.06 In the Red Retail Value Inc. (RVI) is down over 73% at $7.16 Alfi, Inc. (ALF) is down over 21% at $4.47 Zendesk, Inc. (ZEN) is down over 19% at $96.28 MicroVision, Inc. (MVIS) is down over 17% at $7.46 The Glimpse Group, Inc. (VRAR) is down over 13% at $12.64 Western Digital Corporation (WDC) is down over 11% at $50.80 HCW Biologics Inc. (HCWB) is down over 11% at $4.20 Rafael Holdings, Inc. (RFL) is down over 10% at $7.25 Valneva SE (VALN) is down over 8% at $41.39 Pulmatrix, Inc. (PULM) is down over 8% at $0.91 KemPharm, Inc. (KMPH) is down over 4% at $9.55 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT). | In the Green ARCA biopharma, Inc. (ABIO) is up over 23% at $3.23 DBV Technologies S.A. (DBVT) is up over 19% at $3.66 WiMi Hologram Cloud Inc. (WIMI) is up over 16% at $5.08 Vyant Bio, Inc. (VYNT) is up over 12% at $2.45 Tailwind Two Acquisition Corp. (TWNT) is up over 11% at $11.04 Exela Technologies, Inc. (XELA) is up over 10% at $2.00 Getnet Adquirência e Serviços para Meios de Pagamento S.A. (GET) is up over 9% at $1.84 United States Steel Corporation (X) is up over 7% at $25.23 Marpai, Inc. (MRAI) is up over 7% at $6.10 Soligenix, Inc. (SNGX) is up over 7% at $1.06 In the Red Retail Value Inc. (RVI) is down over 73% at $7.16 Alfi, Inc. (ALF) is down over 21% at $4.47 Zendesk, Inc. (ZEN) is down over 19% at $96.28 MicroVision, Inc. (MVIS) is down over 17% at $7.46 The Glimpse Group, Inc. (VRAR) is down over 13% at $12.64 Western Digital Corporation (WDC) is down over 11% at $50.80 HCW Biologics Inc. (HCWB) is down over 11% at $4.20 Rafael Holdings, Inc. (RFL) is down over 10% at $7.25 Valneva SE (VALN) is down over 8% at $41.39 Pulmatrix, Inc. (PULM) is down over 8% at $0.91 KemPharm, Inc. (KMPH) is down over 4% at $9.55 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT). |
29024.0 | 2021-10-03 00:00:00 UTC | Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation | ABIO | https://www.nasdaq.com/articles/heres-why-were-not-too-worried-about-arca-biopharmas-nasdaq%3Aabio-cash-burn-situation-0 | nan | nan | There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.
Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
When Might ARCA biopharma Run Out Of Money?
A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In June 2021, ARCA biopharma had US$63m in cash, and was debt-free. Looking at the last year, the company burnt through US$14m. Therefore, from June 2021 it had 4.5 years of cash runway. A runway of this length affords the company the time and space it needs to develop the business. Depicted below, you can see how its cash holdings have changed over time.
NasdaqCM:ABIO Debt to Equity History October 3rd 2021
How Is ARCA biopharma's Cash Burn Changing Over Time?
ARCA biopharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. The skyrocketing cash burn up 192% year on year certainly tests our nerves. That sort of ramp in expenditure is no doubt intended to generate worthwhile long term returns. ARCA biopharma makes us a little nervous due to its lack of substantial operating revenue. We prefer most of the stocks on this list of stocks that analysts expect to grow.
How Hard Would It Be For ARCA biopharma To Raise More Cash For Growth?
Given its cash burn trajectory, ARCA biopharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).
ARCA biopharma has a market capitalisation of US$43m and burnt through US$14m last year, which is 33% of the company's market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution.
So, Should We Worry About ARCA biopharma's Cash Burn?
On this analysis of ARCA biopharma's cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. Separately, we looked at different risks affecting the company and spotted 4 warning signs for ARCA biopharma (of which 2 are a bit unpleasant!) you should know about.
Of course ARCA biopharma may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History October 3rd 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? ARCA biopharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History October 3rd 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History October 3rd 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. | Given this risk, we thought we'd take a look at whether ARCA biopharma (NASDAQ:ABIO) shareholders should be worried about its cash burn. NasdaqCM:ABIO Debt to Equity History October 3rd 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? Given its cash burn trajectory, ARCA biopharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. |
29025.0 | 2021-04-06 00:00:00 UTC | Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation | ABIO | https://www.nasdaq.com/articles/heres-why-were-not-too-worried-about-arca-biopharmas-nasdaq%3Aabio-cash-burn-situation-2021 | nan | nan | Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.
So, the natural question for ARCA biopharma (NASDAQ:ABIO) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
When Might ARCA biopharma Run Out Of Money?
You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When ARCA biopharma last reported its balance sheet in December 2020, it had zero debt and cash worth US$49m. Importantly, its cash burn was US$7.7m over the trailing twelve months. That means it had a cash runway of about 6.3 years as of December 2020. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. Depicted below, you can see how its cash holdings have changed over time.
NasdaqCM:ABIO Debt to Equity History April 6th 2021
How Is ARCA biopharma's Cash Burn Changing Over Time?
Because ARCA biopharma isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by a very significant 61%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. ARCA biopharma makes us a little nervous due to its lack of substantial operating revenue. We prefer most of the stocks on this list of stocks that analysts expect to grow.
How Easily Can ARCA biopharma Raise Cash?
While ARCA biopharma does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.
ARCA biopharma's cash burn of US$7.7m is about 15% of its US$53m market capitalisation. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.
Is ARCA biopharma's Cash Burn A Worry?
As you can probably tell by now, we're not too worried about ARCA biopharma's cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. On another note, we conducted an in-depth investigation of the company, and identified 3 warning signs for ARCA biopharma (1 is a bit unpleasant!) that you should be aware of before investing here.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NasdaqCM:ABIO Debt to Equity History April 6th 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? So, the natural question for ARCA biopharma (NASDAQ:ABIO) shareholders is whether they should be concerned by its rate of cash burn. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. | NasdaqCM:ABIO Debt to Equity History April 6th 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? So, the natural question for ARCA biopharma (NASDAQ:ABIO) shareholders is whether they should be concerned by its rate of cash burn. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. | So, the natural question for ARCA biopharma (NASDAQ:ABIO) shareholders is whether they should be concerned by its rate of cash burn. NasdaqCM:ABIO Debt to Equity History April 6th 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. | So, the natural question for ARCA biopharma (NASDAQ:ABIO) shareholders is whether they should be concerned by its rate of cash burn. NasdaqCM:ABIO Debt to Equity History April 6th 2021 How Is ARCA biopharma's Cash Burn Changing Over Time? Just because a business does not make any money, does not mean that the stock will go down. |
29026.0 | 2020-11-23 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Ideanomics, DPW, Ashford Hospitality, SmileDirectClub | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-ideanomics-dpw-ashford-hospitality-smiledirectclub-2020-11-23 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes jumped on Monday as data showed U.S. business activity in November expanded at its fastest rate in more than five years, an indication that the economy was making progress at clambering out of a pandemic-driven recession..N
At 10:06 am ET, the Dow Jones Industrial Average .DJI was up 0.91% at 29,530.8. The S&P 500 .SPX was up 0.86% at 3,587.97 and the Nasdaq Composite .IXIC was up 0.49% at 11,913.193. The top three S&P 500 .PG.INX percentage gainers: ** Occidental Petroleum Corp , up 7.6% ** Gap Inc , up 6.2% ** Valero Energy Corp , up 6% The top three S&P 500 .PL.INX percentage losers: ** Catalent Inc , down 3.2% ** Newmont Corporation , down 2.8% ** Kellogg Co , down 1.8% The top three NYSE .PG.N percentage gainers: ** DPW Holdings Inc , up 42.7% ** Renren Inc , up 23.8% ** Switchback Energy Acquisition Corp , up 22.7% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality Trust Inc , down 20.4% ** Legacy Acquisition Corp , down 13.5% ** Montrose Environmental Group Inc , down 13% The top Nasdaq .PG.O percentage gainers: ** Ideanomics Inc , up 70.9 % ** Kaixin Auto Holdings , up 61.4 % The top three Nasdaq .PL.O percentage losers: ** Bellerophon Therapeutics Inc , down 21.6 % ** Niu Technologies , down 13 % ** BioLine RX Ltd , down 10.2 % ** Tesla Inc TSLA.O: up 6.6%
BUZZ-Wedbush raises PT on rising global electric vehicle demand ** Baozun Inc BZUN.O: down 1.2%
BUZZ-Falls as Q3 rev misses estimates ** Foot Locker Inc FL.N: down 1.2%
BUZZ-Piper Sandler cuts to 'underweight' on COVID-19 pressure ** Roku Inc ROKU.O: up 2.9%
BUZZ-Gains after Needham raises PT on advertising strength ** Southwest Airlines Co LUV.N: up 0.8% ** Alaska Air Group Inc ALK.N: up 1.7% ** United Airlines Holdings Inc UAL.O: up 2.2% ** Delta Air Lines Inc DAL.N: up 1.9% ** American Airlines Group Inc AAL.O: up 3.0% ** Spirit Airlines Inc SAVE.N: up 2.7% ** Royal Caribbean Cruises Ltd RCL.N: up 2.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N: up 1.8% ** Carnival Corp CCL.N: up 2.8%
BUZZ-Airlines, cruise operators gain on new vaccine headway ** Sonoma Pharmaceuticals Inc SNOA.O: up 6.2%
BUZZ-Gains on strong Q2 results ** Goldman Sachs Group Inc GS.N: up 2.3% ** JPMorgan Chase & Co JPM.N: up 1.7% ** Morgan Stanley MS.N: up 3.2% ** Bank of America Corp BAC.N: up 1.8% ** Wells Fargo & Co WFC.N: up 2.6% ** Citigroup Inc C.N: up 1.8%
BUZZ-U.S. big banks rise on 'vaccine for the world' data ** Altice USA Inc ATUS.N: up 9.1%
BUZZ-Jumps on $2.5 bln buyback ** FuboTV Inc FUBO.N: up 9.4%
BUZZ-Rises after brokerage raises PT on connected TV upside ** Apex Technology Acquisition Corp APXT.O: up 3%
BUZZ-Rises on $2 bln merger ** HP Inc HPQ.N: up 2.2%
BUZZ-Up as Evercore raises PT in run-up to Q4 results ** Niu Technologies NIU.O: down 13.0%
BUZZ-Falls on Q3 revenue miss, dour outlook ** Ideanomics Inc IDEX.O: up 70.9%
BUZZ-Raises stake in e-tractor developer, shares soar ** China Online Education Group COE.N: up 2.4%
BUZZ-Rises on Q3 results beat ** Daqo New Energy Corp DQ.N: down 5.6%
BUZZ-Drops after Q3 profit miss ** Cytokinetics Inc CYTK.O: down 2.7%
BUZZ-Falls as Amgen ends pact over heart drugs development ** Kemper Corp KMPR.N: up 1.5%
BUZZ-To buy American Access Casualty in $370 mln deal ** SmileDirectClub Inc SDC.O: up 10.8%
BUZZ-Rises on partnership with MetLife ** ARCA Biopharma Inc ABIO.O: up 3.9%
BUZZ-Rises on FDA's 'fast-track' tag for COVID-19 treatment
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.02%
Consumer Discretionary
.SPLRCD
up 0.75%
Consumer Staples
.SPLRCS
up 0.22%
Energy
.SPNY
up 3.49%
Financial
.SPSY
up 1.51%
Health
.SPXHC
up 0.09%
Industrial
.SPLRCI
up 1.39%
Information Technology
.SPLRCT
up 0.63%
Materials
.SPLRCM
up 1.20%
Real Estate
.SPLRCR
up 0.36%
Utilities
.SPLRCU
up 0.24%
(Compiled by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental Petroleum Corp , up 7.6% ** Gap Inc , up 6.2% ** Valero Energy Corp , up 6% The top three S&P 500 .PL.INX percentage losers: ** Catalent Inc , down 3.2% ** Newmont Corporation , down 2.8% ** Kellogg Co , down 1.8% The top three NYSE .PG.N percentage gainers: ** DPW Holdings Inc , up 42.7% ** Renren Inc , up 23.8% ** Switchback Energy Acquisition Corp , up 22.7% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality Trust Inc , down 20.4% ** Legacy Acquisition Corp , down 13.5% ** Montrose Environmental Group Inc , down 13% The top Nasdaq .PG.O percentage gainers: ** Ideanomics Inc , up 70.9 % ** Kaixin Auto Holdings , up 61.4 % The top three Nasdaq .PL.O percentage losers: ** Bellerophon Therapeutics Inc , down 21.6 % ** Niu Technologies , down 13 % ** BioLine RX Ltd , down 10.2 % ** Tesla Inc TSLA.O: up 6.6% BUZZ-Wedbush raises PT on rising global electric vehicle demand ** Baozun Inc BZUN.O: down 1.2% BUZZ-Falls as Q3 rev misses estimates ** Foot Locker Inc FL.N: down 1.2% BUZZ-Piper Sandler cuts to 'underweight' on COVID-19 pressure ** Roku Inc ROKU.O: up 2.9% BUZZ-Gains after Needham raises PT on advertising strength ** Southwest Airlines Co LUV.N: up 0.8% ** Alaska Air Group Inc ALK.N: up 1.7% ** United Airlines Holdings Inc UAL.O: up 2.2% ** Delta Air Lines Inc DAL.N: up 1.9% ** American Airlines Group Inc AAL.O: up 3.0% ** Spirit Airlines Inc SAVE.N: up 2.7% ** Royal Caribbean Cruises Ltd RCL.N: up 2.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N: up 1.8% ** Carnival Corp CCL.N: up 2.8% BUZZ-Airlines, cruise operators gain on new vaccine headway ** Sonoma Pharmaceuticals Inc SNOA.O: up 6.2% BUZZ-Gains on strong Q2 results ** Goldman Sachs Group Inc GS.N: up 2.3% ** JPMorgan Chase & Co JPM.N: up 1.7% ** Morgan Stanley MS.N: up 3.2% ** Bank of America Corp BAC.N: up 1.8% ** Wells Fargo & Co WFC.N: up 2.6% ** Citigroup Inc C.N: up 1.8% BUZZ-U.S. big banks rise on 'vaccine for the world' data ** Altice USA Inc ATUS.N: up 9.1% BUZZ-Jumps on $2.5 bln buyback ** FuboTV Inc FUBO.N: up 9.4% BUZZ-Rises after brokerage raises PT on connected TV upside ** Apex Technology Acquisition Corp APXT.O: up 3% BUZZ-Rises on $2 bln merger ** HP Inc HPQ.N: up 2.2% BUZZ-Up as Evercore raises PT in run-up to Q4 results ** Niu Technologies NIU.O: down 13.0% BUZZ-Falls on Q3 revenue miss, dour outlook ** Ideanomics Inc IDEX.O: up 70.9% BUZZ-Raises stake in e-tractor developer, shares soar ** China Online Education Group COE.N: up 2.4% BUZZ-Rises on Q3 results beat ** Daqo New Energy Corp DQ.N: down 5.6% BUZZ-Drops after Q3 profit miss ** Cytokinetics Inc CYTK.O: down 2.7% BUZZ-Falls as Amgen ends pact over heart drugs development ** Kemper Corp KMPR.N: up 1.5% BUZZ-To buy American Access Casualty in $370 mln deal ** SmileDirectClub Inc SDC.O: up 10.8% BUZZ-Rises on partnership with MetLife ** ARCA Biopharma Inc ABIO.O: up 3.9% BUZZ-Rises on FDA's 'fast-track' tag for COVID-19 treatment The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Monday as data showed U.S. business activity in November expanded at its fastest rate in more than five years, an indication that the economy was making progress at clambering out of a pandemic-driven recession..N At 10:06 am ET, the Dow Jones Industrial Average .DJI was up 0.91% at 29,530.8. up 0.24% (Compiled by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental Petroleum Corp , up 7.6% ** Gap Inc , up 6.2% ** Valero Energy Corp , up 6% The top three S&P 500 .PL.INX percentage losers: ** Catalent Inc , down 3.2% ** Newmont Corporation , down 2.8% ** Kellogg Co , down 1.8% The top three NYSE .PG.N percentage gainers: ** DPW Holdings Inc , up 42.7% ** Renren Inc , up 23.8% ** Switchback Energy Acquisition Corp , up 22.7% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality Trust Inc , down 20.4% ** Legacy Acquisition Corp , down 13.5% ** Montrose Environmental Group Inc , down 13% The top Nasdaq .PG.O percentage gainers: ** Ideanomics Inc , up 70.9 % ** Kaixin Auto Holdings , up 61.4 % The top three Nasdaq .PL.O percentage losers: ** Bellerophon Therapeutics Inc , down 21.6 % ** Niu Technologies , down 13 % ** BioLine RX Ltd , down 10.2 % ** Tesla Inc TSLA.O: up 6.6% BUZZ-Wedbush raises PT on rising global electric vehicle demand ** Baozun Inc BZUN.O: down 1.2% BUZZ-Falls as Q3 rev misses estimates ** Foot Locker Inc FL.N: down 1.2% BUZZ-Piper Sandler cuts to 'underweight' on COVID-19 pressure ** Roku Inc ROKU.O: up 2.9% BUZZ-Gains after Needham raises PT on advertising strength ** Southwest Airlines Co LUV.N: up 0.8% ** Alaska Air Group Inc ALK.N: up 1.7% ** United Airlines Holdings Inc UAL.O: up 2.2% ** Delta Air Lines Inc DAL.N: up 1.9% ** American Airlines Group Inc AAL.O: up 3.0% ** Spirit Airlines Inc SAVE.N: up 2.7% ** Royal Caribbean Cruises Ltd RCL.N: up 2.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N: up 1.8% ** Carnival Corp CCL.N: up 2.8% BUZZ-Airlines, cruise operators gain on new vaccine headway ** Sonoma Pharmaceuticals Inc SNOA.O: up 6.2% BUZZ-Gains on strong Q2 results ** Goldman Sachs Group Inc GS.N: up 2.3% ** JPMorgan Chase & Co JPM.N: up 1.7% ** Morgan Stanley MS.N: up 3.2% ** Bank of America Corp BAC.N: up 1.8% ** Wells Fargo & Co WFC.N: up 2.6% ** Citigroup Inc C.N: up 1.8% BUZZ-U.S. big banks rise on 'vaccine for the world' data ** Altice USA Inc ATUS.N: up 9.1% BUZZ-Jumps on $2.5 bln buyback ** FuboTV Inc FUBO.N: up 9.4% BUZZ-Rises after brokerage raises PT on connected TV upside ** Apex Technology Acquisition Corp APXT.O: up 3% BUZZ-Rises on $2 bln merger ** HP Inc HPQ.N: up 2.2% BUZZ-Up as Evercore raises PT in run-up to Q4 results ** Niu Technologies NIU.O: down 13.0% BUZZ-Falls on Q3 revenue miss, dour outlook ** Ideanomics Inc IDEX.O: up 70.9% BUZZ-Raises stake in e-tractor developer, shares soar ** China Online Education Group COE.N: up 2.4% BUZZ-Rises on Q3 results beat ** Daqo New Energy Corp DQ.N: down 5.6% BUZZ-Drops after Q3 profit miss ** Cytokinetics Inc CYTK.O: down 2.7% BUZZ-Falls as Amgen ends pact over heart drugs development ** Kemper Corp KMPR.N: up 1.5% BUZZ-To buy American Access Casualty in $370 mln deal ** SmileDirectClub Inc SDC.O: up 10.8% BUZZ-Rises on partnership with MetLife ** ARCA Biopharma Inc ABIO.O: up 3.9% BUZZ-Rises on FDA's 'fast-track' tag for COVID-19 treatment The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Monday as data showed U.S. business activity in November expanded at its fastest rate in more than five years, an indication that the economy was making progress at clambering out of a pandemic-driven recession..N At 10:06 am ET, the Dow Jones Industrial Average .DJI was up 0.91% at 29,530.8. up 0.24% (Compiled by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental Petroleum Corp , up 7.6% ** Gap Inc , up 6.2% ** Valero Energy Corp , up 6% The top three S&P 500 .PL.INX percentage losers: ** Catalent Inc , down 3.2% ** Newmont Corporation , down 2.8% ** Kellogg Co , down 1.8% The top three NYSE .PG.N percentage gainers: ** DPW Holdings Inc , up 42.7% ** Renren Inc , up 23.8% ** Switchback Energy Acquisition Corp , up 22.7% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality Trust Inc , down 20.4% ** Legacy Acquisition Corp , down 13.5% ** Montrose Environmental Group Inc , down 13% The top Nasdaq .PG.O percentage gainers: ** Ideanomics Inc , up 70.9 % ** Kaixin Auto Holdings , up 61.4 % The top three Nasdaq .PL.O percentage losers: ** Bellerophon Therapeutics Inc , down 21.6 % ** Niu Technologies , down 13 % ** BioLine RX Ltd , down 10.2 % ** Tesla Inc TSLA.O: up 6.6% BUZZ-Wedbush raises PT on rising global electric vehicle demand ** Baozun Inc BZUN.O: down 1.2% BUZZ-Falls as Q3 rev misses estimates ** Foot Locker Inc FL.N: down 1.2% BUZZ-Piper Sandler cuts to 'underweight' on COVID-19 pressure ** Roku Inc ROKU.O: up 2.9% BUZZ-Gains after Needham raises PT on advertising strength ** Southwest Airlines Co LUV.N: up 0.8% ** Alaska Air Group Inc ALK.N: up 1.7% ** United Airlines Holdings Inc UAL.O: up 2.2% ** Delta Air Lines Inc DAL.N: up 1.9% ** American Airlines Group Inc AAL.O: up 3.0% ** Spirit Airlines Inc SAVE.N: up 2.7% ** Royal Caribbean Cruises Ltd RCL.N: up 2.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N: up 1.8% ** Carnival Corp CCL.N: up 2.8% BUZZ-Airlines, cruise operators gain on new vaccine headway ** Sonoma Pharmaceuticals Inc SNOA.O: up 6.2% BUZZ-Gains on strong Q2 results ** Goldman Sachs Group Inc GS.N: up 2.3% ** JPMorgan Chase & Co JPM.N: up 1.7% ** Morgan Stanley MS.N: up 3.2% ** Bank of America Corp BAC.N: up 1.8% ** Wells Fargo & Co WFC.N: up 2.6% ** Citigroup Inc C.N: up 1.8% BUZZ-U.S. big banks rise on 'vaccine for the world' data ** Altice USA Inc ATUS.N: up 9.1% BUZZ-Jumps on $2.5 bln buyback ** FuboTV Inc FUBO.N: up 9.4% BUZZ-Rises after brokerage raises PT on connected TV upside ** Apex Technology Acquisition Corp APXT.O: up 3% BUZZ-Rises on $2 bln merger ** HP Inc HPQ.N: up 2.2% BUZZ-Up as Evercore raises PT in run-up to Q4 results ** Niu Technologies NIU.O: down 13.0% BUZZ-Falls on Q3 revenue miss, dour outlook ** Ideanomics Inc IDEX.O: up 70.9% BUZZ-Raises stake in e-tractor developer, shares soar ** China Online Education Group COE.N: up 2.4% BUZZ-Rises on Q3 results beat ** Daqo New Energy Corp DQ.N: down 5.6% BUZZ-Drops after Q3 profit miss ** Cytokinetics Inc CYTK.O: down 2.7% BUZZ-Falls as Amgen ends pact over heart drugs development ** Kemper Corp KMPR.N: up 1.5% BUZZ-To buy American Access Casualty in $370 mln deal ** SmileDirectClub Inc SDC.O: up 10.8% BUZZ-Rises on partnership with MetLife ** ARCA Biopharma Inc ABIO.O: up 3.9% BUZZ-Rises on FDA's 'fast-track' tag for COVID-19 treatment The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Monday as data showed U.S. business activity in November expanded at its fastest rate in more than five years, an indication that the economy was making progress at clambering out of a pandemic-driven recession..N At 10:06 am ET, the Dow Jones Industrial Average .DJI was up 0.91% at 29,530.8. up 0.02% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Occidental Petroleum Corp , up 7.6% ** Gap Inc , up 6.2% ** Valero Energy Corp , up 6% The top three S&P 500 .PL.INX percentage losers: ** Catalent Inc , down 3.2% ** Newmont Corporation , down 2.8% ** Kellogg Co , down 1.8% The top three NYSE .PG.N percentage gainers: ** DPW Holdings Inc , up 42.7% ** Renren Inc , up 23.8% ** Switchback Energy Acquisition Corp , up 22.7% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality Trust Inc , down 20.4% ** Legacy Acquisition Corp , down 13.5% ** Montrose Environmental Group Inc , down 13% The top Nasdaq .PG.O percentage gainers: ** Ideanomics Inc , up 70.9 % ** Kaixin Auto Holdings , up 61.4 % The top three Nasdaq .PL.O percentage losers: ** Bellerophon Therapeutics Inc , down 21.6 % ** Niu Technologies , down 13 % ** BioLine RX Ltd , down 10.2 % ** Tesla Inc TSLA.O: up 6.6% BUZZ-Wedbush raises PT on rising global electric vehicle demand ** Baozun Inc BZUN.O: down 1.2% BUZZ-Falls as Q3 rev misses estimates ** Foot Locker Inc FL.N: down 1.2% BUZZ-Piper Sandler cuts to 'underweight' on COVID-19 pressure ** Roku Inc ROKU.O: up 2.9% BUZZ-Gains after Needham raises PT on advertising strength ** Southwest Airlines Co LUV.N: up 0.8% ** Alaska Air Group Inc ALK.N: up 1.7% ** United Airlines Holdings Inc UAL.O: up 2.2% ** Delta Air Lines Inc DAL.N: up 1.9% ** American Airlines Group Inc AAL.O: up 3.0% ** Spirit Airlines Inc SAVE.N: up 2.7% ** Royal Caribbean Cruises Ltd RCL.N: up 2.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N: up 1.8% ** Carnival Corp CCL.N: up 2.8% BUZZ-Airlines, cruise operators gain on new vaccine headway ** Sonoma Pharmaceuticals Inc SNOA.O: up 6.2% BUZZ-Gains on strong Q2 results ** Goldman Sachs Group Inc GS.N: up 2.3% ** JPMorgan Chase & Co JPM.N: up 1.7% ** Morgan Stanley MS.N: up 3.2% ** Bank of America Corp BAC.N: up 1.8% ** Wells Fargo & Co WFC.N: up 2.6% ** Citigroup Inc C.N: up 1.8% BUZZ-U.S. big banks rise on 'vaccine for the world' data ** Altice USA Inc ATUS.N: up 9.1% BUZZ-Jumps on $2.5 bln buyback ** FuboTV Inc FUBO.N: up 9.4% BUZZ-Rises after brokerage raises PT on connected TV upside ** Apex Technology Acquisition Corp APXT.O: up 3% BUZZ-Rises on $2 bln merger ** HP Inc HPQ.N: up 2.2% BUZZ-Up as Evercore raises PT in run-up to Q4 results ** Niu Technologies NIU.O: down 13.0% BUZZ-Falls on Q3 revenue miss, dour outlook ** Ideanomics Inc IDEX.O: up 70.9% BUZZ-Raises stake in e-tractor developer, shares soar ** China Online Education Group COE.N: up 2.4% BUZZ-Rises on Q3 results beat ** Daqo New Energy Corp DQ.N: down 5.6% BUZZ-Drops after Q3 profit miss ** Cytokinetics Inc CYTK.O: down 2.7% BUZZ-Falls as Amgen ends pact over heart drugs development ** Kemper Corp KMPR.N: up 1.5% BUZZ-To buy American Access Casualty in $370 mln deal ** SmileDirectClub Inc SDC.O: up 10.8% BUZZ-Rises on partnership with MetLife ** ARCA Biopharma Inc ABIO.O: up 3.9% BUZZ-Rises on FDA's 'fast-track' tag for COVID-19 treatment The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Monday as data showed U.S. business activity in November expanded at its fastest rate in more than five years, an indication that the economy was making progress at clambering out of a pandemic-driven recession..N At 10:06 am ET, the Dow Jones Industrial Average .DJI was up 0.91% at 29,530.8. The S&P 500 .SPX was up 0.86% at 3,587.97 and the Nasdaq Composite .IXIC was up 0.49% at 11,913.193. |
29027.0 | 2020-11-05 00:00:00 UTC | Pre-market Movers In Healthcare Sector: MITO, LPTX, NTEC, ABIO… | ABIO | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-mito-lptx-ntec-abio...-2020-11-05 | nan | nan | (RTTNews) - What's moving these stocks in the pre-market hours today?
In the Green
1. Stealth BioTherapeutics Corp (MITO) is up over 10% at $1.53 in pre-market trading Thursday, following the receipt of $20 million from Morningside Ventures, under a Development Funding Agreement, to support the clinical development of Elamipretide. Enrollment in a phase IIb study of Elamipretide in geographic atrophy has been completed and preparations are underway to file the first NDA for Elamipretide or the treatment of Barth syndrome. The company is expected to receive up to an additional $15 million from Morningside Ventures upon achieving certain milestones.
2. Leap Therapeutics Inc. (LPTX) is up over 14% at $2.23 in pre-market hours today, as the company gears up to present esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer's 35th Anniversary Annual Meeting on November 9. The company dosed the first patient in a phase IIa clinical trial of DKN-01, in combination with Tislelizumab, BeiGene's anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer as recently as September.
3. HEXO Corp. (HEXO) is up over 12% at $0.70 in pre-market trading today. On October 30, the company announced a proposed consolidation of its common shares on the basis of eight pre-consolidation shares for one post-consolidation share (8:1). The purpose of the consolidation is to increase the company's common share price to regain compliance with the $1.00 minimum share price continued listing standard of the New York Stock Exchange. The consolidation is expected to be implemented soon after the shareholders meeting, which is slated for December 11, 2020.
4. Intec Pharma Ltd. (NTEC), a clinical-stage biopharmaceutical company, is up over 11% at $2.96 in pre-market hours Thursday on no news. A 1-for-20 reverse stock split was implemented on October 30.
In the Red
1. ARCA biopharma Inc. (ABIO) is down over 5% at $3.80 in pre-market trading Thursday on no news. The company expects to initiate a phase IIb clinical trial evaluating AB201 as a potential treatment for COVID19 this quarter, and report topline data in Q1, 2021. The company had cash and cash equivalents of $51.1 million as of September 30, 2020.
2. T2 Biosystems Inc. (TTOO) is down over 5% at $1.43 in pre-market trading Thursday, giving back some of what it gained yesterday. The stock was up more than 11% yesterday, following Q3 results. The total revenue for the third quarter of 2020 was $5.2 million, an increase of 213% compared to the prior year period.
3. Acorda Therapeutics Inc. (ACOR) is down more than 6% at $0.86 in pre-market hours today, adding to yesterday's loss of 15%. The company reported its financial results for the third quarter ended September 30, 2020 on November 3. The total net revenue in Q3, 2020, increased to $53 million from $47.7 million in the year-ago same quarter. However, the product revenue, which comprises of Inbrija and Ampyra, were $34.6 million in Q3, 2020, down from $44.8 million in Q3, 2019.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc. (ABIO) is down over 5% at $3.80 in pre-market trading Thursday on no news. Intec Pharma Ltd. (NTEC), a clinical-stage biopharmaceutical company, is up over 11% at $2.96 in pre-market hours Thursday on no news. The company expects to initiate a phase IIb clinical trial evaluating AB201 as a potential treatment for COVID19 this quarter, and report topline data in Q1, 2021. | ARCA biopharma Inc. (ABIO) is down over 5% at $3.80 in pre-market trading Thursday on no news. Stealth BioTherapeutics Corp (MITO) is up over 10% at $1.53 in pre-market trading Thursday, following the receipt of $20 million from Morningside Ventures, under a Development Funding Agreement, to support the clinical development of Elamipretide. The purpose of the consolidation is to increase the company's common share price to regain compliance with the $1.00 minimum share price continued listing standard of the New York Stock Exchange. | ARCA biopharma Inc. (ABIO) is down over 5% at $3.80 in pre-market trading Thursday on no news. Stealth BioTherapeutics Corp (MITO) is up over 10% at $1.53 in pre-market trading Thursday, following the receipt of $20 million from Morningside Ventures, under a Development Funding Agreement, to support the clinical development of Elamipretide. Leap Therapeutics Inc. (LPTX) is up over 14% at $2.23 in pre-market hours today, as the company gears up to present esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer's 35th Anniversary Annual Meeting on November 9. | ARCA biopharma Inc. (ABIO) is down over 5% at $3.80 in pre-market trading Thursday on no news. (RTTNews) - What's moving these stocks in the pre-market hours today? The company expects to initiate a phase IIb clinical trial evaluating AB201 as a potential treatment for COVID19 this quarter, and report topline data in Q1, 2021. |
29028.0 | 2020-10-07 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Workday, Stable Road Acquisition, RedHill Biopharma, Fox Corp, Disney | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-workday-stable-road-acquisition-redhill-biopharma-fox-corp | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes jumped on Wednesday on hopes of at least a partial deal on more fiscal stimulus after U.S. President Donald Trump abruptly called off negotiations on a comprehensive bill in the previous session. .N
At 13:37 ET, the Dow Jones Industrial Average .DJI was up 1.54% at 28,199.7. The S&P 500 .SPX was up 1.42% at 3,408.73 and the Nasdaq Composite .IXIC was up 1.73% at 11,347.239. The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc ALXN.O, up 8.4% ** Freeport-McMoRan Inc FCX.N, up 6.4% ** Gap Inc GPS.N, up 6.3% The top three S&P 500 .PL.INX percentage losers: ** Everest Re Group Ltd RE.N, down 2.3% ** Hess Corp HES.N, down 2.3% ** Cincinnati Financial Corp CINF.O, down 1.7% The top three NYSE .PG.N percentage gainers: ** ReneSola Ltd SOL.N, up 28.8% ** Planet Green Holdings Corp PLAG.N, up 28.3% ** Natuzzi S.p.A. NTZ.N, up 15.1% The top three NYSE .PL.N percentage losers: ** China Green Agriculture Inc CGA.N, down 19.3% ** Hyliion Holdings Corp HYLN.N, down 9.7% ** Liberty Oilfield Services Inc LBRT.N, down 8.7% The top three Nasdaq .PG.O percentage gainers: ** American Resources Corp AREC.O, up 127% ** Peck Company Holdings Inc PECK.O, up 60.7% ** CVD Equipment Corp CVV.O, up 58% The top two Nasdaq .PL.O percentage losers: ** Electro-Sensors Inc ELSE.O, down 35.8% ** Forum Merger II Corp FMCIU.O, down 17.9% ** Levi Strauss & Co LEVI.N: up 6.1% BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% ** United Airlines Holdings Inc UAL.O: up 4.2% ** Delta Air Lines Inc DAL.N: up 3.1% ** JetBlue Airways Corp JBLU.O: up 5.7% BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 10.8% BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 4.6% BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.1% BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 7.1% BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 3.1% BUZZ-Berenberg starts coverage with 'hold' ** Perion Network Ltd PERI.O: up 12.6% BUZZ-Jumps after lifting H2 forecast ** Workday Inc WDAY.O: up 5.7% BUZZ-Rises as brokerage upgrades rating to "buy", hikes PT ** Netflix Inc NFLX.O: up 5.6% BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 4.1% BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 1.8% BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 4.2% BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 5.8% BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 1.4% BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** Aytu BioScience Inc AYTU.O: down 13.9% BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 14.7% BUZZ-Rises as Japan's hospital to use co's surgical system ** RAVE Restaurant Group Inc RAVE.O: up 105.3% BUZZ-Quadruples on new hiring to lead expansion ** Citius Pharmaceuticals Inc CTXR.O: up 5.9% BUZZ-Citius Pharma rises on licensing agreement for stem cell therapy ** AzurRx BioPharma Inc AZRX.O: flat BUZZ-Rises as CEO reassures on cash position ** Eli Lilly and Co LLY.N: up 2.7% BUZZ-Gains after applying for FDA emergency use for COVID-19 treatment ** Peck Company Holdings Inc PECK.O: up 60.7% BUZZ-Surges on contract for solar project in Rhode Island ** ARCA Biopharma Inc ABIO.O: down 6.7% BUZZ-Surges on FDA nod to begin potential COVID-19 drug trial ** Vaxart Inc VXRT.O: up 2.2% BUZZ-Up on expanding manufacturing deal for COVID-19 vaccine candidate ** Sunworks Inc SUNW.O: up 42.9% BUZZ-Surges on $10 mln commercial, agriculture projects ** Phunware Inc PHUN.O: up 16.6% BUZZ-Rises on Honeywell contracts ** Paychex Inc PAYX.O: up 1.8% BUZZ-Rises as Q1 results beat ** RPM International Inc RPM.N: up 2.2% BUZZ-Climbs on Q1 beat, bullish outlook ** Achieve Life Sciences Inc ACHV.O: up 7.2% BUZZ-Up on launch of late-stage trial of smoking cessation drug ** Ocular Therapeutix Inc OCUL.O: up 24.1% BUZZ-Rises on higher product sales in Q3 ** Element Solutions Inc ESI.N: up 3.6% BUZZ-Rises after announcing share buyback ** Silicon Motion Technology Corp SIMO.O: up 6.8% BUZZ-Up on upbeat preliminary Q3 results ** Gap Inc GPS.N: up 6.3% BUZZ-Gains as Barclays upgrades to 'overweight' ** RedHill Biopharma Ltd RDHL.O: up 1.7% BUZZ-Gains as COVID-19 drug study passes second safety review ** Eton Pharmaceuticals Inc ETON.O: up 4.7% BUZZ-Jumps on new drug application to treat seizures, migraine ** Landec Corp LNDC.O: down 4.8% BUZZ-Falls as first-quarter loss widens ** Alkermes Plc ALKS.O: up 4.8% BUZZ-Rises as FDA posts briefing documents ahead of expert panel meeting ** Crocs Inc CROX.O: flat BUZZ-Rises on tie-up with Justin Bieber ** Elanco Animal Health Inc ELAN.N: up 12.2% BUZZ-Rises as Sachem Head builds $1.2 bln stake in co ** Quanterix Corp QTRX.O: up 11.1% BUZZ-Jumps on contract to advance COVID-19 antigen test ** Clorox Co CLX.N: up 2.2% BUZZ-Rises on unveiling symptom-detecting device amid pandemic ** Vishay Intertechnology Inc VSH.N: up 6.2% BUZZ-Eyes best day in 5 months as Stifel raises to 'buy' ** JPMorgan Chase & Co JPM.N: up 0.9% ** Citigroup Inc C.N: up 0.7% ** Goldman Sachs Group Inc GS.N: up 0.4% ** Wells Fargo & Co WFC.N: up 1.9% ** Morgan Stanley MS.N: up 1.3% ** Bank of America Corp BAC.N: up 1.4% BUZZ-U.S. big banks follow gains on yields as risk sentiment rebounds ** Celanese Corp CE.N: up 3.9% BUZZ-Up after increasing acetate tow prices by 5% ** OrthoPediatrics Corp KIDS.O: up 6.8% BUZZ-Jumps after BTIG raises price target ** Taiwan Liposome Co Ltd TLC.O: up 27.7% BUZZ-Gains on Australia, Taiwan nod for COVID-19 therapy human trials ** Lightspeed POS Inc LSPD.N: up 6.8% BUZZ-Gains on deal with U.S. golf course operator ** American Resources Corp AREC.O: up 127.0% BUZZ-Considers strategic options for unit, shares surge ** Advanced Micro Devices Inc AMD.O: up 2.4% BUZZ-Gains after Jefferies hikes PT ** Lamb Weston Holdings Inc LW.N: up 2.5% BUZZ-French fry seller's stock heats up after upbeat report ** Pfizer Inc PFE.N: down 0.2% ** BioNTech SE BNTX.O: down 1.3% BUZZ-U.S. authorization for Pfizer, BioNTech COVID-19 vaccine unlikely before election ** Kontoor Brands KTB.N: up 8.1% BUZZ-Kontoor Brands: Gains as Barclays hikes PT, upgrades to 'overweight' ** PTC Therapeutics Inc PTCT.O: up 7.1% BUZZ-PTC Therapeutics: Rises after JP Morgan raises rating to overweight ** Haverty Furniture HVT.N: up 5.7% BUZZ-Haverty Furniture: Hits 17-month high on strong sales ** Castor Maritime Inc CTRM.O: up 6.4% BUZZ-Castor Maritime rises on securing charter agreement for new vessel ** Walt Disney Co DIS.N: up 1.7% BUZZ-Third Point's Loeb calls for redirecting dividend to fund content, shares rise ** HC2 Holdings Inc HCHC.N: down 7.1% BUZZ-Falls after commencing rights offering ** Steris Plc STE.N: up 1.7% BUZZ-Steris gains after brokerage raises price target ** Masimo Corp MASI.O: up 3.1% BUZZ-Rises on upbeat forecast; Needham points to elective procedure recovery ** Fox Corp FOXA.O: up 3.5% BUZZ-Rises as BofA hikes PT to Street high ** Tesla Inc TSLA.O: up 3.7% BUZZ-Musk moots idea of making half a million cars in 2020, shares rise
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.63%
Consumer Discretionary
.SPLRCD
up 2.15%
Consumer Staples
.SPLRCS
up 1.06%
Energy
.SPNY
up 0.45%
Financial
.SPSY
up 1.06%
Health
.SPXHC
up 1.51%
Industrial
.SPLRCI
up 1.72%
Information Technology
.SPLRCT
up 1.73%
Materials
.SPLRCM
up 2.10%
Real Estate
.SPLRCR
up 0.37%
Utilities
.SPLRCU
up 0.38%
(Compiled by C Nivedita in Bengaluru)
((c.nivedita@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc ALXN.O, up 8.4% ** Freeport-McMoRan Inc FCX.N, up 6.4% ** Gap Inc GPS.N, up 6.3% The top three S&P 500 .PL.INX percentage losers: ** Everest Re Group Ltd RE.N, down 2.3% ** Hess Corp HES.N, down 2.3% ** Cincinnati Financial Corp CINF.O, down 1.7% The top three NYSE .PG.N percentage gainers: ** ReneSola Ltd SOL.N, up 28.8% ** Planet Green Holdings Corp PLAG.N, up 28.3% ** Natuzzi S.p.A. NTZ.N, up 15.1% The top three NYSE .PL.N percentage losers: ** China Green Agriculture Inc CGA.N, down 19.3% ** Hyliion Holdings Corp HYLN.N, down 9.7% ** Liberty Oilfield Services Inc LBRT.N, down 8.7% The top three Nasdaq .PG.O percentage gainers: ** American Resources Corp AREC.O, up 127% ** Peck Company Holdings Inc PECK.O, up 60.7% ** CVD Equipment Corp CVV.O, up 58% The top two Nasdaq .PL.O percentage losers: ** Electro-Sensors Inc ELSE.O, down 35.8% ** Forum Merger II Corp FMCIU.O, down 17.9% ** Levi Strauss & Co LEVI.N: up 6.1% BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% ** United Airlines Holdings Inc UAL.O: up 4.2% ** Delta Air Lines Inc DAL.N: up 3.1% ** JetBlue Airways Corp JBLU.O: up 5.7% BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 10.8% BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 4.6% BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.1% BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 7.1% BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 3.1% BUZZ-Berenberg starts coverage with 'hold' ** Perion Network Ltd PERI.O: up 12.6% BUZZ-Jumps after lifting H2 forecast ** Workday Inc WDAY.O: up 5.7% BUZZ-Rises as brokerage upgrades rating to "buy", hikes PT ** Netflix Inc NFLX.O: up 5.6% BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 4.1% BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 1.8% BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 4.2% BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 5.8% BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 1.4% BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** Aytu BioScience Inc AYTU.O: down 13.9% BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 14.7% BUZZ-Rises as Japan's hospital to use co's surgical system ** RAVE Restaurant Group Inc RAVE.O: up 105.3% BUZZ-Quadruples on new hiring to lead expansion ** Citius Pharmaceuticals Inc CTXR.O: up 5.9% BUZZ-Citius Pharma rises on licensing agreement for stem cell therapy ** AzurRx BioPharma Inc AZRX.O: flat BUZZ-Rises as CEO reassures on cash position ** Eli Lilly and Co LLY.N: up 2.7% BUZZ-Gains after applying for FDA emergency use for COVID-19 treatment ** Peck Company Holdings Inc PECK.O: up 60.7% BUZZ-Surges on contract for solar project in Rhode Island ** ARCA Biopharma Inc ABIO.O: down 6.7% BUZZ-Surges on FDA nod to begin potential COVID-19 drug trial ** Vaxart Inc VXRT.O: up 2.2% BUZZ-Up on expanding manufacturing deal for COVID-19 vaccine candidate ** Sunworks Inc SUNW.O: up 42.9% BUZZ-Surges on $10 mln commercial, agriculture projects ** Phunware Inc PHUN.O: up 16.6% BUZZ-Rises on Honeywell contracts ** Paychex Inc PAYX.O: up 1.8% BUZZ-Rises as Q1 results beat ** RPM International Inc RPM.N: up 2.2% BUZZ-Climbs on Q1 beat, bullish outlook ** Achieve Life Sciences Inc ACHV.O: up 7.2% BUZZ-Up on launch of late-stage trial of smoking cessation drug ** Ocular Therapeutix Inc OCUL.O: up 24.1% BUZZ-Rises on higher product sales in Q3 ** Element Solutions Inc ESI.N: up 3.6% BUZZ-Rises after announcing share buyback ** Silicon Motion Technology Corp SIMO.O: up 6.8% BUZZ-Up on upbeat preliminary Q3 results ** Gap Inc GPS.N: up 6.3% BUZZ-Gains as Barclays upgrades to 'overweight' ** RedHill Biopharma Ltd RDHL.O: up 1.7% BUZZ-Gains as COVID-19 drug study passes second safety review ** Eton Pharmaceuticals Inc ETON.O: up 4.7% BUZZ-Jumps on new drug application to treat seizures, migraine ** Landec Corp LNDC.O: down 4.8% BUZZ-Falls as first-quarter loss widens ** Alkermes Plc ALKS.O: up 4.8% BUZZ-Rises as FDA posts briefing documents ahead of expert panel meeting ** Crocs Inc CROX.O: flat BUZZ-Rises on tie-up with Justin Bieber ** Elanco Animal Health Inc ELAN.N: up 12.2% BUZZ-Rises as Sachem Head builds $1.2 bln stake in co ** Quanterix Corp QTRX.O: up 11.1% BUZZ-Jumps on contract to advance COVID-19 antigen test ** Clorox Co CLX.N: up 2.2% BUZZ-Rises on unveiling symptom-detecting device amid pandemic ** Vishay Intertechnology Inc VSH.N: up 6.2% BUZZ-Eyes best day in 5 months as Stifel raises to 'buy' ** JPMorgan Chase & Co JPM.N: up 0.9% ** Citigroup Inc C.N: up 0.7% ** Goldman Sachs Group Inc GS.N: up 0.4% ** Wells Fargo & Co WFC.N: up 1.9% ** Morgan Stanley MS.N: up 1.3% ** Bank of America Corp BAC.N: up 1.4% BUZZ-U.S. big banks follow gains on yields as risk sentiment rebounds ** Celanese Corp CE.N: up 3.9% BUZZ-Up after increasing acetate tow prices by 5% ** OrthoPediatrics Corp KIDS.O: up 6.8% BUZZ-Jumps after BTIG raises price target ** Taiwan Liposome Co Ltd TLC.O: up 27.7% BUZZ-Gains on Australia, Taiwan nod for COVID-19 therapy human trials ** Lightspeed POS Inc LSPD.N: up 6.8% BUZZ-Gains on deal with U.S. golf course operator ** American Resources Corp AREC.O: up 127.0% BUZZ-Considers strategic options for unit, shares surge ** Advanced Micro Devices Inc AMD.O: up 2.4% BUZZ-Gains after Jefferies hikes PT ** Lamb Weston Holdings Inc LW.N: up 2.5% BUZZ-French fry seller's stock heats up after upbeat report ** Pfizer Inc PFE.N: down 0.2% ** BioNTech SE BNTX.O: down 1.3% BUZZ-U.S. authorization for Pfizer, BioNTech COVID-19 vaccine unlikely before election ** Kontoor Brands KTB.N: up 8.1% BUZZ-Kontoor Brands: Gains as Barclays hikes PT, upgrades to 'overweight' ** PTC Therapeutics Inc PTCT.O: up 7.1% BUZZ-PTC Therapeutics: Rises after JP Morgan raises rating to overweight ** Haverty Furniture HVT.N: up 5.7% BUZZ-Haverty Furniture: Hits 17-month high on strong sales ** Castor Maritime Inc CTRM.O: up 6.4% BUZZ-Castor Maritime rises on securing charter agreement for new vessel ** Walt Disney Co DIS.N: up 1.7% BUZZ-Third Point's Loeb calls for redirecting dividend to fund content, shares rise ** HC2 Holdings Inc HCHC.N: down 7.1% BUZZ-Falls after commencing rights offering ** Steris Plc STE.N: up 1.7% BUZZ-Steris gains after brokerage raises price target ** Masimo Corp MASI.O: up 3.1% BUZZ-Rises on upbeat forecast; Needham points to elective procedure recovery ** Fox Corp FOXA.O: up 3.5% BUZZ-Rises as BofA hikes PT to Street high ** Tesla Inc TSLA.O: up 3.7% BUZZ-Musk moots idea of making half a million cars in 2020, shares rise The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Wednesday on hopes of at least a partial deal on more fiscal stimulus after U.S. President Donald Trump abruptly called off negotiations on a comprehensive bill in the previous session. up 0.38% (Compiled by C Nivedita in Bengaluru) ((c.nivedita@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc ALXN.O, up 8.4% ** Freeport-McMoRan Inc FCX.N, up 6.4% ** Gap Inc GPS.N, up 6.3% The top three S&P 500 .PL.INX percentage losers: ** Everest Re Group Ltd RE.N, down 2.3% ** Hess Corp HES.N, down 2.3% ** Cincinnati Financial Corp CINF.O, down 1.7% The top three NYSE .PG.N percentage gainers: ** ReneSola Ltd SOL.N, up 28.8% ** Planet Green Holdings Corp PLAG.N, up 28.3% ** Natuzzi S.p.A. NTZ.N, up 15.1% The top three NYSE .PL.N percentage losers: ** China Green Agriculture Inc CGA.N, down 19.3% ** Hyliion Holdings Corp HYLN.N, down 9.7% ** Liberty Oilfield Services Inc LBRT.N, down 8.7% The top three Nasdaq .PG.O percentage gainers: ** American Resources Corp AREC.O, up 127% ** Peck Company Holdings Inc PECK.O, up 60.7% ** CVD Equipment Corp CVV.O, up 58% The top two Nasdaq .PL.O percentage losers: ** Electro-Sensors Inc ELSE.O, down 35.8% ** Forum Merger II Corp FMCIU.O, down 17.9% ** Levi Strauss & Co LEVI.N: up 6.1% BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% ** United Airlines Holdings Inc UAL.O: up 4.2% ** Delta Air Lines Inc DAL.N: up 3.1% ** JetBlue Airways Corp JBLU.O: up 5.7% BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 10.8% BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 4.6% BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.1% BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 7.1% BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 3.1% BUZZ-Berenberg starts coverage with 'hold' ** Perion Network Ltd PERI.O: up 12.6% BUZZ-Jumps after lifting H2 forecast ** Workday Inc WDAY.O: up 5.7% BUZZ-Rises as brokerage upgrades rating to "buy", hikes PT ** Netflix Inc NFLX.O: up 5.6% BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 4.1% BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 1.8% BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 4.2% BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 5.8% BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 1.4% BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** Aytu BioScience Inc AYTU.O: down 13.9% BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 14.7% BUZZ-Rises as Japan's hospital to use co's surgical system ** RAVE Restaurant Group Inc RAVE.O: up 105.3% BUZZ-Quadruples on new hiring to lead expansion ** Citius Pharmaceuticals Inc CTXR.O: up 5.9% BUZZ-Citius Pharma rises on licensing agreement for stem cell therapy ** AzurRx BioPharma Inc AZRX.O: flat BUZZ-Rises as CEO reassures on cash position ** Eli Lilly and Co LLY.N: up 2.7% BUZZ-Gains after applying for FDA emergency use for COVID-19 treatment ** Peck Company Holdings Inc PECK.O: up 60.7% BUZZ-Surges on contract for solar project in Rhode Island ** ARCA Biopharma Inc ABIO.O: down 6.7% BUZZ-Surges on FDA nod to begin potential COVID-19 drug trial ** Vaxart Inc VXRT.O: up 2.2% BUZZ-Up on expanding manufacturing deal for COVID-19 vaccine candidate ** Sunworks Inc SUNW.O: up 42.9% BUZZ-Surges on $10 mln commercial, agriculture projects ** Phunware Inc PHUN.O: up 16.6% BUZZ-Rises on Honeywell contracts ** Paychex Inc PAYX.O: up 1.8% BUZZ-Rises as Q1 results beat ** RPM International Inc RPM.N: up 2.2% BUZZ-Climbs on Q1 beat, bullish outlook ** Achieve Life Sciences Inc ACHV.O: up 7.2% BUZZ-Up on launch of late-stage trial of smoking cessation drug ** Ocular Therapeutix Inc OCUL.O: up 24.1% BUZZ-Rises on higher product sales in Q3 ** Element Solutions Inc ESI.N: up 3.6% BUZZ-Rises after announcing share buyback ** Silicon Motion Technology Corp SIMO.O: up 6.8% BUZZ-Up on upbeat preliminary Q3 results ** Gap Inc GPS.N: up 6.3% BUZZ-Gains as Barclays upgrades to 'overweight' ** RedHill Biopharma Ltd RDHL.O: up 1.7% BUZZ-Gains as COVID-19 drug study passes second safety review ** Eton Pharmaceuticals Inc ETON.O: up 4.7% BUZZ-Jumps on new drug application to treat seizures, migraine ** Landec Corp LNDC.O: down 4.8% BUZZ-Falls as first-quarter loss widens ** Alkermes Plc ALKS.O: up 4.8% BUZZ-Rises as FDA posts briefing documents ahead of expert panel meeting ** Crocs Inc CROX.O: flat BUZZ-Rises on tie-up with Justin Bieber ** Elanco Animal Health Inc ELAN.N: up 12.2% BUZZ-Rises as Sachem Head builds $1.2 bln stake in co ** Quanterix Corp QTRX.O: up 11.1% BUZZ-Jumps on contract to advance COVID-19 antigen test ** Clorox Co CLX.N: up 2.2% BUZZ-Rises on unveiling symptom-detecting device amid pandemic ** Vishay Intertechnology Inc VSH.N: up 6.2% BUZZ-Eyes best day in 5 months as Stifel raises to 'buy' ** JPMorgan Chase & Co JPM.N: up 0.9% ** Citigroup Inc C.N: up 0.7% ** Goldman Sachs Group Inc GS.N: up 0.4% ** Wells Fargo & Co WFC.N: up 1.9% ** Morgan Stanley MS.N: up 1.3% ** Bank of America Corp BAC.N: up 1.4% BUZZ-U.S. big banks follow gains on yields as risk sentiment rebounds ** Celanese Corp CE.N: up 3.9% BUZZ-Up after increasing acetate tow prices by 5% ** OrthoPediatrics Corp KIDS.O: up 6.8% BUZZ-Jumps after BTIG raises price target ** Taiwan Liposome Co Ltd TLC.O: up 27.7% BUZZ-Gains on Australia, Taiwan nod for COVID-19 therapy human trials ** Lightspeed POS Inc LSPD.N: up 6.8% BUZZ-Gains on deal with U.S. golf course operator ** American Resources Corp AREC.O: up 127.0% BUZZ-Considers strategic options for unit, shares surge ** Advanced Micro Devices Inc AMD.O: up 2.4% BUZZ-Gains after Jefferies hikes PT ** Lamb Weston Holdings Inc LW.N: up 2.5% BUZZ-French fry seller's stock heats up after upbeat report ** Pfizer Inc PFE.N: down 0.2% ** BioNTech SE BNTX.O: down 1.3% BUZZ-U.S. authorization for Pfizer, BioNTech COVID-19 vaccine unlikely before election ** Kontoor Brands KTB.N: up 8.1% BUZZ-Kontoor Brands: Gains as Barclays hikes PT, upgrades to 'overweight' ** PTC Therapeutics Inc PTCT.O: up 7.1% BUZZ-PTC Therapeutics: Rises after JP Morgan raises rating to overweight ** Haverty Furniture HVT.N: up 5.7% BUZZ-Haverty Furniture: Hits 17-month high on strong sales ** Castor Maritime Inc CTRM.O: up 6.4% BUZZ-Castor Maritime rises on securing charter agreement for new vessel ** Walt Disney Co DIS.N: up 1.7% BUZZ-Third Point's Loeb calls for redirecting dividend to fund content, shares rise ** HC2 Holdings Inc HCHC.N: down 7.1% BUZZ-Falls after commencing rights offering ** Steris Plc STE.N: up 1.7% BUZZ-Steris gains after brokerage raises price target ** Masimo Corp MASI.O: up 3.1% BUZZ-Rises on upbeat forecast; Needham points to elective procedure recovery ** Fox Corp FOXA.O: up 3.5% BUZZ-Rises as BofA hikes PT to Street high ** Tesla Inc TSLA.O: up 3.7% BUZZ-Musk moots idea of making half a million cars in 2020, shares rise The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Wednesday on hopes of at least a partial deal on more fiscal stimulus after U.S. President Donald Trump abruptly called off negotiations on a comprehensive bill in the previous session. up 0.38% (Compiled by C Nivedita in Bengaluru) ((c.nivedita@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc ALXN.O, up 8.4% ** Freeport-McMoRan Inc FCX.N, up 6.4% ** Gap Inc GPS.N, up 6.3% The top three S&P 500 .PL.INX percentage losers: ** Everest Re Group Ltd RE.N, down 2.3% ** Hess Corp HES.N, down 2.3% ** Cincinnati Financial Corp CINF.O, down 1.7% The top three NYSE .PG.N percentage gainers: ** ReneSola Ltd SOL.N, up 28.8% ** Planet Green Holdings Corp PLAG.N, up 28.3% ** Natuzzi S.p.A. NTZ.N, up 15.1% The top three NYSE .PL.N percentage losers: ** China Green Agriculture Inc CGA.N, down 19.3% ** Hyliion Holdings Corp HYLN.N, down 9.7% ** Liberty Oilfield Services Inc LBRT.N, down 8.7% The top three Nasdaq .PG.O percentage gainers: ** American Resources Corp AREC.O, up 127% ** Peck Company Holdings Inc PECK.O, up 60.7% ** CVD Equipment Corp CVV.O, up 58% The top two Nasdaq .PL.O percentage losers: ** Electro-Sensors Inc ELSE.O, down 35.8% ** Forum Merger II Corp FMCIU.O, down 17.9% ** Levi Strauss & Co LEVI.N: up 6.1% BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% ** United Airlines Holdings Inc UAL.O: up 4.2% ** Delta Air Lines Inc DAL.N: up 3.1% ** JetBlue Airways Corp JBLU.O: up 5.7% BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 10.8% BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 4.6% BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.1% BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 7.1% BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 3.1% BUZZ-Berenberg starts coverage with 'hold' ** Perion Network Ltd PERI.O: up 12.6% BUZZ-Jumps after lifting H2 forecast ** Workday Inc WDAY.O: up 5.7% BUZZ-Rises as brokerage upgrades rating to "buy", hikes PT ** Netflix Inc NFLX.O: up 5.6% BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 4.1% BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 1.8% BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 4.2% BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 5.8% BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 1.4% BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** Aytu BioScience Inc AYTU.O: down 13.9% BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 14.7% BUZZ-Rises as Japan's hospital to use co's surgical system ** RAVE Restaurant Group Inc RAVE.O: up 105.3% BUZZ-Quadruples on new hiring to lead expansion ** Citius Pharmaceuticals Inc CTXR.O: up 5.9% BUZZ-Citius Pharma rises on licensing agreement for stem cell therapy ** AzurRx BioPharma Inc AZRX.O: flat BUZZ-Rises as CEO reassures on cash position ** Eli Lilly and Co LLY.N: up 2.7% BUZZ-Gains after applying for FDA emergency use for COVID-19 treatment ** Peck Company Holdings Inc PECK.O: up 60.7% BUZZ-Surges on contract for solar project in Rhode Island ** ARCA Biopharma Inc ABIO.O: down 6.7% BUZZ-Surges on FDA nod to begin potential COVID-19 drug trial ** Vaxart Inc VXRT.O: up 2.2% BUZZ-Up on expanding manufacturing deal for COVID-19 vaccine candidate ** Sunworks Inc SUNW.O: up 42.9% BUZZ-Surges on $10 mln commercial, agriculture projects ** Phunware Inc PHUN.O: up 16.6% BUZZ-Rises on Honeywell contracts ** Paychex Inc PAYX.O: up 1.8% BUZZ-Rises as Q1 results beat ** RPM International Inc RPM.N: up 2.2% BUZZ-Climbs on Q1 beat, bullish outlook ** Achieve Life Sciences Inc ACHV.O: up 7.2% BUZZ-Up on launch of late-stage trial of smoking cessation drug ** Ocular Therapeutix Inc OCUL.O: up 24.1% BUZZ-Rises on higher product sales in Q3 ** Element Solutions Inc ESI.N: up 3.6% BUZZ-Rises after announcing share buyback ** Silicon Motion Technology Corp SIMO.O: up 6.8% BUZZ-Up on upbeat preliminary Q3 results ** Gap Inc GPS.N: up 6.3% BUZZ-Gains as Barclays upgrades to 'overweight' ** RedHill Biopharma Ltd RDHL.O: up 1.7% BUZZ-Gains as COVID-19 drug study passes second safety review ** Eton Pharmaceuticals Inc ETON.O: up 4.7% BUZZ-Jumps on new drug application to treat seizures, migraine ** Landec Corp LNDC.O: down 4.8% BUZZ-Falls as first-quarter loss widens ** Alkermes Plc ALKS.O: up 4.8% BUZZ-Rises as FDA posts briefing documents ahead of expert panel meeting ** Crocs Inc CROX.O: flat BUZZ-Rises on tie-up with Justin Bieber ** Elanco Animal Health Inc ELAN.N: up 12.2% BUZZ-Rises as Sachem Head builds $1.2 bln stake in co ** Quanterix Corp QTRX.O: up 11.1% BUZZ-Jumps on contract to advance COVID-19 antigen test ** Clorox Co CLX.N: up 2.2% BUZZ-Rises on unveiling symptom-detecting device amid pandemic ** Vishay Intertechnology Inc VSH.N: up 6.2% BUZZ-Eyes best day in 5 months as Stifel raises to 'buy' ** JPMorgan Chase & Co JPM.N: up 0.9% ** Citigroup Inc C.N: up 0.7% ** Goldman Sachs Group Inc GS.N: up 0.4% ** Wells Fargo & Co WFC.N: up 1.9% ** Morgan Stanley MS.N: up 1.3% ** Bank of America Corp BAC.N: up 1.4% BUZZ-U.S. big banks follow gains on yields as risk sentiment rebounds ** Celanese Corp CE.N: up 3.9% BUZZ-Up after increasing acetate tow prices by 5% ** OrthoPediatrics Corp KIDS.O: up 6.8% BUZZ-Jumps after BTIG raises price target ** Taiwan Liposome Co Ltd TLC.O: up 27.7% BUZZ-Gains on Australia, Taiwan nod for COVID-19 therapy human trials ** Lightspeed POS Inc LSPD.N: up 6.8% BUZZ-Gains on deal with U.S. golf course operator ** American Resources Corp AREC.O: up 127.0% BUZZ-Considers strategic options for unit, shares surge ** Advanced Micro Devices Inc AMD.O: up 2.4% BUZZ-Gains after Jefferies hikes PT ** Lamb Weston Holdings Inc LW.N: up 2.5% BUZZ-French fry seller's stock heats up after upbeat report ** Pfizer Inc PFE.N: down 0.2% ** BioNTech SE BNTX.O: down 1.3% BUZZ-U.S. authorization for Pfizer, BioNTech COVID-19 vaccine unlikely before election ** Kontoor Brands KTB.N: up 8.1% BUZZ-Kontoor Brands: Gains as Barclays hikes PT, upgrades to 'overweight' ** PTC Therapeutics Inc PTCT.O: up 7.1% BUZZ-PTC Therapeutics: Rises after JP Morgan raises rating to overweight ** Haverty Furniture HVT.N: up 5.7% BUZZ-Haverty Furniture: Hits 17-month high on strong sales ** Castor Maritime Inc CTRM.O: up 6.4% BUZZ-Castor Maritime rises on securing charter agreement for new vessel ** Walt Disney Co DIS.N: up 1.7% BUZZ-Third Point's Loeb calls for redirecting dividend to fund content, shares rise ** HC2 Holdings Inc HCHC.N: down 7.1% BUZZ-Falls after commencing rights offering ** Steris Plc STE.N: up 1.7% BUZZ-Steris gains after brokerage raises price target ** Masimo Corp MASI.O: up 3.1% BUZZ-Rises on upbeat forecast; Needham points to elective procedure recovery ** Fox Corp FOXA.O: up 3.5% BUZZ-Rises as BofA hikes PT to Street high ** Tesla Inc TSLA.O: up 3.7% BUZZ-Musk moots idea of making half a million cars in 2020, shares rise The 11 major S&P 500 sectors: Communication Services .N At 13:37 ET, the Dow Jones Industrial Average .DJI was up 1.54% at 28,199.7. up 0.63% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc ALXN.O, up 8.4% ** Freeport-McMoRan Inc FCX.N, up 6.4% ** Gap Inc GPS.N, up 6.3% The top three S&P 500 .PL.INX percentage losers: ** Everest Re Group Ltd RE.N, down 2.3% ** Hess Corp HES.N, down 2.3% ** Cincinnati Financial Corp CINF.O, down 1.7% The top three NYSE .PG.N percentage gainers: ** ReneSola Ltd SOL.N, up 28.8% ** Planet Green Holdings Corp PLAG.N, up 28.3% ** Natuzzi S.p.A. NTZ.N, up 15.1% The top three NYSE .PL.N percentage losers: ** China Green Agriculture Inc CGA.N, down 19.3% ** Hyliion Holdings Corp HYLN.N, down 9.7% ** Liberty Oilfield Services Inc LBRT.N, down 8.7% The top three Nasdaq .PG.O percentage gainers: ** American Resources Corp AREC.O, up 127% ** Peck Company Holdings Inc PECK.O, up 60.7% ** CVD Equipment Corp CVV.O, up 58% The top two Nasdaq .PL.O percentage losers: ** Electro-Sensors Inc ELSE.O, down 35.8% ** Forum Merger II Corp FMCIU.O, down 17.9% ** Levi Strauss & Co LEVI.N: up 6.1% BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% ** United Airlines Holdings Inc UAL.O: up 4.2% ** Delta Air Lines Inc DAL.N: up 3.1% ** JetBlue Airways Corp JBLU.O: up 5.7% BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 10.8% BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 4.6% BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.1% BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 7.1% BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 3.1% BUZZ-Berenberg starts coverage with 'hold' ** Perion Network Ltd PERI.O: up 12.6% BUZZ-Jumps after lifting H2 forecast ** Workday Inc WDAY.O: up 5.7% BUZZ-Rises as brokerage upgrades rating to "buy", hikes PT ** Netflix Inc NFLX.O: up 5.6% BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 4.1% BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 1.8% BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 4.2% BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 5.8% BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 1.4% BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** Aytu BioScience Inc AYTU.O: down 13.9% BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 14.7% BUZZ-Rises as Japan's hospital to use co's surgical system ** RAVE Restaurant Group Inc RAVE.O: up 105.3% BUZZ-Quadruples on new hiring to lead expansion ** Citius Pharmaceuticals Inc CTXR.O: up 5.9% BUZZ-Citius Pharma rises on licensing agreement for stem cell therapy ** AzurRx BioPharma Inc AZRX.O: flat BUZZ-Rises as CEO reassures on cash position ** Eli Lilly and Co LLY.N: up 2.7% BUZZ-Gains after applying for FDA emergency use for COVID-19 treatment ** Peck Company Holdings Inc PECK.O: up 60.7% BUZZ-Surges on contract for solar project in Rhode Island ** ARCA Biopharma Inc ABIO.O: down 6.7% BUZZ-Surges on FDA nod to begin potential COVID-19 drug trial ** Vaxart Inc VXRT.O: up 2.2% BUZZ-Up on expanding manufacturing deal for COVID-19 vaccine candidate ** Sunworks Inc SUNW.O: up 42.9% BUZZ-Surges on $10 mln commercial, agriculture projects ** Phunware Inc PHUN.O: up 16.6% BUZZ-Rises on Honeywell contracts ** Paychex Inc PAYX.O: up 1.8% BUZZ-Rises as Q1 results beat ** RPM International Inc RPM.N: up 2.2% BUZZ-Climbs on Q1 beat, bullish outlook ** Achieve Life Sciences Inc ACHV.O: up 7.2% BUZZ-Up on launch of late-stage trial of smoking cessation drug ** Ocular Therapeutix Inc OCUL.O: up 24.1% BUZZ-Rises on higher product sales in Q3 ** Element Solutions Inc ESI.N: up 3.6% BUZZ-Rises after announcing share buyback ** Silicon Motion Technology Corp SIMO.O: up 6.8% BUZZ-Up on upbeat preliminary Q3 results ** Gap Inc GPS.N: up 6.3% BUZZ-Gains as Barclays upgrades to 'overweight' ** RedHill Biopharma Ltd RDHL.O: up 1.7% BUZZ-Gains as COVID-19 drug study passes second safety review ** Eton Pharmaceuticals Inc ETON.O: up 4.7% BUZZ-Jumps on new drug application to treat seizures, migraine ** Landec Corp LNDC.O: down 4.8% BUZZ-Falls as first-quarter loss widens ** Alkermes Plc ALKS.O: up 4.8% BUZZ-Rises as FDA posts briefing documents ahead of expert panel meeting ** Crocs Inc CROX.O: flat BUZZ-Rises on tie-up with Justin Bieber ** Elanco Animal Health Inc ELAN.N: up 12.2% BUZZ-Rises as Sachem Head builds $1.2 bln stake in co ** Quanterix Corp QTRX.O: up 11.1% BUZZ-Jumps on contract to advance COVID-19 antigen test ** Clorox Co CLX.N: up 2.2% BUZZ-Rises on unveiling symptom-detecting device amid pandemic ** Vishay Intertechnology Inc VSH.N: up 6.2% BUZZ-Eyes best day in 5 months as Stifel raises to 'buy' ** JPMorgan Chase & Co JPM.N: up 0.9% ** Citigroup Inc C.N: up 0.7% ** Goldman Sachs Group Inc GS.N: up 0.4% ** Wells Fargo & Co WFC.N: up 1.9% ** Morgan Stanley MS.N: up 1.3% ** Bank of America Corp BAC.N: up 1.4% BUZZ-U.S. big banks follow gains on yields as risk sentiment rebounds ** Celanese Corp CE.N: up 3.9% BUZZ-Up after increasing acetate tow prices by 5% ** OrthoPediatrics Corp KIDS.O: up 6.8% BUZZ-Jumps after BTIG raises price target ** Taiwan Liposome Co Ltd TLC.O: up 27.7% BUZZ-Gains on Australia, Taiwan nod for COVID-19 therapy human trials ** Lightspeed POS Inc LSPD.N: up 6.8% BUZZ-Gains on deal with U.S. golf course operator ** American Resources Corp AREC.O: up 127.0% BUZZ-Considers strategic options for unit, shares surge ** Advanced Micro Devices Inc AMD.O: up 2.4% BUZZ-Gains after Jefferies hikes PT ** Lamb Weston Holdings Inc LW.N: up 2.5% BUZZ-French fry seller's stock heats up after upbeat report ** Pfizer Inc PFE.N: down 0.2% ** BioNTech SE BNTX.O: down 1.3% BUZZ-U.S. authorization for Pfizer, BioNTech COVID-19 vaccine unlikely before election ** Kontoor Brands KTB.N: up 8.1% BUZZ-Kontoor Brands: Gains as Barclays hikes PT, upgrades to 'overweight' ** PTC Therapeutics Inc PTCT.O: up 7.1% BUZZ-PTC Therapeutics: Rises after JP Morgan raises rating to overweight ** Haverty Furniture HVT.N: up 5.7% BUZZ-Haverty Furniture: Hits 17-month high on strong sales ** Castor Maritime Inc CTRM.O: up 6.4% BUZZ-Castor Maritime rises on securing charter agreement for new vessel ** Walt Disney Co DIS.N: up 1.7% BUZZ-Third Point's Loeb calls for redirecting dividend to fund content, shares rise ** HC2 Holdings Inc HCHC.N: down 7.1% BUZZ-Falls after commencing rights offering ** Steris Plc STE.N: up 1.7% BUZZ-Steris gains after brokerage raises price target ** Masimo Corp MASI.O: up 3.1% BUZZ-Rises on upbeat forecast; Needham points to elective procedure recovery ** Fox Corp FOXA.O: up 3.5% BUZZ-Rises as BofA hikes PT to Street high ** Tesla Inc TSLA.O: up 3.7% BUZZ-Musk moots idea of making half a million cars in 2020, shares rise The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Wednesday on hopes of at least a partial deal on more fiscal stimulus after U.S. President Donald Trump abruptly called off negotiations on a comprehensive bill in the previous session. .N At 13:37 ET, the Dow Jones Industrial Average .DJI was up 1.54% at 28,199.7. |
29029.0 | 2020-09-22 00:00:00 UTC | ABIO Joins Battle Against COVID-19, ERYP On Watch, LPCN To Report NASH Study Results In Q1 | ABIO | https://www.nasdaq.com/articles/abio-joins-battle-against-covid-19-eryp-on-watch-lpcn-to-report-nash-study-results-in-q1 | nan | nan | (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress related to its COVID-19 drug candidate, ADC Therapeutics' submission of Loncastuximab tesirine BLA, BridgeBio's initiation of ADH1 study, ERYTECH Pharma's anticipated milestones, and the progress in Lipocine's NASH trial.
Read on…
1. ARCA biopharma Joins battle Against COVID-19
ARCA biopharma Inc. (ABIO) has submitted an Investigational New Drug application with the FDA, seeking clearance to initiate a phase IIb/III trial of AB201 for the treatment of patients hospitalized with COVID-19.
AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections.
If cleared, the company anticipates initiating the phase IIb portion of the trial as early as the fourth quarter of this year.
ABIO closed Monday's trading at $4.63, down 10.62%. In after-hours, the stock was up 2.59% at $4.75.
2. ADC Therapeutics Submits Lonca BLA
ADC Therapeutics SA (ADCT) has submitted a Biologics License Application to the FDA for Loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Loncastuximab Tesirine or Lonca is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds to human CD19, a protein. While the expression of CD19 in healthy tissue is restricted, it is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia.
The BLA submission is based on data from a pivotal phase II trial, dubbed LOTIS 2, in which Loncastuximab Tesirine demonstrated an overall response rate of 48.3% and a complete response rate of 24.1%.
The LOTIS 2 trial involved patients with relapsed or refractory diffuse large B-cell lymphoma following two or more than two lines of prior systemic therapy.
The company has also initiated LOTIS 5, a phase III confirmatory clinical trial of Lonca in combination with Rituximab, which is intended to support a supplemental BLA for Loncastuximab Tesirine to be used as second-line therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
ADCT closed Monday's trading at $45.25, down 0.55%.
3. BridgeBio Pharma On Track
BridgeBio Pharma Inc.'s (BBIO) affiliate Calcilytix Therapeutics Inc. has initiated a phase II single-center study of Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the National Institutes of Health.
ADH1 is a rare, inherited disease caused by gain-of-function mutations in the calcium-sensing receptor (CaSR) resulting in abnormally low serum calcium and high urine calcium and a range of debilitating symptoms. Currently, there are no approved therapies for ADH1.
The phase II trial is designed to enroll up to 16 individuals with ADH1 and will evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and efficacy of single and multiple doses of Encaleret.
The topline proof-of-concept results from this phase II study are expected next year.
BBIO closed Monday's trading at $39.66, down 6.00%.
4. ERYTECH to Report Final Phase II ALL Data by Year-end
ERYTECH Pharma (ERYP) has a couple of events to keep an eye on in the coming months.
The company expects interim superiority analysis of its pivotal phase III clinical trial of lead product candidate, Eryaspase, in second-line metastatic pancreatic cancer to be conducted in the first quarter of 2021.
The trial, dubbed TRYbeCA-1, has randomized more than 450 of the approximately 500 patients to be enrolled in the trial.
According to the company, the interim analysis can result in the trial being allowed to continue toward a final analysis, expected in the second half of 2021, or be concluded early if the trial successfully meets the primary endpoint of prolonging overall survival.
A phase II trial of Eryaspase in acute lymphoblastic leukemia (ALL) patients who developed hypersensitivity to pegylated asparaginase, dubbed NOR-GRASPALL-2016 trial, is ongoing. This study is sponsored by the Nordic Organization of Pediatric Hematology and Oncology (NOPHO).
Preliminary findings of the NOR-GRASPALL-2016 study reported in June this year suggested that Eryaspase achieved the target level and duration of asparaginase activity in the second-line acute lymphoblastic leukemia (ALL) patients. Hypersensitivity to asparaginase remains an important concern in the treatment of ALL patients. The final data from this study is expected by the end of 2020.
ERYP closed Monday's trading at $7.30, up 3.40%.
5. Lipocine Awaits NASH Trial Results
Lipocine Inc. (LPCN) has completed enrollment in its phase II study of LPCN 1144 in confirmed non-cirrhotic non-alcoholic steatohepatitis subjects, dubbed LiFT.
The LiFT study, which has a treatment period of 38 weeks, has randomized 56 subjects 1:1:1 to two test arms and one placebo arm.
The company expects to report the primary endpoint, i.e., the top-line change in liver fat data measured by MRI-PDFF, in January 2021.
The company's Tlando, an investigational testosterone replacement therapy, is still awaiting the FDA decision which was originally due on August 28, 2020.
LPCN closed Monday's trading at $1.59, down 0.93%.
6. Stocks That Moved On No News
CorMedix Inc. (CRMD) closed Monday's trading at $5.72, up 24.08%.
Sonoma Pharmaceuticals, Inc. (SNOA) closed Monday's trading at $9.13, up 15.57%.
Humanigen Inc. (HGEN) closed Monday's trading at $11.07, up 14.72%.
Wave Life Sciences Ltd. (WVE) closed Monday's trading at $15.05, down 22.98%.
Pieris Pharmaceuticals Inc. (PIRS) closed Monday's trading at $2.33, down 21.02%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Joins battle Against COVID-19 ARCA biopharma Inc. (ABIO) has submitted an Investigational New Drug application with the FDA, seeking clearance to initiate a phase IIb/III trial of AB201 for the treatment of patients hospitalized with COVID-19. ABIO closed Monday's trading at $4.63, down 10.62%. The company has also initiated LOTIS 5, a phase III confirmatory clinical trial of Lonca in combination with Rituximab, which is intended to support a supplemental BLA for Loncastuximab Tesirine to be used as second-line therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma. | ARCA biopharma Joins battle Against COVID-19 ARCA biopharma Inc. (ABIO) has submitted an Investigational New Drug application with the FDA, seeking clearance to initiate a phase IIb/III trial of AB201 for the treatment of patients hospitalized with COVID-19. ABIO closed Monday's trading at $4.63, down 10.62%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress related to its COVID-19 drug candidate, ADC Therapeutics' submission of Loncastuximab tesirine BLA, BridgeBio's initiation of ADH1 study, ERYTECH Pharma's anticipated milestones, and the progress in Lipocine's NASH trial. | ARCA biopharma Joins battle Against COVID-19 ARCA biopharma Inc. (ABIO) has submitted an Investigational New Drug application with the FDA, seeking clearance to initiate a phase IIb/III trial of AB201 for the treatment of patients hospitalized with COVID-19. ABIO closed Monday's trading at $4.63, down 10.62%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress related to its COVID-19 drug candidate, ADC Therapeutics' submission of Loncastuximab tesirine BLA, BridgeBio's initiation of ADH1 study, ERYTECH Pharma's anticipated milestones, and the progress in Lipocine's NASH trial. | ARCA biopharma Joins battle Against COVID-19 ARCA biopharma Inc. (ABIO) has submitted an Investigational New Drug application with the FDA, seeking clearance to initiate a phase IIb/III trial of AB201 for the treatment of patients hospitalized with COVID-19. ABIO closed Monday's trading at $4.63, down 10.62%. The company has also initiated LOTIS 5, a phase III confirmatory clinical trial of Lonca in combination with Rituximab, which is intended to support a supplemental BLA for Loncastuximab Tesirine to be used as second-line therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma. |
29030.0 | 2020-09-21 00:00:00 UTC | ARCA Biopharma Submits IND Application To FDA For AB201 As Potential COVID-19 Treatment | ABIO | https://www.nasdaq.com/articles/arca-biopharma-submits-ind-application-to-fda-for-ab201-as-potential-covid-19-treatment | nan | nan | (RTTNews) - ARCA biopharma Inc. (ABIO) said Monday that it has submitted an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19.
Pending FDA feedback, ARCA expects to initiate the Phase 2b portion of a sequential Phase 2b/3 clinical evaluation of AB201 as early as the fourth quarter of this year.
AB201 is a small recombinant protein being developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ARCA biopharma Inc. (ABIO) said Monday that it has submitted an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19. AB201 is a small recombinant protein being developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. | (RTTNews) - ARCA biopharma Inc. (ABIO) said Monday that it has submitted an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19. Pending FDA feedback, ARCA expects to initiate the Phase 2b portion of a sequential Phase 2b/3 clinical evaluation of AB201 as early as the fourth quarter of this year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ARCA biopharma Inc. (ABIO) said Monday that it has submitted an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ARCA biopharma Inc. (ABIO) said Monday that it has submitted an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19. Pending FDA feedback, ARCA expects to initiate the Phase 2b portion of a sequential Phase 2b/3 clinical evaluation of AB201 as early as the fourth quarter of this year. AB201 is a small recombinant protein being developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19. |
29031.0 | 2020-09-15 00:00:00 UTC | Pre-market Movers In Healthcare Sector: NVUS, MRNS, ABIO, LPCN, CLRB, VXRT… | ABIO | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-nvus-mrns-abio-lpcn-clrb-vxrt...-2020-09-15 | nan | nan | (RTTNews) - What's moving these stocks in the pre-market hours today?
In the Green
1. Novus Therapeutics Inc. (NVUS) is up over 158% at $0.98 in pre-market trading Tuesday, following news of its acquisition of Anelixis Therapeutics Inc., a privately-held clinical-stage biotechnology company developing a next-generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.
2. Marinus Pharmaceuticals, Inc. (MRNS) is up more than 68% at $3.55 in pre-market hours, following positive top-line results from its phase III clinical trial of oral Ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures. The company plans to submit an NDA for oral Ganaxolone in the treatment of CDD to the FDA in mid-2021 and a Marketing Authorization Application to the European Medicines Agency by the end of Q3 2021.
3. ARCA biopharma Inc. (ABIO) is up over 23% at $5.89 in pre-market hours today on no specific news. The company is due to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 this month and initiate a phase IIb trial as early as next quarter.
4. Immuron Limited (IMRN) is up over 9% at $8.62 in pre-market trading Tuesday. The company's flagship product is Travelan, a novel, over the counter ("OTC") product for the prevention of Travellers' diarrhea.
5. Tiziana Life Sciences PLC (TLSA) is up over 10% at $3.59 in pre-market trading Tuesday. The company expects to initiate a clinical trial of TZLS-501 in COVID-19 patients by Q1 2021.
6. Cellectar Biosciences Inc. (CLRB) is up more than 8% at $1.30 in pre-market hours. The company is scheduled to make a presentation at the H.C. Wainwright 22nd Annual Global Investment Conference today at 3:30 pm Eastern Time.
7. Lipocine Inc. (LPCN) is up over 4% at $1.39 in pre-market hours. The company's Tlando, an investigational testosterone replacement therapy, is under FDA review with a decision which was originally due on August 28. However, on August 28, the FDA informed the company that it needs some more time and that the review will be completed in the coming weeks.
8. DBV Technologies S.A. (DBVT) is up over 7% at $2.14 in pre-market hours. The company's investigational Viaskin Peanut, a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years, was denied FDA approval last month.
In the Red
1. Vaxart Inc. (VXRT) is down more than 6% at $7.30 in pre-market hours Tuesday, giving back some of what it gained yesterday. The stock had gained more than 46% yesterday, following FDA clearance for phase I clinical trial of its oral COVID-19 vaccine candidate. Recruitment in the study is expected to start next month.
2. Innate Pharma S.A. (IPHA) is down over 4% at $4.20 in pre-market trading Tuesday. A phase II trial of Lacutamab, dubbed TELLOMAK, for patients with Sézary syndrome and mycosis fungoides is underway. Data from this trial for mycosis fungoides is expected in 2021 and that of Sézary syndrome in 2022. A phase III trial of Monalizumab in combination with cetuximab in patients suffering from recurrent or metastatic head and neck squamous cell cancer is expected to be initiated in the second half of 2020.
3. Miragen Therapeutics, Inc. (MGEN) is down more than 3% at $0.90 in pre-market hours today. The company has appointed Lee Rauch as President and CEO, following the resignation of William Marshall. In addition, Miragen has decided to conduct a comprehensive review of available strategic alternatives with a focus on maximizing stockholder value.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc. (ABIO) is up over 23% at $5.89 in pre-market hours today on no specific news. Marinus Pharmaceuticals, Inc. (MRNS) is up more than 68% at $3.55 in pre-market hours, following positive top-line results from its phase III clinical trial of oral Ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures. The company plans to submit an NDA for oral Ganaxolone in the treatment of CDD to the FDA in mid-2021 and a Marketing Authorization Application to the European Medicines Agency by the end of Q3 2021. | ARCA biopharma Inc. (ABIO) is up over 23% at $5.89 in pre-market hours today on no specific news. Marinus Pharmaceuticals, Inc. (MRNS) is up more than 68% at $3.55 in pre-market hours, following positive top-line results from its phase III clinical trial of oral Ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures. The company is due to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 this month and initiate a phase IIb trial as early as next quarter. | ARCA biopharma Inc. (ABIO) is up over 23% at $5.89 in pre-market hours today on no specific news. Novus Therapeutics Inc. (NVUS) is up over 158% at $0.98 in pre-market trading Tuesday, following news of its acquisition of Anelixis Therapeutics Inc., a privately-held clinical-stage biotechnology company developing a next-generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. Marinus Pharmaceuticals, Inc. (MRNS) is up more than 68% at $3.55 in pre-market hours, following positive top-line results from its phase III clinical trial of oral Ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures. | ARCA biopharma Inc. (ABIO) is up over 23% at $5.89 in pre-market hours today on no specific news. The company is due to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 this month and initiate a phase IIb trial as early as next quarter. The company expects to initiate a clinical trial of TZLS-501 in COVID-19 patients by Q1 2021. |
29032.0 | 2020-08-06 00:00:00 UTC | ABIO To Start Phase 2 COVID-19 Trial In Q4, ACIU On Track, BCLI Expects ALS Trial Data In Nov. | ABIO | https://www.nasdaq.com/articles/abio-to-start-phase-2-covid-19-trial-in-q4-aciu-on-track-bcli-expects-als-trial-data-in | nan | nan | (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress in its COVID-19 drug candidate, AC Immune' upcoming milestones, BrainStorm Cell's November catalyst, Bristol-Myers/Pfizer's Eliquis patent suit ruling, and Novavax's positive phase I data from its COVID-19 vaccine trial.
Read on…
1. ARCA biopharma To Explore AB201 for COVID-19
ARCA biopharma Inc. (ABIO) is planning to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 in the third quarter of this year, seeking clearance to initiate a phase II trial.
If the company gets the go-ahead from the FDA, the phase II trial of AB201 is expected to be initiated in the fourth quarter of this year.
Gencaro, the company's lead investigational drug, is being developed for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population. Initiation of a phase III trial of Gencaro, dubbed PRECISION-AF, is on hold due to the ongoing COVID-19 pandemic.
The enrollment in the PRECISION-AF trial could start in 2021, according to ARCA.
ABIO closed Wednesday's trading at $6.77, down 0.15%.
2. AC Immune to Report Alzheimer's Trial Data in 2H20
AC Immune SA (ACIU) has an important catalyst to watch out for in the second half of this year.
The company's lead anti-Tau antibody is Semorinemab - being co-developed in collaboration with Roche's Genetech. Semorinemab is under a phase II trial for the treatment of patients with prodromal to mild Alzheimer's. The topline data from this trial is expected in the second half of 2020.
As recently as last month, the company advanced its anti-Tau Alzheimer's vaccine ACI-35.030 into a phase 1b/2a clinical trial.
ACIU closed Wednesday's trading at $6.57, down 6.81%.
3. BrainStorm Getting Ready to Reveal ALS Trial Results
BrainStorm Cell Therapeutics Inc. (BCLI) has a couple of catalysts lined up for the coming months.
A phase III pivotal trial investigating NurOwn in amyotrophic lateral sclerosis is underway, with topline data readout expected by the end of November this year.
A phase II clinical trial of NurOwn is ongoing in progressive multiple sclerosis and is expected to complete dosing by the end of 2020.
The company is planning a phase II proof-of-concept clinical trial of NurOwn in Alzheimer's disease at several leading AD centers in the Netherlands and France.
BCLI closed Wednesday's trading at $13.11, down 2.09%.
4. Bristol-Myers/Pfizer Prevail in Eliquis Patent Challenge
In a patent suit filed by Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) against Sigmapharm Laboratories LLC, Unichem Laboratories Ltd. and Sunshine Lake Pharma Co. Ltd over blood thinner Eliquis, the Court has ruled in favor of the two big pharma companies.
Pfizer and Bristol-Myers Squibb have a worldwide collaboration to develop and commercialize Eliquis that was discovered by Bristol-Myers.
Sigmapharm Labs, Unichem Labs, and Sunshine Lake are some of the generic drug makers that have been seeking to get FDA approval for their generic versions of Eliquis.
According to Bristol-Myers and Pfizer, the key composition of matter patent on Eliquis in the U.S. expires only in 2031. So, now that the Court has ruled in favor of Pfizer and Bristol-Myers, the three generic manufacturers currently involved in the case, will not be able to launch the generic versions of Eliquis until 2031.
However, based on settlement agreements reached with other generic manufacturers, it is expected that the generic entry could occur after 2026 but before 2031, subject to appeals and future challenges.
The FDA approved generic versions of Eliquis, made by Mylan and Micro Labs last December, which marked the first-ever generic versions of that drug.
In the first quarter of 2020, Eliquis brought in global revenue of $2.64 billion for Bristol-Myers and $1.30 billion for Pfizer.
BMY closed Wednesday's trading at $59.69, up 0.37%. In after-hours, the stock was up 4.21% at $62.20.
5. Novavax Rallies On Positive Phase I trial results of COVID-19 Vaccine
Shares of Novavax Inc. (NVAX) touched an all-time high of $189.40 in intraday trading on Wednesday, following positive phase I data from its phase I/II trial of its COVID-19 vaccine candidate NVX-CoV2373.
In the phase I part, which evaluated NVX-CoV2373 adjuvanted with Matrix-M, the vaccine candidate was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
"All subjects developed anti-spike IgG antibodies after a single dose of the vaccine, many of them also developing wild-type virus neutralizing antibody responses, and after Dose 2, 100% of participants developed wild-type virus neutralizing antibody responses", noted the company.
The trial was supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and was conducted at two sites in Australia.
NVAX closed Wednesday's trading at $173.49, up 10.38%.
6. Stocks That Moved On No News
Biofrontera AG (BFRA) closed Wednesday's trading at $26.80, up 378.57%.
Alimera Sciences Inc. (ALIM) closed Wednesday's trading at $6.98, up 27.84%.
Iteos Therapeutics Inc. (ITOS) closed Wednesday's trading at $28.88, up 17.21%.
Alterity Therapeutics Limited (ATHE) closed Wednesday's trading at $2.91, down 15.16%.
Inozyme Pharma Inc. (INZY) closed Wednesday's trading at $22.43, down 9.30%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma To Explore AB201 for COVID-19 ARCA biopharma Inc. (ABIO) is planning to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 in the third quarter of this year, seeking clearance to initiate a phase II trial. ABIO closed Wednesday's trading at $6.77, down 0.15%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress in its COVID-19 drug candidate, AC Immune' upcoming milestones, BrainStorm Cell's November catalyst, Bristol-Myers/Pfizer's Eliquis patent suit ruling, and Novavax's positive phase I data from its COVID-19 vaccine trial. | ARCA biopharma To Explore AB201 for COVID-19 ARCA biopharma Inc. (ABIO) is planning to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 in the third quarter of this year, seeking clearance to initiate a phase II trial. ABIO closed Wednesday's trading at $6.77, down 0.15%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress in its COVID-19 drug candidate, AC Immune' upcoming milestones, BrainStorm Cell's November catalyst, Bristol-Myers/Pfizer's Eliquis patent suit ruling, and Novavax's positive phase I data from its COVID-19 vaccine trial. | ARCA biopharma To Explore AB201 for COVID-19 ARCA biopharma Inc. (ABIO) is planning to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 in the third quarter of this year, seeking clearance to initiate a phase II trial. ABIO closed Wednesday's trading at $6.77, down 0.15%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma's progress in its COVID-19 drug candidate, AC Immune' upcoming milestones, BrainStorm Cell's November catalyst, Bristol-Myers/Pfizer's Eliquis patent suit ruling, and Novavax's positive phase I data from its COVID-19 vaccine trial. | ARCA biopharma To Explore AB201 for COVID-19 ARCA biopharma Inc. (ABIO) is planning to file an Investigational New Drug application for AB201 as a potential treatment for COVID-19 in the third quarter of this year, seeking clearance to initiate a phase II trial. ABIO closed Wednesday's trading at $6.77, down 0.15%. A phase II clinical trial of NurOwn is ongoing in progressive multiple sclerosis and is expected to complete dosing by the end of 2020. |
29033.0 | 2020-06-01 00:00:00 UTC | Health Care Sector Update for 06/01/2020: ABIO,EBS,GILD,OCGN | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-06-01-2020%3A-abioebsgildocgn-2020-06-01 | nan | nan | Health care stocks trimmed a portion of their earlier declines, with the NYSE Health Care Index Monday falling 0.8% while the SPDR Health Care Select Sector ETF fell 1%.
The Nasdaq Biotechnology index fell 0.5%.
In company news, ARCA biopharma (ABIO) dropped 27% after Monday disclosing plans for a $9.4 million direct placement of 348,000 shares of its common stock and 694,222 at $9 apiece, or 37.3% under Friday's closing price. The net proceeds will be used to begin testing of its AB201 drug candidate to treat abnormal blood clotting in patients with COVID-19.
Emergent BioSolutions (EBS) advanced almost 7% after the specialty drugmaker Monday said it received a $628 million task order under its existing contract with the Biomedical Advanced Research and Development Authority to provide molecule-to-market manufacturing capacity for potential COVID-19 vaccines and expanding the company's viral and non-viral contract manufacturing.
Gilead Sciences (GILD) slid about 3.4% despite the drugmaker earlier Monday reporting more encouraging data for its remdesivir drug candidate as a potential treatment for COVID-19. A five-day treatment regimen showed patients treated with remdesivir over five days were 65% more likely to demonstrate clinical improvement from the disease after 11 days compared with patients in the standard of care group.
Ocugen (OCGN) dropped nearly 26% after the biopharmaceuticals company Monday said it was discontinuing a phase III trial comparing its OCU300 drug candidate in patients with host disease following ocular grafts when an independent data monitoring committee concluded the study was unlikely to meet its co-primary endpoints upon completion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, ARCA biopharma (ABIO) dropped 27% after Monday disclosing plans for a $9.4 million direct placement of 348,000 shares of its common stock and 694,222 at $9 apiece, or 37.3% under Friday's closing price. Gilead Sciences (GILD) slid about 3.4% despite the drugmaker earlier Monday reporting more encouraging data for its remdesivir drug candidate as a potential treatment for COVID-19. Ocugen (OCGN) dropped nearly 26% after the biopharmaceuticals company Monday said it was discontinuing a phase III trial comparing its OCU300 drug candidate in patients with host disease following ocular grafts when an independent data monitoring committee concluded the study was unlikely to meet its co-primary endpoints upon completion. | In company news, ARCA biopharma (ABIO) dropped 27% after Monday disclosing plans for a $9.4 million direct placement of 348,000 shares of its common stock and 694,222 at $9 apiece, or 37.3% under Friday's closing price. Health care stocks trimmed a portion of their earlier declines, with the NYSE Health Care Index Monday falling 0.8% while the SPDR Health Care Select Sector ETF fell 1%. Gilead Sciences (GILD) slid about 3.4% despite the drugmaker earlier Monday reporting more encouraging data for its remdesivir drug candidate as a potential treatment for COVID-19. | In company news, ARCA biopharma (ABIO) dropped 27% after Monday disclosing plans for a $9.4 million direct placement of 348,000 shares of its common stock and 694,222 at $9 apiece, or 37.3% under Friday's closing price. Health care stocks trimmed a portion of their earlier declines, with the NYSE Health Care Index Monday falling 0.8% while the SPDR Health Care Select Sector ETF fell 1%. Emergent BioSolutions (EBS) advanced almost 7% after the specialty drugmaker Monday said it received a $628 million task order under its existing contract with the Biomedical Advanced Research and Development Authority to provide molecule-to-market manufacturing capacity for potential COVID-19 vaccines and expanding the company's viral and non-viral contract manufacturing. | In company news, ARCA biopharma (ABIO) dropped 27% after Monday disclosing plans for a $9.4 million direct placement of 348,000 shares of its common stock and 694,222 at $9 apiece, or 37.3% under Friday's closing price. Health care stocks trimmed a portion of their earlier declines, with the NYSE Health Care Index Monday falling 0.8% while the SPDR Health Care Select Sector ETF fell 1%. The Nasdaq Biotechnology index fell 0.5%. |
29034.0 | 2020-06-01 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Coty, Tesla, Zoom Video, Zynga | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-coty-tesla-zoom-video-zynga-2020-06-01 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks rose on Monday as investors chose to look past violent protests across the country over racial inequality and focused more on economic data that bolstered views of a quick post-pandemic recovery. .N
At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.38% at 25,479.55. The S&P 500 .SPX was up 0.47% at 3,058.67 and the Nasdaq Composite .IXIC was up 0.77% at 9,563.184. The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc COTY.N, up 18.2% ** Gap Inc GPS.N, up 12.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N, up 10.2% The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc PFE.N, down 7% ** NortonLifelock Inc NLOK.OQ, down 4.3% ** Gilead Sciences Inc GILD.OQ, down 3.4% The top three NYSE .PG.N percentage gainers: ** Myovant Sciences Ltd MYOV.N, up 45.3% ** Circor International Inc CIR.N, up 34.4% ** Blue Apron Holdings Inc APRN.N, up 20% The top three NYSE .PL.N percentage losers: ** Evolent Health Inc EVH.N, down 23.9% ** IQ Leaders GTAA Tracker Etf QGTA.N, down 12.4% ** Direxion Daily Dow Jones Internet Bear Etf WEBS.N, down 9.1% The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc Ord CETX.O, up 195.7% ** Digital Ally DGLY.O, up 94.6% ** Alied Esport Entertainment Inc AESE.O, up 92.4% The top three Nasdaq .PL.O percentage losers: ** Arca Biopharma Inc ABIO.O, down 25.3% ** Cyclacel Pharmaceuticals Inc CYCCP.O, down 21.6% ** Harpoon Therapeutics Inc. HARP.O, down 16.8% ** Intellia Therapeutics Inc NTLA.O: up 11.7% ** Regeneron Pharmaceuticals Inc REGN.O: down 1.1%
BUZZ- Intellia Therapeutics rises on expanding partnership with Regeneron ** Coty Inc COTY.N: up 18.1%
BUZZ- Soars as ex-Chief Executive Harf returns as CEO ** Viavi Solutions Inc VIAV.O: up 5.2%
BUZZ- JPMorgan upgrades on test and measurement equipment demand ** Edison Nation Inc EDNT.O: down 6.2%
BUZZ- Slides after co reports lower Q1 preliminary revenue ** Digital Ally Inc DGLY.O: up 94.6% ** Cemtrex Inc CETX.O: 186.1% ** Axon Enterprises Inc AAXN.O: up 15.8%
BUZZ-Security services stocks surge amid violent U.S. protests ** World Wrestling Entertainment Inc WWE.N: up 1.8%
BUZZ-World Wrestling Entertainment: Hulks up on launch of free version of WWE Network ** Celyad SA CYAD.BR: up 11.9%
BUZZ- Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer ** HeadHunter Group Plc HHR.O: up 11.8%
BUZZ- Jumps as hiring recovers in Russia ** Tesla Inc TSLA.O: up 5.7% ** Virgin Galactic Holdings Inc SPCE.N: up 3.8%
BUZZ- Rises after owner Musk's SpaceX delivers astronauts to ISS ** Zynga Inc ZNGA.O: up 4.5%
BUZZ- Analysts give thumbs up to Peak acquisition, shares rise ** Zoom Video Communications ZM.O: up 13.5%
BUZZ-Zoom Video zooms past $200 ahead of qtrly report on Tuesday
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.62%
Consumer Discretionary
.SPLRCD
up 1.05%
Consumer Staples
.SPLRCS
up 0.80%
Energy
.SPNY
up 1.63%
Financial
.SPSY
up 1.50%
Health
.SPXHC
down 0.98%
Industrial
.SPLRCI
up 0.58%
Information Technology
.SPLRCT
up 0.16%
Materials
.SPLRCM
up 0.48%
Real Estate
.SPLRCR
up 2.29%
Utilities
.SPLRCU
up 0.50%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc COTY.N, up 18.2% ** Gap Inc GPS.N, up 12.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N, up 10.2% The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc PFE.N, down 7% ** NortonLifelock Inc NLOK.OQ, down 4.3% ** Gilead Sciences Inc GILD.OQ, down 3.4% The top three NYSE .PG.N percentage gainers: ** Myovant Sciences Ltd MYOV.N, up 45.3% ** Circor International Inc CIR.N, up 34.4% ** Blue Apron Holdings Inc APRN.N, up 20% The top three NYSE .PL.N percentage losers: ** Evolent Health Inc EVH.N, down 23.9% ** IQ Leaders GTAA Tracker Etf QGTA.N, down 12.4% ** Direxion Daily Dow Jones Internet Bear Etf WEBS.N, down 9.1% The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc Ord CETX.O, up 195.7% ** Digital Ally DGLY.O, up 94.6% ** Alied Esport Entertainment Inc AESE.O, up 92.4% The top three Nasdaq .PL.O percentage losers: ** Arca Biopharma Inc ABIO.O, down 25.3% ** Cyclacel Pharmaceuticals Inc CYCCP.O, down 21.6% ** Harpoon Therapeutics Inc. HARP.O, down 16.8% ** Intellia Therapeutics Inc NTLA.O: up 11.7% ** Regeneron Pharmaceuticals Inc REGN.O: down 1.1% BUZZ- Intellia Therapeutics rises on expanding partnership with Regeneron ** Coty Inc COTY.N: up 18.1% BUZZ- Soars as ex-Chief Executive Harf returns as CEO ** Viavi Solutions Inc VIAV.O: up 5.2% BUZZ- JPMorgan upgrades on test and measurement equipment demand ** Edison Nation Inc EDNT.O: down 6.2% BUZZ- Slides after co reports lower Q1 preliminary revenue ** Digital Ally Inc DGLY.O: up 94.6% ** Cemtrex Inc CETX.O: 186.1% ** Axon Enterprises Inc AAXN.O: up 15.8% BUZZ-Security services stocks surge amid violent U.S. protests ** World Wrestling Entertainment Inc WWE.N: up 1.8% BUZZ-World Wrestling Entertainment: Hulks up on launch of free version of WWE Network ** Celyad SA CYAD.BR: up 11.9% BUZZ- Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer ** HeadHunter Group Plc HHR.O: up 11.8% BUZZ- Jumps as hiring recovers in Russia ** Tesla Inc TSLA.O: up 5.7% ** Virgin Galactic Holdings Inc SPCE.N: up 3.8% BUZZ- Rises after owner Musk's SpaceX delivers astronauts to ISS ** Zynga Inc ZNGA.O: up 4.5% BUZZ- Analysts give thumbs up to Peak acquisition, shares rise ** Zoom Video Communications ZM.O: up 13.5% BUZZ-Zoom Video zooms past $200 ahead of qtrly report on Tuesday The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks rose on Monday as investors chose to look past violent protests across the country over racial inequality and focused more on economic data that bolstered views of a quick post-pandemic recovery. up 0.50% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc COTY.N, up 18.2% ** Gap Inc GPS.N, up 12.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N, up 10.2% The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc PFE.N, down 7% ** NortonLifelock Inc NLOK.OQ, down 4.3% ** Gilead Sciences Inc GILD.OQ, down 3.4% The top three NYSE .PG.N percentage gainers: ** Myovant Sciences Ltd MYOV.N, up 45.3% ** Circor International Inc CIR.N, up 34.4% ** Blue Apron Holdings Inc APRN.N, up 20% The top three NYSE .PL.N percentage losers: ** Evolent Health Inc EVH.N, down 23.9% ** IQ Leaders GTAA Tracker Etf QGTA.N, down 12.4% ** Direxion Daily Dow Jones Internet Bear Etf WEBS.N, down 9.1% The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc Ord CETX.O, up 195.7% ** Digital Ally DGLY.O, up 94.6% ** Alied Esport Entertainment Inc AESE.O, up 92.4% The top three Nasdaq .PL.O percentage losers: ** Arca Biopharma Inc ABIO.O, down 25.3% ** Cyclacel Pharmaceuticals Inc CYCCP.O, down 21.6% ** Harpoon Therapeutics Inc. HARP.O, down 16.8% ** Intellia Therapeutics Inc NTLA.O: up 11.7% ** Regeneron Pharmaceuticals Inc REGN.O: down 1.1% BUZZ- Intellia Therapeutics rises on expanding partnership with Regeneron ** Coty Inc COTY.N: up 18.1% BUZZ- Soars as ex-Chief Executive Harf returns as CEO ** Viavi Solutions Inc VIAV.O: up 5.2% BUZZ- JPMorgan upgrades on test and measurement equipment demand ** Edison Nation Inc EDNT.O: down 6.2% BUZZ- Slides after co reports lower Q1 preliminary revenue ** Digital Ally Inc DGLY.O: up 94.6% ** Cemtrex Inc CETX.O: 186.1% ** Axon Enterprises Inc AAXN.O: up 15.8% BUZZ-Security services stocks surge amid violent U.S. protests ** World Wrestling Entertainment Inc WWE.N: up 1.8% BUZZ-World Wrestling Entertainment: Hulks up on launch of free version of WWE Network ** Celyad SA CYAD.BR: up 11.9% BUZZ- Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer ** HeadHunter Group Plc HHR.O: up 11.8% BUZZ- Jumps as hiring recovers in Russia ** Tesla Inc TSLA.O: up 5.7% ** Virgin Galactic Holdings Inc SPCE.N: up 3.8% BUZZ- Rises after owner Musk's SpaceX delivers astronauts to ISS ** Zynga Inc ZNGA.O: up 4.5% BUZZ- Analysts give thumbs up to Peak acquisition, shares rise ** Zoom Video Communications ZM.O: up 13.5% BUZZ-Zoom Video zooms past $200 ahead of qtrly report on Tuesday The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks rose on Monday as investors chose to look past violent protests across the country over racial inequality and focused more on economic data that bolstered views of a quick post-pandemic recovery. .N At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.38% at 25,479.55. | The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc COTY.N, up 18.2% ** Gap Inc GPS.N, up 12.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N, up 10.2% The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc PFE.N, down 7% ** NortonLifelock Inc NLOK.OQ, down 4.3% ** Gilead Sciences Inc GILD.OQ, down 3.4% The top three NYSE .PG.N percentage gainers: ** Myovant Sciences Ltd MYOV.N, up 45.3% ** Circor International Inc CIR.N, up 34.4% ** Blue Apron Holdings Inc APRN.N, up 20% The top three NYSE .PL.N percentage losers: ** Evolent Health Inc EVH.N, down 23.9% ** IQ Leaders GTAA Tracker Etf QGTA.N, down 12.4% ** Direxion Daily Dow Jones Internet Bear Etf WEBS.N, down 9.1% The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc Ord CETX.O, up 195.7% ** Digital Ally DGLY.O, up 94.6% ** Alied Esport Entertainment Inc AESE.O, up 92.4% The top three Nasdaq .PL.O percentage losers: ** Arca Biopharma Inc ABIO.O, down 25.3% ** Cyclacel Pharmaceuticals Inc CYCCP.O, down 21.6% ** Harpoon Therapeutics Inc. HARP.O, down 16.8% ** Intellia Therapeutics Inc NTLA.O: up 11.7% ** Regeneron Pharmaceuticals Inc REGN.O: down 1.1% BUZZ- Intellia Therapeutics rises on expanding partnership with Regeneron ** Coty Inc COTY.N: up 18.1% BUZZ- Soars as ex-Chief Executive Harf returns as CEO ** Viavi Solutions Inc VIAV.O: up 5.2% BUZZ- JPMorgan upgrades on test and measurement equipment demand ** Edison Nation Inc EDNT.O: down 6.2% BUZZ- Slides after co reports lower Q1 preliminary revenue ** Digital Ally Inc DGLY.O: up 94.6% ** Cemtrex Inc CETX.O: 186.1% ** Axon Enterprises Inc AAXN.O: up 15.8% BUZZ-Security services stocks surge amid violent U.S. protests ** World Wrestling Entertainment Inc WWE.N: up 1.8% BUZZ-World Wrestling Entertainment: Hulks up on launch of free version of WWE Network ** Celyad SA CYAD.BR: up 11.9% BUZZ- Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer ** HeadHunter Group Plc HHR.O: up 11.8% BUZZ- Jumps as hiring recovers in Russia ** Tesla Inc TSLA.O: up 5.7% ** Virgin Galactic Holdings Inc SPCE.N: up 3.8% BUZZ- Rises after owner Musk's SpaceX delivers astronauts to ISS ** Zynga Inc ZNGA.O: up 4.5% BUZZ- Analysts give thumbs up to Peak acquisition, shares rise ** Zoom Video Communications ZM.O: up 13.5% BUZZ-Zoom Video zooms past $200 ahead of qtrly report on Tuesday The 11 major S&P 500 sectors: Communication Services up 0.62% Consumer Discretionary up 1.05% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc COTY.N, up 18.2% ** Gap Inc GPS.N, up 12.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N, up 10.2% The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc PFE.N, down 7% ** NortonLifelock Inc NLOK.OQ, down 4.3% ** Gilead Sciences Inc GILD.OQ, down 3.4% The top three NYSE .PG.N percentage gainers: ** Myovant Sciences Ltd MYOV.N, up 45.3% ** Circor International Inc CIR.N, up 34.4% ** Blue Apron Holdings Inc APRN.N, up 20% The top three NYSE .PL.N percentage losers: ** Evolent Health Inc EVH.N, down 23.9% ** IQ Leaders GTAA Tracker Etf QGTA.N, down 12.4% ** Direxion Daily Dow Jones Internet Bear Etf WEBS.N, down 9.1% The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc Ord CETX.O, up 195.7% ** Digital Ally DGLY.O, up 94.6% ** Alied Esport Entertainment Inc AESE.O, up 92.4% The top three Nasdaq .PL.O percentage losers: ** Arca Biopharma Inc ABIO.O, down 25.3% ** Cyclacel Pharmaceuticals Inc CYCCP.O, down 21.6% ** Harpoon Therapeutics Inc. HARP.O, down 16.8% ** Intellia Therapeutics Inc NTLA.O: up 11.7% ** Regeneron Pharmaceuticals Inc REGN.O: down 1.1% BUZZ- Intellia Therapeutics rises on expanding partnership with Regeneron ** Coty Inc COTY.N: up 18.1% BUZZ- Soars as ex-Chief Executive Harf returns as CEO ** Viavi Solutions Inc VIAV.O: up 5.2% BUZZ- JPMorgan upgrades on test and measurement equipment demand ** Edison Nation Inc EDNT.O: down 6.2% BUZZ- Slides after co reports lower Q1 preliminary revenue ** Digital Ally Inc DGLY.O: up 94.6% ** Cemtrex Inc CETX.O: 186.1% ** Axon Enterprises Inc AAXN.O: up 15.8% BUZZ-Security services stocks surge amid violent U.S. protests ** World Wrestling Entertainment Inc WWE.N: up 1.8% BUZZ-World Wrestling Entertainment: Hulks up on launch of free version of WWE Network ** Celyad SA CYAD.BR: up 11.9% BUZZ- Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer ** HeadHunter Group Plc HHR.O: up 11.8% BUZZ- Jumps as hiring recovers in Russia ** Tesla Inc TSLA.O: up 5.7% ** Virgin Galactic Holdings Inc SPCE.N: up 3.8% BUZZ- Rises after owner Musk's SpaceX delivers astronauts to ISS ** Zynga Inc ZNGA.O: up 4.5% BUZZ- Analysts give thumbs up to Peak acquisition, shares rise ** Zoom Video Communications ZM.O: up 13.5% BUZZ-Zoom Video zooms past $200 ahead of qtrly report on Tuesday The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks rose on Monday as investors chose to look past violent protests across the country over racial inequality and focused more on economic data that bolstered views of a quick post-pandemic recovery. .N At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.38% at 25,479.55. |
29035.0 | 2020-06-01 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Gilead, Virgin Galactic, General Electric | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gilead-virgin-galactic-general-electric-2020-06-01 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks edged higher on Monday on prospects of a post-pandemic economic recovery, but the sentiment remained fragile amid protests across the country over race and an ongoing standoff between Washington and Beijing. .N
At 11:30 ET, the Dow Jones Industrial Average .DJI was up 0.14% at 25,417.6. The S&P 500 .SPX was up 0.10% at 3,047.22 and the Nasdaq Composite .IXIC was up 0.32% at 9,519.982. The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc , up 19 % ** Gap Inc , up 13.3 % ** Alliance Data Systems Corp , up 9.6 % The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc , down 8.2 % ** Gilead Sciences Inc , down 4.1 % ** NortonLifeLock Inc , down 3.6 % The top three NYSE .PG.N percentage gainers: ** Navigator Holdings Ltd , up 31.4 % ** Myovant Sciences Ltd , up 27.9 % ** Circor International Inc , up 20.6 % The top three NYSE .PL.N percentage losers: ** Evolent Health Inc , down 26.9 % ** Maiden Holdings Ltd , down 10.1 % ** Credit Suisse Velocity Shares , down 9 % The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc , up 149.2 % ** Digital Ally Inc , up 106.3 % ** Allied Esports Entertainment Inc , up 96.3 % The top three Nasdaq .PL.O percentage losers: ** Iterum Theraputics , down 51.1 % ** Arca Biopharma Inc , down 24.6 % ** Cyclacel Pharmaceuticals Inc. , down 21.6 % ** Smith & Wesson Brands Inc SWBI.O: up 17.1% ** Sturm Ruger & Co Inc RGR.N: up 11.8% ** Vista Outdoor Inc VSTO.N: up 10.5%
BUZZ-Shares of gun makers jump on raging protests across U.S. cities ** CTI BioPharma corp CTIC.O: up 9.8%
BUZZ- Up on enrolling first patient in COVID-19 drug study ** Cerence Inc CRNC.O: up 5.6%
BUZZ-Up after Cowen raises PT on benefits from rising connected cars ** Proteostasis Therapeutics Inc PTI.O: UP 8.3%
BUZZ- up after in vitro treatment study for COVID-19 shows promise ** Novus Therapeutics Inc NVUS.O: down 54%
BUZZ- Plunges as co explores options after drug trial fails ** Gilead Sciences Inc GILD.O : down 3.6%
BUZZ- Drops on mixed remdesivir results in moderate COVID-19 patients ** Virgin Galactic Holdings Inc SPCE.N: up 3.5%
BUZZ-Lifts off after SpaceX's successful mission ** Ocugen Inc OCGN.O: down 28%
BUZZ- Plummets after co scraps trial of lead eye disorder drug ** General Electric Co GE.N: up 2.1%
BUZZ- JPM's Tusa sees increased risk of credit rating downgrade
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.41%
Consumer Discretionary
.SPLRCD
up 0.71%
Consumer Staples
.SPLRCS
up 0.45%
Energy
.SPNY
up 0.40%
Financial
.SPSY
up 1.34%
Health
.SPXHC
down 1.51%
Industrial
.SPLRCI
up 0.51%
Information Technology
.SPLRCT
down 0.26%
Materials
.SPLRCM
up 0.35%
Real Estate
.SPLRCR
up 1.66%
Utilities
.SPLRCU
up 0.03%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks edged higher on Monday on prospects of a post-pandemic economic recovery, but the sentiment remained fragile amid protests across the country over race and an ongoing standoff between Washington and Beijing. The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc , up 19 % ** Gap Inc , up 13.3 % ** Alliance Data Systems Corp , up 9.6 % The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc , down 8.2 % ** Gilead Sciences Inc , down 4.1 % ** NortonLifeLock Inc , down 3.6 % The top three NYSE .PG.N percentage gainers: ** Navigator Holdings Ltd , up 31.4 % ** Myovant Sciences Ltd , up 27.9 % ** Circor International Inc , up 20.6 % The top three NYSE .PL.N percentage losers: ** Evolent Health Inc , down 26.9 % ** Maiden Holdings Ltd , down 10.1 % ** Credit Suisse Velocity Shares , down 9 % The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc , up 149.2 % ** Digital Ally Inc , up 106.3 % ** Allied Esports Entertainment Inc , up 96.3 % The top three Nasdaq .PL.O percentage losers: ** Iterum Theraputics , down 51.1 % ** Arca Biopharma Inc , down 24.6 % ** Cyclacel Pharmaceuticals Inc. , down 21.6 % ** Smith & Wesson Brands Inc SWBI.O: up 17.1% ** Sturm Ruger & Co Inc RGR.N: up 11.8% ** Vista Outdoor Inc VSTO.N: up 10.5% BUZZ-Shares of gun makers jump on raging protests across U.S. cities ** CTI BioPharma corp CTIC.O: up 9.8% BUZZ- Up on enrolling first patient in COVID-19 drug study ** Cerence Inc CRNC.O: up 5.6% BUZZ-Up after Cowen raises PT on benefits from rising connected cars ** Proteostasis Therapeutics Inc PTI.O: UP 8.3% BUZZ- up after in vitro treatment study for COVID-19 shows promise ** Novus Therapeutics Inc NVUS.O: down 54% BUZZ- Plunges as co explores options after drug trial fails ** Gilead Sciences Inc GILD.O : down 3.6% BUZZ- Drops on mixed remdesivir results in moderate COVID-19 patients ** Virgin Galactic Holdings Inc SPCE.N: up 3.5% BUZZ-Lifts off after SpaceX's successful mission ** Ocugen Inc OCGN.O: down 28% BUZZ- Plummets after co scraps trial of lead eye disorder drug ** General Electric Co GE.N: up 2.1% BUZZ- JPM's Tusa sees increased risk of credit rating downgrade The 11 major S&P 500 sectors: Communication Services up 0.03% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks edged higher on Monday on prospects of a post-pandemic economic recovery, but the sentiment remained fragile amid protests across the country over race and an ongoing standoff between Washington and Beijing. The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc , up 19 % ** Gap Inc , up 13.3 % ** Alliance Data Systems Corp , up 9.6 % The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc , down 8.2 % ** Gilead Sciences Inc , down 4.1 % ** NortonLifeLock Inc , down 3.6 % The top three NYSE .PG.N percentage gainers: ** Navigator Holdings Ltd , up 31.4 % ** Myovant Sciences Ltd , up 27.9 % ** Circor International Inc , up 20.6 % The top three NYSE .PL.N percentage losers: ** Evolent Health Inc , down 26.9 % ** Maiden Holdings Ltd , down 10.1 % ** Credit Suisse Velocity Shares , down 9 % The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc , up 149.2 % ** Digital Ally Inc , up 106.3 % ** Allied Esports Entertainment Inc , up 96.3 % The top three Nasdaq .PL.O percentage losers: ** Iterum Theraputics , down 51.1 % ** Arca Biopharma Inc , down 24.6 % ** Cyclacel Pharmaceuticals Inc. , down 21.6 % ** Smith & Wesson Brands Inc SWBI.O: up 17.1% ** Sturm Ruger & Co Inc RGR.N: up 11.8% ** Vista Outdoor Inc VSTO.N: up 10.5% BUZZ-Shares of gun makers jump on raging protests across U.S. cities ** CTI BioPharma corp CTIC.O: up 9.8% BUZZ- Up on enrolling first patient in COVID-19 drug study ** Cerence Inc CRNC.O: up 5.6% BUZZ-Up after Cowen raises PT on benefits from rising connected cars ** Proteostasis Therapeutics Inc PTI.O: UP 8.3% BUZZ- up after in vitro treatment study for COVID-19 shows promise ** Novus Therapeutics Inc NVUS.O: down 54% BUZZ- Plunges as co explores options after drug trial fails ** Gilead Sciences Inc GILD.O : down 3.6% BUZZ- Drops on mixed remdesivir results in moderate COVID-19 patients ** Virgin Galactic Holdings Inc SPCE.N: up 3.5% BUZZ-Lifts off after SpaceX's successful mission ** Ocugen Inc OCGN.O: down 28% BUZZ- Plummets after co scraps trial of lead eye disorder drug ** General Electric Co GE.N: up 2.1% BUZZ- JPM's Tusa sees increased risk of credit rating downgrade The 11 major S&P 500 sectors: Communication Services up 0.03% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | .N At 11:30 ET, the Dow Jones Industrial Average .DJI was up 0.14% at 25,417.6. The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc , up 19 % ** Gap Inc , up 13.3 % ** Alliance Data Systems Corp , up 9.6 % The top three S&P 500 .PL.INX percentage losers: ** Pfizer Inc , down 8.2 % ** Gilead Sciences Inc , down 4.1 % ** NortonLifeLock Inc , down 3.6 % The top three NYSE .PG.N percentage gainers: ** Navigator Holdings Ltd , up 31.4 % ** Myovant Sciences Ltd , up 27.9 % ** Circor International Inc , up 20.6 % The top three NYSE .PL.N percentage losers: ** Evolent Health Inc , down 26.9 % ** Maiden Holdings Ltd , down 10.1 % ** Credit Suisse Velocity Shares , down 9 % The top three Nasdaq .PG.O percentage gainers: ** Cemtrex Inc , up 149.2 % ** Digital Ally Inc , up 106.3 % ** Allied Esports Entertainment Inc , up 96.3 % The top three Nasdaq .PL.O percentage losers: ** Iterum Theraputics , down 51.1 % ** Arca Biopharma Inc , down 24.6 % ** Cyclacel Pharmaceuticals Inc. , down 21.6 % ** Smith & Wesson Brands Inc SWBI.O: up 17.1% ** Sturm Ruger & Co Inc RGR.N: up 11.8% ** Vista Outdoor Inc VSTO.N: up 10.5% BUZZ-Shares of gun makers jump on raging protests across U.S. cities ** CTI BioPharma corp CTIC.O: up 9.8% BUZZ- Up on enrolling first patient in COVID-19 drug study ** Cerence Inc CRNC.O: up 5.6% BUZZ-Up after Cowen raises PT on benefits from rising connected cars ** Proteostasis Therapeutics Inc PTI.O: UP 8.3% BUZZ- up after in vitro treatment study for COVID-19 shows promise ** Novus Therapeutics Inc NVUS.O: down 54% BUZZ- Plunges as co explores options after drug trial fails ** Gilead Sciences Inc GILD.O : down 3.6% BUZZ- Drops on mixed remdesivir results in moderate COVID-19 patients ** Virgin Galactic Holdings Inc SPCE.N: up 3.5% BUZZ-Lifts off after SpaceX's successful mission ** Ocugen Inc OCGN.O: down 28% BUZZ- Plummets after co scraps trial of lead eye disorder drug ** General Electric Co GE.N: up 2.1% BUZZ- JPM's Tusa sees increased risk of credit rating downgrade The 11 major S&P 500 sectors: Communication Services up 0.41% Consumer Discretionary | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks edged higher on Monday on prospects of a post-pandemic economic recovery, but the sentiment remained fragile amid protests across the country over race and an ongoing standoff between Washington and Beijing. .N At 11:30 ET, the Dow Jones Industrial Average .DJI was up 0.14% at 25,417.6. The S&P 500 .SPX was up 0.10% at 3,047.22 and the Nasdaq Composite .IXIC was up 0.32% at 9,519.982. |
29036.0 | 2020-05-29 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Sonoma Pharma, Jaguar Health, Zscaler | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-sonoma-pharma-jaguar-health-zscaler-2020-05-29 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock futures dropped on Friday as investors braced for President Donald Trump's response to China's national security legislation for Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. .N
At 07:30 ET, Dow e-minis 1YMc1 were down 0.44% at 25,346. S&P 500 e-minis ESc1 were down 0.29% at 3,029.25, while Nasdaq 100 e-minis NQc1 were down 0.26% at 9,435.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 90.2% ** GasLog Partners LP Unit , up 14.2% ** California Resources Corp , up 13.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Weidai Ltd , down 10.4% ** Apergy Corp , down 10.2% ** Albemarle Corporation , down 9.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 94.1% ** Jaguar Health Inc , up 18.3% ** Sesen Bio Inc , up 17.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Toughbuilt Industries Inc , down 20.5% ** Arca Biopharma Inc , down 19.9% ** Marinus Pharmaceuticals Inc , down 16.8% ** Sonoma Pharmaceutical Inc SNOA.O: up 94.1% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 18.3% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 15.6% premarket BUZZ-Jumps as work-from-home trends drive results beat
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock futures dropped on Friday as investors braced for President Donald Trump's response to China's national security legislation for Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. .N At 07:30 ET, Dow e-minis 1YMc1 were down 0.44% at 25,346. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 90.2% ** GasLog Partners LP Unit , up 14.2% ** California Resources Corp , up 13.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Weidai Ltd , down 10.4% ** Apergy Corp , down 10.2% ** Albemarle Corporation , down 9.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 94.1% ** Jaguar Health Inc , up 18.3% ** Sesen Bio Inc , up 17.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Toughbuilt Industries Inc , down 20.5% ** Arca Biopharma Inc , down 19.9% ** Marinus Pharmaceuticals Inc , down 16.8% ** Sonoma Pharmaceutical Inc SNOA.O: up 94.1% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 18.3% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 15.6% premarket BUZZ-Jumps as work-from-home trends drive results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock futures dropped on Friday as investors braced for President Donald Trump's response to China's national security legislation for Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. S&P 500 e-minis ESc1 were down 0.29% at 3,029.25, while Nasdaq 100 e-minis NQc1 were down 0.26% at 9,435.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 90.2% ** GasLog Partners LP Unit , up 14.2% ** California Resources Corp , up 13.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Weidai Ltd , down 10.4% ** Apergy Corp , down 10.2% ** Albemarle Corporation , down 9.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 94.1% ** Jaguar Health Inc , up 18.3% ** Sesen Bio Inc , up 17.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Toughbuilt Industries Inc , down 20.5% ** Arca Biopharma Inc , down 19.9% ** Marinus Pharmaceuticals Inc , down 16.8% ** Sonoma Pharmaceutical Inc SNOA.O: up 94.1% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 18.3% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 15.6% premarket BUZZ-Jumps as work-from-home trends drive results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock futures dropped on Friday as investors braced for President Donald Trump's response to China's national security legislation for Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. S&P 500 e-minis ESc1 were down 0.29% at 3,029.25, while Nasdaq 100 e-minis NQc1 were down 0.26% at 9,435.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 90.2% ** GasLog Partners LP Unit , up 14.2% ** California Resources Corp , up 13.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Weidai Ltd , down 10.4% ** Apergy Corp , down 10.2% ** Albemarle Corporation , down 9.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 94.1% ** Jaguar Health Inc , up 18.3% ** Sesen Bio Inc , up 17.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Toughbuilt Industries Inc , down 20.5% ** Arca Biopharma Inc , down 19.9% ** Marinus Pharmaceuticals Inc , down 16.8% ** Sonoma Pharmaceutical Inc SNOA.O: up 94.1% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 18.3% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 15.6% premarket BUZZ-Jumps as work-from-home trends drive results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock futures dropped on Friday as investors braced for President Donald Trump's response to China's national security legislation for Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. .N At 07:30 ET, Dow e-minis 1YMc1 were down 0.44% at 25,346. S&P 500 e-minis ESc1 were down 0.29% at 3,029.25, while Nasdaq 100 e-minis NQc1 were down 0.26% at 9,435.5. |
29037.0 | 2020-05-29 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Phio Pharma, Sonoma Pharma, Adaptimmune | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-phio-pharma-sonoma-pharma-adaptimmune-2020-05-29 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes fell on Friday as investors were on edge ahead of a U.S. response to China's national security law on Hong Kong that threatens to take the shine off another month of strong gains for the stock market. .N
At 11:25 a.m. ET, the Dow Jones Industrial Average .DJI was down 0.70% at 25,223.75. The S&P 500 .SPX was down 0.47% at 3,015.61 and the Nasdaq Composite .IXIC was down 0.05% at 9,364.599. The top three S&P 500 .PG.INX percentage gainers: ** Dollar General Corp , up 3.6% ** Citrix Systems Inc , up 3% ** Domino's Pizza Inc , up 2.7% The top three S&P 500 .PL.INX percentage losers: ** DXC Technology Co , down 9.9% ** Nordstrom Inc , down 9.9% ** Coty Inc , down 7.9% The top three NYSE .PG.N percentage gainers: ** Culp Inc , up 17.8% ** Williams-Sonoma Inc , up 16.2% ** Invesco S&P 500 Value with Momentum ETF , up 13.5% The top three NYSE .PL.N percentage losers: ** AMTD International Inc , down 22.3% ** Canopy Growth Corp , down 20.2% ** Triumph Group Inc , down 17.8% The top three Nasdaq .PG.O percentage gainers: ** Sonoma Pharmaceuticals Inc , up 165.1% ** Phio Pharmaceuticals Corp , up 96.4% ** Adaptimmune Therapeutics Plc , up 92.4% The top three Nasdaq .PL.O percentage losers: ** Minerva Neurosciences Inc , down 81.1% ** Arca Biopharma Inc , down 31% ** Arvinas Inc , down 28.7% ** Phio Pharmaceuticals Inc PHIO.O: up 96.4%
BUZZ-More than doubles as pipeline shows 'great promise' in hindering tumor growth ** Arcus Biosciences Inc RCUS.N: up 12.0%
BUZZ-Rebounds as equity raise upsized by 50% ** China Finance Online Co Ltd JRJC.O: up 12.7%
BUZZ-Jumps as quarterly loss narrows ** Comstock Holding Companies Inc CHCI.O: up 25.0%
BUZZ-Surges on strong quarterly revenue ** TRACON Pharmaceuticals Inc TCON.O: up 7.2%
BUZZ-Up on highlighting positive data from cancer therapy studies ** Zagg Inc ZAGG.O: down 5.9%
BUZZ-Slumps after disappointing results [BUZZ-Zagg Inc: Slumps after disappointing results] ** Zentalis Pharmaceuticals Inc ZNTL.O: down 1.9%
BUZZ- Zentalis to mitigate COVID-19 impact to trials through geographical expansion - SVB Leerink ** Minerva Neurosciences Inc NERV.O: down 81.1%
BUZZ-Plunges after schizophrenia drug fails trial ** Glu Mobile Inc GLUU.O: up 11.5%
BUZZ-Jumps as co raises bookings forecast ** Five Below Inc FIVE.O: up 1.4%
BUZZ-Up on reopening over 75% stores ** Salesforce.com Inc CRM.N: down 4.1%
BUZZ-Slips as co cuts annual estimates on virus hit ** Adaptimmune Therapeutics Inc ADAP.O: up 92.4%
BUZZ-More than doubles on updated data from cell therapy studies ** Culp Inc CULP.N: up 17.8%
BUZZ-Climbs as Stifel upgrades, says stock inexpensive ** Sonoma Pharmaceutical Inc SNOA.O: up 165.1% BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 20.0% BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 24.9% BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 4.8% BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 7.7% BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 16.4% BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 7.1% BUZZ-Falls after pricing $40 mln stock offering ** Thor Industries Inc THO.N: up 1.9% BUZZ-Rises on strong RV demand outlook ** ToughBuilt Industries Inc TBLT.O: down 21.8% BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 41.2% BUZZ-Surges on transaction support agreement ** Goldman Sachs Group Inc GS.N: down 0.9% ** JPMorgan Chase & Co JPM.N: down 1.6% ** Citigroup Inc C.N: down 1.6% ** Wells Fargo & Co WFC.N: down 1.6% ** Bank of America Corp BAC.N: down 1.3%
** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. Banks: Drop as yields edge lower ** DXC Technology Inc DXC.N: down 9.9% BUZZ-Drops on PT cuts after dividend suspension, revenue miss ** Abercrombie & Fitch Co ANF.N: up 2.5% BUZZ-Street View: Abercrombie and Fitch has potential for growth through the year ** Vir Biotechnology Inc VIR.O: up 1.0% BUZZ-Up on finalizing Biogen collab for potential COVID-19 treatment
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.36%
Consumer Discretionary
.SPLRCD
up 0.03%
Consumer Staples
.SPLRCS
down 0.74%
Energy
.SPNY
down 1.22%
Financial
.SPSY
down 1.03%
Health
.SPXHC
down 0.54%
Industrial
.SPLRCI
down 1.14%
Information Technology
.SPLRCT
down 0.09%
Materials
.SPLRCM
down 0.33%
Real Estate
.SPLRCR
down 0.81%
Utilities
.SPLRCU
down 0.15%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday as investors were on edge ahead of a U.S. response to China's national security law on Hong Kong that threatens to take the shine off another month of strong gains for the stock market. The top three S&P 500 .PG.INX percentage gainers: ** Dollar General Corp , up 3.6% ** Citrix Systems Inc , up 3% ** Domino's Pizza Inc , up 2.7% The top three S&P 500 .PL.INX percentage losers: ** DXC Technology Co , down 9.9% ** Nordstrom Inc , down 9.9% ** Coty Inc , down 7.9% The top three NYSE .PG.N percentage gainers: ** Culp Inc , up 17.8% ** Williams-Sonoma Inc , up 16.2% ** Invesco S&P 500 Value with Momentum ETF , up 13.5% The top three NYSE .PL.N percentage losers: ** AMTD International Inc , down 22.3% ** Canopy Growth Corp , down 20.2% ** Triumph Group Inc , down 17.8% The top three Nasdaq .PG.O percentage gainers: ** Sonoma Pharmaceuticals Inc , up 165.1% ** Phio Pharmaceuticals Corp , up 96.4% ** Adaptimmune Therapeutics Plc , up 92.4% The top three Nasdaq .PL.O percentage losers: ** Minerva Neurosciences Inc , down 81.1% ** Arca Biopharma Inc , down 31% ** Arvinas Inc , down 28.7% ** Phio Pharmaceuticals Inc PHIO.O: up 96.4% BUZZ-More than doubles as pipeline shows 'great promise' in hindering tumor growth ** Arcus Biosciences Inc RCUS.N: up 12.0% BUZZ-Rebounds as equity raise upsized by 50% ** China Finance Online Co Ltd JRJC.O: up 12.7% BUZZ-Jumps as quarterly loss narrows ** Comstock Holding Companies Inc CHCI.O: up 25.0% BUZZ-Surges on strong quarterly revenue ** TRACON Pharmaceuticals Inc TCON.O: up 7.2% BUZZ-Up on highlighting positive data from cancer therapy studies ** Zagg Inc ZAGG.O: down 5.9% BUZZ-Slumps after disappointing results [BUZZ-Zagg Inc: Slumps after disappointing results] ** Zentalis Pharmaceuticals Inc ZNTL.O: down 1.9% BUZZ- Zentalis to mitigate COVID-19 impact to trials through geographical expansion - SVB Leerink ** Minerva Neurosciences Inc NERV.O: down 81.1% BUZZ-Plunges after schizophrenia drug fails trial ** Glu Mobile Inc GLUU.O: up 11.5% BUZZ-Jumps as co raises bookings forecast ** Five Below Inc FIVE.O: up 1.4% BUZZ-Up on reopening over 75% stores ** Salesforce.com Inc CRM.N: down 4.1% BUZZ-Slips as co cuts annual estimates on virus hit ** Adaptimmune Therapeutics Inc ADAP.O: up 92.4% BUZZ-More than doubles on updated data from cell therapy studies ** Culp Inc CULP.N: up 17.8% BUZZ-Climbs as Stifel upgrades, says stock inexpensive ** Sonoma Pharmaceutical Inc SNOA.O: up 165.1% BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 20.0% BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 24.9% BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 4.8% BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 7.7% BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 16.4% BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 7.1% BUZZ-Falls after pricing $40 mln stock offering ** Thor Industries Inc THO.N: up 1.9% BUZZ-Rises on strong RV demand outlook ** ToughBuilt Industries Inc TBLT.O: down 21.8% BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 41.2% BUZZ-Surges on transaction support agreement ** Goldman Sachs Group Inc GS.N: down 0.9% ** JPMorgan Chase & Co JPM.N: down 1.6% ** Citigroup Inc C.N: down 1.6% ** Wells Fargo & Co WFC.N: down 1.6% ** Bank of America Corp BAC.N: down 1.3% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. Banks: Drop as yields edge lower ** DXC Technology Inc DXC.N: down 9.9% BUZZ-Drops on PT cuts after dividend suspension, revenue miss ** Abercrombie & Fitch Co ANF.N: up 2.5% BUZZ-Street View: Abercrombie and Fitch has potential for growth through the year ** Vir Biotechnology Inc VIR.O: up 1.0% BUZZ-Up on finalizing Biogen collab for potential COVID-19 treatment The 11 major S&P 500 sectors: Communication Services down 0.15% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday as investors were on edge ahead of a U.S. response to China's national security law on Hong Kong that threatens to take the shine off another month of strong gains for the stock market. The top three S&P 500 .PG.INX percentage gainers: ** Dollar General Corp , up 3.6% ** Citrix Systems Inc , up 3% ** Domino's Pizza Inc , up 2.7% The top three S&P 500 .PL.INX percentage losers: ** DXC Technology Co , down 9.9% ** Nordstrom Inc , down 9.9% ** Coty Inc , down 7.9% The top three NYSE .PG.N percentage gainers: ** Culp Inc , up 17.8% ** Williams-Sonoma Inc , up 16.2% ** Invesco S&P 500 Value with Momentum ETF , up 13.5% The top three NYSE .PL.N percentage losers: ** AMTD International Inc , down 22.3% ** Canopy Growth Corp , down 20.2% ** Triumph Group Inc , down 17.8% The top three Nasdaq .PG.O percentage gainers: ** Sonoma Pharmaceuticals Inc , up 165.1% ** Phio Pharmaceuticals Corp , up 96.4% ** Adaptimmune Therapeutics Plc , up 92.4% The top three Nasdaq .PL.O percentage losers: ** Minerva Neurosciences Inc , down 81.1% ** Arca Biopharma Inc , down 31% ** Arvinas Inc , down 28.7% ** Phio Pharmaceuticals Inc PHIO.O: up 96.4% BUZZ-More than doubles as pipeline shows 'great promise' in hindering tumor growth ** Arcus Biosciences Inc RCUS.N: up 12.0% BUZZ-Rebounds as equity raise upsized by 50% ** China Finance Online Co Ltd JRJC.O: up 12.7% BUZZ-Jumps as quarterly loss narrows ** Comstock Holding Companies Inc CHCI.O: up 25.0% BUZZ-Surges on strong quarterly revenue ** TRACON Pharmaceuticals Inc TCON.O: up 7.2% BUZZ-Up on highlighting positive data from cancer therapy studies ** Zagg Inc ZAGG.O: down 5.9% BUZZ-Slumps after disappointing results [BUZZ-Zagg Inc: Slumps after disappointing results] ** Zentalis Pharmaceuticals Inc ZNTL.O: down 1.9% BUZZ- Zentalis to mitigate COVID-19 impact to trials through geographical expansion - SVB Leerink ** Minerva Neurosciences Inc NERV.O: down 81.1% BUZZ-Plunges after schizophrenia drug fails trial ** Glu Mobile Inc GLUU.O: up 11.5% BUZZ-Jumps as co raises bookings forecast ** Five Below Inc FIVE.O: up 1.4% BUZZ-Up on reopening over 75% stores ** Salesforce.com Inc CRM.N: down 4.1% BUZZ-Slips as co cuts annual estimates on virus hit ** Adaptimmune Therapeutics Inc ADAP.O: up 92.4% BUZZ-More than doubles on updated data from cell therapy studies ** Culp Inc CULP.N: up 17.8% BUZZ-Climbs as Stifel upgrades, says stock inexpensive ** Sonoma Pharmaceutical Inc SNOA.O: up 165.1% BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 20.0% BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 24.9% BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 4.8% BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 7.7% BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 16.4% BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 7.1% BUZZ-Falls after pricing $40 mln stock offering ** Thor Industries Inc THO.N: up 1.9% BUZZ-Rises on strong RV demand outlook ** ToughBuilt Industries Inc TBLT.O: down 21.8% BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 41.2% BUZZ-Surges on transaction support agreement ** Goldman Sachs Group Inc GS.N: down 0.9% ** JPMorgan Chase & Co JPM.N: down 1.6% ** Citigroup Inc C.N: down 1.6% ** Wells Fargo & Co WFC.N: down 1.6% ** Bank of America Corp BAC.N: down 1.3% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. Banks: Drop as yields edge lower ** DXC Technology Inc DXC.N: down 9.9% BUZZ-Drops on PT cuts after dividend suspension, revenue miss ** Abercrombie & Fitch Co ANF.N: up 2.5% BUZZ-Street View: Abercrombie and Fitch has potential for growth through the year ** Vir Biotechnology Inc VIR.O: up 1.0% BUZZ-Up on finalizing Biogen collab for potential COVID-19 treatment The 11 major S&P 500 sectors: Communication Services down 0.15% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Dollar General Corp , up 3.6% ** Citrix Systems Inc , up 3% ** Domino's Pizza Inc , up 2.7% The top three S&P 500 .PL.INX percentage losers: ** DXC Technology Co , down 9.9% ** Nordstrom Inc , down 9.9% ** Coty Inc , down 7.9% The top three NYSE .PG.N percentage gainers: ** Culp Inc , up 17.8% ** Williams-Sonoma Inc , up 16.2% ** Invesco S&P 500 Value with Momentum ETF , up 13.5% The top three NYSE .PL.N percentage losers: ** AMTD International Inc , down 22.3% ** Canopy Growth Corp , down 20.2% ** Triumph Group Inc , down 17.8% The top three Nasdaq .PG.O percentage gainers: ** Sonoma Pharmaceuticals Inc , up 165.1% ** Phio Pharmaceuticals Corp , up 96.4% ** Adaptimmune Therapeutics Plc , up 92.4% The top three Nasdaq .PL.O percentage losers: ** Minerva Neurosciences Inc , down 81.1% ** Arca Biopharma Inc , down 31% ** Arvinas Inc , down 28.7% ** Phio Pharmaceuticals Inc PHIO.O: up 96.4% BUZZ-More than doubles as pipeline shows 'great promise' in hindering tumor growth ** Arcus Biosciences Inc RCUS.N: up 12.0% BUZZ-Rebounds as equity raise upsized by 50% ** China Finance Online Co Ltd JRJC.O: up 12.7% BUZZ-Jumps as quarterly loss narrows ** Comstock Holding Companies Inc CHCI.O: up 25.0% BUZZ-Surges on strong quarterly revenue ** TRACON Pharmaceuticals Inc TCON.O: up 7.2% BUZZ-Up on highlighting positive data from cancer therapy studies ** Zagg Inc ZAGG.O: down 5.9% BUZZ-Slumps after disappointing results [BUZZ-Zagg Inc: Slumps after disappointing results] ** Zentalis Pharmaceuticals Inc ZNTL.O: down 1.9% BUZZ- Zentalis to mitigate COVID-19 impact to trials through geographical expansion - SVB Leerink ** Minerva Neurosciences Inc NERV.O: down 81.1% BUZZ-Plunges after schizophrenia drug fails trial ** Glu Mobile Inc GLUU.O: up 11.5% BUZZ-Jumps as co raises bookings forecast ** Five Below Inc FIVE.O: up 1.4% BUZZ-Up on reopening over 75% stores ** Salesforce.com Inc CRM.N: down 4.1% BUZZ-Slips as co cuts annual estimates on virus hit ** Adaptimmune Therapeutics Inc ADAP.O: up 92.4% BUZZ-More than doubles on updated data from cell therapy studies ** Culp Inc CULP.N: up 17.8% BUZZ-Climbs as Stifel upgrades, says stock inexpensive ** Sonoma Pharmaceutical Inc SNOA.O: up 165.1% BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 20.0% BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 24.9% BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 4.8% BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 7.7% BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 16.4% BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 7.1% BUZZ-Falls after pricing $40 mln stock offering ** Thor Industries Inc THO.N: up 1.9% BUZZ-Rises on strong RV demand outlook ** ToughBuilt Industries Inc TBLT.O: down 21.8% BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 41.2% BUZZ-Surges on transaction support agreement ** Goldman Sachs Group Inc GS.N: down 0.9% ** JPMorgan Chase & Co JPM.N: down 1.6% ** Citigroup Inc C.N: down 1.6% ** Wells Fargo & Co WFC.N: down 1.6% ** Bank of America Corp BAC.N: down 1.3% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. Banks: Drop as yields edge lower ** DXC Technology Inc DXC.N: down 9.9% BUZZ-Drops on PT cuts after dividend suspension, revenue miss ** Abercrombie & Fitch Co ANF.N: up 2.5% BUZZ-Street View: Abercrombie and Fitch has potential for growth through the year ** Vir Biotechnology Inc VIR.O: up 1.0% BUZZ-Up on finalizing Biogen collab for potential COVID-19 treatment The 11 major S&P 500 sectors: Communication Services down 0.36% Consumer Discretionary up 0.03% Consumer Staples | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday as investors were on edge ahead of a U.S. response to China's national security law on Hong Kong that threatens to take the shine off another month of strong gains for the stock market. ET, the Dow Jones Industrial Average .DJI was down 0.70% at 25,223.75. The S&P 500 .SPX was down 0.47% at 3,015.61 and the Nasdaq Composite .IXIC was down 0.05% at 9,364.599. |
29038.0 | 2020-05-29 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Sonoma Pharma, Marinus Pharma, Party City | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-sonoma-pharma-marinus-pharma-party-city-2020-05-29 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and the Dow were set to open lower on Friday as investors braced for a U.S. response to China's national security law on Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. .N
At 8:02 a.m. ET, Dow e-minis 1YMc1 were down 0.44% at 25,344. S&P 500 e-minis ESc1 were down 0.27% at 3,029.75, while Nasdaq 100 e-minis NQc1 were up 0.13% at 9,472.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 67.6% ** Valmont Industries Inc , up 38.5% ** Big Lots Inc , up 14.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Canopy Growth Corp , down 19.9% ** Weidai Ltd , down 10.4% ** Cross Timbers Royalty Trust , down 8.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 177.3% ** Onconova Therapeutics Equity Warrants , up 85.2% ** Adaptimmune Therapeutics Plc , up 47.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Larimar Therapeutics Inc , down 66.2% ** ARCA Biopharma Inc , down 28.9% ** Arvinas Inc , down 24.2% ** Sonoma Pharmaceutical Inc SNOA.O: up 177.3% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 32.8% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 19.5% premarket BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 14.5% premarket BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 8.7% premarket BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 8.5% premarket BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 13.9% premarket BUZZ-Falls after pricing $40 mln stock offering ** ToughBuilt Industries Inc TBLT.O: down 19.5% premarket BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 67.6% premarket BUZZ-Surges on transaction support agreement ** PG&E Corp PCG.N: up 5.6% premarket BUZZ-Rises on regulatory nod for Chapter 11 reorganization plan
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow were set to open lower on Friday as investors braced for a U.S. response to China's national security law on Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. ET, Dow e-minis 1YMc1 were down 0.44% at 25,344. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 67.6% ** Valmont Industries Inc , up 38.5% ** Big Lots Inc , up 14.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Canopy Growth Corp , down 19.9% ** Weidai Ltd , down 10.4% ** Cross Timbers Royalty Trust , down 8.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 177.3% ** Onconova Therapeutics Equity Warrants , up 85.2% ** Adaptimmune Therapeutics Plc , up 47.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Larimar Therapeutics Inc , down 66.2% ** ARCA Biopharma Inc , down 28.9% ** Arvinas Inc , down 24.2% ** Sonoma Pharmaceutical Inc SNOA.O: up 177.3% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 32.8% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 19.5% premarket BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 14.5% premarket BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 8.7% premarket BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 8.5% premarket BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 13.9% premarket BUZZ-Falls after pricing $40 mln stock offering ** ToughBuilt Industries Inc TBLT.O: down 19.5% premarket BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 67.6% premarket BUZZ-Surges on transaction support agreement ** PG&E Corp PCG.N: up 5.6% premarket BUZZ-Rises on regulatory nod for Chapter 11 reorganization plan (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow were set to open lower on Friday as investors braced for a U.S. response to China's national security law on Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. ET, Dow e-minis 1YMc1 were down 0.44% at 25,344. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 67.6% ** Valmont Industries Inc , up 38.5% ** Big Lots Inc , up 14.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Canopy Growth Corp , down 19.9% ** Weidai Ltd , down 10.4% ** Cross Timbers Royalty Trust , down 8.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 177.3% ** Onconova Therapeutics Equity Warrants , up 85.2% ** Adaptimmune Therapeutics Plc , up 47.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Larimar Therapeutics Inc , down 66.2% ** ARCA Biopharma Inc , down 28.9% ** Arvinas Inc , down 24.2% ** Sonoma Pharmaceutical Inc SNOA.O: up 177.3% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 32.8% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 19.5% premarket BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 14.5% premarket BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 8.7% premarket BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 8.5% premarket BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 13.9% premarket BUZZ-Falls after pricing $40 mln stock offering ** ToughBuilt Industries Inc TBLT.O: down 19.5% premarket BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 67.6% premarket BUZZ-Surges on transaction support agreement ** PG&E Corp PCG.N: up 5.6% premarket BUZZ-Rises on regulatory nod for Chapter 11 reorganization plan (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow were set to open lower on Friday as investors braced for a U.S. response to China's national security law on Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. S&P 500 e-minis ESc1 were down 0.27% at 3,029.75, while Nasdaq 100 e-minis NQc1 were up 0.13% at 9,472.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Party City Holdco Inc , up 67.6% ** Valmont Industries Inc , up 38.5% ** Big Lots Inc , up 14.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Canopy Growth Corp , down 19.9% ** Weidai Ltd , down 10.4% ** Cross Timbers Royalty Trust , down 8.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sonoma Pharmaceuticals Inc , up 177.3% ** Onconova Therapeutics Equity Warrants , up 85.2% ** Adaptimmune Therapeutics Plc , up 47.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Larimar Therapeutics Inc , down 66.2% ** ARCA Biopharma Inc , down 28.9% ** Arvinas Inc , down 24.2% ** Sonoma Pharmaceutical Inc SNOA.O: up 177.3% premarket BUZZ-Surges after COVID-19 disinfectant approved in Australia ** Jaguar Health Inc JAGX.O: up 32.8% premarket BUZZ-Jumps on approval to test diarrhea drug for COVID-19 ** Zscaler Inc ZS.O: up 19.5% premarket BUZZ-Jumps as work-from-home trends drive results beat ** Big Lots Inc BIG.N: up 14.5% premarket BUZZ-Surges on robust comparable sales, strong Q2 start ** VMware Inc VMW.N: up 8.7% premarket BUZZ-Jumps on revenue beat; brokerages raise PT ** Williams-Sonoma Inc WSM.N: up 8.5% premarket BUZZ-Jumps as results top estimates on higher online sales ** Marinus Pharmaceuticals Inc MRNS.O: down 13.9% premarket BUZZ-Falls after pricing $40 mln stock offering ** ToughBuilt Industries Inc TBLT.O: down 19.5% premarket BUZZ-Falls after pricing stock and warrant offering ** Party City Holdco Inc PRTY.N: up 67.6% premarket BUZZ-Surges on transaction support agreement ** PG&E Corp PCG.N: up 5.6% premarket BUZZ-Rises on regulatory nod for Chapter 11 reorganization plan (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow were set to open lower on Friday as investors braced for a U.S. response to China's national security law on Hong Kong, threatening to take the shine off another month of strong gains for Wall Street. ET, Dow e-minis 1YMc1 were down 0.44% at 25,344. S&P 500 e-minis ESc1 were down 0.27% at 3,029.75, while Nasdaq 100 e-minis NQc1 were up 0.13% at 9,472.5. |
29039.0 | 2020-05-28 00:00:00 UTC | Stock Alert: ARCA Biopharma Surges 175% On News Of COVID-19 Treatment | ABIO | https://www.nasdaq.com/articles/stock-alert%3A-arca-biopharma-surges-175-on-news-of-covid-19-treatment-2020-05-28 | nan | nan | (RTTNews) - Shares of ARCA biopharma Inc. (ABIO) soared nearly 175% on Thursday morning after the company announced a program for COVID-19 treatment.
ARCA Biopharma is launching a new development program surrounding AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response, the company said in a statement.
COVID-19 associated coagulopathy is one of the most serious side effects seen in COVID-19 patients. AB201 has undergone clinical testing in a Phase 2 trial including more than 700 patients. The treatment has generated substantial safety data that the company said could speed up the development process.
Michael Bristow, ARCA's CEO, said, "The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID-19 while vaccine development is underway and for patients for whom a vaccine is not effective."
ABIO is currently trading at $10.83, $6.88 or 174.18%, on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Shares of ARCA biopharma Inc. (ABIO) soared nearly 175% on Thursday morning after the company announced a program for COVID-19 treatment. ABIO is currently trading at $10.83, $6.88 or 174.18%, on the Nasdaq. ARCA Biopharma is launching a new development program surrounding AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response, the company said in a statement. | (RTTNews) - Shares of ARCA biopharma Inc. (ABIO) soared nearly 175% on Thursday morning after the company announced a program for COVID-19 treatment. ABIO is currently trading at $10.83, $6.88 or 174.18%, on the Nasdaq. ARCA Biopharma is launching a new development program surrounding AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response, the company said in a statement. | (RTTNews) - Shares of ARCA biopharma Inc. (ABIO) soared nearly 175% on Thursday morning after the company announced a program for COVID-19 treatment. ABIO is currently trading at $10.83, $6.88 or 174.18%, on the Nasdaq. ARCA Biopharma is launching a new development program surrounding AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response, the company said in a statement. | (RTTNews) - Shares of ARCA biopharma Inc. (ABIO) soared nearly 175% on Thursday morning after the company announced a program for COVID-19 treatment. ABIO is currently trading at $10.83, $6.88 or 174.18%, on the Nasdaq. COVID-19 associated coagulopathy is one of the most serious side effects seen in COVID-19 patients. |
29040.0 | 2020-05-28 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Aerpio Pharma, Arena Pharma, Triumph Group | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-aerpio-pharma-arena-pharma-triumph-group-2020-05-28 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 looked set for a subdued open on Thursday as investors paused for breath after three days of gains and weighed signs of an economic recovery against underlying tensions between the United States and China. .N
At 8:20 a.m. ET, Dow e-minis 1YMc1 were up 0.59% at 25,685. S&P 500 e-minis ESc1 were up 0.16% at 3,040.5, while Nasdaq 100 e-minis NQc1 were down 0.63% at 9,373.25. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Knowles Corp , up 19.6% ** Triumph Group Inc , up 19.2% ** CBL & Associates Properties Inc , up 17.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hertz Global Holdings Inc , down 15.3% ** U.S. Silica Holdings Inc , down 11% ** Goldman Sachs MLP and Energy Renasissance Fund , down 8.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Hexindai Inc , up 152.1% ** Arca Biopharma Inc , up 68.4% ** Technical Communications Corp , up 60.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Greenpro Capital Corp , down 24% ** Neurotrope Inc , down 14.3% ** Sintx Technologies Inc , down 14.2% ** Bill.com Holdings Inc BILL.N: up 2.6% premarket BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 43.2% premarket BUZZ-Surges after eye drug selected for COVID-19 study ** Consolidated Edison Inc ED.N: down 0.2% premarket BUZZ-JPM flags risk from anti-gas infrastructure efforts ** Hertz Global Holdings Inc HTZ.N: down 15.3% premarket BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 4.3% premarket BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 4.7% premarket ** Spirit AeroSystems Holdings Inc SPR.N: up 5.9% premarket ** General Electric Co GE.N: up 2.6% premarket ** Raytheon Technologies Corp RTX.N: up 2.2% premarket BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 0.8% premarket BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 6.1% premarket BUZZ-Drops after pricing $100 mln stock offering ** Canadian Solar Inc CSIQ.O: up 3.0% premarket BUZZ-Rises on returning to profit in Q1, co sees soft market in H2 ** Triumph Group Inc TGI.N: up 19.2% premarket BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 11.6% premarket BUZZ-Falls on $250 mln stock deal plans ** Dollar Tree Inc DLTR.O: up 8.1% premarket BUZZ-Surges as panic buying drives Q1 sales
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 looked set for a subdued open on Thursday as investors paused for breath after three days of gains and weighed signs of an economic recovery against underlying tensions between the United States and China. ET, Dow e-minis 1YMc1 were up 0.59% at 25,685. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Knowles Corp , up 19.6% ** Triumph Group Inc , up 19.2% ** CBL & Associates Properties Inc , up 17.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hertz Global Holdings Inc , down 15.3% ** U.S. Silica Holdings Inc , down 11% ** Goldman Sachs MLP and Energy Renasissance Fund , down 8.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Hexindai Inc , up 152.1% ** Arca Biopharma Inc , up 68.4% ** Technical Communications Corp , up 60.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Greenpro Capital Corp , down 24% ** Neurotrope Inc , down 14.3% ** Sintx Technologies Inc , down 14.2% ** Bill.com Holdings Inc BILL.N: up 2.6% premarket BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 43.2% premarket BUZZ-Surges after eye drug selected for COVID-19 study ** Consolidated Edison Inc ED.N: down 0.2% premarket BUZZ-JPM flags risk from anti-gas infrastructure efforts ** Hertz Global Holdings Inc HTZ.N: down 15.3% premarket BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 4.3% premarket BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 4.7% premarket ** Spirit AeroSystems Holdings Inc SPR.N: up 5.9% premarket ** General Electric Co GE.N: up 2.6% premarket ** Raytheon Technologies Corp RTX.N: up 2.2% premarket BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 0.8% premarket BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 6.1% premarket BUZZ-Drops after pricing $100 mln stock offering ** Canadian Solar Inc CSIQ.O: up 3.0% premarket BUZZ-Rises on returning to profit in Q1, co sees soft market in H2 ** Triumph Group Inc TGI.N: up 19.2% premarket BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 11.6% premarket BUZZ-Falls on $250 mln stock deal plans ** Dollar Tree Inc DLTR.O: up 8.1% premarket BUZZ-Surges as panic buying drives Q1 sales (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 looked set for a subdued open on Thursday as investors paused for breath after three days of gains and weighed signs of an economic recovery against underlying tensions between the United States and China. S&P 500 e-minis ESc1 were up 0.16% at 3,040.5, while Nasdaq 100 e-minis NQc1 were down 0.63% at 9,373.25. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Knowles Corp , up 19.6% ** Triumph Group Inc , up 19.2% ** CBL & Associates Properties Inc , up 17.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hertz Global Holdings Inc , down 15.3% ** U.S. Silica Holdings Inc , down 11% ** Goldman Sachs MLP and Energy Renasissance Fund , down 8.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Hexindai Inc , up 152.1% ** Arca Biopharma Inc , up 68.4% ** Technical Communications Corp , up 60.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Greenpro Capital Corp , down 24% ** Neurotrope Inc , down 14.3% ** Sintx Technologies Inc , down 14.2% ** Bill.com Holdings Inc BILL.N: up 2.6% premarket BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 43.2% premarket BUZZ-Surges after eye drug selected for COVID-19 study ** Consolidated Edison Inc ED.N: down 0.2% premarket BUZZ-JPM flags risk from anti-gas infrastructure efforts ** Hertz Global Holdings Inc HTZ.N: down 15.3% premarket BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 4.3% premarket BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 4.7% premarket ** Spirit AeroSystems Holdings Inc SPR.N: up 5.9% premarket ** General Electric Co GE.N: up 2.6% premarket ** Raytheon Technologies Corp RTX.N: up 2.2% premarket BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 0.8% premarket BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 6.1% premarket BUZZ-Drops after pricing $100 mln stock offering ** Canadian Solar Inc CSIQ.O: up 3.0% premarket BUZZ-Rises on returning to profit in Q1, co sees soft market in H2 ** Triumph Group Inc TGI.N: up 19.2% premarket BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 11.6% premarket BUZZ-Falls on $250 mln stock deal plans ** Dollar Tree Inc DLTR.O: up 8.1% premarket BUZZ-Surges as panic buying drives Q1 sales (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 looked set for a subdued open on Thursday as investors paused for breath after three days of gains and weighed signs of an economic recovery against underlying tensions between the United States and China. S&P 500 e-minis ESc1 were up 0.16% at 3,040.5, while Nasdaq 100 e-minis NQc1 were down 0.63% at 9,373.25. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Knowles Corp , up 19.6% ** Triumph Group Inc , up 19.2% ** CBL & Associates Properties Inc , up 17.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hertz Global Holdings Inc , down 15.3% ** U.S. Silica Holdings Inc , down 11% ** Goldman Sachs MLP and Energy Renasissance Fund , down 8.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Hexindai Inc , up 152.1% ** Arca Biopharma Inc , up 68.4% ** Technical Communications Corp , up 60.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Greenpro Capital Corp , down 24% ** Neurotrope Inc , down 14.3% ** Sintx Technologies Inc , down 14.2% ** Bill.com Holdings Inc BILL.N: up 2.6% premarket BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 43.2% premarket BUZZ-Surges after eye drug selected for COVID-19 study ** Consolidated Edison Inc ED.N: down 0.2% premarket BUZZ-JPM flags risk from anti-gas infrastructure efforts ** Hertz Global Holdings Inc HTZ.N: down 15.3% premarket BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 4.3% premarket BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 4.7% premarket ** Spirit AeroSystems Holdings Inc SPR.N: up 5.9% premarket ** General Electric Co GE.N: up 2.6% premarket ** Raytheon Technologies Corp RTX.N: up 2.2% premarket BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 0.8% premarket BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 6.1% premarket BUZZ-Drops after pricing $100 mln stock offering ** Canadian Solar Inc CSIQ.O: up 3.0% premarket BUZZ-Rises on returning to profit in Q1, co sees soft market in H2 ** Triumph Group Inc TGI.N: up 19.2% premarket BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 11.6% premarket BUZZ-Falls on $250 mln stock deal plans ** Dollar Tree Inc DLTR.O: up 8.1% premarket BUZZ-Surges as panic buying drives Q1 sales (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 looked set for a subdued open on Thursday as investors paused for breath after three days of gains and weighed signs of an economic recovery against underlying tensions between the United States and China. ET, Dow e-minis 1YMc1 were up 0.59% at 25,685. S&P 500 e-minis ESc1 were up 0.16% at 3,040.5, while Nasdaq 100 e-minis NQc1 were down 0.63% at 9,373.25. |
29041.0 | 2020-05-28 00:00:00 UTC | ARCA Biopharma To Evaluate AB201 In Treatment Of COVID-19 Associated Coagulopathy | ABIO | https://www.nasdaq.com/articles/arca-biopharma-to-evaluate-ab201-in-treatment-of-covid-19-associated-coagulopathy-2020-05 | nan | nan | (RTTNews) - ARCA biopharma, Inc. (ABIO) announced a new development program to evaluate AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. The company expects filing an Investigational New Drug application with the U.S. FDA in the third quarter and initiating late-stage clinical testing in the second half of the current year.
Michael Bristow, ARCA's CEO, said, "The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID-19 while vaccine development is underway and for patients for whom a vaccine is not effective."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ARCA biopharma, Inc. (ABIO) announced a new development program to evaluate AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. The company expects filing an Investigational New Drug application with the U.S. FDA in the third quarter and initiating late-stage clinical testing in the second half of the current year. Michael Bristow, ARCA's CEO, said, "The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID-19 while vaccine development is underway and for patients for whom a vaccine is not effective." | (RTTNews) - ARCA biopharma, Inc. (ABIO) announced a new development program to evaluate AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. Michael Bristow, ARCA's CEO, said, "The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID-19 while vaccine development is underway and for patients for whom a vaccine is not effective." The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ARCA biopharma, Inc. (ABIO) announced a new development program to evaluate AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. The company expects filing an Investigational New Drug application with the U.S. FDA in the third quarter and initiating late-stage clinical testing in the second half of the current year. Michael Bristow, ARCA's CEO, said, "The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID-19 while vaccine development is underway and for patients for whom a vaccine is not effective." | (RTTNews) - ARCA biopharma, Inc. (ABIO) announced a new development program to evaluate AB201, a potent selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. The company expects filing an Investigational New Drug application with the U.S. FDA in the third quarter and initiating late-stage clinical testing in the second half of the current year. Michael Bristow, ARCA's CEO, said, "The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID-19 while vaccine development is underway and for patients for whom a vaccine is not effective." |
29042.0 | 2020-05-28 00:00:00 UTC | ABIO Jumps On Joining COVID-19 Drug Fray, GMAB Hits Trial Goal, IMRA On Watch | ABIO | https://www.nasdaq.com/articles/abio-jumps-on-joining-covid-19-drug-fray-gmab-hits-trial-goal-imra-on-watch-2020-05-28 | nan | nan | (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma joining the battle against COVID-19; Genmab's positive results from amyloidosis trial; MacroGenics' regulatory update related to breast cancer drug candidate Margetuximab and Simulations Plus receiving the FDA grant award.
Read on…
1. ARCA Jumps Into COVID-19 Drug Fray; Stock Explodes Over 300%
ARCA biopharma Inc. (ABIO) has decided to evaluate AB201, a potent, selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response.
COVID-19 associated coagulopathy or CAC is one of the most serious adverse effects seen in COVID-19 patients.
The Company anticipates filing an Investigational New Drug (IND) application for AB201 with the FDA in the third quarter and initiating late-stage clinical testing in the second half of this year.
As of March 31, 2020, the Company had cash and cash equivalents of only $6.7 million.
ABIO closed Thursday's trading at $19.21, up 386.33%.
2. Genmab ANDROMEDA Trial Hits Key Goal
Shares of Genmab A/S (GMAB) closed at an all-time high of $30.97 on Thursday, thanks to positive topline results from its ANDROMEDA trial.
ANDROMEDA is a phase III study of subcutaneous Daratumumab in combination with Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD ) for patients with newly diagnosed light-chain (AL) amyloidosis.
Janssen Biotech Inc. obtained an exclusive worldwide license to develop, manufacture and commercialize Daratumumab from Genmab in 2012.
The ANDROMEDA study, conducted by Janssen, met the primary endpoint of the percentage of patients with hematologic complete response. Patients in the study treated with Daratumumab in combination with CyBorD had a 53.3% hematologic complete response compared to 18.1% of patients who were treated with CyBorD alone.
GMAB closed Thursday's trading at $30.97, up 4.31%.
3. Imara Gearing Up For The Big Event
Shares of Imara Inc. (IMRA) continues to gain momentum as the Company gears up to present interim data from the ongoing phase IIa study of IMR-687 in patients with sickle cell disease at the 25th Annual European Hematology Association (EHA) Congress to be held virtually June 11-21, 2020.
Enrollment in the IMR-687 phase IIa clinical trial in sickle cell patients was completed in January of this year, with top-line data expected in the fourth quarter of 2020.
IMRA closed Thursday's trading at $32.38, up 11.27%.
4. MacroGenics To Face FDA In December; No Panel Review
MacroGenics Inc. (MGNX) has been notified that the FDA has no plans to hold an AdComm meeting to review the Company's Biologics License Application for Margetuximab, proposed for the treatment of patients with pre-treated metastatic HER2-positive breast cancer in combination with chemotherapy.
The regulatory agency's final decision date set for Margetuximab review remains unchanged, which is December 18, 2020.
MGNX closed Thursday's trading at $23.00, down 0.61%.
5. Simulations Plus Secures Grant Award
Shares of Simulations Plus Inc. (SLP), a developer of drug discovery/development software, touched an all-time high on Thursday, following the receipt of a new Grant Award from the FDA.
The Company has been awarded a new funded cooperative agreement for up to $400,000 over three years to develop physiologically based pharmacokinetics/pharmacodynamics (PBPK/PD) approaches to support interspecies translation for ocular drug delivery in GastroPlus.
GastroPlus is a mechanistically based simulation software package that simulates intravenous, oral, oral cavity, ocular, inhalation, and dermal/subcutaneous absorption, pharmacokinetics, and pharmacodynamics in humans and animals, according to the Company.
For its second quarter of fiscal year 2020, the period ended February 29, 2020, net revenues increased 22.2% to $10.3 million from $8.5 million in the year-ago period. Net income for the recent second quarter increased to $2.2 million from $2.1 million in the year-ago quarter while earnings per share remained unchanged at $0.12 per share. The second-quarter results were reported last month.
SLP closed Thursday's trading at $48.43, up 22.61%.
6. Stocks That Moved On No News
Organogenesis Holdings Inc. (ORGO) closed Thursday's trading at $4.61, up 33.24%.
IDEAYA Biosciences Inc. (IDYA) closed Thursday's trading at $9.40, up 22.64%.
Flexion Therapeutics Inc. (FLXN) closed Thursday's trading at $11.65, up 12.83%.
NantKwest Inc. (NK) closed Thursday's trading at $6.61, down 12.80%.
Verrica Pharmaceuticals Inc. (VRCA) closed Thursday's trading at $12.20, down 11.98%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA Jumps Into COVID-19 Drug Fray; Stock Explodes Over 300% ARCA biopharma Inc. (ABIO) has decided to evaluate AB201, a potent, selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. ABIO closed Thursday's trading at $19.21, up 386.33%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma joining the battle against COVID-19; Genmab's positive results from amyloidosis trial; MacroGenics' regulatory update related to breast cancer drug candidate Margetuximab and Simulations Plus receiving the FDA grant award. | ARCA Jumps Into COVID-19 Drug Fray; Stock Explodes Over 300% ARCA biopharma Inc. (ABIO) has decided to evaluate AB201, a potent, selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. ABIO closed Thursday's trading at $19.21, up 386.33%. (RTTNews) - Today's Daily Dose brings you news about ARCA biopharma joining the battle against COVID-19; Genmab's positive results from amyloidosis trial; MacroGenics' regulatory update related to breast cancer drug candidate Margetuximab and Simulations Plus receiving the FDA grant award. | ARCA Jumps Into COVID-19 Drug Fray; Stock Explodes Over 300% ARCA biopharma Inc. (ABIO) has decided to evaluate AB201, a potent, selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. ABIO closed Thursday's trading at $19.21, up 386.33%. Genmab ANDROMEDA Trial Hits Key Goal Shares of Genmab A/S (GMAB) closed at an all-time high of $30.97 on Thursday, thanks to positive topline results from its ANDROMEDA trial. | ABIO closed Thursday's trading at $19.21, up 386.33%. ARCA Jumps Into COVID-19 Drug Fray; Stock Explodes Over 300% ARCA biopharma Inc. (ABIO) has decided to evaluate AB201, a potent, selective inhibitor of tissue factor, as a potential treatment for COVID-19 associated coagulopathy and the related inflammatory response. IMRA closed Thursday's trading at $32.38, up 11.27%. |
29043.0 | 2020-05-28 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Blue Hat, ARCA Biopharma, Aerpio Pharma | ABIO | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-blue-hat-arca-biopharma-aerpio-pharma-2020-05-28 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's major indexes rose on Thursday, boosted by gains in healthcare and technology stocks, as investors hoped for a swift economic recovery from a coronavirus-driven economic slump. .N
At 11:26 ET, the Dow Jones Industrial Average .DJI was up 0.34% at 25,635.61. The S&P 500 .SPX was up 0.38% at 3,047.63 and the Nasdaq Composite .IXIC was up 0.35% at 9,444.881. The top three S&P 500 .PG.INX percentage gainers: ** Dollar Tree Inc , up 11% ** Alexion Pharmaceuticals, Inc , up 8.8% ** NortonLifeLock Inc , up 5.1% The top three S&P 500 .PL.INX percentage losers: ** HP Inc , down 12.3% ** Nordstrom Inc , down 5.6% ** DXC Technology Co , down 5.5% The top three NYSE .PG.N percentage gainers: ** Triumph Group Inc , up 36.1% ** Nine Energy Service Inc , up 16.8% ** Nabors Industries Ltd , up 15.5% The top three NYSE .PL.N percentage losers: ** Townsquare Media Inc , down 12.4% ** REX American Resources Corp , down 12.3% ** HP Inc , down 12.3% The top three Nasdaq .PG.O percentage gainers: ** Arca Biopharma Inc , up 186.7% ** PhaseBio Pharmaceuticals Inc , up 41.9% ** Organogenesis Holdings Inc , up 37.6% The top three Nasdaq .PL.O percentage losers: ** Luckin Coffee Inc , down 16.3 % ** Euroseas Ltd , down 14.4% ** Iovance Biotherapeutics Inc , down 11.6% ** Sabre Corp SABR.O: down 4.0%
BUZZ-Dips as travel bookings remain "severely depressed" ** Cerecor Inc CERC.O: up 12.0%
BUZZ-Gains on U.S. FDA nod for COVID-19 treatment study ** Yeti Holdings Inc YETI.N: down 3.5%
BUZZ-Second sale by holders this month dents shares ** Golar LNG Ltd GLNG.O: up 5.7%
BUZZ-Rises on better-than-expected interim Q1 results ** Blue Hat Interactive Entertainment Technology BHAT.O: up 61.8%
BUZZ-Jumps on partnership to expand augmented reality classes in China ** ARCA Biopharma Inc ABIO.O: up 186.7%
BUZZ-Surges on plans to test treatment for COVID-19 blood disorder ** Arcus Biosciences Inc RCUS.N: up 8.7%
BUZZ-Rises as co launches stock offering after Gilead investment ** Momo Inc MOMO.O: down 2.7%
BUZZ-Falls as Q1 revenue, paying users decline ** REX American Resources Corp REX.N: down 11.0%
BUZZ-Slips on posting Q1 loss vs yr-ago profit on lower ethanol output ** Clovis Oncology Inc CLVS.O: up 5.0%
BUZZ-Rises after recommendation for expanded use of cancer drug ** Essent Group Ltd ESNT.N: down 5.8%
BUZZ-Slides after mortgage insurer launches S&P MidCap inclusion share offering ** Bill.com Holdings Inc BILL.N: up 5.2% BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 65.0% BUZZ-Surges after eye drug selected for COVID-19 study ** Hertz Global Holdings Inc HTZ.N: down 17.5% BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 6.8% BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 2.8% ** Spirit AeroSystems Holdings Inc SPR.N: up 0.2% ** General Electric Co GE.N: down 2.7% ** Raytheon Technologies Corp RTX.N: up 2.0% BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 1.8% BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 5.8% BUZZ-Drops after pricing $100 mln stock offering ** Triumph Group Inc TGI.N: up 36.6% BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 6.6% BUZZ-Falls after co prices upsized $275 mln stock deal ** Dollar Tree Inc DLTR.O: up 11.0% BUZZ-Surges as panic buying drives Q1 sales ** Endologix Inc ELGX.O: down 2.9% BUZZ-Set to open at record low on going concern doubts ** UP Fintech Holdings Ltd TIGR.O: down 3.6% BUZZ-Jumps on returning to profit in Q1 ** Abercrombie & Fitch Co ANF.N: down 5.7% BUZZ-Slips on wider-than-expected loss
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.31%
Consumer Discretionary
.SPLRCD
up 0.17%
Consumer Staples
.SPLRCS
up 0.96%
Energy
.SPNY
down 1.50%
Financial
.SPSY
down 1.21%
Health
.SPXHC
up 1.90%
Industrial
.SPLRCI
up 0.14%
Information Technology
.SPLRCT
up 0.40%
Materials
.SPLRCM
up 0.88%
Real Estate
.SPLRCR
up 0.13%
Utilities
.SPLRCU
up 2.53%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Dollar Tree Inc , up 11% ** Alexion Pharmaceuticals, Inc , up 8.8% ** NortonLifeLock Inc , up 5.1% The top three S&P 500 .PL.INX percentage losers: ** HP Inc , down 12.3% ** Nordstrom Inc , down 5.6% ** DXC Technology Co , down 5.5% The top three NYSE .PG.N percentage gainers: ** Triumph Group Inc , up 36.1% ** Nine Energy Service Inc , up 16.8% ** Nabors Industries Ltd , up 15.5% The top three NYSE .PL.N percentage losers: ** Townsquare Media Inc , down 12.4% ** REX American Resources Corp , down 12.3% ** HP Inc , down 12.3% The top three Nasdaq .PG.O percentage gainers: ** Arca Biopharma Inc , up 186.7% ** PhaseBio Pharmaceuticals Inc , up 41.9% ** Organogenesis Holdings Inc , up 37.6% The top three Nasdaq .PL.O percentage losers: ** Luckin Coffee Inc , down 16.3 % ** Euroseas Ltd , down 14.4% ** Iovance Biotherapeutics Inc , down 11.6% ** Sabre Corp SABR.O: down 4.0% BUZZ-Dips as travel bookings remain "severely depressed" ** Cerecor Inc CERC.O: up 12.0% BUZZ-Gains on U.S. FDA nod for COVID-19 treatment study ** Yeti Holdings Inc YETI.N: down 3.5% BUZZ-Second sale by holders this month dents shares ** Golar LNG Ltd GLNG.O: up 5.7% BUZZ-Rises on better-than-expected interim Q1 results ** Blue Hat Interactive Entertainment Technology BHAT.O: up 61.8% BUZZ-Jumps on partnership to expand augmented reality classes in China ** ARCA Biopharma Inc ABIO.O: up 186.7% BUZZ-Surges on plans to test treatment for COVID-19 blood disorder ** Arcus Biosciences Inc RCUS.N: up 8.7% BUZZ-Rises as co launches stock offering after Gilead investment ** Momo Inc MOMO.O: down 2.7% BUZZ-Falls as Q1 revenue, paying users decline ** REX American Resources Corp REX.N: down 11.0% BUZZ-Slips on posting Q1 loss vs yr-ago profit on lower ethanol output ** Clovis Oncology Inc CLVS.O: up 5.0% BUZZ-Rises after recommendation for expanded use of cancer drug ** Essent Group Ltd ESNT.N: down 5.8% BUZZ-Slides after mortgage insurer launches S&P MidCap inclusion share offering ** Bill.com Holdings Inc BILL.N: up 5.2% BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 65.0% BUZZ-Surges after eye drug selected for COVID-19 study ** Hertz Global Holdings Inc HTZ.N: down 17.5% BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 6.8% BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 2.8% ** Spirit AeroSystems Holdings Inc SPR.N: up 0.2% ** General Electric Co GE.N: down 2.7% ** Raytheon Technologies Corp RTX.N: up 2.0% BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 1.8% BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 5.8% BUZZ-Drops after pricing $100 mln stock offering ** Triumph Group Inc TGI.N: up 36.6% BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 6.6% BUZZ-Falls after co prices upsized $275 mln stock deal ** Dollar Tree Inc DLTR.O: up 11.0% BUZZ-Surges as panic buying drives Q1 sales ** Endologix Inc ELGX.O: down 2.9% BUZZ-Set to open at record low on going concern doubts ** UP Fintech Holdings Ltd TIGR.O: down 3.6% BUZZ-Jumps on returning to profit in Q1 ** Abercrombie & Fitch Co ANF.N: down 5.7% BUZZ-Slips on wider-than-expected loss The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's major indexes rose on Thursday, boosted by gains in healthcare and technology stocks, as investors hoped for a swift economic recovery from a coronavirus-driven economic slump. up 2.53% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Dollar Tree Inc , up 11% ** Alexion Pharmaceuticals, Inc , up 8.8% ** NortonLifeLock Inc , up 5.1% The top three S&P 500 .PL.INX percentage losers: ** HP Inc , down 12.3% ** Nordstrom Inc , down 5.6% ** DXC Technology Co , down 5.5% The top three NYSE .PG.N percentage gainers: ** Triumph Group Inc , up 36.1% ** Nine Energy Service Inc , up 16.8% ** Nabors Industries Ltd , up 15.5% The top three NYSE .PL.N percentage losers: ** Townsquare Media Inc , down 12.4% ** REX American Resources Corp , down 12.3% ** HP Inc , down 12.3% The top three Nasdaq .PG.O percentage gainers: ** Arca Biopharma Inc , up 186.7% ** PhaseBio Pharmaceuticals Inc , up 41.9% ** Organogenesis Holdings Inc , up 37.6% The top three Nasdaq .PL.O percentage losers: ** Luckin Coffee Inc , down 16.3 % ** Euroseas Ltd , down 14.4% ** Iovance Biotherapeutics Inc , down 11.6% ** Sabre Corp SABR.O: down 4.0% BUZZ-Dips as travel bookings remain "severely depressed" ** Cerecor Inc CERC.O: up 12.0% BUZZ-Gains on U.S. FDA nod for COVID-19 treatment study ** Yeti Holdings Inc YETI.N: down 3.5% BUZZ-Second sale by holders this month dents shares ** Golar LNG Ltd GLNG.O: up 5.7% BUZZ-Rises on better-than-expected interim Q1 results ** Blue Hat Interactive Entertainment Technology BHAT.O: up 61.8% BUZZ-Jumps on partnership to expand augmented reality classes in China ** ARCA Biopharma Inc ABIO.O: up 186.7% BUZZ-Surges on plans to test treatment for COVID-19 blood disorder ** Arcus Biosciences Inc RCUS.N: up 8.7% BUZZ-Rises as co launches stock offering after Gilead investment ** Momo Inc MOMO.O: down 2.7% BUZZ-Falls as Q1 revenue, paying users decline ** REX American Resources Corp REX.N: down 11.0% BUZZ-Slips on posting Q1 loss vs yr-ago profit on lower ethanol output ** Clovis Oncology Inc CLVS.O: up 5.0% BUZZ-Rises after recommendation for expanded use of cancer drug ** Essent Group Ltd ESNT.N: down 5.8% BUZZ-Slides after mortgage insurer launches S&P MidCap inclusion share offering ** Bill.com Holdings Inc BILL.N: up 5.2% BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 65.0% BUZZ-Surges after eye drug selected for COVID-19 study ** Hertz Global Holdings Inc HTZ.N: down 17.5% BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 6.8% BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 2.8% ** Spirit AeroSystems Holdings Inc SPR.N: up 0.2% ** General Electric Co GE.N: down 2.7% ** Raytheon Technologies Corp RTX.N: up 2.0% BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 1.8% BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 5.8% BUZZ-Drops after pricing $100 mln stock offering ** Triumph Group Inc TGI.N: up 36.6% BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 6.6% BUZZ-Falls after co prices upsized $275 mln stock deal ** Dollar Tree Inc DLTR.O: up 11.0% BUZZ-Surges as panic buying drives Q1 sales ** Endologix Inc ELGX.O: down 2.9% BUZZ-Set to open at record low on going concern doubts ** UP Fintech Holdings Ltd TIGR.O: down 3.6% BUZZ-Jumps on returning to profit in Q1 ** Abercrombie & Fitch Co ANF.N: down 5.7% BUZZ-Slips on wider-than-expected loss The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's major indexes rose on Thursday, boosted by gains in healthcare and technology stocks, as investors hoped for a swift economic recovery from a coronavirus-driven economic slump. up 2.53% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Dollar Tree Inc , up 11% ** Alexion Pharmaceuticals, Inc , up 8.8% ** NortonLifeLock Inc , up 5.1% The top three S&P 500 .PL.INX percentage losers: ** HP Inc , down 12.3% ** Nordstrom Inc , down 5.6% ** DXC Technology Co , down 5.5% The top three NYSE .PG.N percentage gainers: ** Triumph Group Inc , up 36.1% ** Nine Energy Service Inc , up 16.8% ** Nabors Industries Ltd , up 15.5% The top three NYSE .PL.N percentage losers: ** Townsquare Media Inc , down 12.4% ** REX American Resources Corp , down 12.3% ** HP Inc , down 12.3% The top three Nasdaq .PG.O percentage gainers: ** Arca Biopharma Inc , up 186.7% ** PhaseBio Pharmaceuticals Inc , up 41.9% ** Organogenesis Holdings Inc , up 37.6% The top three Nasdaq .PL.O percentage losers: ** Luckin Coffee Inc , down 16.3 % ** Euroseas Ltd , down 14.4% ** Iovance Biotherapeutics Inc , down 11.6% ** Sabre Corp SABR.O: down 4.0% BUZZ-Dips as travel bookings remain "severely depressed" ** Cerecor Inc CERC.O: up 12.0% BUZZ-Gains on U.S. FDA nod for COVID-19 treatment study ** Yeti Holdings Inc YETI.N: down 3.5% BUZZ-Second sale by holders this month dents shares ** Golar LNG Ltd GLNG.O: up 5.7% BUZZ-Rises on better-than-expected interim Q1 results ** Blue Hat Interactive Entertainment Technology BHAT.O: up 61.8% BUZZ-Jumps on partnership to expand augmented reality classes in China ** ARCA Biopharma Inc ABIO.O: up 186.7% BUZZ-Surges on plans to test treatment for COVID-19 blood disorder ** Arcus Biosciences Inc RCUS.N: up 8.7% BUZZ-Rises as co launches stock offering after Gilead investment ** Momo Inc MOMO.O: down 2.7% BUZZ-Falls as Q1 revenue, paying users decline ** REX American Resources Corp REX.N: down 11.0% BUZZ-Slips on posting Q1 loss vs yr-ago profit on lower ethanol output ** Clovis Oncology Inc CLVS.O: up 5.0% BUZZ-Rises after recommendation for expanded use of cancer drug ** Essent Group Ltd ESNT.N: down 5.8% BUZZ-Slides after mortgage insurer launches S&P MidCap inclusion share offering ** Bill.com Holdings Inc BILL.N: up 5.2% BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 65.0% BUZZ-Surges after eye drug selected for COVID-19 study ** Hertz Global Holdings Inc HTZ.N: down 17.5% BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 6.8% BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 2.8% ** Spirit AeroSystems Holdings Inc SPR.N: up 0.2% ** General Electric Co GE.N: down 2.7% ** Raytheon Technologies Corp RTX.N: up 2.0% BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 1.8% BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 5.8% BUZZ-Drops after pricing $100 mln stock offering ** Triumph Group Inc TGI.N: up 36.6% BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 6.6% BUZZ-Falls after co prices upsized $275 mln stock deal ** Dollar Tree Inc DLTR.O: up 11.0% BUZZ-Surges as panic buying drives Q1 sales ** Endologix Inc ELGX.O: down 2.9% BUZZ-Set to open at record low on going concern doubts ** UP Fintech Holdings Ltd TIGR.O: down 3.6% BUZZ-Jumps on returning to profit in Q1 ** Abercrombie & Fitch Co ANF.N: down 5.7% BUZZ-Slips on wider-than-expected loss The 11 major S&P 500 sectors: Communication Services down 0.31% Consumer Discretionary up 0.17% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Dollar Tree Inc , up 11% ** Alexion Pharmaceuticals, Inc , up 8.8% ** NortonLifeLock Inc , up 5.1% The top three S&P 500 .PL.INX percentage losers: ** HP Inc , down 12.3% ** Nordstrom Inc , down 5.6% ** DXC Technology Co , down 5.5% The top three NYSE .PG.N percentage gainers: ** Triumph Group Inc , up 36.1% ** Nine Energy Service Inc , up 16.8% ** Nabors Industries Ltd , up 15.5% The top three NYSE .PL.N percentage losers: ** Townsquare Media Inc , down 12.4% ** REX American Resources Corp , down 12.3% ** HP Inc , down 12.3% The top three Nasdaq .PG.O percentage gainers: ** Arca Biopharma Inc , up 186.7% ** PhaseBio Pharmaceuticals Inc , up 41.9% ** Organogenesis Holdings Inc , up 37.6% The top three Nasdaq .PL.O percentage losers: ** Luckin Coffee Inc , down 16.3 % ** Euroseas Ltd , down 14.4% ** Iovance Biotherapeutics Inc , down 11.6% ** Sabre Corp SABR.O: down 4.0% BUZZ-Dips as travel bookings remain "severely depressed" ** Cerecor Inc CERC.O: up 12.0% BUZZ-Gains on U.S. FDA nod for COVID-19 treatment study ** Yeti Holdings Inc YETI.N: down 3.5% BUZZ-Second sale by holders this month dents shares ** Golar LNG Ltd GLNG.O: up 5.7% BUZZ-Rises on better-than-expected interim Q1 results ** Blue Hat Interactive Entertainment Technology BHAT.O: up 61.8% BUZZ-Jumps on partnership to expand augmented reality classes in China ** ARCA Biopharma Inc ABIO.O: up 186.7% BUZZ-Surges on plans to test treatment for COVID-19 blood disorder ** Arcus Biosciences Inc RCUS.N: up 8.7% BUZZ-Rises as co launches stock offering after Gilead investment ** Momo Inc MOMO.O: down 2.7% BUZZ-Falls as Q1 revenue, paying users decline ** REX American Resources Corp REX.N: down 11.0% BUZZ-Slips on posting Q1 loss vs yr-ago profit on lower ethanol output ** Clovis Oncology Inc CLVS.O: up 5.0% BUZZ-Rises after recommendation for expanded use of cancer drug ** Essent Group Ltd ESNT.N: down 5.8% BUZZ-Slides after mortgage insurer launches S&P MidCap inclusion share offering ** Bill.com Holdings Inc BILL.N: up 5.2% BUZZ-Piper Sandler sees robust growth over next decade, upgrades ** Aerpio Pharmaceutical Inc ARPO.O: up 65.0% BUZZ-Surges after eye drug selected for COVID-19 study ** Hertz Global Holdings Inc HTZ.N: down 17.5% BUZZ-Slumps after Icahn unloads entire stake at "significant" loss ** Nio Inc NIO.N: down 6.8% BUZZ-Falls after missing quarterly revenue estimates ** Boeing Co BA.N: up 2.8% ** Spirit AeroSystems Holdings Inc SPR.N: up 0.2% ** General Electric Co GE.N: down 2.7% ** Raytheon Technologies Corp RTX.N: up 2.0% BUZZ-Boeing suppliers: Rise after planemaker resumes 737 MAX production ** NextEra Energy Partners LP NEP.N: up 1.8% BUZZ-Stands to benefit from equity funding efforts - JPM ** BioCryst Pharmaceuticals Inc BCRX.O: down 5.8% BUZZ-Drops after pricing $100 mln stock offering ** Triumph Group Inc TGI.N: up 36.6% BUZZ-Set for third day of gains on profit beat ** Arena Pharmaceuticals Inc ARNA.O: down 6.6% BUZZ-Falls after co prices upsized $275 mln stock deal ** Dollar Tree Inc DLTR.O: up 11.0% BUZZ-Surges as panic buying drives Q1 sales ** Endologix Inc ELGX.O: down 2.9% BUZZ-Set to open at record low on going concern doubts ** UP Fintech Holdings Ltd TIGR.O: down 3.6% BUZZ-Jumps on returning to profit in Q1 ** Abercrombie & Fitch Co ANF.N: down 5.7% BUZZ-Slips on wider-than-expected loss The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's major indexes rose on Thursday, boosted by gains in healthcare and technology stocks, as investors hoped for a swift economic recovery from a coronavirus-driven economic slump. .N At 11:26 ET, the Dow Jones Industrial Average .DJI was up 0.34% at 25,635.61. |
29044.0 | 2019-09-11 00:00:00 UTC | Health Care Sector Update for 09/11/2019: ABIO,TTOO,LXRX,TLRY | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-09-11-2019%3A-abiottoolxrxtlry-2019-09-11 | nan | nan | Top Health Care Stocks
JNJ +1.05%
PFE -0.25%
ABT +1.35%
MRK +1.21%
AMGN -0.73%
Health care stocks added slightly to their earlier advance, with the NYSE Health Care Index climbing over 0.6% while the shares of health care companies in the S&P 500 also were up nearly 0.8% as a group. The Nasdaq Biotechnology index was ahead almost 1.5% in late trade.
Among health care stocks moving on news:
(+) ARCA biopharma (ABIO) rose 10.5% on Wednesday after saying the response to its Gencaro drug candidate appears to be greater in patients with less severe left ventricular dysfunction, a patient population that currently has few therapeutic options to prevent atrial fibrillation or heart failure. The company will present more data from phase IIb testing of Gencaro at the Heart Failure Society of America meeting beginning Friday in Philadelphia.
In other sector news:
(+) T2 Biosystems (TTOO) jumped 80% on Wednesday after the diagnostic products company said it has restructured a term loan agreement with CRG Servicing. It extended the interest-only payment period by an extra year until March 2022 and lowered the minimum revenue targets for 2020 to 2022 below its current financial forecast in exchange for issuing 10-year warrants to CRG to buy up to 568,291 shares at $1.55 apiece and cut the exercise price for warrants previously issued to CRG to the same price.
(+) Lexicon Pharmaceuticals (LXRX) was nearly 30% higher, easing from a 58% spike soon after Wednesday's opening bell, after the firm terminated its alliance with Sanofi (SNY) to develop and commercialize its Zynquista diabetes drug. The company retains all rights to Zynquista and will receive $208 million upfront along with another $52 million due within 12 months.
(-) Tilray (TLRY) dropped more than 1% after the cannabis company announced plans to sell up to $400 million of its Class 2 common shares through an at-the-market offering through Cowen & Co.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (+) ARCA biopharma (ABIO) rose 10.5% on Wednesday after saying the response to its Gencaro drug candidate appears to be greater in patients with less severe left ventricular dysfunction, a patient population that currently has few therapeutic options to prevent atrial fibrillation or heart failure. The company will present more data from phase IIb testing of Gencaro at the Heart Failure Society of America meeting beginning Friday in Philadelphia. (+) Lexicon Pharmaceuticals (LXRX) was nearly 30% higher, easing from a 58% spike soon after Wednesday's opening bell, after the firm terminated its alliance with Sanofi (SNY) to develop and commercialize its Zynquista diabetes drug. | Among health care stocks moving on news: (+) ARCA biopharma (ABIO) rose 10.5% on Wednesday after saying the response to its Gencaro drug candidate appears to be greater in patients with less severe left ventricular dysfunction, a patient population that currently has few therapeutic options to prevent atrial fibrillation or heart failure. Top Health Care Stocks Health care stocks added slightly to their earlier advance, with the NYSE Health Care Index climbing over 0.6% while the shares of health care companies in the S&P 500 also were up nearly 0.8% as a group. | Among health care stocks moving on news: (+) ARCA biopharma (ABIO) rose 10.5% on Wednesday after saying the response to its Gencaro drug candidate appears to be greater in patients with less severe left ventricular dysfunction, a patient population that currently has few therapeutic options to prevent atrial fibrillation or heart failure. Health care stocks added slightly to their earlier advance, with the NYSE Health Care Index climbing over 0.6% while the shares of health care companies in the S&P 500 also were up nearly 0.8% as a group. It extended the interest-only payment period by an extra year until March 2022 and lowered the minimum revenue targets for 2020 to 2022 below its current financial forecast in exchange for issuing 10-year warrants to CRG to buy up to 568,291 shares at $1.55 apiece and cut the exercise price for warrants previously issued to CRG to the same price. | Among health care stocks moving on news: (+) ARCA biopharma (ABIO) rose 10.5% on Wednesday after saying the response to its Gencaro drug candidate appears to be greater in patients with less severe left ventricular dysfunction, a patient population that currently has few therapeutic options to prevent atrial fibrillation or heart failure. Top Health Care Stocks Health care stocks added slightly to their earlier advance, with the NYSE Health Care Index climbing over 0.6% while the shares of health care companies in the S&P 500 also were up nearly 0.8% as a group. |
29045.0 | 2019-06-03 00:00:00 UTC | 6 Top Gainers In Pharma Sector (MRTX, NK, GNCA...) | ABIO | https://www.nasdaq.com/articles/6-top-gainers-pharma-sector-mrtx-nk-gnca...-2019-06-03 | nan | nan | (RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.
1. Navidea Biopharmaceuticals Inc (NAVB)
Gained 37.60% to close Monday's (June 3) trading at $1.72.
News: No news
Recent event:
On May 8, the Company reported first quarter 2019 financial results.
The net loss attributable to common stockholders for the first quarter of 2019 narrowed to $2.4 million or $0.24 per share from $6.7 million or $0.83 per share for the same period in 2018.
Total revenues for the first quarter of 2019 declined to $136,000 from $276,000 in the same period of 2018, primarily due to a reduction in grant revenue from the NIH supporting Manocept development.
2. Mirati Therapeutics Inc. (MRTX)
Gained 31.58% to close Monday's trading at $89.20.
News: Mirati stock rose following presentation of Amgen's encouraging phase I data of KRAS G12C inhibitor AMG 510 at the ASCO meeting.
Miratis is also developing a KRAS G12C inhibitor by the name MRTX849, and a phase 1/2 multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors With KRAS G12C mutation was started in January of this year.
3. ARCA biopharma Inc. (ABIO)
ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.
The Company's lead product candidate is Gencaro, which is in development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).
Gained 27.12% to close Monday's trading at $7.36.
News: No news
Near-term Catalyst:
Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year.
4. NantKwest Inc. (NK)
Gained 25.24% to close Monday's trading at $1.29.
News: The Company's t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma.
5. ASLAN Pharmaceuticals Limited (ASLN)
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company.
Gained 16.83% to close Monday's trading at $3.40.
News: No news
Clinical Trials & Near-term Catalysts:
-- A pivotal study of Varlitinib in second-line biliary tract cancer, dubbed TreeTopp, is underway. The topline data from this study is expected in the second half of 2019. -- A single-arm study of Varlitinib in second-line biliary tract cancer in China is ongoing and data readout is expected after the TreeTopp study. -- A phase II study of ASLAN003 in acute myeloid leukemia is underway. -- A phase I study of ASLAN004 in atopic dermatitis is ongoing.
6. Genocea Biosciences Inc. (GNCA)
Gained 19.61% to close Monday's trading at $6.71.
News: The Company announced clinical results from its ongoing Phase 1/2a trial for GEN-009, its lead neoantigen vaccine candidate.
According to the Company, in the five patients for whom immune response results are available to date, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: Mirati stock rose following presentation of Amgen's encouraging phase I data of KRAS G12C inhibitor AMG 510 at the ASCO meeting. The Company's lead product candidate is Gencaro, which is in development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Clinical Trials & Near-term Catalysts: -- A pivotal study of Varlitinib in second-line biliary tract cancer, dubbed TreeTopp, is underway. News: The Company announced clinical results from its ongoing Phase 1/2a trial for GEN-009, its lead neoantigen vaccine candidate. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Near-term Catalyst: Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year. News: No news Clinical Trials & Near-term Catalysts: -- A pivotal study of Varlitinib in second-line biliary tract cancer, dubbed TreeTopp, is underway. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Near-term Catalyst: Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year. News: No news Clinical Trials & Near-term Catalysts: -- A pivotal study of Varlitinib in second-line biliary tract cancer, dubbed TreeTopp, is underway. |
29046.0 | 2019-05-09 00:00:00 UTC | Health Care Sector Update for 05/09/2019: AMRX,BIO,AGEN,ABIO | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-05-09-2019%3A-amrxbioagenabio-2019-05-09 | nan | nan | Top Health Care Stocks
JNJ -0.81%
PFE +0.27%
ABT +0.14%
MRK +0.28%
AMGN +0.23%
Health care stocks fell in late trade, including an almost 0.3% decline for the NYSE Health Care Index in Thursday trade. Shares of health care companies in the S&P 500 also were down over 0.1% as a group while the Nasdaq Biotechnology index slid more than 0.1%.
Among health care stocks moving on news:
(-) Amneal Pharmaceuticals (AMRX) dropped over 19% to a worst-ever $10.58 a share on Thursday after the drugmaker reported non-GAAP net income trailing analyst estimates for its Q1 ended March 31. Excluding one-time items, the company earned $0.14 per share, unchanged from the first three months of 2018 but still lagging the Capital IQ consensus call looking for a rise in its Q1 profit to $0.18 per share.
In other sector news:
(+) Agenus (AGEN) climbed more than 8% after the immuno-oncology company earned $0.12 per share during its Q1 ended March 31, reversing a $0.53 per share net loss during the year-ago period and beating the two-analyst mean looking for a $0.30 per share net loss.
(+) Bio-Rad Laboratories (BIO) climbed 4% after reporting adjusted Q1 net income of $1.65 per share, up from $1.17 per share during the same quarter last year and easily breezing past the $1.15 per share analyst mean. Revenue rose to $554 million during the January-to-March reporting period but still topped the $549.57 million Capital IQ consensus.
(-) ARCA biopharma (ABIO) has turned lower Thursday afternoon, giving back a 16.5% advance soon after Thursday's opening bell. The genetically-targeted medicines company reported a $1.86 per share Q1 net loss for the three months ended March 31, almost halving its $3.61 per share loss during the same quarter last year and beating the Capital IQ consensus by $0.12 per share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ARCA biopharma (ABIO) has turned lower Thursday afternoon, giving back a 16.5% advance soon after Thursday's opening bell. Shares of health care companies in the S&P 500 also were down over 0.1% as a group while the Nasdaq Biotechnology index slid more than 0.1%. Among health care stocks moving on news: (-) Amneal Pharmaceuticals (AMRX) dropped over 19% to a worst-ever $10.58 a share on Thursday after the drugmaker reported non-GAAP net income trailing analyst estimates for its Q1 ended March 31. | (-) ARCA biopharma (ABIO) has turned lower Thursday afternoon, giving back a 16.5% advance soon after Thursday's opening bell. In other sector news: (+) Agenus (AGEN) climbed more than 8% after the immuno-oncology company earned $0.12 per share during its Q1 ended March 31, reversing a $0.53 per share net loss during the year-ago period and beating the two-analyst mean looking for a $0.30 per share net loss. Revenue rose to $554 million during the January-to-March reporting period but still topped the $549.57 million Capital IQ consensus. | (-) ARCA biopharma (ABIO) has turned lower Thursday afternoon, giving back a 16.5% advance soon after Thursday's opening bell. Among health care stocks moving on news: (-) Amneal Pharmaceuticals (AMRX) dropped over 19% to a worst-ever $10.58 a share on Thursday after the drugmaker reported non-GAAP net income trailing analyst estimates for its Q1 ended March 31. In other sector news: (+) Agenus (AGEN) climbed more than 8% after the immuno-oncology company earned $0.12 per share during its Q1 ended March 31, reversing a $0.53 per share net loss during the year-ago period and beating the two-analyst mean looking for a $0.30 per share net loss. | (-) ARCA biopharma (ABIO) has turned lower Thursday afternoon, giving back a 16.5% advance soon after Thursday's opening bell. Top Health Care Stocks Among health care stocks moving on news: (-) Amneal Pharmaceuticals (AMRX) dropped over 19% to a worst-ever $10.58 a share on Thursday after the drugmaker reported non-GAAP net income trailing analyst estimates for its Q1 ended March 31. |
29047.0 | 2019-05-09 00:00:00 UTC | Health Care Sector Update for 05/09/2019: ABIO, AGEN, ENDP, JNJ, PFE, ABT, MRK, AMGN | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-05-09-2019%3A-abio-agen-endp-jnj-pfe-abt-mrk-amgn-2019-05-09 | nan | nan | Top Health Care Stocks:
JNJ: -0.48%
PFE: -1.47%
ABT: Flat
MRK: -1.48%
AMGN: -0.67%
Health care majors were flat to lower pre-market Thursday.
Early movers include:
(+) ARCA biopharma (ABIO), which was advancing 9% after the company said Q1 net loss per share narrowed to $1.86 from a loss of $3.61 in the year-ago period and topped the CapIQ mean for a loss of $1.98.
(+) Agenus (AGEN) was trading more than 5% higher after the company reported Q1 earnings of $0.12 per diluted share, up compared with a loss of $0.53 per share a year ago and the $0.30 average loss estimate from two analysts polled by Capital IQ.
(+) Endo International (ENDP) was more than 4% higher after it reported Q1 adjusted EPS of $0.53, down from $0.67 a year ago but still above the $0.43 Capital IQ mean.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Early movers include: (+) ARCA biopharma (ABIO), which was advancing 9% after the company said Q1 net loss per share narrowed to $1.86 from a loss of $3.61 in the year-ago period and topped the CapIQ mean for a loss of $1.98. Health care majors were flat to lower pre-market Thursday. (+) Agenus (AGEN) was trading more than 5% higher after the company reported Q1 earnings of $0.12 per diluted share, up compared with a loss of $0.53 per share a year ago and the $0.30 average loss estimate from two analysts polled by Capital IQ. | Early movers include: (+) ARCA biopharma (ABIO), which was advancing 9% after the company said Q1 net loss per share narrowed to $1.86 from a loss of $3.61 in the year-ago period and topped the CapIQ mean for a loss of $1.98. Top Health Care Stocks: (+) Agenus (AGEN) was trading more than 5% higher after the company reported Q1 earnings of $0.12 per diluted share, up compared with a loss of $0.53 per share a year ago and the $0.30 average loss estimate from two analysts polled by Capital IQ. | Early movers include: (+) ARCA biopharma (ABIO), which was advancing 9% after the company said Q1 net loss per share narrowed to $1.86 from a loss of $3.61 in the year-ago period and topped the CapIQ mean for a loss of $1.98. Health care majors were flat to lower pre-market Thursday. (+) Agenus (AGEN) was trading more than 5% higher after the company reported Q1 earnings of $0.12 per diluted share, up compared with a loss of $0.53 per share a year ago and the $0.30 average loss estimate from two analysts polled by Capital IQ. | Early movers include: (+) ARCA biopharma (ABIO), which was advancing 9% after the company said Q1 net loss per share narrowed to $1.86 from a loss of $3.61 in the year-ago period and topped the CapIQ mean for a loss of $1.98. Health care majors were flat to lower pre-market Thursday. (+) Agenus (AGEN) was trading more than 5% higher after the company reported Q1 earnings of $0.12 per diluted share, up compared with a loss of $0.53 per share a year ago and the $0.30 average loss estimate from two analysts polled by Capital IQ. |
29048.0 | 2019-05-02 00:00:00 UTC | 6 Top Gainers In Pharma Sector (DFFN, QTNT, ORGO...) | ABIO | https://www.nasdaq.com/articles/6-top-gainers-pharma-sector-dffn-qtnt-orgo...-2019-05-02 | nan | nan | (RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.
1. Diffusion Pharmaceuticals Inc. (DFFN)
Diffusion Pharma is a clinical stage biotechnology company developing treatments for life-threatening medical conditions.
Gained 91.56% to close Thursday's (May 2) trading at $5.90.
News: No news
Clinical Trials:
The Company's lead drug candidate is Trans Sodium Crocinate.
A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer, dubbed INTACT, is underway. The Company was given FDA clearance last September to conduct a phase II on-ambulance trial of Trans Sodium Crocinate for the treatment of stroke, named PHAST-TSC.
Cash position:
Diffusion had cash and cash equivalents of $8.0 million as of December 31, 2018. The Company believes its cash and cash equivalents are sufficient to fund operations into July 2019.
2. ARCA biopharma Inc. (ABIO)
ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.
The Company's lead product candidate is Gencaro, which is in development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).
Gained 23.41% to close Thursday's trading at $12.65.
News: No news
Near-term Catalyst:
Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year.
3. Auris Medical Holding AG (EARS)
Auris Medical is a biopharmaceutical company developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.
Gained 15.51% to close Thursday's trading at $5.14.
News: No news
Clinical Trials & Near-term Catalysts:
The lead drug candidate is Keyzilen (AM-101) for tinnitus. The Company has completed the design of a new Phase 2/3 trial for Keyzilen program, and intends to discuss and validate the trial design with the FDA and EMA.
Preparations for a phase II proof-of-concept study of AM-125 in acute vertigo, dubbed TRAVERS, and Phase 1b trial with AM-201 in antipsychotic-induced weight gain are progressing.
In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi (AM-111) for acute inner ear hearing loss and Keyzilen (AM-101) for acute inner ear tinnitus.
Recent event:
On May 1, 2019, a 1-for-20 reverse stock split became effective. The reverse stock split was implemented to regain compliance with the $1.00 minimum bid price requirement for continued listing on NASDAQ.
4. Citius Pharmaceuticals Inc. (CTXR)
Gained 14% to close Thursday's trading at $1.14.
News: No news
Pipeline:
A phase III trial of Mino-Lok Therapy in combination with systemic antibiotics in the treatment of catheter-related bloodstream infections enrolled the first patient as recently as February of this year. This trial is planned to enroll 700 patients in 50 participating institutions, all located in the U.S. There will be interim analyses at the 50% and 75% point of the trial as measured by the number of patients treated. Also in the pipeline is CITI-002 to treat hemorrhoids, which is a phase IIb-ready compound.
5. Quotient Limited (QTNT)
Quotient Limited is a commercial-stage diagnostics company, involved in blood grouping and serological disease screening tests.
Gained 12.13% to close Thursday's trading at $8.97.
News: The Company announced receipt of the CE Mark for its initial Immunohematology (IH) Microarray for use with its CE Marked MosaiQ diagnostic platform.
6. Organogenesis Holdings Inc. (ORGO)
Organogenesis is a regenerative medicine company developing products for the advanced wound care, and surgical and sports medicine markets.
Gained 11.91% to close Thursday's trading at $7.89.
News: The Company has received an Innovative Technology contract from Vizient Inc. for its portfolio of advanced wound care and surgical and sports medicine products.
Vizient is a health care performance improvement company, with more than 3,100 hospital and health system members.
Near-term Catalyst:
The Company is slated to report first quarter fiscal year 2019 financial results before the market opens on May 10, 2019.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer, dubbed INTACT, is underway. The Company was given FDA clearance last September to conduct a phase II on-ambulance trial of Trans Sodium Crocinate for the treatment of stroke, named PHAST-TSC. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Clinical Trials: The Company's lead drug candidate is Trans Sodium Crocinate. News: No news Clinical Trials & Near-term Catalysts: The lead drug candidate is Keyzilen (AM-101) for tinnitus. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Clinical Trials: The Company's lead drug candidate is Trans Sodium Crocinate. News: No news Near-term Catalyst: Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Near-term Catalyst: Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year. News: No news Clinical Trials & Near-term Catalysts: The lead drug candidate is Keyzilen (AM-101) for tinnitus. |
29049.0 | 2019-05-02 00:00:00 UTC | Health Care Sector Update for 05/02/2019: ABIO, CI, TFX, JNJ, PFE, ABT, MRK, AMGN | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-for-05-02-2019%3A-abio-ci-tfx-jnj-pfe-abt-mrk-amgn-2019-05-02 | nan | nan | Top Health Care Stocks:
JNJ: -0.1%
PFE: +0.20%
ABT: -0.20%
MRK: +0.03%
AMGN: Flat
Health care heavyweights were mixed pre-market Thursday.
Stocks moving on news include:
(+) ARCA biopharma (ABIO), which was surging by over 66% after the company said data from an exploratory phase 2 trial show a majority of heart patients undergoing its bucindolol therapy demonstrated a "more favorable response" than to standard beta-blocker therapy.
In other sector news:
(+) Cigna (CI) was slightly higher after it reported Q1 adjusted earnings of $3.90 per share, down from $4.11 per share in the same quarter last year and higher than the Capital IQ forecast of $3.73 per share.
(+) Teleflex (TFX) was marginally higher as it booked Q1 adjusted earnings of $2.24 per share, up from $2.15 in the same period a year ago and topping the estimate of $2.17 from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks moving on news include: (+) ARCA biopharma (ABIO), which was surging by over 66% after the company said data from an exploratory phase 2 trial show a majority of heart patients undergoing its bucindolol therapy demonstrated a "more favorable response" than to standard beta-blocker therapy. AMGN: Flat Health care heavyweights were mixed pre-market Thursday. (+) Teleflex (TFX) was marginally higher as it booked Q1 adjusted earnings of $2.24 per share, up from $2.15 in the same period a year ago and topping the estimate of $2.17 from analysts polled by Capital IQ. | Stocks moving on news include: (+) ARCA biopharma (ABIO), which was surging by over 66% after the company said data from an exploratory phase 2 trial show a majority of heart patients undergoing its bucindolol therapy demonstrated a "more favorable response" than to standard beta-blocker therapy. Top Health Care Stocks: AMGN: Flat Health care heavyweights were mixed pre-market Thursday. | Stocks moving on news include: (+) ARCA biopharma (ABIO), which was surging by over 66% after the company said data from an exploratory phase 2 trial show a majority of heart patients undergoing its bucindolol therapy demonstrated a "more favorable response" than to standard beta-blocker therapy. In other sector news: (+) Cigna (CI) was slightly higher after it reported Q1 adjusted earnings of $3.90 per share, down from $4.11 per share in the same quarter last year and higher than the Capital IQ forecast of $3.73 per share. (+) Teleflex (TFX) was marginally higher as it booked Q1 adjusted earnings of $2.24 per share, up from $2.15 in the same period a year ago and topping the estimate of $2.17 from analysts polled by Capital IQ. | Stocks moving on news include: (+) ARCA biopharma (ABIO), which was surging by over 66% after the company said data from an exploratory phase 2 trial show a majority of heart patients undergoing its bucindolol therapy demonstrated a "more favorable response" than to standard beta-blocker therapy. Top Health Care Stocks: AMGN: Flat Health care heavyweights were mixed pre-market Thursday. |
29050.0 | 2019-05-01 00:00:00 UTC | 6 Top Gainers In Pharma Sector (ABIO, PRPO, VCYT...) | ABIO | https://www.nasdaq.com/articles/6-top-gainers-pharma-sector-abio-prpo-vcyt...-2019-05-01 | nan | nan | (RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.
1. ARCA biopharma Inc. (ABIO)
ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.
The Company's lead product candidate is Gencaro, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year.
Gained 98.64% to close Wednesday's (May 1) trading at $10.25.
News: The Company announced that the results of its phase IIb trial, which compared the effectiveness of Gencaro (bucindolol) against active control metoprolol succinate (TOPROL-XL) for the maintenance of sinus rhythm in a genetically-defined heart failure population with atrial fibrillation, dubbed GENETIC-AF, are published in the Journal of American College of Cardiology: Heart Failure.
The lead author of the paper Jonathan Piccini concluded that although Gencaro did not reduce the recurrence of atrial fibrillation (AF), atrial flutter (AFL) or all-cause mortality (ACM) compared to metoprolol, the majority of patients in the trial demonstrated a more favorable response to genetically-targeted Gencaro compared to standard beta-blocker therapy. Piccini added that the data are very encouraging and merit further investigation in future Phase 3 trials.
The results were reported by the Company on February 26, 2018, which sent the shares down nearly 72% to $8.10 that day.
2. Precipio Inc. (PRPO)
Precipio is a cancer diagnostics company.
Gained 38.84% to close Wednesday's trading at $8.40.
News: The Company announced that it will provide a corporate update on May 6, 2019.
Recent events:
-- On April 29, 2019, the Company signed a services contract with a health care management group serving several major hospitals based in Cairo, Egypt. The contract is expected to generate over $1.5 million in revenues annually for Precipio.
-- In order to regain compliance with the Nasdaq minimum bid price requirement of $1.00, Precipio implemented a 1-for-15 reverse stock split on April 26, 2019, and its shares began trading on a split-adjusted basis at the open of business on Monday, April 29, 2019.
3. Pacira Pharmaceuticals Inc. (PCRX)
Pacira BioSciences provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The Company's lead marketed product is Exparel, a long-acting non-opioid pain drug.
Gained 16.15% to close Wednesday's trading at $46.25.
News: Pacira's competitor Heron Therapeutics Inc. (HRTX) has been issued a Complete Response Letter for its pain drug candidate HTX-011. The FDA has sought additional Chemistry and Manufacturing Controls (CMC), and non-clinical information related to HTX-011 from Heron.
4. CohBar Inc. (CWBR)
CohBar is a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases.
Gained 13.06% to close Wednesday's trading at $2.77.
News: No news
Near-term Catalyst:
The company is slated to report its first quarter 2019 financial results and will provide an update on its business on May 7, 2019.
5. ReWalk Robotics Ltd. (RWLK)
Rewalk manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.
Gained 12.17% to close Wednesday's trading at $3.87.
News: No news
Recent events:
-- On April 26, 2019, the Company regained compliance with Nasdaq Listing Rules related to the minimum $35 million market value of listed securities requirement and $2.5 million shareholders' equity and $500,000 net income standards.
-- On February 8, 2019, the Company reported financial results for the fourth quarter and full-year ended December 31, 2018. Total revenue for the fourth quarter of 2018 was $1.6 million compared to $1.5 million in the prior year quarter.
Near-term Catalyst:
-- The Company is scheduled to release its first quarter 2019 financial results next week (May 10 - May 14).
6. Veracyte Inc. (VCYT)
Veracyte is a commercial-stage genomic diagnostics company.
Gained 10.06% to close Wednesday's trading at $25.17.
News: The Company reported a narrower loss on 27% revenue growth, and boosted its 2019 annual revenue guidance.
Net loss narrowed to $1.92 million or $0.05 per share on revenue of $29.53 million. This compared with a net loss of $9.2 million or $0.27 per share and revenue of $20 million in the year-ago quarter.
For 2019, the Company now expects annual revenue to be in the range of $117 million to $121 million from its prior guidance range of $113 million to $117 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: The Company announced that the results of its phase IIb trial, which compared the effectiveness of Gencaro (bucindolol) against active control metoprolol succinate (TOPROL-XL) for the maintenance of sinus rhythm in a genetically-defined heart failure population with atrial fibrillation, dubbed GENETIC-AF, are published in the Journal of American College of Cardiology: Heart Failure. The lead author of the paper Jonathan Piccini concluded that although Gencaro did not reduce the recurrence of atrial fibrillation (AF), atrial flutter (AFL) or all-cause mortality (ACM) compared to metoprolol, the majority of patients in the trial demonstrated a more favorable response to genetically-targeted Gencaro compared to standard beta-blocker therapy. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: No news Near-term Catalyst: The company is slated to report its first quarter 2019 financial results and will provide an update on its business on May 7, 2019. News: No news Recent events: -- On April 26, 2019, the Company regained compliance with Nasdaq Listing Rules related to the minimum $35 million market value of listed securities requirement and $2.5 million shareholders' equity and $500,000 net income standards. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: The Company announced that the results of its phase IIb trial, which compared the effectiveness of Gencaro (bucindolol) against active control metoprolol succinate (TOPROL-XL) for the maintenance of sinus rhythm in a genetically-defined heart failure population with atrial fibrillation, dubbed GENETIC-AF, are published in the Journal of American College of Cardiology: Heart Failure. News: No news Recent events: -- On April 26, 2019, the Company regained compliance with Nasdaq Listing Rules related to the minimum $35 million market value of listed securities requirement and $2.5 million shareholders' equity and $500,000 net income standards. | ARCA biopharma Inc. (ABIO) ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. News: The Company announced that the results of its phase IIb trial, which compared the effectiveness of Gencaro (bucindolol) against active control metoprolol succinate (TOPROL-XL) for the maintenance of sinus rhythm in a genetically-defined heart failure population with atrial fibrillation, dubbed GENETIC-AF, are published in the Journal of American College of Cardiology: Heart Failure. News: No news Recent events: -- On April 26, 2019, the Company regained compliance with Nasdaq Listing Rules related to the minimum $35 million market value of listed securities requirement and $2.5 million shareholders' equity and $500,000 net income standards. |
29051.0 | 2019-02-20 00:00:00 UTC | U.S. STOCKS ON THE MOVE-Southwest, Tesla, CVS Health | ABIO | https://www.nasdaq.com/articles/us-stocks-move-southwest-tesla-cvs-health-2019-02-20 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stocks were little changed on Wednesday as investors weighed the latest developments in trade talks between the United States and China, while waiting for minutes from the Federal Reserve's January policy-setting meeting.
At 10:08 ET, the Dow Jones Industrial Average was up 0.02 percent at 25,896.2. The S&P 500 was up 0.02 percent at 2,780.35 and the Nasdaq Composite was up 0.20 percent at 7,501.67.
The top three S&P 500 percentage gainers:
** Garmin Ltd, up 14.6 pct
** Devon Energy Corp, up 11.1 pct
** CF Industries Holdings Inc, up 5.3 pct
The top three S&P 500 percentage losers:
** CVS Health Corp, down 8.5 pct
** Henry Schein Inc, down 7.6 pct
** Concho Resources Inc, down 6.5 pct
The top three NYSE percentage gainers:
** Devon Energy Corp, up 11.1 pct
** LSC Communications Inc, up 10.5 pct
** Quad/Graphics Inc, up 10.1 pct
The top three NYSE percentage losers:
** Owens & Minor Inc, down 18.5 pct
** Ocwen Financial Corp, down 15.4 pct
** CVS Health Corp, down 8.5 pct
The top three Nasdaq percentage gainers:
** Kandi Technologies Group Inc, up 35.8 pct
** LeMaitre Vascular Inc, up 18.9 pct
** OneSpan Inc, up 18.1 pct
The top three Nasdaq percentage losers:
** PHI Inc, down 24.4 pct
** Sienna Biopharmaceuticals Inc, down 21.4 pct
** IntriCon Corp, down 15.9 pct
** Southwest Airlines Co: down 5.3 pct
Drifts lower on weak forecasts, from carrier and GS
Southwest probes cancellations, says shutdown cost $60 mln
** CVS Health Corp: down 8.5 pct
Shares slide on weak 2019 profit forecast
CVS Health's forecast points to more pain at long-term care business
** Garmin Ltd: up 14.6 pct
Surges to new 11-yr high on results, div hike plan
Garmin forecasts full-year revenue, profit above estimates, shares rise
** New Residential Investment Corp: down 3.7 pct
Falls on $665 mln stock offering
** CenturyLink Inc: down 1.2 pct
"Don't fear the reaper," says top-rated analyst
** Armour Residential REIT Inc: down 3.0 pct
Drops on upsized stock deal
** Owens & Minor Inc: down 18.5 pct
Set to open at 6-wk low on weak results, forecast
** Henry Schein Inc: down 7.6 pct
Falls on Q4 revenue miss; profit forecast disappoints
** LendingClub Corp: down 6.4 pct
Falls on disappointing forecast; Morgan Stanley, BTIG cut PT
** Clearside Biomedical Inc: up 22.8 pct
Jumps after FDA sets action date for co's vision loss drug
** ARCA Biopharma Inc: up 78.3 pct
Surges on agreement with FDA on heart therapy pathway
** Sienna Biopharmaceuticals Inc: down 21.4 pct
Drops on $20 mln stock deal to fund psoriasis drug
** Teva Pharmaceutical Industries Ltd: down 2.5 pct
Mizuho sees delay in return to growth, downgrades
** Tesla Inc: down 0.5 pct
Slips after top lawyer's exit
Tesla's top lawyer leaves two months into the job
** Bausch Health Companies Inc: down 3.8 pct
Climbs on Q4 beat, promising forecast
** Compass Diversified Holdings: up 0.8 pct
Rises on sale of hemp foods unit to Tilray
** Pure Storage Inc: down 2.2 pct
Raymond James downgrades Pure Storage on Nvidia, NetApp indicators
** Arlington Asset Investment Corp: down 6.1 pct
Falls amid mortgage REIT offering hat trick
** Wix.com Ltd: down 9.4 pct
Israel'sWix.com Q4 profit up, sees 25 revenue growth in 2019
** Devon Energy Corp: up 11.1 pct
Shares boosted as co beats production estimates
** Lantheus Holdings Inc: up 10.6 pct
Hits new 52-wk high on strong Q4 report
** Ovid Therapeutics Inc: down 30.0 pct
Plunges to record low on $30 mln equity raise
The 11 major S&P 500 sectors:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were little changed on Wednesday as investors weighed the latest developments in trade talks between the United States and China, while waiting for minutes from the Federal Reserve's January policy-setting meeting. At 10:08 ET, the Dow Jones Industrial Average was up 0.02 percent at 25,896.2. The top three S&P 500 percentage gainers: ** Garmin Ltd, up 14.6 pct ** Devon Energy Corp, up 11.1 pct ** CF Industries Holdings Inc, up 5.3 pct The top three S&P 500 percentage losers: ** CVS Health Corp, down 8.5 pct ** Henry Schein Inc, down 7.6 pct ** Concho Resources Inc, down 6.5 pct The top three NYSE percentage gainers: ** Devon Energy Corp, up 11.1 pct ** LSC Communications Inc, up 10.5 pct ** Quad/Graphics Inc, up 10.1 pct The top three NYSE percentage losers: ** Owens & Minor Inc, down 18.5 pct ** Ocwen Financial Corp, down 15.4 pct ** CVS Health Corp, down 8.5 pct The top three Nasdaq percentage gainers: ** Kandi Technologies Group Inc, up 35.8 pct ** LeMaitre Vascular Inc, up 18.9 pct ** OneSpan Inc, up 18.1 pct The top three Nasdaq percentage losers: ** PHI Inc, down 24.4 pct ** Sienna Biopharmaceuticals Inc, down 21.4 pct ** IntriCon Corp, down 15.9 pct ** Southwest Airlines Co: down 5.3 pct Drifts lower on weak forecasts, from carrier and GS Southwest probes cancellations, says shutdown cost $60 mln ** CVS Health Corp: down 8.5 pct Shares slide on weak 2019 profit forecast CVS Health's forecast points to more pain at long-term care business ** Garmin Ltd: up 14.6 pct Surges to new 11-yr high on results, div hike plan Garmin forecasts full-year revenue, profit above estimates, shares rise ** New Residential Investment Corp: down 3.7 pct Falls on $665 mln stock offering ** CenturyLink Inc: down 1.2 pct "Don't fear the reaper," says top-rated analyst ** Armour Residential REIT Inc: down 3.0 pct Drops on upsized stock deal ** Owens & Minor Inc: down 18.5 pct Set to open at 6-wk low on weak results, forecast ** Henry Schein Inc: down 7.6 pct Falls on Q4 revenue miss; profit forecast disappoints ** LendingClub Corp: down 6.4 pct Falls on disappointing forecast; Morgan Stanley, BTIG cut PT ** Clearside Biomedical Inc: up 22.8 pct Jumps after FDA sets action date for co's vision loss drug ** ARCA Biopharma Inc: up 78.3 pct Surges on agreement with FDA on heart therapy pathway ** Sienna Biopharmaceuticals Inc: down 21.4 pct Drops on $20 mln stock deal to fund psoriasis drug ** Teva Pharmaceutical Industries Ltd: down 2.5 pct Mizuho sees delay in return to growth, downgrades ** Tesla Inc: down 0.5 pct Slips after top lawyer's exit Tesla's top lawyer leaves two months into the job ** Bausch Health Companies Inc: down 3.8 pct Climbs on Q4 beat, promising forecast ** Compass Diversified Holdings: up 0.8 pct Rises on sale of hemp foods unit to Tilray ** Pure Storage Inc: down 2.2 pct Raymond James downgrades Pure Storage on Nvidia, NetApp indicators ** Arlington Asset Investment Corp: down 6.1 pct Falls amid mortgage REIT offering hat trick ** Wix.com Ltd: down 9.4 pct Israel'sWix.com Q4 profit up, sees 25 revenue growth in 2019 ** Devon Energy Corp: up 11.1 pct Shares boosted as co beats production estimates ** Lantheus Holdings Inc: up 10.6 pct Hits new 52-wk high on strong Q4 report ** Ovid Therapeutics Inc: down 30.0 pct Plunges to record low on $30 mln equity raise The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were little changed on Wednesday as investors weighed the latest developments in trade talks between the United States and China, while waiting for minutes from the Federal Reserve's January policy-setting meeting. The S&P 500 was up 0.02 percent at 2,780.35 and the Nasdaq Composite was up 0.20 percent at 7,501.67. The top three S&P 500 percentage gainers: ** Garmin Ltd, up 14.6 pct ** Devon Energy Corp, up 11.1 pct ** CF Industries Holdings Inc, up 5.3 pct The top three S&P 500 percentage losers: ** CVS Health Corp, down 8.5 pct ** Henry Schein Inc, down 7.6 pct ** Concho Resources Inc, down 6.5 pct The top three NYSE percentage gainers: ** Devon Energy Corp, up 11.1 pct ** LSC Communications Inc, up 10.5 pct ** Quad/Graphics Inc, up 10.1 pct The top three NYSE percentage losers: ** Owens & Minor Inc, down 18.5 pct ** Ocwen Financial Corp, down 15.4 pct ** CVS Health Corp, down 8.5 pct The top three Nasdaq percentage gainers: ** Kandi Technologies Group Inc, up 35.8 pct ** LeMaitre Vascular Inc, up 18.9 pct ** OneSpan Inc, up 18.1 pct The top three Nasdaq percentage losers: ** PHI Inc, down 24.4 pct ** Sienna Biopharmaceuticals Inc, down 21.4 pct ** IntriCon Corp, down 15.9 pct ** Southwest Airlines Co: down 5.3 pct Drifts lower on weak forecasts, from carrier and GS Southwest probes cancellations, says shutdown cost $60 mln ** CVS Health Corp: down 8.5 pct Shares slide on weak 2019 profit forecast CVS Health's forecast points to more pain at long-term care business ** Garmin Ltd: up 14.6 pct Surges to new 11-yr high on results, div hike plan Garmin forecasts full-year revenue, profit above estimates, shares rise ** New Residential Investment Corp: down 3.7 pct Falls on $665 mln stock offering ** CenturyLink Inc: down 1.2 pct "Don't fear the reaper," says top-rated analyst ** Armour Residential REIT Inc: down 3.0 pct Drops on upsized stock deal ** Owens & Minor Inc: down 18.5 pct Set to open at 6-wk low on weak results, forecast ** Henry Schein Inc: down 7.6 pct Falls on Q4 revenue miss; profit forecast disappoints ** LendingClub Corp: down 6.4 pct Falls on disappointing forecast; Morgan Stanley, BTIG cut PT ** Clearside Biomedical Inc: up 22.8 pct Jumps after FDA sets action date for co's vision loss drug ** ARCA Biopharma Inc: up 78.3 pct Surges on agreement with FDA on heart therapy pathway ** Sienna Biopharmaceuticals Inc: down 21.4 pct Drops on $20 mln stock deal to fund psoriasis drug ** Teva Pharmaceutical Industries Ltd: down 2.5 pct Mizuho sees delay in return to growth, downgrades ** Tesla Inc: down 0.5 pct Slips after top lawyer's exit Tesla's top lawyer leaves two months into the job ** Bausch Health Companies Inc: down 3.8 pct Climbs on Q4 beat, promising forecast ** Compass Diversified Holdings: up 0.8 pct Rises on sale of hemp foods unit to Tilray ** Pure Storage Inc: down 2.2 pct Raymond James downgrades Pure Storage on Nvidia, NetApp indicators ** Arlington Asset Investment Corp: down 6.1 pct Falls amid mortgage REIT offering hat trick ** Wix.com Ltd: down 9.4 pct Israel'sWix.com Q4 profit up, sees 25 revenue growth in 2019 ** Devon Energy Corp: up 11.1 pct Shares boosted as co beats production estimates ** Lantheus Holdings Inc: up 10.6 pct Hits new 52-wk high on strong Q4 report ** Ovid Therapeutics Inc: down 30.0 pct Plunges to record low on $30 mln equity raise The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were little changed on Wednesday as investors weighed the latest developments in trade talks between the United States and China, while waiting for minutes from the Federal Reserve's January policy-setting meeting. The S&P 500 was up 0.02 percent at 2,780.35 and the Nasdaq Composite was up 0.20 percent at 7,501.67. The top three S&P 500 percentage gainers: ** Garmin Ltd, up 14.6 pct ** Devon Energy Corp, up 11.1 pct ** CF Industries Holdings Inc, up 5.3 pct The top three S&P 500 percentage losers: ** CVS Health Corp, down 8.5 pct ** Henry Schein Inc, down 7.6 pct ** Concho Resources Inc, down 6.5 pct The top three NYSE percentage gainers: ** Devon Energy Corp, up 11.1 pct ** LSC Communications Inc, up 10.5 pct ** Quad/Graphics Inc, up 10.1 pct The top three NYSE percentage losers: ** Owens & Minor Inc, down 18.5 pct ** Ocwen Financial Corp, down 15.4 pct ** CVS Health Corp, down 8.5 pct The top three Nasdaq percentage gainers: ** Kandi Technologies Group Inc, up 35.8 pct ** LeMaitre Vascular Inc, up 18.9 pct ** OneSpan Inc, up 18.1 pct The top three Nasdaq percentage losers: ** PHI Inc, down 24.4 pct ** Sienna Biopharmaceuticals Inc, down 21.4 pct ** IntriCon Corp, down 15.9 pct ** Southwest Airlines Co: down 5.3 pct Drifts lower on weak forecasts, from carrier and GS Southwest probes cancellations, says shutdown cost $60 mln ** CVS Health Corp: down 8.5 pct Shares slide on weak 2019 profit forecast CVS Health's forecast points to more pain at long-term care business ** Garmin Ltd: up 14.6 pct Surges to new 11-yr high on results, div hike plan Garmin forecasts full-year revenue, profit above estimates, shares rise ** New Residential Investment Corp: down 3.7 pct Falls on $665 mln stock offering ** CenturyLink Inc: down 1.2 pct "Don't fear the reaper," says top-rated analyst ** Armour Residential REIT Inc: down 3.0 pct Drops on upsized stock deal ** Owens & Minor Inc: down 18.5 pct Set to open at 6-wk low on weak results, forecast ** Henry Schein Inc: down 7.6 pct Falls on Q4 revenue miss; profit forecast disappoints ** LendingClub Corp: down 6.4 pct Falls on disappointing forecast; Morgan Stanley, BTIG cut PT ** Clearside Biomedical Inc: up 22.8 pct Jumps after FDA sets action date for co's vision loss drug ** ARCA Biopharma Inc: up 78.3 pct Surges on agreement with FDA on heart therapy pathway ** Sienna Biopharmaceuticals Inc: down 21.4 pct Drops on $20 mln stock deal to fund psoriasis drug ** Teva Pharmaceutical Industries Ltd: down 2.5 pct Mizuho sees delay in return to growth, downgrades ** Tesla Inc: down 0.5 pct Slips after top lawyer's exit Tesla's top lawyer leaves two months into the job ** Bausch Health Companies Inc: down 3.8 pct Climbs on Q4 beat, promising forecast ** Compass Diversified Holdings: up 0.8 pct Rises on sale of hemp foods unit to Tilray ** Pure Storage Inc: down 2.2 pct Raymond James downgrades Pure Storage on Nvidia, NetApp indicators ** Arlington Asset Investment Corp: down 6.1 pct Falls amid mortgage REIT offering hat trick ** Wix.com Ltd: down 9.4 pct Israel'sWix.com Q4 profit up, sees 25 revenue growth in 2019 ** Devon Energy Corp: up 11.1 pct Shares boosted as co beats production estimates ** Lantheus Holdings Inc: up 10.6 pct Hits new 52-wk high on strong Q4 report ** Ovid Therapeutics Inc: down 30.0 pct Plunges to record low on $30 mln equity raise The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were little changed on Wednesday as investors weighed the latest developments in trade talks between the United States and China, while waiting for minutes from the Federal Reserve's January policy-setting meeting. At 10:08 ET, the Dow Jones Industrial Average was up 0.02 percent at 25,896.2. The S&P 500 was up 0.02 percent at 2,780.35 and the Nasdaq Composite was up 0.20 percent at 7,501.67. |
29052.0 | 2019-02-20 00:00:00 UTC | Mid-Morning Market Update: Markets Mostly Flat; CVS Health Issues Weak Earnings Outlook | ABIO | https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-flat-cvs-health-issues-weak-earnings-outlook-2019 | nan | nan | Following the market opening Wednesday, the Dow traded down 0.01 percent to 25,889.73 while the NASDAQ climbed 0.1 percent to 7,497.51. The S&P also fell, dropping 0.03 percent to 2,778.93.
Leading and Lagging Sectors
Wednesday morning, the materials shares climbed 0.9 percent. Meanwhile, top gainers in the sector included Summit Materials, Inc. (NYSE: SUM ) up 5 percent, and Harmony Gold Mining Company Limited (NYSE: HMY ) up 6 percent.
In trading on Wednesday, real estate shares fell 0.4 percent.
Top Headline
CVS Health Corp (NYSE: CVS ) issued weak earnings forecast for FY19. The company reported upbea t earnings for its fourth quarter, while sales missed view.
CVS Health said it earned $2.14 per share in the fourth quarter on revenue of $54.42 billion. However, analysts were expecting earnings of $2.05 per share and revenue of $54.58 billion.
CVS Health expects FY19 adjusted earnings of $6.68 to $6.88 per share, versus analysts' estimates of $7.41 per share.
Equities Trading UP
ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 80 percent to $0.695 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug.
Shares of Kandi Technologies Group, Inc. (NASDAQ: KNDI ) shot up 36 percent to $8.07 after the company reported NHTSA approval of 2 electric vehicle models.
OneSpan Inc. (NASDAQ: OSPN ) shares were also up, gaining 18 percent to $19.80 after the company reported upbeat Q4 results.
Equities Trading DOWN
Ovid Therapeutics Inc. (NASDAQ: OVID ) shares dropped 30 percent to $1.80 after reporting pricing of $30 million of securities in concurrent public offerings of common and preferred stock.
Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 21 percent to $2.3566 after the company priced an 8 million share stock offering at $2.50 per share.
Owens & Minor, Inc. (NYSE: OMI ) was down, falling around 18 percent to $6.53 after the company reported downbeat Q4 earnings and issued weak 2019 earnings forecast.
Commodities
In commodity news, oil traded down 0.7 percent to $55.72 while gold traded up 0.2 percent to $1,346.80.
Silver traded up 0.3 percent Wednesday to $16.12, while copper rose 0.1 percent to $2.8815.
Eurozone
European shares were higher today. The eurozone's STOXX 600 gained 0.3 percent, the Spanish Ibex Index rose 0.4 percent, while Italy's FTSE MIB Index climbed 0.1 percent. Meanwhile the German DAX gained 0.5 percent, and the French CAC 40 rose 0.3 percent while U.K. shares rose 0.4 percent.
Economics
The Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET.
Data on farm prices for December will be released at 3:00 p.m. ET.
© 2019 Benzinga.com. Benzinga does not provide investment advice . All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 80 percent to $0.695 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Shares of Kandi Technologies Group, Inc. (NASDAQ: KNDI ) shot up 36 percent to $8.07 after the company reported NHTSA approval of 2 electric vehicle models. OneSpan Inc. (NASDAQ: OSPN ) shares were also up, gaining 18 percent to $19.80 after the company reported upbeat Q4 results. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 80 percent to $0.695 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Top Headline CVS Health Corp (NYSE: CVS ) issued weak earnings forecast for FY19. Equities Trading DOWN Ovid Therapeutics Inc. (NASDAQ: OVID ) shares dropped 30 percent to $1.80 after reporting pricing of $30 million of securities in concurrent public offerings of common and preferred stock. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 80 percent to $0.695 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 21 percent to $2.3566 after the company priced an 8 million share stock offering at $2.50 per share. The eurozone's STOXX 600 gained 0.3 percent, the Spanish Ibex Index rose 0.4 percent, while Italy's FTSE MIB Index climbed 0.1 percent. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 80 percent to $0.695 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Following the market opening Wednesday, the Dow traded down 0.01 percent to 25,889.73 while the NASDAQ climbed 0.1 percent to 7,497.51. The company reported upbea t earnings for its fourth quarter, while sales missed view. |
29053.0 | 2019-02-20 00:00:00 UTC | U.S. STOCKS ON THE MOVE-CVS Health, Garmin, ARCA Biopharma, LendingClub | ABIO | https://www.nasdaq.com/articles/us-stocks-move-cvs-health-garmin-arca-biopharma-lendingclub-2019-02-20 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stock index futures were slightly lower on Wednesday after a handful of downbeat earnings reports, while investors weighed the latest developments in trade talks between the United States and China.
At 8:54 ET, Dow e-minis were down 0.05 percent at 25,871. S&P 500 e-minis were unchanged at 2,778.75, while Nasdaq 100 e-minis were up 0.15 percent at 7,079.
The top three NYSE percentage gainers premarket:
** Compass Diversified Holdings, up 12.2 pct
** Venator Materials PLC, up 8.2 pct
** Invitae Corp, up 7.5 pct
The top three NYSE percentage losers premarket:
** Test Symbol NTEST D, down 81.3 pct
** Owens & Minor Inc, down 18.5 pct
** Aerojet Rocketdyne Holdings Inc, down 15.7 pct
The top three Nasdaq percentage gainers premarket:
** ARCA biopharma Inc, up 132.6 pct
** BioSig Technologies Inc, up 28.0 pct
** Kandi Technologies Group Inc, up 28.5 pct
The top three Nasdaq percentage losers premarket:
** Aceto Corp, down 68.9 pct
** Sienna Biopharmaceuticals Inc, down 19.7 pct
** Ovid Therapeutics Inc, down 15.6 pct
** Southwest Airlines Co: down 4.6 pct premarket
Southwest: Drifts lower on weak forecasts, from carrier and GS
** CVS Health Corp: down 8.7 pct premarket
Shares slide on weak 2019 profit forecast
** Garmin Ltd: up 7.7 pct premarket
Surges to new 11-yr high on results, div hike plan
** New Residential Investment Corp: down 3.2 pct premarket
Falls on $665 mln stock offering
** CenturyLink Inc: down 1.5 pct premarket
: "Don't fear the reaper," says top-rated analyst
** Armour Residential REIT Inc: down 2.2 pct premarket
Drops on upsized stock deal
** Owens & Minor Inc: down 18.5 pct premarket
Set to open at 6-wk low on weak results, forecast
** ARCA Biopharma Inc: up 132.6 pct premarket
Surges on agreement with FDA on heart therapy pathway
** Henry Schein Inc: down 6.5 pct premarket
Henry Schein: Falls on Q4 revenue miss; profit forecast disappoints
** LendingClub Corp: down 6.1 pct premarket
Falls on disappointing forecast; Morgan Stanley, BTIG cut PT
** Clearside Biomedical Inc: up 13.8 pct premarket
Jumps after FDA sets action date for co's vision loss drug
** Sienna Biopharmaceuticals Inc: down 19.7 pct premarket
Drops on $20 mln stock deal to fund psoriasis drug
** Teva Pharmaceutical Industries Ltd: down 0.4 pct premarket
Mizuho sees delay in return to growth, downgrades
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures were slightly lower on Wednesday after a handful of downbeat earnings reports, while investors weighed the latest developments in trade talks between the United States and China. At 8:54 ET, Dow e-minis were down 0.05 percent at 25,871. The top three NYSE percentage gainers premarket: ** Compass Diversified Holdings, up 12.2 pct ** Venator Materials PLC, up 8.2 pct ** Invitae Corp, up 7.5 pct The top three NYSE percentage losers premarket: ** Test Symbol NTEST D, down 81.3 pct ** Owens & Minor Inc, down 18.5 pct ** Aerojet Rocketdyne Holdings Inc, down 15.7 pct The top three Nasdaq percentage gainers premarket: ** ARCA biopharma Inc, up 132.6 pct ** BioSig Technologies Inc, up 28.0 pct ** Kandi Technologies Group Inc, up 28.5 pct The top three Nasdaq percentage losers premarket: ** Aceto Corp, down 68.9 pct ** Sienna Biopharmaceuticals Inc, down 19.7 pct ** Ovid Therapeutics Inc, down 15.6 pct ** Southwest Airlines Co: down 4.6 pct premarket Southwest: Drifts lower on weak forecasts, from carrier and GS ** CVS Health Corp: down 8.7 pct premarket Shares slide on weak 2019 profit forecast ** Garmin Ltd: up 7.7 pct premarket Surges to new 11-yr high on results, div hike plan ** New Residential Investment Corp: down 3.2 pct premarket Falls on $665 mln stock offering ** CenturyLink Inc: down 1.5 pct premarket : "Don't fear the reaper," says top-rated analyst ** Armour Residential REIT Inc: down 2.2 pct premarket Drops on upsized stock deal ** Owens & Minor Inc: down 18.5 pct premarket Set to open at 6-wk low on weak results, forecast ** ARCA Biopharma Inc: up 132.6 pct premarket Surges on agreement with FDA on heart therapy pathway ** Henry Schein Inc: down 6.5 pct premarket Henry Schein: Falls on Q4 revenue miss; profit forecast disappoints ** LendingClub Corp: down 6.1 pct premarket Falls on disappointing forecast; Morgan Stanley, BTIG cut PT ** Clearside Biomedical Inc: up 13.8 pct premarket Jumps after FDA sets action date for co's vision loss drug ** Sienna Biopharmaceuticals Inc: down 19.7 pct premarket Drops on $20 mln stock deal to fund psoriasis drug ** Teva Pharmaceutical Industries Ltd: down 0.4 pct premarket Mizuho sees delay in return to growth, downgrades The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures were slightly lower on Wednesday after a handful of downbeat earnings reports, while investors weighed the latest developments in trade talks between the United States and China. S&P 500 e-minis were unchanged at 2,778.75, while Nasdaq 100 e-minis were up 0.15 percent at 7,079. The top three NYSE percentage gainers premarket: ** Compass Diversified Holdings, up 12.2 pct ** Venator Materials PLC, up 8.2 pct ** Invitae Corp, up 7.5 pct The top three NYSE percentage losers premarket: ** Test Symbol NTEST D, down 81.3 pct ** Owens & Minor Inc, down 18.5 pct ** Aerojet Rocketdyne Holdings Inc, down 15.7 pct The top three Nasdaq percentage gainers premarket: ** ARCA biopharma Inc, up 132.6 pct ** BioSig Technologies Inc, up 28.0 pct ** Kandi Technologies Group Inc, up 28.5 pct The top three Nasdaq percentage losers premarket: ** Aceto Corp, down 68.9 pct ** Sienna Biopharmaceuticals Inc, down 19.7 pct ** Ovid Therapeutics Inc, down 15.6 pct ** Southwest Airlines Co: down 4.6 pct premarket Southwest: Drifts lower on weak forecasts, from carrier and GS ** CVS Health Corp: down 8.7 pct premarket Shares slide on weak 2019 profit forecast ** Garmin Ltd: up 7.7 pct premarket Surges to new 11-yr high on results, div hike plan ** New Residential Investment Corp: down 3.2 pct premarket Falls on $665 mln stock offering ** CenturyLink Inc: down 1.5 pct premarket : "Don't fear the reaper," says top-rated analyst ** Armour Residential REIT Inc: down 2.2 pct premarket Drops on upsized stock deal ** Owens & Minor Inc: down 18.5 pct premarket Set to open at 6-wk low on weak results, forecast ** ARCA Biopharma Inc: up 132.6 pct premarket Surges on agreement with FDA on heart therapy pathway ** Henry Schein Inc: down 6.5 pct premarket Henry Schein: Falls on Q4 revenue miss; profit forecast disappoints ** LendingClub Corp: down 6.1 pct premarket Falls on disappointing forecast; Morgan Stanley, BTIG cut PT ** Clearside Biomedical Inc: up 13.8 pct premarket Jumps after FDA sets action date for co's vision loss drug ** Sienna Biopharmaceuticals Inc: down 19.7 pct premarket Drops on $20 mln stock deal to fund psoriasis drug ** Teva Pharmaceutical Industries Ltd: down 0.4 pct premarket Mizuho sees delay in return to growth, downgrades The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At 8:54 ET, Dow e-minis were down 0.05 percent at 25,871. S&P 500 e-minis were unchanged at 2,778.75, while Nasdaq 100 e-minis were up 0.15 percent at 7,079. The top three NYSE percentage gainers premarket: ** Compass Diversified Holdings, up 12.2 pct ** Venator Materials PLC, up 8.2 pct ** Invitae Corp, up 7.5 pct The top three NYSE percentage losers premarket: ** Test Symbol NTEST D, down 81.3 pct ** Owens & Minor Inc, down 18.5 pct ** Aerojet Rocketdyne Holdings Inc, down 15.7 pct The top three Nasdaq percentage gainers premarket: ** ARCA biopharma Inc, up 132.6 pct ** BioSig Technologies Inc, up 28.0 pct ** Kandi Technologies Group Inc, up 28.5 pct The top three Nasdaq percentage losers premarket: ** Aceto Corp, down 68.9 pct ** Sienna Biopharmaceuticals Inc, down 19.7 pct ** Ovid Therapeutics Inc, down 15.6 pct ** Southwest Airlines Co: down 4.6 pct premarket Southwest: Drifts lower on weak forecasts, from carrier and GS ** CVS Health Corp: down 8.7 pct premarket Shares slide on weak 2019 profit forecast ** Garmin Ltd: up 7.7 pct premarket Surges to new 11-yr high on results, div hike plan ** New Residential Investment Corp: down 3.2 pct premarket Falls on $665 mln stock offering ** CenturyLink Inc: down 1.5 pct premarket : "Don't fear the reaper," says top-rated analyst ** Armour Residential REIT Inc: down 2.2 pct premarket Drops on upsized stock deal ** Owens & Minor Inc: down 18.5 pct premarket Set to open at 6-wk low on weak results, forecast ** ARCA Biopharma Inc: up 132.6 pct premarket Surges on agreement with FDA on heart therapy pathway ** Henry Schein Inc: down 6.5 pct premarket Henry Schein: Falls on Q4 revenue miss; profit forecast disappoints ** LendingClub Corp: down 6.1 pct premarket Falls on disappointing forecast; Morgan Stanley, BTIG cut PT ** Clearside Biomedical Inc: up 13.8 pct premarket Jumps after FDA sets action date for co's vision loss drug ** Sienna Biopharmaceuticals Inc: down 19.7 pct premarket Drops on $20 mln stock deal to fund psoriasis drug ** Teva Pharmaceutical Industries Ltd: down 0.4 pct premarket Mizuho sees delay in return to growth, downgrades The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures were slightly lower on Wednesday after a handful of downbeat earnings reports, while investors weighed the latest developments in trade talks between the United States and China. At 8:54 ET, Dow e-minis were down 0.05 percent at 25,871. S&P 500 e-minis were unchanged at 2,778.75, while Nasdaq 100 e-minis were up 0.15 percent at 7,079. |
29054.0 | 2019-02-20 00:00:00 UTC | US Futures Little Changed Ahead of Fed Minutes | ABIO | https://www.nasdaq.com/articles/us-futures-little-changed-ahead-fed-minutes-2019-02-20 | nan | nan | US stock futures were little changed Wednesday as traders stayed on the sidelines awaiting for the release of minutes from the latest policy meeting of the Federal Reserve while also monitoring the latest round of US-China trade talks.
Oil prices nudged lower with global benchmark Brent crude down 0.66%, and US crude West Texas Intermediate was down 0.77% recently after a report from US officials forecasting record levels in shale production next month.
There are no major economic data due for release.
In equities, shares of Arca Biopharma ( ABIO ) were 78.3% higher pre-bell after the biopharmaceutical company reached an agreement with the Food and Drug Administration for a special protocol assessment for a clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, shares of Arca Biopharma ( ABIO ) were 78.3% higher pre-bell after the biopharmaceutical company reached an agreement with the Food and Drug Administration for a special protocol assessment for a clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. US stock futures were little changed Wednesday as traders stayed on the sidelines awaiting for the release of minutes from the latest policy meeting of the Federal Reserve while also monitoring the latest round of US-China trade talks. Oil prices nudged lower with global benchmark Brent crude down 0.66%, and US crude West Texas Intermediate was down 0.77% recently after a report from US officials forecasting record levels in shale production next month. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In equities, shares of Arca Biopharma ( ABIO ) were 78.3% higher pre-bell after the biopharmaceutical company reached an agreement with the Food and Drug Administration for a special protocol assessment for a clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. Oil prices nudged lower with global benchmark Brent crude down 0.66%, and US crude West Texas Intermediate was down 0.77% recently after a report from US officials forecasting record levels in shale production next month. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In equities, shares of Arca Biopharma ( ABIO ) were 78.3% higher pre-bell after the biopharmaceutical company reached an agreement with the Food and Drug Administration for a special protocol assessment for a clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. US stock futures were little changed Wednesday as traders stayed on the sidelines awaiting for the release of minutes from the latest policy meeting of the Federal Reserve while also monitoring the latest round of US-China trade talks. | In equities, shares of Arca Biopharma ( ABIO ) were 78.3% higher pre-bell after the biopharmaceutical company reached an agreement with the Food and Drug Administration for a special protocol assessment for a clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. US stock futures were little changed Wednesday as traders stayed on the sidelines awaiting for the release of minutes from the latest policy meeting of the Federal Reserve while also monitoring the latest round of US-China trade talks. Oil prices nudged lower with global benchmark Brent crude down 0.66%, and US crude West Texas Intermediate was down 0.77% recently after a report from US officials forecasting record levels in shale production next month. |
29055.0 | 2019-02-20 00:00:00 UTC | Mid-Afternoon Market Update: Crude Oil Up 1.5%; Kandi Technologies Shares Spike Higher | ABIO | https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-15-kandi-technologies-shares-spike-higher-2019-02-20 | nan | nan | Toward the end of trading Wednesday, the Dow traded up 0.24 percent to 25,954.13 while the NASDAQ declined 0.05 percent to 7,483.43. The S&P also rose, gaining 0.18 percent to 2,784.70.
Leading and Lagging Sectors
Wednesday afternoon, the materials shares climbed 2 percent. Meanwhile, top gainers in the sector included Lithium Americas Corp. (NYSE: LAC ) up 9 percent, and Taseko Mines Limited (NYSE: TGB ) up 8 percent.
In trading on Wednesday, real estate shares fell 0.6 percent.
Top Headline
CVS Health Corp (NYSE: CVS ) issued weak earnings forecast for FY19. The company reported upbea t earnings for its fourth quarter, while sales missed view.
CVS Health said it earned $2.14 per share in the fourth quarter on revenue of $54.42 billion. However, analysts were expecting earnings of $2.05 per share and revenue of $54.58 billion.
CVS Health expects FY19 adjusted earnings of $6.68 to $6.88 per share, versus analysts' estimates of $7.41 per share.
Equities Trading UP
ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 48 percent to $0.5711 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug.
Shares of Kandi Technologies Group, Inc. (NASDAQ: KNDI ) shot up 42 percent to $8.43. The Chinese joint venture company announced Wednesday the U.S. National Highway Traffic Safety Administration approved two purely electric models for importation and registration. Kandi subsidiary SC Autosports will pioneer the launch of Model EX3 and Model K22 in the U.S. market.
LeMaitre Vascular, Inc. (NASDAQ: LMAT ) shares were also up, gaining 24 percent to $31.10 after the company posted upbeat Q4 results and issued a strong FY19 outlook.
Equities Trading DOWN
Ovid Therapeutics Inc. (NASDAQ: OVID ) shares dropped 32 percent to $1.76 after reporting pricing of $30 million of securities in concurrent public offerings of common and preferred stock.
Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 21 percent to $2.36 after the company priced an 8 million share stock offering at $2.50 per share.
Aceto Corporation (NASDAQ: ACET ) was down, falling around 61 percent to $0.4003 after the company filed for Chapter 11 bankruptcy relief and announced the proposed sale of its chemicals business for $338 million.
Commodities
In commodity news, oil traded up 1.5 percent to $56.92 while gold traded up 0.2 percent to $1,347.40.
Silver traded up 1.3 percent Wednesday to $16.28, while copper rose 1.6 percent to $2.924.
Eurozone
European shares closed higher today. The eurozone's STOXX 600 gained 0.67 percent, the Spanish Ibex Index rose 0.49 percent, while Italy's FTSE MIB Index climbed 0.38 percent. Meanwhile the German DAX gained 0.82 percent, and the French CAC 40 rose 0.69 percent while U.K. shares rose 0.69 percent.
Economics
The Federal Open Market Committee released minutes of its latest meeting.
Data on farm prices for December will be released at 3:00 p.m. ET.
© 2019 Benzinga.com. Benzinga does not provide investment advice . All rights reserved.
Get insight into trading platforms. Compare the best online stock brokerages.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 48 percent to $0.5711 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. The Chinese joint venture company announced Wednesday the U.S. National Highway Traffic Safety Administration approved two purely electric models for importation and registration. Aceto Corporation (NASDAQ: ACET ) was down, falling around 61 percent to $0.4003 after the company filed for Chapter 11 bankruptcy relief and announced the proposed sale of its chemicals business for $338 million. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 48 percent to $0.5711 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Top Headline CVS Health Corp (NYSE: CVS ) issued weak earnings forecast for FY19. Equities Trading DOWN Ovid Therapeutics Inc. (NASDAQ: OVID ) shares dropped 32 percent to $1.76 after reporting pricing of $30 million of securities in concurrent public offerings of common and preferred stock. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 48 percent to $0.5711 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Toward the end of trading Wednesday, the Dow traded up 0.24 percent to 25,954.13 while the NASDAQ declined 0.05 percent to 7,483.43. Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 21 percent to $2.36 after the company priced an 8 million share stock offering at $2.50 per share. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 48 percent to $0.5711 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. The company reported upbea t earnings for its fourth quarter, while sales missed view. Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 21 percent to $2.36 after the company priced an 8 million share stock offering at $2.50 per share. |
29056.0 | 2019-02-20 00:00:00 UTC | Mid-Day Market Update: LeMaitre Vascular Surges Following Strong Q4 Results; Sienna Biopharmaceuticals Shares Slide | ABIO | https://www.nasdaq.com/articles/mid-day-market-update-lemaitre-vascular-surges-following-strong-q4-results-sienna | nan | nan | Midway through trading Wednesday, the Dow traded up 0.14 percent to 25,926.45 while the NASDAQ climbed 0.31 percent to 7,509.82. The S&P also rose, gaining 0.15 percent to 2,783.97.
Leading and Lagging Sectors
On Wednesday, the materials shares climbed 1.4 percent. Meanwhile, top gainers in the sector included Intrepid Potash, Inc. (NYSE: IPI ) up 7 percent, and CF Industries Holdings, Inc. (NYSE: CF ) up 6 percent.
In trading on Wednesday, real estate shares fell 0.6 percent.
Top Headline
CVS Health Corp (NYSE: CVS ) issued weak earnings forecast for FY19. The company reported upbea t earnings for its fourth quarter, while sales missed view.
CVS Health said it earned $2.14 per share in the fourth quarter on revenue of $54.42 billion. However, analysts were expecting earnings of $2.05 per share and revenue of $54.58 billion.
CVS Health expects FY19 adjusted earnings of $6.68 to $6.88 per share, versus analysts' estimates of $7.41 per share.
Equities Trading UP
ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 81 percent to $0.7019 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug.
Shares of Kandi Technologies Group, Inc. (NASDAQ: KNDI ) shot up 40 percent to $8.33 after the company reported NHTSA approval of 2 electric vehicle models.
LeMaitre Vascular, Inc. (NASDAQ: LMAT ) shares were also up, gaining 23 percent to $30.75 after the company posted upbeat Q4 results and issued a strong FY19 outlook.
Equities Trading DOWN
Ovid Therapeutics Inc. (NASDAQ: OVID ) shares dropped 31 percent to $1.78 after reporting pricing of $30 million of securities in concurrent public offerings of common and preferred stock.
Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 22 percent to $2.3199 after the company priced an 8 million share stock offering at $2.50 per share.
Owens & Minor, Inc. (NYSE: OMI ) was down, falling around 17 percent to $6.62 after the company reported downbeat Q4 earnings and issued weak 2019 earnings forecast.
Commodities
In commodity news, oil traded up 0.2 percent to $56.20 while gold traded up 0.1 percent to $1,346.10.
Silver traded up 0.4 percent Wednesday to $16.03, while copper rose 0.9 percent to $2.905.
Eurozone
European shares were higher today. The eurozone's STOXX 600 gained 0.6 percent, the Spanish Ibex Index rose 0.3 percent, while Italy's FTSE MIB Index climbed 0.2 percent. Meanwhile the German DAX gained 0.7 percent, and the French CAC 40 rose 0.6 percent while U.K. shares rose 0.6 percent.
Economics
The Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET.
Data on farm prices for December will be released at 3:00 p.m. ET.
© 2019 Benzinga.com. Benzinga does not provide investment advice . All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 81 percent to $0.7019 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Shares of Kandi Technologies Group, Inc. (NASDAQ: KNDI ) shot up 40 percent to $8.33 after the company reported NHTSA approval of 2 electric vehicle models. LeMaitre Vascular, Inc. (NASDAQ: LMAT ) shares were also up, gaining 23 percent to $30.75 after the company posted upbeat Q4 results and issued a strong FY19 outlook. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 81 percent to $0.7019 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Top Headline CVS Health Corp (NYSE: CVS ) issued weak earnings forecast for FY19. Equities Trading DOWN Ovid Therapeutics Inc. (NASDAQ: OVID ) shares dropped 31 percent to $1.78 after reporting pricing of $30 million of securities in concurrent public offerings of common and preferred stock. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 81 percent to $0.7019 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Shares of Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) were down 22 percent to $2.3199 after the company priced an 8 million share stock offering at $2.50 per share. The eurozone's STOXX 600 gained 0.6 percent, the Spanish Ibex Index rose 0.3 percent, while Italy's FTSE MIB Index climbed 0.2 percent. | Equities Trading UP ARCA biopharma, Inc. (NASDAQ: ABIO ) shares got a boost, shooting up 81 percent to $0.7019 after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support approval for its Cardiovascular drug. Midway through trading Wednesday, the Dow traded up 0.14 percent to 25,926.45 while the NASDAQ climbed 0.31 percent to 7,509.82. The S&P also rose, gaining 0.15 percent to 2,783.97. |
29057.0 | 2018-11-15 00:00:00 UTC | Health Care Sector Update for 11/15/2018: ARNA, UTHR, QURE, ABIO | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-11152018-arna-uthr-qure-abio-2018-11-15 | nan | nan | Top Health Care Stocks
JNJ, -0.1%
PFE, +0.4%
ABT, +1.7%
MRK, +0.8%
AMGN, +1.5%
Health care stocks turned positive ahead of Thursday's closing bell, recovering from earlier losses as NYSE Health Care Index gaining 0.4%. Shares of health care companies in the S&P 500 also were up 0.8% as a group while the Nasdaq Biotechnology index was ahead over 2% today.
Among health care stocks moving on news:
(+) Arena Pharmaceuticals ( ARNA ) rose almost 20% higher in Thursday'sa afternoon trade after the biopharmaceuticals company said it has signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. Under the terms of the agreement, Arena will receive an $800 million upfront payment from United in exchange for exclusive, world-wide rights to develop, produce and commericalize Ralinepag. Arena also is eligible for up to $400 million in additional payments as drug development reaches certain regulatory milestone and would receive tiered royalty payments in the low double-percentage digits based on annual net sales. United Therapeutics also was higher today, rising over 4% in recent trading.
In other sector news:
(+) uniQure N.V ( QURE ) was soared more than 37% Thursday after the gene therapy company reported topline trial data showing its AMT-061 drug candidate produced therapeutic levels of Factor IX activity in all three enrolled patients with severe and moderately severe hemophilia B six weeks after dosing. The company is expecting to submit data from the Phase IIb trial to U.S. and European regulators by the end of the year and beginning Phase III testing during the first three months of 2019.
(-) ARCA biopharma ( ABIO ) was down nearly 213% on Thursday after the medical device company said U.S. regulators were again reviewing a special protocol assessment for a proposed Phase III trial of ACRA's Gencaro beta-blocker and vasodilator medication that's being developed as a potential genetically-targeted treatment for patients with heart failure who are risk for atrial fibrillation. The U.S. Food and Drug Administration issued a No Agreement letter to the company in October although the two sides are expected to discuss any remaining issues with the SPA application in December. The company late Wednesday reported its Q3 financial results, including a net loss of $0.11 per share for the three months ended Sept. 30, narrowing its $0.39 per share loss last year and besting the Street view expecting a $0.19 per share net loss.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ARCA biopharma ( ABIO ) was down nearly 213% on Thursday after the medical device company said U.S. regulators were again reviewing a special protocol assessment for a proposed Phase III trial of ACRA's Gencaro beta-blocker and vasodilator medication that's being developed as a potential genetically-targeted treatment for patients with heart failure who are risk for atrial fibrillation. Among health care stocks moving on news: (+) Arena Pharmaceuticals ( ARNA ) rose almost 20% higher in Thursday'sa afternoon trade after the biopharmaceuticals company said it has signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. Under the terms of the agreement, Arena will receive an $800 million upfront payment from United in exchange for exclusive, world-wide rights to develop, produce and commericalize Ralinepag. | (-) ARCA biopharma ( ABIO ) was down nearly 213% on Thursday after the medical device company said U.S. regulators were again reviewing a special protocol assessment for a proposed Phase III trial of ACRA's Gencaro beta-blocker and vasodilator medication that's being developed as a potential genetically-targeted treatment for patients with heart failure who are risk for atrial fibrillation. In other sector news: (+) uniQure N.V ( QURE ) was soared more than 37% Thursday after the gene therapy company reported topline trial data showing its AMT-061 drug candidate produced therapeutic levels of Factor IX activity in all three enrolled patients with severe and moderately severe hemophilia B six weeks after dosing. The company is expecting to submit data from the Phase IIb trial to U.S. and European regulators by the end of the year and beginning Phase III testing during the first three months of 2019. | (-) ARCA biopharma ( ABIO ) was down nearly 213% on Thursday after the medical device company said U.S. regulators were again reviewing a special protocol assessment for a proposed Phase III trial of ACRA's Gencaro beta-blocker and vasodilator medication that's being developed as a potential genetically-targeted treatment for patients with heart failure who are risk for atrial fibrillation. Health care stocks turned positive ahead of Thursday's closing bell, recovering from earlier losses as NYSE Health Care Index gaining 0.4%. Among health care stocks moving on news: (+) Arena Pharmaceuticals ( ARNA ) rose almost 20% higher in Thursday'sa afternoon trade after the biopharmaceuticals company said it has signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. | (-) ARCA biopharma ( ABIO ) was down nearly 213% on Thursday after the medical device company said U.S. regulators were again reviewing a special protocol assessment for a proposed Phase III trial of ACRA's Gencaro beta-blocker and vasodilator medication that's being developed as a potential genetically-targeted treatment for patients with heart failure who are risk for atrial fibrillation. Shares of health care companies in the S&P 500 also were up 0.8% as a group while the Nasdaq Biotechnology index was ahead over 2% today. Among health care stocks moving on news: (+) Arena Pharmaceuticals ( ARNA ) rose almost 20% higher in Thursday'sa afternoon trade after the biopharmaceuticals company said it has signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. |
29058.0 | 2018-11-15 00:00:00 UTC | Health Care Sector Update for 11/15/2018: ARNA,UTHR,QURE,ABIO | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-11152018-arnauthrqureabio-2018-11-15 | nan | nan | Top Health Care Stocks
JNJ -0.01%
PFE +0.68%
ABT +1.12%
MRK +0.70%
AMGN +1.62%
Health care stocks gained, including a 0.1% advance for the NYSE Health Care Index this afternoon. Shares of health care companies in the S&P 500 were up 0.7% as a group, while the Nasdaq Biotechnology index was ahead more than 2% today.
Among health care stocks moving on news:
(+) Arena Pharmaceuticals ( ARNA ) jumped almost 31% higher at one point on Thursday after the biopharmaceuticals company said it signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. United Therapeutics also was higher, rising 5% in recent trading.
In other sector news:
(+) uniQure N.V ( QURE ) was soaring Thursday, rising as much as almost 54%, after the gene therapy company reported topline trial data showing its AMT-061 candidate produced therapeutic levels of Factor IX activity in all three enrolled patients with severe and moderately severe hemophilia B six weeks after dosing. The company is expecting to submit data from the Phase IIb trial to US and European regulators by the end of the year and beginning Phase III testing during the first three months of 2019.
(-) ARCA biopharma ( ABIO ) was down 17% on Thursday after the company late Wednesday said the FDA is currently giving further consideration to the company's SPA application for the Phase 3 clinical trial of Gencaro following the company's provision of supporting information in response to an initial No Agreement letter received at the end of October. The company said it requested a meeting with the FDA in December to discuss any remaining issues in the application. ARCA also reported Q3 financial results, including a net loss of $0.11 per share, narrower than its $0.39 per share loss in the same period last year and topping the Street view expecting a $0.19 per share net loss.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ARCA biopharma ( ABIO ) was down 17% on Thursday after the company late Wednesday said the FDA is currently giving further consideration to the company's SPA application for the Phase 3 clinical trial of Gencaro following the company's provision of supporting information in response to an initial No Agreement letter received at the end of October. Shares of health care companies in the S&P 500 were up 0.7% as a group, while the Nasdaq Biotechnology index was ahead more than 2% today. Among health care stocks moving on news: (+) Arena Pharmaceuticals ( ARNA ) jumped almost 31% higher at one point on Thursday after the biopharmaceuticals company said it signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. | (-) ARCA biopharma ( ABIO ) was down 17% on Thursday after the company late Wednesday said the FDA is currently giving further consideration to the company's SPA application for the Phase 3 clinical trial of Gencaro following the company's provision of supporting information in response to an initial No Agreement letter received at the end of October. Top Health Care Stocks ARCA also reported Q3 financial results, including a net loss of $0.11 per share, narrower than its $0.39 per share loss in the same period last year and topping the Street view expecting a $0.19 per share net loss. | (-) ARCA biopharma ( ABIO ) was down 17% on Thursday after the company late Wednesday said the FDA is currently giving further consideration to the company's SPA application for the Phase 3 clinical trial of Gencaro following the company's provision of supporting information in response to an initial No Agreement letter received at the end of October. Among health care stocks moving on news: (+) Arena Pharmaceuticals ( ARNA ) jumped almost 31% higher at one point on Thursday after the biopharmaceuticals company said it signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. ARCA also reported Q3 financial results, including a net loss of $0.11 per share, narrower than its $0.39 per share loss in the same period last year and topping the Street view expecting a $0.19 per share net loss. | (-) ARCA biopharma ( ABIO ) was down 17% on Thursday after the company late Wednesday said the FDA is currently giving further consideration to the company's SPA application for the Phase 3 clinical trial of Gencaro following the company's provision of supporting information in response to an initial No Agreement letter received at the end of October. Shares of health care companies in the S&P 500 were up 0.7% as a group, while the Nasdaq Biotechnology index was ahead more than 2% today. Among health care stocks moving on news: (+) Arena Pharmaceuticals ( ARNA ) jumped almost 31% higher at one point on Thursday after the biopharmaceuticals company said it signed a global license agreement with United Therapeutics Corp ( UTHR ) for its Ralinepag prospective treatment for pulmonary arterial hypertension. |
29059.0 | 2017-11-16 00:00:00 UTC | Health Care Sector Update for 11/16/2017: MRTX,ABIO,NTEC | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-11162017-mrtxabiontec-2017-11-16 | nan | nan | Top Health Care Stocks
JNJ -0.21%
PFE +0.30%
ABT +1.31%
MRK +0.57%
AMGN +1.31%
Health care stocks were mostly higher in recent trading, with the NYSE Health Care Index rising more than 0.7% while shares of health care companies in the S&P 500 were up more than 0.9% as a group.
In company news, Mirati Therapeutics ( MRTX ) reached a 17-month high on Thursday, posting a more than 24% advance to reach its best price since June 2016 at $17.50 a share, after the genetics-based oncology treatment company priced a $26 million public offering of nearly 2.02 million shares at $13 apiece, a 7.5% discount from Wednesday's closing price.
The company also issued pre-funded warrants to certain investors to buy up to 4.14 million additional shares at $12.999, or 0.1 cent under the offering price less the exercise price, and boosting the gross proceeds to nearly $80 million.
After paying underwriter discounts and other offering expenses, Mirati expects to use the net proceeds for general corporate purposes, including clinical development of its sitravatinib and mocetinostat product candidates as well as preclinical and clinical development of its KRAS inhibitor and other early-stage drugs.
In other sector news,
(+) ABIO, (+25.8%) Receives patent (EPO No. 2515899) from the European Patent Office for its method of treating cardiovascular disease and related symptoms with thiol-substituted isosorbide mononitrate based on genetic targeting. Patent applications still pending in the U.S. and Canada.
(-) NTEC, (-11.1%) Reports Q3 net loss of $0.29 per share, improving on a $0.40 per share loss during the year-ago period and beating the single-analyst call expecting a $0.34 per share net loss. The company had no revenue, as expected, during the three months ended Sept. 30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABIO, (+25.8%) Receives patent (EPO No. In company news, Mirati Therapeutics ( MRTX ) reached a 17-month high on Thursday, posting a more than 24% advance to reach its best price since June 2016 at $17.50 a share, after the genetics-based oncology treatment company priced a $26 million public offering of nearly 2.02 million shares at $13 apiece, a 7.5% discount from Wednesday's closing price. After paying underwriter discounts and other offering expenses, Mirati expects to use the net proceeds for general corporate purposes, including clinical development of its sitravatinib and mocetinostat product candidates as well as preclinical and clinical development of its KRAS inhibitor and other early-stage drugs. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) ABIO, (+25.8%) Receives patent (EPO No. In company news, Mirati Therapeutics ( MRTX ) reached a 17-month high on Thursday, posting a more than 24% advance to reach its best price since June 2016 at $17.50 a share, after the genetics-based oncology treatment company priced a $26 million public offering of nearly 2.02 million shares at $13 apiece, a 7.5% discount from Wednesday's closing price. | In other sector news, (+) ABIO, (+25.8%) Receives patent (EPO No. Health care stocks were mostly higher in recent trading, with the NYSE Health Care Index rising more than 0.7% while shares of health care companies in the S&P 500 were up more than 0.9% as a group. In company news, Mirati Therapeutics ( MRTX ) reached a 17-month high on Thursday, posting a more than 24% advance to reach its best price since June 2016 at $17.50 a share, after the genetics-based oncology treatment company priced a $26 million public offering of nearly 2.02 million shares at $13 apiece, a 7.5% discount from Wednesday's closing price. | In other sector news, (+) ABIO, (+25.8%) Receives patent (EPO No. Top Health Care Stocks Health care stocks were mostly higher in recent trading, with the NYSE Health Care Index rising more than 0.7% while shares of health care companies in the S&P 500 were up more than 0.9% as a group. |
29060.0 | 2017-01-18 00:00:00 UTC | Health Care Sector Update for 01/18/2017: ABIO | ABIO | https://www.nasdaq.com/articles/health-care-sector-update-01182017-abio-2017-01-18 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.1%
ABT: -0.2%
MRK: flat
AMGN: flat
Health-care shares were mainly unchanged in pre-market trade on Wednesday.
In health-care stocks news, Arca Biopharma Inc. ( ABIO ), a biopharmaceutical company, said it has randomized its 150th patient in a clinical trial evaluating Gencaro (bucindolol hydrochloride) to treat atrial fibrillation ( AF ).
Shares in the company were unchanged at $2.60 in pre-market trade on Wednesday. The stock has traded between $2.15 and $4.35 over the past 52 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Arca Biopharma Inc. ( ABIO ), a biopharmaceutical company, said it has randomized its 150th patient in a clinical trial evaluating Gencaro (bucindolol hydrochloride) to treat atrial fibrillation ( AF ). Top Health-care stocks: JNJ: flat Shares in the company were unchanged at $2.60 in pre-market trade on Wednesday. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health-care stocks news, Arca Biopharma Inc. ( ABIO ), a biopharmaceutical company, said it has randomized its 150th patient in a clinical trial evaluating Gencaro (bucindolol hydrochloride) to treat atrial fibrillation ( AF ). MRK: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Wednesday. | In health-care stocks news, Arca Biopharma Inc. ( ABIO ), a biopharmaceutical company, said it has randomized its 150th patient in a clinical trial evaluating Gencaro (bucindolol hydrochloride) to treat atrial fibrillation ( AF ). MRK: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Wednesday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Arca Biopharma Inc. ( ABIO ), a biopharmaceutical company, said it has randomized its 150th patient in a clinical trial evaluating Gencaro (bucindolol hydrochloride) to treat atrial fibrillation ( AF ). Top Health-care stocks: JNJ: flat MRK: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Wednesday. |
29061.0 | 2015-04-14 00:00:00 UTC | ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog | ABIO | https://www.nasdaq.com/articles/arca-biopharma-gains-on-fast-track-status-for-gencaro-analyst-blog-2015-04-14 | nan | nan | ARCA biopharma, Inc.ABIO shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro.
Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the prevention of atrial fibrillation/atrial flutter (AF) in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction or HFREF).
We note that the FDA grants Fast Track designation to those candidates that are being developed for the treatment of serious conditions with unmet medical need. The overall goal of the process is to get new drugs to patients faster. Fast Track status will allow the company to communicate with the FDA frequently throughout the development and review process, with the aim of expediting the candidate's approval. Moreover, the company is eligible to make a rolling submission of its new drug application for the candidate, which will be considered for priority review.
Presently, Gencaro is being evaluated in a phase IIb/III study (GENETIC-AF) for the above mentioned indication. The company expects to complete patient enrolment in the phase IIb part of the study by the end of 2016.
ARCA biopharma has a collaboration with Medtronic MDT for the GENETIC-AF study.
We are encouraged by the FDA granting Fast Track designation to Gencaro. According to the company's press release, AF is estimated to affect more than 2.7 million people in the U.S. with as many as 250,000 to 500,000 new cases being diagnosed each year.
Gencaro is the lead candidate in ARCA biopharma's pipeline and we expect investor focus to remain on updates pertaining to its development.
ARCA biopharma currently carries a Zacks Rank #3 (Hold). Amgen Inc. AMGN and ANI Pharmaceuticals, Inc. ANIP are better-ranked stocks in the health care sector. Both hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
ARCA BIOPHARMA (ABIO): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma, Inc.ABIO shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ARCA BIOPHARMA (ABIO): Get Free Report To read this article on Zacks.com click here. Fast Track status will allow the company to communicate with the FDA frequently throughout the development and review process, with the aim of expediting the candidate's approval. | ARCA biopharma, Inc.ABIO shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ARCA BIOPHARMA (ABIO): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma, Inc.ABIO shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ARCA BIOPHARMA (ABIO): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ARCA biopharma, Inc.ABIO shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ARCA BIOPHARMA (ABIO): Get Free Report To read this article on Zacks.com click here. Fast Track status will allow the company to communicate with the FDA frequently throughout the development and review process, with the aim of expediting the candidate's approval. |
29062.0 | 2013-12-04 00:00:00 UTC | Sector Update: Healthcare | ABIO | https://www.nasdaq.com/articles/sector-update-healthcare-2013-12-04-1 | nan | nan | Healthcare stocks are mostly lower, with the NYSE Healthcare Sector Index sinking 0.6% while shares of healthcare companies in the S&P 500 are down 0.5% as a group.
In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding on to a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation.
ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. The company plans to begin enrolling patients for a Phase IIb/III trial of the beta-blocker and vasodilator during the first three months of 2014.
In other sector news,
(+) CCXI, (+3.8%) Reported positive top-line data from the first two steps of Phase II testing of its CCX168 drug candidate to treat anti-neutrophil cytoplasmic antibody-associated renal vasculitis, an autoimmune disease inflaming smaller blood vessels.
(-) AMBI, (-36.0%) Decides against submitting new drug application for its quizartinib drug candidate based on the Phase II and Phase IIb clinical testing of the prospective treatment for acute myeloid leukemia, instead planning for a Phase III trial.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding on to a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. The company plans to begin enrolling patients for a Phase IIb/III trial of the beta-blocker and vasodilator during the first three months of 2014. | In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding on to a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. In other sector news, (+) CCXI, (+3.8%) Reported positive top-line data from the first two steps of Phase II testing of its CCX168 drug candidate to treat anti-neutrophil cytoplasmic antibody-associated renal vasculitis, an autoimmune disease inflaming smaller blood vessels. | In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding on to a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. (-) AMBI, (-36.0%) Decides against submitting new drug application for its quizartinib drug candidate based on the Phase II and Phase IIb clinical testing of the prospective treatment for acute myeloid leukemia, instead planning for a Phase III trial. | In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding on to a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. Healthcare stocks are mostly lower, with the NYSE Healthcare Sector Index sinking 0.6% while shares of healthcare companies in the S&P 500 are down 0.5% as a group. |
29063.0 | 2013-12-04 00:00:00 UTC | Healthcare Stocks Stumbling; Biopharma Rallies After Atrial Fibrillation Drug Accepted by FDA | ABIO | https://www.nasdaq.com/articles/healthcare-stocks-stumbling-biopharma-rallies-after-atrial-fibrillation-drug-accepted-fda | nan | nan | Top Healthcare Stocks
JNJ -0.31%
PFE +0.10%
ABT -0.43%
MRK -1.32%
AMGN -0.39%
Healthcare stocks are mostly lower, with the NYSE Healthcare Sector Index sinking 0.6% while shares of healthcare companies in the S&P 500 are down 0.5% as a group.
In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation.
ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. The company plans to begin enrolling patients for a Phase IIb/III trial of the beta-blocker and vasodilator during the first three months of 2014.
In other sector news,
(+) CCXI, (+3.8%) Reported positive top-line data from the first two steps of Phase II testing of its CCX168 drug candidate to treat anti-neutrophil cytoplasmic antibody-associated renal vasculitis, an autoimmune disease inflaming smaller blood vessels.
(-) AMBI, (-36.0%) Decides against submitting new drug application for its quizartinib drug candidate based on the Phase II and Phase IIb clinical testing of the prospective treatment for acute myeloid leukemia, instead planning for a Phase III trial.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. The company plans to begin enrolling patients for a Phase IIb/III trial of the beta-blocker and vasodilator during the first three months of 2014. | In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. In other sector news, (+) CCXI, (+3.8%) Reported positive top-line data from the first two steps of Phase II testing of its CCX168 drug candidate to treat anti-neutrophil cytoplasmic antibody-associated renal vasculitis, an autoimmune disease inflaming smaller blood vessels. | In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. Healthcare stocks are mostly lower, with the NYSE Healthcare Sector Index sinking 0.6% while shares of healthcare companies in the S&P 500 are down 0.5% as a group. | In company news, Biopharma ( ABIO ) is moving off its best levels of the session, holding a 37% advance at $1.97 a share after again re-testing its intra-day high of $2.15 and following the U.S. Food and Drug Administration's accepting the company's Investigational New Drug application for its Gencaro drug candidate to treat atrial fibrillation. ABIO says it has identified common genetic variations it believes predicts individual patient responses to Gencaro, potentially making it the first genetically-targeted therapy to prevent atrial fibrillation. Top Healthcare Stocks |
29064.0 | 2023-12-16 00:00:00 UTC | Paychex (PAYX) to Report Q2 Earnings: Here's What to Expect | ABM | https://www.nasdaq.com/articles/paychex-payx-to-report-q2-earnings%3A-heres-what-to-expect | nan | nan | Paychex, Inc. PAYX is scheduled to release its second-quarter fiscal 2024 results on Dec 21, before market open.
The company has a decent earnings surprise history, with earnings surpassing the Zacks Consensus Estimate in three of the four trailing quarters and missing on one instance, with the average earnings surprise being 2.3%.
Expectations From PAYX in Q2
The Zacks Consensus Estimate for the top line is currently pegged at $1.27 billion, up 6.5% from the year-ago actual figure. We expect to see continued demand for advisory assistance and HR outsourcing solutions.
Paychex, Inc. Price and EPS Surprise
Paychex, Inc. price-eps-surprise | Paychex, Inc. Quote
Revenues from Management Solutions are expected to rise 4.7% on a year-over-year basis, our estimate for which is currently pegged at $937.7 million. Such an increase can be correlated with an increased number of clients and client employees, product penetration, price realization and persisting demand for Human Capital Management ancillary services.
Our estimate for PEO and insurance solution revenues is currently pegged at $290.6 million, which indicates a 6.3% increase from the year-ago reported figure. This is due to the increase in the average number of worksite employees and an expected rise in revenues per client.
We expect interest on funds held for clients to increase 51.3% year over year to $32.8 million. The company is anticipated to enjoy higher average interest rates.
The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is $1.07 per share, which indicates 8.1% growth from the year-ago figure. The continuing trend of demand situation and revenue growth is expected to have driven the growth.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for PAYX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
PAYX has an Earnings ESP of +0.72% and a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sneak Peek Into Recent Results of Key Sector Players
Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases:
ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings (considering 5 cents from non-recurring items) were $1.01 per share, which beat the consensus estimate by 8.6% and increased 13.5% from the last fiscal year’s quarterly figure.
Total revenues of $2.09 billion beat the consensus mark by 2.8% and improved 4.1% from the last fiscal year’s quarterly figure. The upside was backed by solid segmental performance, strength from new accounts that came online late last year and the acquisition of RavenVolt. Quarterly revenue growth included 3.8% organic growth and a 0.3% upside from acquisitions.
S&P Global Inc. SPGI reported impressive third-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate.
SPGI’s adjusted earnings per share (excluding 88 cents from non-recurring items) of $3.21 rose 9.6% year over year and beat the consensus estimate by 5.3%. Revenues of $3.08 billion surpassed the consensus estimate by 2% and improved 8% year over year, backed by strong performance in all divisions.
Verisk Analytics Inc. VRSK reported impressive third-quarter 2023 results, wherein earnings and revenues beat the respective estimates.
VRSK’s adjusted earnings (excluding 23 cents from non-recurring items) were $1.52 per share, beating the Zacks Consensus Estimate and increasing 4.1% from the year-ago reported figure. Such a beat was supported by strong growth in Underwriting Data Solutions, Life Insurance and Extreme Events Solutions.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Paychex, Inc. (PAYX) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report
S&P Global Inc. (SPGI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sneak Peek Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Paychex, Inc. (PAYX) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. Adjusted earnings (considering 5 cents from non-recurring items) were $1.01 per share, which beat the consensus estimate by 8.6% and increased 13.5% from the last fiscal year’s quarterly figure. | Sneak Peek Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Paychex, Inc. (PAYX) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. VRSK’s adjusted earnings (excluding 23 cents from non-recurring items) were $1.52 per share, beating the Zacks Consensus Estimate and increasing 4.1% from the year-ago reported figure. | Sneak Peek Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Paychex, Inc. (PAYX) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has a decent earnings surprise history, with earnings surpassing the Zacks Consensus Estimate in three of the four trailing quarters and missing on one instance, with the average earnings surprise being 2.3%. | Sneak Peek Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Paychex, Inc. (PAYX) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has a decent earnings surprise history, with earnings surpassing the Zacks Consensus Estimate in three of the four trailing quarters and missing on one instance, with the average earnings surprise being 2.3%. |
29065.0 | 2023-12-16 00:00:00 UTC | 5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches | ABM | https://www.nasdaq.com/articles/5-broker-favorite-stocks-to-keep-an-eye-on-as-2024-approaches | nan | nan | Year 2023, which is in its last leg, has witnessed extreme volatility from high interest rates and geo-political woes. However, cooling down inflation following the Fed’s interest rate hike policy to combat elevated inflation markets is a positive.
The Fed’s December FOMC meeting dot-plot has shown that, on average, Fed officials are expecting at least three rate cuts of 25 basis points each in 2024, followed by four more rate cuts of one percentage point in 2025. Investors would like to take advantage of this optimistic forecast by designing a winning portfolio of stocks. However, doing this without proper guidance from investing experts is hazardous.
Experts in the field of investing are brokers, as they have at their disposal a lot more information on a company and its prospects than individual investors. Keeping tabs on broker-favored stocks like American Airlines AAL, ABM Industries ABM, Cardinal Health CAH,Cleveland-Cliffs CLF and Cencora COR in this scenario appears to be prudent.
Why Broker-Advice Works Wonders
Brokers have an in-depth understanding of stocks and great knowledge of the industry and the broader economy. They scrutinize the company’s fundamentals and place them against the prevalent economic scenario to find out how attractive a stock is as an investment option or otherwise.
Only after undertaking thorough research can brokers arrive at their recommendation (buy, sell or hold) on a stock. Such well-researched information is not available to individual investors. Therefore, they, in the absence of proper guidance, may end up selecting the wrong stocks in their portfolio. This might result in their hard-earned money, which they have invested in stock markets, going down the drain. To avoid such an unfortunate scenario from materializing, it is highly desirable for investors to be guided by broker advice, while deciding their course of action on a particular stock.
Formulating a Winning Portfolio
We have designed a screener to arrive at stocks based on improving analyst recommendations and upward earnings estimate revisions over the last four weeks. However, considering only these factors does not make our strategy foolproof, as the top line has not been considered.
Actually, according to many market watchers, a top-line outperformance is more credible for a company than a mere earnings outperformance. To address top-line concerns, we have included the price/sales ratio in our screener as it serves as a strong complementary valuation metric.
Screening Criteria
#(Up-Down Rating)/ Total (4 weeks) =Top #75: This gives the list of the top 75 companies that have witnessed net upgrades over the last four weeks.
Percentage change in Q (1) est. (4 weeks) = Top #10: This gives us the top 10 stocks that have witnessed earnings estimate revisions over the past four weeks for the upcoming quarter.
To ensure that the strategy is a winning one, covering all bases, we have added the following screening parameters:
Price-to-Sales = Bot%10: The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of more than 7,700 stocks with respect to this ratio.
Price greater than 5: A stock trading below $5 will not likely create significant interest for most investors.
Average Daily Volume greater than 100,000 shares over the last 20 trading days: Volume has to be significant to ensure that these are easily traded.
Market value ($ mil) = Top #3000: This gives us stocks that are in the top 3000 if one judges by market capitalization.
Com/ADR/Canadian = Com: This takes out the ADR and Canadian stocks.
Here are five of the 10 stocks that made it through the screen:
American Airlines is based in Fort Worth, TX. The gradual increase in air travel demand (particularly for leisure) is aiding AAL. However, high operating costs are hurting the bottom line.
Over the past 30 days, the stock has seen the Zacks Consensus Estimate for 2024 earnings being revised 1% upward. AAL currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
New York-based ABM Industries is a provider of integrated facility solutions in the United States and internationally. ABM currently carries a Zacks Rank #3. The company has an impressive surprise history, with its earnings surpassing the Zacks Consensus Estimate in three of the last four quarters (missing the mark on the other occasion), the average beat being 1.4%.
The company's comprehensive transformational initiative called 2020 Vision has helped it attain long-term profitable growth through an industry-based go-to-market approach. Multi-year comprehensive strategic plan, ELEVATE is expected to accelerate ABM’s organic growth, improve its strategic and comprehensive positioning, and reinforce profitability.
Headquartered in Dublin, OH, Cardinal Health is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. The company’s diversified portfolio represents significant long-term opportunities. Further, it follows an acquisition-driven strategy.
CAH, currently carrying a Zacks Rank of 3, has an impressive surprise history, with its earnings surpassing the Zacks Consensus Estimate in each of the last four quarters, the average being 15.7%.
Cleveland-Cliffs is a leading iron ore producer in the United States. It supplies differentiated iron ore pellets under long-term contracts to major blast furnace steel producers in North America. The Mining and Pelletizing operation gains from low-cost, high-quality iron ore pellet production with substantial logistics and transportation advantages to serve the Great Lakes steel market. The company should gain from its merger with AK Steel Holding Corporation.
Over the past 60 days, the Zacks Consensus Estimate for CLF’s 2024 earnings has been revised 6.34% upward. Cleveland-Cliffs currently carries a Zacks Rank #3.
Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical services companies. The company should benefit from the strength in the U.S. Healthcare Solutions business. Cencora currently carries a Zacks Rank #3.
The Zacks Consensus Estimate for the current year has inched up 0.5% over the past 60 days. COR has outpaced the Zacks Consensus Estimate for earnings in each of the last four quarters by an average of 3.88%.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Cleveland-Cliffs Inc. (CLF) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Cencora, Inc. (COR) : Free Stock Analysis Report
American Airlines Group Inc. (AAL) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Keeping tabs on broker-favored stocks like American Airlines AAL, ABM Industries ABM, Cardinal Health CAH,Cleveland-Cliffs CLF and Cencora COR in this scenario appears to be prudent. New York-based ABM Industries is a provider of integrated facility solutions in the United States and internationally. ABM currently carries a Zacks Rank #3. | Keeping tabs on broker-favored stocks like American Airlines AAL, ABM Industries ABM, Cardinal Health CAH,Cleveland-Cliffs CLF and Cencora COR in this scenario appears to be prudent. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cleveland-Cliffs Inc. (CLF) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report American Airlines Group Inc. (AAL) : Free Stock Analysis Report To read this article on Zacks.com click here. New York-based ABM Industries is a provider of integrated facility solutions in the United States and internationally. | Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cleveland-Cliffs Inc. (CLF) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report American Airlines Group Inc. (AAL) : Free Stock Analysis Report To read this article on Zacks.com click here. Keeping tabs on broker-favored stocks like American Airlines AAL, ABM Industries ABM, Cardinal Health CAH,Cleveland-Cliffs CLF and Cencora COR in this scenario appears to be prudent. New York-based ABM Industries is a provider of integrated facility solutions in the United States and internationally. | Keeping tabs on broker-favored stocks like American Airlines AAL, ABM Industries ABM, Cardinal Health CAH,Cleveland-Cliffs CLF and Cencora COR in this scenario appears to be prudent. New York-based ABM Industries is a provider of integrated facility solutions in the United States and internationally. ABM currently carries a Zacks Rank #3. |
29066.0 | 2023-12-14 00:00:00 UTC | ABM Industries (ABM) Price Target Increased by 12.27% to 52.87 | ABM | https://www.nasdaq.com/articles/abm-industries-abm-price-target-increased-by-12.27-to-52.87 | nan | nan | The average one-year price target for ABM Industries (NYSE:ABM) has been revised to 52.87 / share. This is an increase of 12.27% from the prior estimate of 47.09 dated November 26, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 42.42 to a high of 63.00 / share. The average price target represents an increase of 15.16% from the latest reported closing price of 45.91 / share.
What is the Fund Sentiment?
There are 562 funds or institutions reporting positions in ABM Industries. This is a decrease of 6 owner(s) or 1.06% in the last quarter. Average portfolio weight of all funds dedicated to ABM is 0.21%, an increase of 1.06%. Total shares owned by institutions decreased in the last three months by 1.65% to 71,889K shares.
The put/call ratio of ABM is 0.71, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,467K shares representing 6.82% ownership of the company. In it's prior filing, the firm reported owning 4,639K shares, representing a decrease of 3.86%. The firm decreased its portfolio allocation in ABM by 6.29% over the last quarter.
Alliancebernstein holds 2,695K shares representing 4.11% ownership of the company. In it's prior filing, the firm reported owning 89K shares, representing an increase of 96.68%. The firm increased its portfolio allocation in ABM by 2,422.67% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,041K shares representing 3.11% ownership of the company. In it's prior filing, the firm reported owning 2,040K shares, representing an increase of 0.07%. The firm decreased its portfolio allocation in ABM by 2.56% over the last quarter.
Macquarie Group holds 1,929K shares representing 2.94% ownership of the company. In it's prior filing, the firm reported owning 1,857K shares, representing an increase of 3.71%. The firm decreased its portfolio allocation in ABM by 44.47% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,703K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 1,707K shares, representing a decrease of 0.21%. The firm decreased its portfolio allocation in ABM by 1.85% over the last quarter.
ABM Industries Background Information
(This description is provided by the company.)
ABM Industries Inc. is a facility management provider in the United States. ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. As of 2013, the company has over 130,000 employees, over 350 offices, and various international locations.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. The average one-year price target for ABM Industries (NYSE:ABM) has been revised to 52.87 / share. There are 562 funds or institutions reporting positions in ABM Industries. | The average one-year price target for ABM Industries (NYSE:ABM) has been revised to 52.87 / share. There are 562 funds or institutions reporting positions in ABM Industries. Average portfolio weight of all funds dedicated to ABM is 0.21%, an increase of 1.06%. | The average one-year price target for ABM Industries (NYSE:ABM) has been revised to 52.87 / share. There are 562 funds or institutions reporting positions in ABM Industries. Average portfolio weight of all funds dedicated to ABM is 0.21%, an increase of 1.06%. | Average portfolio weight of all funds dedicated to ABM is 0.21%, an increase of 1.06%. The average one-year price target for ABM Industries (NYSE:ABM) has been revised to 52.87 / share. There are 562 funds or institutions reporting positions in ABM Industries. |
29067.0 | 2023-12-13 00:00:00 UTC | Should Value Investors Buy ABM Industries (ABM) Stock? | ABM | https://www.nasdaq.com/articles/should-value-investors-buy-abm-industries-abm-stock-2 | nan | nan | While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
ABM Industries (ABM) is a stock many investors are watching right now. ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with P/E ratio of 15.83 right now. For comparison, its industry sports an average P/E of 34.71. Over the last 12 months, ABM's Forward P/E has been as high as 15.83 and as low as 10.26, with a median of 12.11.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. ABM has a P/S ratio of 0.38. This compares to its industry's average P/S of 0.66.
These figures are just a handful of the metrics value investors tend to look at, but they help show that ABM Industries is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, ABM feels like a great value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM Industries (ABM) is a stock many investors are watching right now. ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Over the last 12 months, ABM's Forward P/E has been as high as 15.83 and as low as 10.26, with a median of 12.11. | ABM Industries (ABM) is a stock many investors are watching right now. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. | ABM Industries (ABM) is a stock many investors are watching right now. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. | ABM Industries (ABM) is a stock many investors are watching right now. ABM has a P/S ratio of 0.38. These figures are just a handful of the metrics value investors tend to look at, but they help show that ABM Industries is likely being undervalued right now. |
29068.0 | 2023-12-13 00:00:00 UTC | Accenture (ACN) to Announce Q1 Earnings: Here's What to Expect | ABM | https://www.nasdaq.com/articles/accenture-acn-to-announce-q1-earnings%3A-heres-what-to-expect | nan | nan | Accenture plc ACN is scheduled to release its first-quarter fiscal 2024 results on Dec 19, before market open.
The company has a decent earnings surprise history, with earnings surpassing the Zacks Consensus Estimate in each of the four trailing quarters, the average earnings surprise being 6.3%.
Expectations From ACN in Q1
The Zacks Consensus Estimate for the top line is currently pegged at $16.23 billion, up 3.1% from the year-ago actual figure. The growth can be correlated to the expected continuance of demand in domains such as the transition to cloud services, updating and modernizing ERP systems, advancements in data, artificial intelligence (AI) and the rise of Generation AI.
Accenture PLC Price and EPS Surprise
A
Accenture PLC price-eps-surprise | Accenture PLC Quote
We expect Consulting revenues for the fiscal first quarter to be $8.47 billion, indicating a slight increase from the year-ago figure. Revenues from the Managed Services segment are likely to have increased 5.8% on a year-over-year basis, our estimate for which is currently pegged at $7.73 billion.
Our estimate for the Products segment’s revenues in the to-be-reported quarter is pegged at $4.83 billion, indicating a 3.5% increase year over year. We expect revenues from the Communications, Media & Technology segment to decline 2.8% from first-quarter fiscal 2023 actuals to $2.9 billion. Our estimate for the Health & Public Servicesegment’s revenues in the to-be-reported quarter is pegged at $3.17 billion, indicating a 5.8% increase from the year-ago reported figure.
Our estimate for the Resources segment’s revenues in the to-be-reported quarter is pegged at $2.24 billion, indicating a 4.7% increase year over year. Revenues from the Financial Services segment are likely to have increased 3.4% on a year-over-year basis, our estimate for which is currently pegged at $3.07 billion.
Moving to geographical markets, we expect revenues from North America to have increased slightly to $7.66 billion due to segmental improvements. Our expectations of revenues from Europe is pegged at $5.38 billion, up 6% from the year-ago figure.
The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged at $3.14 per share, which indicates a 2% increase from the year-ago figure. The uptick is likely to be due to the expected favorable demand and utilization situation mixed with disciplined cost allocation.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for ACN this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
ACN has an Earnings ESP of 0.00% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Sneak Peak Into Recent Results of Key Sector Players
Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases:
ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings (considering 5 cents from non-recurring items) were $1.01 per share, which beat the consensus estimate by 8.6% and increased 13.5% from the last fiscal year’s quarterly figure.
Total revenues of $2.09 billion beat the consensus mark by 2.8% and improved 4.1% from the last fiscal year’s quarterly figure. The upside was backed by solid segmental performance, strength from new accounts that came online late last year and the acquisition of RavenVolt. Quarterly revenue growth included 3.8% organic growth and a 0.3% upside from acquisitions.
S&P Global Inc. SPGI reported impressive third-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate.
SPGI’s adjusted earnings per share (excluding 88 cents from non-recurring items) of $3.21 rose 9.6% year over year and beat the consensus estimate by 5.3%. Revenues of $3.08 billion surpassed the consensus estimate by 2% and improved 8% year over year, backed by strong performance in all divisions.
Verisk Analytics Inc. VRSK reported impressive third-quarter 2023 results, wherein earnings and revenues beat the respective estimates.
VRSK’s adjusted earnings (excluding 23 cents from non-recurring items) were $1.52 per share, beating the Zacks Consensus Estimate and increasing 4.1% from the year-ago reported figure. Such a beat was supported by strong growth in Underwriting Data Solutions, Life Insurance and Extreme Events Solutions.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Accenture PLC (ACN) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report
S&P Global Inc. (SPGI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sneak Peak Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Accenture PLC (ACN) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. Our estimate for the Health & Public Servicesegment’s revenues in the to-be-reported quarter is pegged at $3.17 billion, indicating a 5.8% increase from the year-ago reported figure. | Sneak Peak Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Accenture PLC (ACN) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. VRSK’s adjusted earnings (excluding 23 cents from non-recurring items) were $1.52 per share, beating the Zacks Consensus Estimate and increasing 4.1% from the year-ago reported figure. | Sneak Peak Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Accenture PLC (ACN) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has a decent earnings surprise history, with earnings surpassing the Zacks Consensus Estimate in each of the four trailing quarters, the average earnings surprise being 6.3%. | Sneak Peak Into Recent Results of Key Sector Players Here are a few stocks from the broader Business Services sector that have performed well in their recent earnings releases: ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report Accenture PLC (ACN) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. ACN has an Earnings ESP of 0.00% and a Zacks Rank of 2. |
29069.0 | 2023-12-12 00:00:00 UTC | Noteworthy Wednesday Option Activity: IRON, IIPR, ABM | ABM | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-iron-iipr-abm | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Disc Medicine Inc (Symbol: IRON), where a total volume of 1,659 contracts has been traded thus far today, a contract volume which is representative of approximately 165,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 70.9% of IRON's average daily trading volume over the past month, of 234,125 shares. Particularly high volume was seen for the $50 strike put option expiring January 19, 2024, with 500 contracts trading so far today, representing approximately 50,000 underlying shares of IRON. Below is a chart showing IRON's trailing twelve month trading history, with the $50 strike highlighted in orange:
Innovative Industrial Properties Inc (Symbol: IIPR) options are showing a volume of 1,584 contracts thus far today. That number of contracts represents approximately 158,400 underlying shares, working out to a sizeable 69.4% of IIPR's average daily trading volume over the past month, of 228,340 shares. Especially high volume was seen for the $90 strike call option expiring April 19, 2024, with 402 contracts trading so far today, representing approximately 40,200 underlying shares of IIPR. Below is a chart showing IIPR's trailing twelve month trading history, with the $90 strike highlighted in orange:
And ABM Industries, Inc. (Symbol: ABM) options are showing a volume of 2,574 contracts thus far today. That number of contracts represents approximately 257,400 underlying shares, working out to a sizeable 67.7% of ABM's average daily trading volume over the past month, of 379,960 shares. Particularly high volume was seen for the $60 strike call option expiring December 15, 2023, with 372 contracts trading so far today, representing approximately 37,200 underlying shares of ABM. Below is a chart showing ABM's trailing twelve month trading history, with the $60 strike highlighted in orange:
For the various different available expirations for IRON options, IIPR options, or ABM options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
MLP shares outstanding history
Top Ten Hedge Funds Holding TOMZ
VIAS Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $60 strike call option expiring December 15, 2023, with 372 contracts trading so far today, representing approximately 37,200 underlying shares of ABM. Below is a chart showing IIPR's trailing twelve month trading history, with the $90 strike highlighted in orange: And ABM Industries, Inc. (Symbol: ABM) options are showing a volume of 2,574 contracts thus far today. That number of contracts represents approximately 257,400 underlying shares, working out to a sizeable 67.7% of ABM's average daily trading volume over the past month, of 379,960 shares. | Below is a chart showing IIPR's trailing twelve month trading history, with the $90 strike highlighted in orange: And ABM Industries, Inc. (Symbol: ABM) options are showing a volume of 2,574 contracts thus far today. That number of contracts represents approximately 257,400 underlying shares, working out to a sizeable 67.7% of ABM's average daily trading volume over the past month, of 379,960 shares. Particularly high volume was seen for the $60 strike call option expiring December 15, 2023, with 372 contracts trading so far today, representing approximately 37,200 underlying shares of ABM. | Below is a chart showing IIPR's trailing twelve month trading history, with the $90 strike highlighted in orange: And ABM Industries, Inc. (Symbol: ABM) options are showing a volume of 2,574 contracts thus far today. Particularly high volume was seen for the $60 strike call option expiring December 15, 2023, with 372 contracts trading so far today, representing approximately 37,200 underlying shares of ABM. That number of contracts represents approximately 257,400 underlying shares, working out to a sizeable 67.7% of ABM's average daily trading volume over the past month, of 379,960 shares. | That number of contracts represents approximately 257,400 underlying shares, working out to a sizeable 67.7% of ABM's average daily trading volume over the past month, of 379,960 shares. Below is a chart showing ABM's trailing twelve month trading history, with the $60 strike highlighted in orange: For the various different available expirations for IRON options, IIPR options, or ABM options, visit StockOptionsChannel.com. Below is a chart showing IIPR's trailing twelve month trading history, with the $90 strike highlighted in orange: And ABM Industries, Inc. (Symbol: ABM) options are showing a volume of 2,574 contracts thus far today. |
29070.0 | 2023-12-12 00:00:00 UTC | Why ABM Industries Stock Just Popped 15% | ABM | https://www.nasdaq.com/articles/why-abm-industries-stock-just-popped-15 | nan | nan | Shares of facility services (janitorial, maintenance, and parking) provider ABM Industries (NYSE: ABM) are off to the races on Wednesday, rising 14.8% through 12:55 p.m. ET after beating expectations for Q4 earnings this morning.
Heading into its fiscal Q4 2023, analysts had forecast ABM would earn $0.92 per share (adjusted for one-time items) on sales of just over $2 billion. In fact, ABM earned $1.01 per share, adjusted, and on sales of $2.1 billion -- and beat on guidance as well.
ABM's sales and earnings
Now, not all the news was as exciting as the fact the company beat expectations. Actual sales growth in Q4 was only a modest 4%. Q4 earnings calculated according to generally accepted accounting principles (GAAP), while up an impressive 32% year over year, were only $0.96 per share, a nickel less than adjusted earnings.
But still, a beat is a beat -- and it looks like investors will take it.
CEO Scott Salmirs credited strong profit margins for the improvement in net income, highlighting "strong operating performances in our Aviation and Technical Solutions segments" and "solid performances in our Manufacturing & Distribution ... and Education segments," while the commercial real estate business encountered more difficulties.
Is ABM stock a buy?
All that being said, Q4 brought to a close a successful year in which modest, 4% sales growth yielded a respectable 11% growth in earnings. With $3.79 per share (GAAP) earned this year, ABM stock now sells for only 13.4 times earnings.
Factor in a respectable 2% dividend yield, and I'd say that price is just about right for this growth rate -- with caveats, such as:
Caveat No. 1: ABM beat on guidance this morning, but even so, its forecast for $3.20 to $3.40 per share in adjusted income next year (management did not give GAAP guidance) implies that profits will decline in 2024 -- perhaps by as much as 9%. That's a bit disappointing.
Caveat No. 2: Adding to my worries, free cash flow at the company in 2023 was only $190 million. Compared to the company's $251 million in reported net income, that means ABM is currently generating only about $0.75 in real cash profit for every $1 it reports in net income. So at a price-to-free cash flow ratio of 17.5 -- and with a sizable amount of debt on the balance sheet -- ABM is arguably quite a bit more expensive than it looks at first glance.
Ultimately, therefore, between the prospect of an imminent earnings decline and weak free cash flow that probably foreshadows such a decline, I don't think ABM stock is a buy today.
Should you invest $1,000 in Abm Industries right now?
Before you buy stock in Abm Industries, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abm Industries wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
See the 10 stocks
*Stock Advisor returns as of December 11, 2023
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Heading into its fiscal Q4 2023, analysts had forecast ABM would earn $0.92 per share (adjusted for one-time items) on sales of just over $2 billion. So at a price-to-free cash flow ratio of 17.5 -- and with a sizable amount of debt on the balance sheet -- ABM is arguably quite a bit more expensive than it looks at first glance. Shares of facility services (janitorial, maintenance, and parking) provider ABM Industries (NYSE: ABM) are off to the races on Wednesday, rising 14.8% through 12:55 p.m. | In fact, ABM earned $1.01 per share, adjusted, and on sales of $2.1 billion -- and beat on guidance as well. Before you buy stock in Abm Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abm Industries wasn't one of them. Shares of facility services (janitorial, maintenance, and parking) provider ABM Industries (NYSE: ABM) are off to the races on Wednesday, rising 14.8% through 12:55 p.m. | With $3.79 per share (GAAP) earned this year, ABM stock now sells for only 13.4 times earnings. Ultimately, therefore, between the prospect of an imminent earnings decline and weak free cash flow that probably foreshadows such a decline, I don't think ABM stock is a buy today. Before you buy stock in Abm Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abm Industries wasn't one of them. | With $3.79 per share (GAAP) earned this year, ABM stock now sells for only 13.4 times earnings. 1: ABM beat on guidance this morning, but even so, its forecast for $3.20 to $3.40 per share in adjusted income next year (management did not give GAAP guidance) implies that profits will decline in 2024 -- perhaps by as much as 9%. Before you buy stock in Abm Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abm Industries wasn't one of them. |
29071.0 | 2023-12-12 00:00:00 UTC | ABM Crosses Above Average Analyst Target | ABM | https://www.nasdaq.com/articles/abm-crosses-above-average-analyst-target | nan | nan | In recent trading, shares of ABM Industries, Inc. (Symbol: ABM) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.04/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 5 different analyst targets within the Zacks coverage universe contributing to that average for ABM Industries, Inc., but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $40.00. And then on the other side of the spectrum one analyst has a target as high as $52.00. The standard deviation is $4.636.
But the whole reason to look at the average ABM price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABM crossing above that average target price of $44.00/share, investors in ABM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $44.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover ABM Industries, Inc.:
RECENT ABM ANALYST RATINGS BREAKDOWN
» Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 0 0 0 1
Buy ratings: 1 1 1 1
Hold ratings: 6 5 5 5
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 2.86 2.83 2.83 2.57
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ABM — FREE.
10 ETFs With Most Upside To Analyst Targets »
Also see:
MAR Technical Analysis
Top Ten Hedge Funds Holding BPS
SJM Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But the whole reason to look at the average ABM price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABM crossing above that average target price of $44.00/share, investors in ABM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $44.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of ABM Industries, Inc. (Symbol: ABM) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.04/share. | In recent trading, shares of ABM Industries, Inc. (Symbol: ABM) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.04/share. But the whole reason to look at the average ABM price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. There are 5 different analyst targets within the Zacks coverage universe contributing to that average for ABM Industries, Inc., but the average is just that — a mathematical average. | There are 5 different analyst targets within the Zacks coverage universe contributing to that average for ABM Industries, Inc., but the average is just that — a mathematical average. And so with ABM crossing above that average target price of $44.00/share, investors in ABM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $44.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of ABM Industries, Inc. (Symbol: ABM) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.04/share. | In recent trading, shares of ABM Industries, Inc. (Symbol: ABM) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.04/share. There are 5 different analyst targets within the Zacks coverage universe contributing to that average for ABM Industries, Inc., but the average is just that — a mathematical average. But the whole reason to look at the average ABM price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. |
29072.0 | 2023-12-12 00:00:00 UTC | Company News for Dec 14, 2023 | ABM | https://www.nasdaq.com/articles/company-news-for-dec-14-2023 | nan | nan | Shares of ABM Industries Incorporated (ABM) surged 17.9% after the company reported fourth-quarter fiscal 2023 earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share.
Pfizer Inc.’s (PFE) shares fell 6.2% after the company announced its 2024 profit and revenue forecast which was disappointing because of a sharp decline in demand for its Covid-19 products.
Shares of The Home Depot, Inc. (HD) jumped 3.1% boosted by the broader real estate rally.
The Goldman Sachs Group, Inc.’s (GS) shares gained 2.9% on the broader Dow rally.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
The Home Depot, Inc. (HD) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ABM Industries Incorporated (ABM) surged 17.9% after the company reported fourth-quarter fiscal 2023 earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report The Home Depot, Inc. (HD) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc.’s (PFE) shares fell 6.2% after the company announced its 2024 profit and revenue forecast which was disappointing because of a sharp decline in demand for its Covid-19 products. | Shares of ABM Industries Incorporated (ABM) surged 17.9% after the company reported fourth-quarter fiscal 2023 earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report The Home Depot, Inc. (HD) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. The Goldman Sachs Group, Inc.’s (GS) shares gained 2.9% on the broader Dow rally. | Shares of ABM Industries Incorporated (ABM) surged 17.9% after the company reported fourth-quarter fiscal 2023 earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report The Home Depot, Inc. (HD) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report The Home Depot, Inc. (HD) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of ABM Industries Incorporated (ABM) surged 17.9% after the company reported fourth-quarter fiscal 2023 earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. Pfizer Inc.’s (PFE) shares fell 6.2% after the company announced its 2024 profit and revenue forecast which was disappointing because of a sharp decline in demand for its Covid-19 products. |
29073.0 | 2023-12-12 00:00:00 UTC | ABM Industries (ABM) Q4 Earnings and Revenues Beat Estimates | ABM | https://www.nasdaq.com/articles/abm-industries-abm-q4-earnings-and-revenues-beat-estimates | nan | nan | ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
Adjusted earnings (considering 5 cents from non-recurring items) were $1.01 per share, which beat the consensus estimate by 8.6% and increased 13.5% from last fiscal year’s quarterly figure.
Total revenues of $2.09 billion beat the consensus mark by 2.8% and improved 4.1% from the last fiscal year’s quarterly figure. The upside was backed by solid segmental performance, strength from new accounts that came online late last year and the acquisition of RavenVolt. Quarterly revenue growth included 3.8% organic growth and a 0.3% upside from acquisitions.
Segment-Wise Revenues
The Business & Industry segment’s revenues increased 0.4% from the last fiscal year’s quarterly figure to $1.03 billion and beat our estimate by 4.6%.
ABM Industries Incorporated Price, Consensus and EPS Surprise
ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote
Revenues from the Manufacturing & Distribution segment rose 5.4% to $391.2 million, beating our estimate by 4.5%. The Aviation segment’s revenues rose 15.8% from the last fiscal year’s quarterly figure to $248.2 million and surpassed our estimate by 12.6%.
Technical Solutions and Education segments’ revenues increased 6.2% and 5.8% from the prior-year fiscal quarter’s levels to $190.8 million and $229.8 million, respectively.
Operating Results
Adjusted EBITDA was $144.2 million, up 10.3% from the prior-year period. Adjusted EBITDA margin was 7.2% compared with 6.8% reported in the prior-year period.
Balance Sheet & Cash Flow
ABM Industries exited fourth-quarter fiscal 2023 with cash and cash equivalents of $69.5 million compared with $97.7 million at the end of the prior fiscal quarter. Long-term debt was $1.28 billion compared with $1.29 billion at the end of the prior fiscal quarter.
Net cash provided by operating activities totaled $139.1 million for the reported quarter. Free cash flow was $121.2 million.
2024 Guidance
For fiscal 2024, ABM Industries expects adjusted earnings per share to be in the range of $3.20-$3.40. The Zacks Consensus Estimate for earnings of $3.29 per share is pegged below the midpoint of the guided range ($3.30). Adjusted EBITDA margin is anticipated to be between 6.2% and 6.5%. Interest expense is expected to be between $82 million and $86 million.
ABM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stocks to Consider
Here are a few stocks from the broader Business Services sector that have also performed well in their recent earnings releases:
S&P Global Inc. SPGI reported impressive third-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate.
SPGI’s adjusted earnings per share (excluding 88 cents from non-recurring items) of $3.21 rose 9.6% year over year and beat the consensus estimate by 5.3%. Revenues of $3.08 billion surpassed the consensus estimate by 2% and improved 8% year over year, backed by strong performance in all divisions.
Verisk Analytics Inc. VRSK reported impressive third-quarter 2023 results, wherein earnings and revenues beat the respective consensus estimates.
VRSK’s adjusted earnings (excluding 23 cents from non-recurring items) were $1.52 per share, beating the Zacks Consensus Estimate and increasing 4.1% from the year-ago reported figure. Such a beat was supported by strong growth in underwriting data solutions, life insurance and extreme events solutions.
Fiserv, Inc. FI reported impressive third-quarter 2023 results, wherein earnings and revenues surpassed the Zacks Consensus Estimate.
FI’s adjusted earnings per share (excluding 40 cents from non-recurring items) of $1.96 exceeded the consensus mark by 1% and increased 20% year over year. Adjusted revenues of $4.62 billion surpassed the consensus estimate by 0.53% and increased 8.2% year over year.
Organic revenue growth was 12% in the quarter, driven by 20% and 6% growth in the Acceptance and Payments segments, respectively.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report
Fiserv, Inc. (FI) : Free Stock Analysis Report
S&P Global Inc. (SPGI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Revenues from the Manufacturing & Distribution segment rose 5.4% to $391.2 million, beating our estimate by 4.5%. Balance Sheet & Cash Flow ABM Industries exited fourth-quarter fiscal 2023 with cash and cash equivalents of $69.5 million compared with $97.7 million at the end of the prior fiscal quarter. | ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report Fiserv, Inc. (FI) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Revenues from the Manufacturing & Distribution segment rose 5.4% to $391.2 million, beating our estimate by 4.5%. | ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report Fiserv, Inc. (FI) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Revenues from the Manufacturing & Distribution segment rose 5.4% to $391.2 million, beating our estimate by 4.5%. | ABM Industries Inc. ABM reported impressive fourth-quarter fiscal 2023 results, wherein earnings and revenues beat the Zacks Consensus Estimate. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Revenues from the Manufacturing & Distribution segment rose 5.4% to $391.2 million, beating our estimate by 4.5%. Balance Sheet & Cash Flow ABM Industries exited fourth-quarter fiscal 2023 with cash and cash equivalents of $69.5 million compared with $97.7 million at the end of the prior fiscal quarter. |
29074.0 | 2023-12-12 00:00:00 UTC | Interesting ABM Put And Call Options For February 2024 | ABM | https://www.nasdaq.com/articles/interesting-abm-put-and-call-options-for-february-2024 | nan | nan | Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the February 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABM options chain for the new February 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $45.00 strike price has a current bid of 10 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $45.00, but will also collect the premium, putting the cost basis of the shares at $44.90 (before broker commissions). To an investor already interested in purchasing shares of ABM, that could represent an attractive alternative to paying $47.61/share today.
Because the $45.00 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.22% return on the cash commitment, or 1.27% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for ABM Industries, Inc., and highlighting in green where the $45.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of 10 cents. If an investor was to purchase shares of ABM stock at the current price level of $47.61/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $50.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 5.23% if the stock gets called away at the February 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABM shares really soar, which is why looking at the trailing twelve month trading history for ABM Industries, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing ABM's trailing twelve month trading history, with the $50.00 strike highlighted in red:
Considering the fact that the $50.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.21% boost of extra return to the investor, or 1.20% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $47.61) to be 33%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
ESPO market cap history
ETFs Holding MCRB
Institutional Holders of CPHI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a chart showing ABM's trailing twelve month trading history, with the $50.00 strike highlighted in red: Considering the fact that the $50.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the February 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABM options chain for the new February 2024 contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABM's trailing twelve month trading history, with the $50.00 strike highlighted in red: Considering the fact that the $50.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the February 2024 expiration. | Below is a chart showing the trailing twelve month trading history for ABM Industries, Inc., and highlighting in green where the $45.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of 10 cents. Below is a chart showing ABM's trailing twelve month trading history, with the $50.00 strike highlighted in red: Considering the fact that the $50.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the February 2024 expiration. | Below is a chart showing the trailing twelve month trading history for ABM Industries, Inc., and highlighting in green where the $45.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of 10 cents. Below is a chart showing ABM's trailing twelve month trading history, with the $50.00 strike highlighted in red: Considering the fact that the $50.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the February 2024 expiration. |
29075.0 | 2023-12-11 00:00:00 UTC | ABM Industries Gains After Q3 Profit Beats Estimates | ABM | https://www.nasdaq.com/articles/abm-industries-gains-after-q3-profit-beats-estimates | nan | nan | (RTTNews) - ABM Industries Inc. (ABM) shares are gaining more than 13 percent on Wednesday morning trade after the company reported increased fourth-quarter earnings that surpassed the Street estimates
The quarterly earnings were $62.8 million, or $0.96 percent, compared to $48.9 million, or $0.73 per share in the previous year. On an adjusted basis, earnings were $66.2 million or $1.01 per share. Wall Street analysts were looking for $0.92 per share.
Revenues were $2.092 billion, up from $2.011 billion last year.
Looking ahead to the fiscal 2024, the company expects adjusted earnings per share in a range of $3.20 to $3.40. Analysts are projecting $3.41 per share.
Currently, shares are at $50.53, up 13.54 percent, from the previous close of $44.36 on a volume of 598,164.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ABM Industries Inc. (ABM) shares are gaining more than 13 percent on Wednesday morning trade after the company reported increased fourth-quarter earnings that surpassed the Street estimates The quarterly earnings were $62.8 million, or $0.96 percent, compared to $48.9 million, or $0.73 per share in the previous year. Looking ahead to the fiscal 2024, the company expects adjusted earnings per share in a range of $3.20 to $3.40. Currently, shares are at $50.53, up 13.54 percent, from the previous close of $44.36 on a volume of 598,164. | (RTTNews) - ABM Industries Inc. (ABM) shares are gaining more than 13 percent on Wednesday morning trade after the company reported increased fourth-quarter earnings that surpassed the Street estimates The quarterly earnings were $62.8 million, or $0.96 percent, compared to $48.9 million, or $0.73 per share in the previous year. On an adjusted basis, earnings were $66.2 million or $1.01 per share. Looking ahead to the fiscal 2024, the company expects adjusted earnings per share in a range of $3.20 to $3.40. | (RTTNews) - ABM Industries Inc. (ABM) shares are gaining more than 13 percent on Wednesday morning trade after the company reported increased fourth-quarter earnings that surpassed the Street estimates The quarterly earnings were $62.8 million, or $0.96 percent, compared to $48.9 million, or $0.73 per share in the previous year. On an adjusted basis, earnings were $66.2 million or $1.01 per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - ABM Industries Inc. (ABM) shares are gaining more than 13 percent on Wednesday morning trade after the company reported increased fourth-quarter earnings that surpassed the Street estimates The quarterly earnings were $62.8 million, or $0.96 percent, compared to $48.9 million, or $0.73 per share in the previous year. On an adjusted basis, earnings were $66.2 million or $1.01 per share. Wall Street analysts were looking for $0.92 per share. |
29076.0 | 2023-12-11 00:00:00 UTC | ABM Industries (ABM) Reports Q4 Earnings: What Key Metrics Have to Say | ABM | https://www.nasdaq.com/articles/abm-industries-abm-reports-q4-earnings%3A-what-key-metrics-have-to-say | nan | nan | For the quarter ended October 2023, ABM Industries (ABM) reported revenue of $2.09 billion, up 4.1% over the same period last year. EPS came in at $1.01, compared to $0.89 in the year-ago quarter.
The reported revenue represents a surprise of +2.77% over the Zacks Consensus Estimate of $2.04 billion. With the consensus EPS estimate being $0.93, the EPS surprise was +8.60%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Manufacturing & Distribution: $391.20 million versus $380.72 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
Revenues- Education: $229.80 million versus the three-analyst average estimate of $220.11 million. The reported number represents a year-over-year change of +5.9%.
Revenues- Business & Industry: $1.03 billion versus $1.01 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.4% change.
Revenues- Technical Solutions: $190.80 million versus the three-analyst average estimate of $201.30 million. The reported number represents a year-over-year change of +6.2%.
Revenues- Aviation: $248.20 million versus $231.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.
Operating profit- Business & Industry: $84.60 million versus the three-analyst average estimate of $82.37 million.
Operating profit (loss)- Manufacturing & Distribution: $42 million compared to the $44.38 million average estimate based on three analysts.
Operating profit- Technical Solutions: $24.40 million compared to the $14.92 million average estimate based on three analysts.
Operating profit- Aviation: $16.40 million versus the three-analyst average estimate of $11.39 million.
Operating profit- Education: $10.20 million versus the three-analyst average estimate of $8.98 million.
View all Key Company Metrics for ABM Industries here>>>
Shares of ABM Industries have returned +6.6% over the past month versus the Zacks S&P 500 composite's +5.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For the quarter ended October 2023, ABM Industries (ABM) reported revenue of $2.09 billion, up 4.1% over the same period last year. Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacturing & Distribution: $391.20 million versus $380.72 million estimated by three analysts on average. View all Key Company Metrics for ABM Industries here>>> | Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacturing & Distribution: $391.20 million versus $380.72 million estimated by three analysts on average. For the quarter ended October 2023, ABM Industries (ABM) reported revenue of $2.09 billion, up 4.1% over the same period last year. View all Key Company Metrics for ABM Industries here>>> | Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacturing & Distribution: $391.20 million versus $380.72 million estimated by three analysts on average. For the quarter ended October 2023, ABM Industries (ABM) reported revenue of $2.09 billion, up 4.1% over the same period last year. View all Key Company Metrics for ABM Industries here>>> | Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacturing & Distribution: $391.20 million versus $380.72 million estimated by three analysts on average. View all Key Company Metrics for ABM Industries here>>> For the quarter ended October 2023, ABM Industries (ABM) reported revenue of $2.09 billion, up 4.1% over the same period last year. |
29077.0 | 2023-12-11 00:00:00 UTC | ABM Industries (ABM) Tops Q4 Earnings and Revenue Estimates | ABM | https://www.nasdaq.com/articles/abm-industries-abm-tops-q4-earnings-and-revenue-estimates | nan | nan | ABM Industries (ABM) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.89 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 8.60%. A quarter ago, it was expected that this provider of cleaning and other maintenance services for commercial buildings, hospitals and airports would post earnings of $0.88 per share when it actually produced earnings of $0.79, delivering a surprise of -10.23%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
ABM Industries, which belongs to the Zacks Building Products - Maintenance Service industry, posted revenues of $2.09 billion for the quarter ended October 2023, surpassing the Zacks Consensus Estimate by 2.77%. This compares to year-ago revenues of $2.01 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
ABM Industries shares have lost about 0.1% since the beginning of the year versus the S&P 500's gain of 20.9%.
What's Next for ABM Industries?
While ABM Industries has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for ABM Industries: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.73 on $2 billion in revenues for the coming quarter and $3.29 on $8.09 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products - Maintenance Service is currently in the top 1% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Paychex (PAYX), another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended November 2023. The results are expected to be released on December 21.
This payroll processor and human-resources services provider is expected to post quarterly earnings of $1.07 per share in its upcoming report, which represents a year-over-year change of +8.1%. The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level.
Paychex's revenues are expected to be $1.27 billion, up 6.5% from the year-ago quarter.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Paychex, Inc. (PAYX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM Industries (ABM) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. ABM Industries, which belongs to the Zacks Building Products - Maintenance Service industry, posted revenues of $2.09 billion for the quarter ended October 2023, surpassing the Zacks Consensus Estimate by 2.77%. ABM Industries shares have lost about 0.1% since the beginning of the year versus the S&P 500's gain of 20.9%. | ABM Industries, which belongs to the Zacks Building Products - Maintenance Service industry, posted revenues of $2.09 billion for the quarter ended October 2023, surpassing the Zacks Consensus Estimate by 2.77%. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Paychex, Inc. (PAYX) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries (ABM) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. | ABM Industries (ABM) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. ABM Industries, which belongs to the Zacks Building Products - Maintenance Service industry, posted revenues of $2.09 billion for the quarter ended October 2023, surpassing the Zacks Consensus Estimate by 2.77%. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Paychex, Inc. (PAYX) : Free Stock Analysis Report To read this article on Zacks.com click here. | ABM Industries (ABM) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. ABM Industries, which belongs to the Zacks Building Products - Maintenance Service industry, posted revenues of $2.09 billion for the quarter ended October 2023, surpassing the Zacks Consensus Estimate by 2.77%. ABM Industries shares have lost about 0.1% since the beginning of the year versus the S&P 500's gain of 20.9%. |
29078.0 | 2023-12-08 00:00:00 UTC | Gear Up for ABM Industries (ABM) Q4 Earnings: Wall Street Estimates for Key Metrics | ABM | https://www.nasdaq.com/articles/gear-up-for-abm-industries-abm-q4-earnings%3A-wall-street-estimates-for-key-metrics | nan | nan | In its upcoming report, ABM Industries (ABM) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 4.5% compared to the same period last year. Revenues are forecasted to be $2.04 billion, representing a year-over-year increase of 1.3%.
Over the last 30 days, there has been an upward revision of 1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some ABM Industries metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenues- Business & Industry' will reach $1.01 billion. The estimate suggests a change of -2.3% year over year.
The consensus estimate for 'Revenues- Aviation' stands at $231.88 million. The estimate indicates a year-over-year change of +8.2%.
Analysts' assessment points toward 'Revenues- Education' reaching $220.11 million. The estimate points to a change of +1.4% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Manufacturing & Distribution' should come in at $380.72 million. The estimate indicates a change of +2.6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Technical Solutions' of $201.30 million. The estimate suggests a change of +12.1% year over year.
The combined assessment of analysts suggests that 'Operating profit- Business & Industry' will likely reach $82.37 million. The estimate compares to the year-ago value of $92.40 million.
The average prediction of analysts places 'Operating profit (loss)- Manufacturing & Distribution' at $44.38 million. The estimate is in contrast to the year-ago figure of $41.20 million.
Analysts expect 'Operating profit- Technical Solutions' to come in at $14.92 million. Compared to the present estimate, the company reported $20.90 million in the same quarter last year.
It is projected by analysts that the 'Operating profit- Education' will reach $8.98 million. Compared to the present estimate, the company reported $8.30 million in the same quarter last year.
View all Key Company Metrics for ABM Industries here>>>
Shares of ABM Industries have demonstrated returns of +10.1% over the past month compared to the Zacks S&P 500 composite's +4.9% change. With a Zacks Rank #3 (Hold), ABM is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That said, let's delve into the average estimates of some ABM Industries metrics that Wall Street analysts commonly model and monitor. In its upcoming report, ABM Industries (ABM) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 4.5% compared to the same period last year. View all Key Company Metrics for ABM Industries here>>> | In its upcoming report, ABM Industries (ABM) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 4.5% compared to the same period last year. That said, let's delve into the average estimates of some ABM Industries metrics that Wall Street analysts commonly model and monitor. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. | In its upcoming report, ABM Industries (ABM) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 4.5% compared to the same period last year. That said, let's delve into the average estimates of some ABM Industries metrics that Wall Street analysts commonly model and monitor. View all Key Company Metrics for ABM Industries here>>> | In its upcoming report, ABM Industries (ABM) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 4.5% compared to the same period last year. That said, let's delve into the average estimates of some ABM Industries metrics that Wall Street analysts commonly model and monitor. View all Key Company Metrics for ABM Industries here>>> |
29079.0 | 2023-12-06 00:00:00 UTC | ABM Industries (ABM) Earnings Expected to Grow: Should You Buy? | ABM | https://www.nasdaq.com/articles/abm-industries-abm-earnings-expected-to-grow%3A-should-you-buy | nan | nan | Wall Street expects a year-over-year increase in earnings on higher revenues when ABM Industries (ABM) reports results for the quarter ended October 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on December 13. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This provider of cleaning and other maintenance services for commercial buildings, hospitals and airports is expected to post quarterly earnings of $0.93 per share in its upcoming report, which represents a year-over-year change of +4.5%.
Revenues are expected to be $2.04 billion, up 1.3% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for ABM Industries?
For ABM Industries, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +4%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that ABM Industries will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that ABM Industries would post earnings of $0.88 per share when it actually produced earnings of $0.79, delivering a surprise of -10.23%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
ABM Industries appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street expects a year-over-year increase in earnings on higher revenues when ABM Industries (ABM) reports results for the quarter ended October 2023. How Have the Numbers Shaped Up for ABM Industries? For ABM Industries, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. | Wall Street expects a year-over-year increase in earnings on higher revenues when ABM Industries (ABM) reports results for the quarter ended October 2023. How Have the Numbers Shaped Up for ABM Industries? For ABM Industries, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. | For ABM Industries, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. Wall Street expects a year-over-year increase in earnings on higher revenues when ABM Industries (ABM) reports results for the quarter ended October 2023. How Have the Numbers Shaped Up for ABM Industries? | Wall Street expects a year-over-year increase in earnings on higher revenues when ABM Industries (ABM) reports results for the quarter ended October 2023. How Have the Numbers Shaped Up for ABM Industries? For ABM Industries, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. |
29080.0 | 2023-12-05 00:00:00 UTC | Validea's Top Industrial Stocks Based On Peter Lynch - 12/5/2023 | ABM | https://www.nasdaq.com/articles/valideas-top-industrial-stocks-based-on-peter-lynch-12-5-2023 | nan | nan | The following are the top rated Industrial stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Its segments include Business & Industry (B&I), Manufacturing & Distribution (M&D), Education, Aviation, and Technical Solutions. B&I segment includes janitorial, facilities engineering, and parking services for commercial real estate properties, sports and entertainment venues, and non-acute healthcare facilities. M&D segment provides facility services, engineering, janitorial, and other specialized services in manufacturing and distribution. Education segment delivers custodial, landscaping and grounds, facilities engineering, and parking services for public school districts, private schools, colleges, and universities. Aviation segment supports airlines and airports with services ranging from parking and janitorial to passenger assistance, catering logistics, air cabin maintenance and transportation. Technical Solutions segment includes mechanical and electrical services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABM INDUSTRIES INC
ABM Guru Analysis
ABM Fundamental Analysis
FEDEX CORP (FDX) is a large-cap growth stock in the Air Courier industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FedEx Corporation (FedEx) provides a portfolio of transportation, e-commerce and business services through companies competing collectively and operating independently, under the FedEx brand. The Company's segments include FedEx Express, FedEx Ground, FedEx Freight and FedEx Services. The FedEx Express segment offers a range of United States domestic and international shipping services for delivery of packages and freight. The FedEx Ground segment provides small-package ground delivery services, which includes day-certain service to any business address in the United States and Canada, as well as residential delivery services through its FedEx Home Delivery service. The FedEx Freight segment offers less-than-truckload (LTL) freight services. The FedEx Services segment provides sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the Company's operating segments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of FEDEX CORP
FDX Guru Analysis
FDX Fundamental Analysis
PREFORMED LINE PRODUCTS COMPANY (PLPC) is a small-cap value stock in the Misc. Fabricated Products industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Preformed Line Products Company is a designer and manufacturer of products and systems employed in the construction and maintenance of overhead, ground-mounted and underground networks for energy, telecommunication, cable, data communication and other similar industries. It provides formed wire solutions, connectors, fiber optic and copper splice closures, solar hardware mounting applications, and electric vehicle charging station foundations. Its products include energy products, communications products, and special industry products. The energy products are used for supporting, protecting, terminating and splicing transmission and distribution lines as well as bolted, welded, and compressed connectors for substations. The communications products include rugged outside plant (OSP) closures to protect and support wireline and wireless networks. The special industry products include hardware assemblies, pole line hardware, plastic products, and interior/exterior connectors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of PREFORMED LINE PRODUCTS COMPANY
PLPC Guru Analysis
PLPC Fundamental Analysis
KORN FERRY (KFY) is a mid-cap growth stock in the Business Services industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Korn Ferry is an organizational consulting company. The Company operates through eight segments: Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search Asia Pacific, Executive Search Latin America, Professional Search & Interim and RPO. Its segments operate through five lines of business: Consulting, Digital, Executive Search, Professional Search & Interim and recruitment process outsourcing (RPO). Consulting aligns organization structure, performance and people to drive growth by addressing organizational strategy, assessment, succession, and leadership. Digital uses an artificial intelligence-based machine-learning platform to identify structure, roles, capabilities and behaviors needed. Executive Search helps organizations recruit board level, chief executive and other senior executive and general management talent. Professional Search & Interim delivers enterprise talent acquisition solutions for professional level middle and upper management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of KORN FERRY
KFY Guru Analysis
KFY Fundamental Analysis
ARCOSA INC (ACA) is a mid-cap value stock in the Construction Services industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Arcosa, Inc. is a provider of infrastructure-related products and solutions with brands serving construction, engineered structure, and transportation markets in North America. The Company's segments are Construction Products, Engineered Structures and Transportation Products. Its Construction Products segment produces and sells natural and recycled aggregates, specialty materials, and construction site support equipment, including trench shields and shoring products. Its Engineered Structures segment manufactures and sells steel structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic structures, and telecommunication structures. This segment also manufactures distribution tanks. The Transportation Products segment manufactures and sells inland barges, fiberglass barge covers, winches, marine hardware, and steel components for railcars and other transportation and industrial equipment.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ARCOSA INC
ACA Guru Analysis
ACA Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis FEDEX CORP (FDX) is a large-cap growth stock in the Air Courier industry. | ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis FEDEX CORP (FDX) is a large-cap growth stock in the Air Courier industry. | ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis FEDEX CORP (FDX) is a large-cap growth stock in the Air Courier industry. | ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis FEDEX CORP (FDX) is a large-cap growth stock in the Air Courier industry. |
29081.0 | 2023-12-05 00:00:00 UTC | Why Earnings Season Could Be Great for ABM Industries (ABM) | ABM | https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-abm-industries-abm | nan | nan | Investors are always looking for stocks that are poised to beat at earnings season and ABM Industries Incorporated ABM may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because ABM Industries is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABM in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at 97 cents per share for ABM, compared to a broader Zacks Consensus Estimate of 93 cents per share. This suggests that analysts have very recently bumped up their estimates for ABM, giving the stock a Zacks Earnings ESP of +4.00% heading into earnings season.
ABM Industries Incorporated Price and EPS Surprise
ABM Industries Incorporated price-eps-surprise | ABM Industries Incorporated Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that ABM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for ABM Industries, and that a beat might be in the cards for the upcoming report.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABM in this report. Given that ABM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for ABM Industries, and that a beat might be in the cards for the upcoming report. | This suggests that analysts have very recently bumped up their estimates for ABM, giving the stock a Zacks Earnings ESP of +4.00% heading into earnings season. ABM Industries Incorporated Price and EPS Surprise ABM Industries Incorporated price-eps-surprise | ABM Industries Incorporated Quote Why is this Important? Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. | This suggests that analysts have very recently bumped up their estimates for ABM, giving the stock a Zacks Earnings ESP of +4.00% heading into earnings season. ABM Industries Incorporated Price and EPS Surprise ABM Industries Incorporated price-eps-surprise | ABM Industries Incorporated Quote Why is this Important? Investors are always looking for stocks that are poised to beat at earnings season and ABM Industries Incorporated ABM may be one such company. | This suggests that analysts have very recently bumped up their estimates for ABM, giving the stock a Zacks Earnings ESP of +4.00% heading into earnings season. Given that ABM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for ABM Industries, and that a beat might be in the cards for the upcoming report. |
29082.0 | 2023-11-23 00:00:00 UTC | Reasons to Hold ABM Industries (ABM) in Your Portfolio | ABM | https://www.nasdaq.com/articles/reasons-to-hold-abm-industries-abm-in-your-portfolio | nan | nan | ABM Industries'ABM success can be attributed to its strategic initiative, 2020 Vision, which has played a pivotal role in achieving sustainable and profitable long-term growth by adopting an industry-focused go-to-market approach. Rising wages and a competitive talent market are causes of concern for the company.
ABM has an impressive Growth Score of A. This style score condenses all the essential metrics from a company’s financial statements to get a true sense of the quality and sustainability of its growth.
Factors That Bode Well
In 2015, ABM embarked on a transformative journey named "2020 Vision" with the objective of achieving sustainable and profitable growth through an industry-focused go-to-market strategy. As part of this initiative, the company centralized crucial functional areas, bolstered its sales capabilities and made strategic investments in service delivery tools and processes to support essential operating practices for its long-term success. These efforts have, in turn, elevated the quality of ABM's Janitorial, Parking, Facilities Services, Building & Energy Solutions, and Airline Services, thus solidifying its position as a leading integrated facilities management company.
ABM Industries pursues growth through a combined strategy of strategic acquisitions and organic investment. The company's long-term strategic plan, ELEVATE, is designed to enhance client offerings, improve transparency and efficiency, develop in-house talent management capabilities and modernize the digital ecosystem. ELEVATE is anticipated to significantly drive ABM Industries' organic growth, fortify its strategic positioning and bolster profitability.
ABM Industries Incorporated Revenue (TTM)
ABM Industries Incorporated revenue-ttm | ABM Industries Incorporated Quote
We find ABM Industries' commitment to shareholder rewards commendable, particularly through dividend payments and share repurchases. In fiscal years 2022, 2021 and 2020, the company distributed dividends amounting to $51.9 million, $51 million and $49.3 million, respectively. Additionally, it allocated $9.8 million and $5.1 million to share repurchases in 2022 and 2020, respectively, while abstaining from such actions in 2021. These financial moves reflect the company's dedication to creating value for shareholders and underscore its confidence in the strength of its business.
Some Risks
ABM Industries' current ratio at the end of third-quarter was pegged at 1.47, lower than the current ratio of 1.53 reported at the end of the prior quarter. Decreasing current ratio does not bode well for the company.
In 2022, the company faced challenges with labor shortages, rising wage inflation and intensified competition in the job market. Persistence of these issues could result in higher costs, including increased spending on overtime and a greater reliance on temporary staff to meet customer demands. Additionally, attracting and retaining employees may require offering higher wage rates.
ABM currently holds a Zacks Rank #3 (Hold).
Stocks to Consider
Here are a few better-ranked stocks from the Business Services sector that may be considered:
DocuSign DOCU:TheZacks Consensus Estimate of DocuSign’s 2023 revenues indicates 8.6% growth from the year-ago figure while earnings are expected to grow by 29.1%. The company has beaten the consensus estimate in all four quarters, with an average surprise of 27.1%.
The company holds a Zacks Rank of 2 (Buy) and has a VGM Score of B. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Broadridge Financial Solutions BR:TheZacks Consensus Estimate of Broadridge’s 2023 revenues indicates 7.7% growth from the year-ago figure while earnings are expected to grow by 10.1%. The company has beaten the consensus estimate in three of the past four quarters and matched on one instance, with an average surprise of 5.4%.
BR holds a Zacks Rank of 2.
Fiserv FI:The Zacks Consensus Estimate of Fiserv’s 2023 revenues indicates 8.1% growth from the year-ago figure while earnings are expected to grow by 15.4%. The company has beaten the consensus estimate in two of the past four quarters while matching in the other two instances, the average surprise being 0.6%.
The company holds a Zacks Rank #2.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Fiserv, Inc. (FI) : Free Stock Analysis Report
DocuSign (DOCU) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM Industries'ABM success can be attributed to its strategic initiative, 2020 Vision, which has played a pivotal role in achieving sustainable and profitable long-term growth by adopting an industry-focused go-to-market approach. ABM has an impressive Growth Score of A. Factors That Bode Well In 2015, ABM embarked on a transformative journey named "2020 Vision" with the objective of achieving sustainable and profitable growth through an industry-focused go-to-market strategy. | ABM Industries Incorporated Revenue (TTM) ABM Industries Incorporated revenue-ttm | ABM Industries Incorporated Quote We find ABM Industries' commitment to shareholder rewards commendable, particularly through dividend payments and share repurchases. Click to get this free report Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Fiserv, Inc. (FI) : Free Stock Analysis Report DocuSign (DOCU) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries'ABM success can be attributed to its strategic initiative, 2020 Vision, which has played a pivotal role in achieving sustainable and profitable long-term growth by adopting an industry-focused go-to-market approach. | ABM Industries Incorporated Revenue (TTM) ABM Industries Incorporated revenue-ttm | ABM Industries Incorporated Quote We find ABM Industries' commitment to shareholder rewards commendable, particularly through dividend payments and share repurchases. Click to get this free report Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Fiserv, Inc. (FI) : Free Stock Analysis Report DocuSign (DOCU) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries'ABM success can be attributed to its strategic initiative, 2020 Vision, which has played a pivotal role in achieving sustainable and profitable long-term growth by adopting an industry-focused go-to-market approach. | ELEVATE is anticipated to significantly drive ABM Industries' organic growth, fortify its strategic positioning and bolster profitability. ABM Industries'ABM success can be attributed to its strategic initiative, 2020 Vision, which has played a pivotal role in achieving sustainable and profitable long-term growth by adopting an industry-focused go-to-market approach. ABM has an impressive Growth Score of A. |
29083.0 | 2023-11-14 00:00:00 UTC | TOMI Environmental Solutions, Inc. (TOMZ) Reports Q3 Loss, Misses Revenue Estimates | ABM | https://www.nasdaq.com/articles/tomi-environmental-solutions-inc.-tomz-reports-q3-loss-misses-revenue-estimates | nan | nan | TOMI Environmental Solutions, Inc. (TOMZ) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -150%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced break-even earnings, delivering a surprise of -100%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
TOMI Environmental Solutions, Inc., which belongs to the Zacks Waste Removal Services industry, posted revenues of $1.47 million for the quarter ended September 2023, missing the Zacks Consensus Estimate by 48.42%. This compares to year-ago revenues of $1.76 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
TOMI Environmental Solutions, Inc. Shares have added about 91.1% since the beginning of the year versus the S&P 500's gain of 14.9%.
What's Next for TOMI Environmental Solutions, Inc.
While TOMI Environmental Solutions, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for TOMI Environmental Solutions, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.03 on $5.79 million in revenues for the coming quarter and -$0.05 on $13 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Waste Removal Services is currently in the top 21% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
ABM Industries (ABM), another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended October 2023.
This provider of cleaning and other maintenance services for commercial buildings, hospitals and airports is expected to post quarterly earnings of $0.92 per share in its upcoming report, which represents a year-over-year change of +3.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
ABM Industries' revenues are expected to be $2.04 billion, up 1.4% from the year-ago quarter.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TOMI Environmental Solutions, Inc. (TOMZ) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM Industries (ABM), another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended October 2023. ABM Industries' revenues are expected to be $2.04 billion, up 1.4% from the year-ago quarter. Click to get this free report TOMI Environmental Solutions, Inc. (TOMZ) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report TOMI Environmental Solutions, Inc. (TOMZ) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries (ABM), another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended October 2023. ABM Industries' revenues are expected to be $2.04 billion, up 1.4% from the year-ago quarter. | Click to get this free report TOMI Environmental Solutions, Inc. (TOMZ) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM Industries (ABM), another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended October 2023. ABM Industries' revenues are expected to be $2.04 billion, up 1.4% from the year-ago quarter. | ABM Industries (ABM), another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended October 2023. ABM Industries' revenues are expected to be $2.04 billion, up 1.4% from the year-ago quarter. Click to get this free report TOMI Environmental Solutions, Inc. (TOMZ) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. |
29084.0 | 2023-11-14 00:00:00 UTC | Truist Securities Initiates Coverage of ABM Industries (ABM) with Hold Recommendation | ABM | https://www.nasdaq.com/articles/truist-securities-initiates-coverage-of-abm-industries-abm-with-hold-recommendation | nan | nan | Fintel reports that on November 13, 2023, Truist Securities initiated coverage of ABM Industries (NYSE:ABM) with a Hold recommendation.
Analyst Price Forecast Suggests 20.06% Upside
As of November 1, 2023, the average one-year price target for ABM Industries is 47.74. The forecasts range from a low of 40.40 to a high of $59.85. The average price target represents an increase of 20.06% from its latest reported closing price of 39.76.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. The projected annual non-GAAP EPS is 3.74.
ABM Industries Declares $0.22 Dividend
On September 7, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). Shareholders of record as of October 5, 2023 received the payment on November 6, 2023. Previously, the company paid $0.22 per share.
At the current share price of $39.76 / share, the stock's dividend yield is 2.21%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.92%, the lowest has been 1.42%, and the highest has been 3.62%. The standard deviation of yields is 0.27 (n=235).
The current dividend yield is 1.08 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.24. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.19%, demonstrating that it has increased its dividend over time.
What is the Fund Sentiment?
There are 564 funds or institutions reporting positions in ABM Industries. This is an increase of 10 owner(s) or 1.81% in the last quarter. Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 6.18%. Total shares owned by institutions decreased in the last three months by 2.69% to 71,193K shares.
The put/call ratio of ABM is 0.47, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,639K shares representing 7.08% ownership of the company. In it's prior filing, the firm reported owning 4,814K shares, representing a decrease of 3.76%. The firm decreased its portfolio allocation in ABM by 11.42% over the last quarter.
SDY - SPDR(R) S&P(R) Dividend ETF holds 3,542K shares representing 5.41% ownership of the company. In it's prior filing, the firm reported owning 3,630K shares, representing a decrease of 2.48%. The firm decreased its portfolio allocation in ABM by 4.21% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,040K shares representing 3.11% ownership of the company. In it's prior filing, the firm reported owning 2,033K shares, representing an increase of 0.33%. The firm decreased its portfolio allocation in ABM by 12.14% over the last quarter.
Macquarie Group holds 1,857K shares representing 2.83% ownership of the company. In it's prior filing, the firm reported owning 1,836K shares, representing an increase of 1.11%. The firm decreased its portfolio allocation in ABM by 1.67% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,707K shares representing 2.60% ownership of the company. In it's prior filing, the firm reported owning 1,730K shares, representing a decrease of 1.36%. The firm decreased its portfolio allocation in ABM by 10.92% over the last quarter.
ABM Industries Background Information
(This description is provided by the company.)
ABM Industries Inc. is a facility management provider in the United States. ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. As of 2013, the company has over 130,000 employees, over 350 offices, and various international locations.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. Fintel reports that on November 13, 2023, Truist Securities initiated coverage of ABM Industries (NYSE:ABM) with a Hold recommendation. Analyst Price Forecast Suggests 20.06% Upside As of November 1, 2023, the average one-year price target for ABM Industries is 47.74. | Fintel reports that on November 13, 2023, Truist Securities initiated coverage of ABM Industries (NYSE:ABM) with a Hold recommendation. Analyst Price Forecast Suggests 20.06% Upside As of November 1, 2023, the average one-year price target for ABM Industries is 47.74. The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. | ABM Industries Declares $0.22 Dividend On September 7, 2023 the company declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). Fintel reports that on November 13, 2023, Truist Securities initiated coverage of ABM Industries (NYSE:ABM) with a Hold recommendation. Analyst Price Forecast Suggests 20.06% Upside As of November 1, 2023, the average one-year price target for ABM Industries is 47.74. | The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. Fintel reports that on November 13, 2023, Truist Securities initiated coverage of ABM Industries (NYSE:ABM) with a Hold recommendation. Analyst Price Forecast Suggests 20.06% Upside As of November 1, 2023, the average one-year price target for ABM Industries is 47.74. |
29085.0 | 2023-11-07 00:00:00 UTC | Validea's Top Industrial Stocks Based On Joel Greenblatt - 11/7/2023 | ABM | https://www.nasdaq.com/articles/valideas-top-industrial-stocks-based-on-joel-greenblatt-11-7-2023 | nan | nan | The following are the top rated Industrial stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
CRANE NXT CO (CXT) is a mid-cap growth stock in the Electronic Instr. & Controls industry. The rating according to our strategy based on Joel Greenblatt is 90% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Crane NXT, Co. is an industrial technology company. The Company provides technology solutions to secure, detect, and authenticate what matters to its customers. Its primary end markets include governments and a range of consumer related end markets including retail and gaming. The Company operates through two segments: Crane Payment Innovations (CPI) and Crane Currency. The CPI segment provides electronic equipment and associated software leveraging proprietary core capabilities with various detection and sensing technologies for applications including verification and authentication of payment transactions. CPI also provides advanced automation solutions, and processing systems, field service solutions, and remote diagnostics and productivity software solutions. The Crane Currency segment provides advanced security solutions based on proprietary technology for securing physical products, including banknotes, consumer goods and industrial products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: PASS
Detailed Analysis of CRANE NXT CO
CXT Guru Analysis
CXT Fundamental Analysis
RESIDEO TECHNOLOGIES INC (REZI) is a mid-cap value stock in the Electronic Instr. & Controls industry. The rating according to our strategy based on Joel Greenblatt is 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Resideo Technologies, Inc. is a manufacturer and developer of technology-driven products and components. It has two segments: Products and Solutions, and ADI Global Distribution. Products and Solutions segment offers temperature and humidity control, thermal and combustion solutions, water and indoor air quality solutions, smoke and carbon monoxide detection home safety products and fire suppression products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions, cloud infrastructure, installation and maintenance tools, and related software. ADI Global Distribution segment is a wholesale distributor of low-voltage security products including security, fire, access control and video products, and participates significantly in the related markets of smart home, access control, power, audio, ProAV, networking, communications, wire and cable, enterprise connectivity, and structured wiring products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of RESIDEO TECHNOLOGIES INC
REZI Guru Analysis
REZI Fundamental Analysis
BRADY CORP (BRC) is a mid-cap growth stock in the Computer Hardware industry. The rating according to our strategy based on Joel Greenblatt is 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Brady Corporation is a manufacturer and supplier of identification solutions and workplace safety products. The Company operates through two segments: Americas & Asia and Europe & Australia. The Company's identification solutions are involved in the design, manufacturing, and distribution of high-performance and innovative identification and healthcare products. Its workplace safety manufactures a range of stock and custom identification products and is a distributor of a wide variety of resale products. Its product identification includes materials, printing systems and bar code scanners for product identification, brand protection labeling, work in process labeling, finished product identification, and industrial track and trace applications. Its facility safety and identification and protection include safety signs, floor-marking tape, pipe markers, labeling systems, spill control products, and software and services for safety compliance auditing, procedures writing and training.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of BRADY CORP
BRC Guru Analysis
BRC Fundamental Analysis
ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. The rating according to our strategy based on Joel Greenblatt is 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Its segments include Business & Industry (B&I), Manufacturing & Distribution (M&D), Education, Aviation, and Technical Solutions. B&I segment includes janitorial, facilities engineering, and parking services for commercial real estate properties, sports and entertainment venues, and non-acute healthcare facilities. M&D segment provides facility services, engineering, janitorial, and other specialized services in manufacturing and distribution. Education segment delivers custodial, landscaping and grounds, facilities engineering, and parking services for public school districts, private schools, colleges, and universities. Aviation segment supports airlines and airports with services ranging from parking and janitorial to passenger assistance, catering logistics, air cabin maintenance and transportation. Technical Solutions segment includes mechanical and electrical services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of ABM INDUSTRIES INC
ABM Guru Analysis
ABM Fundamental Analysis
Joel Greenblatt Portfolio
Top Joel Greenblatt Stocks
About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of BRADY CORP BRC Guru Analysis BRC Fundamental Analysis ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis Joel Greenblatt Portfolio Top Joel Greenblatt Stocks About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. | Detailed Analysis of BRADY CORP BRC Guru Analysis BRC Fundamental Analysis ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis Joel Greenblatt Portfolio Top Joel Greenblatt Stocks About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. | Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis Joel Greenblatt Portfolio Top Joel Greenblatt Stocks About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. Detailed Analysis of BRADY CORP BRC Guru Analysis BRC Fundamental Analysis ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. | Detailed Analysis of ABM INDUSTRIES INC ABM Guru Analysis ABM Fundamental Analysis Joel Greenblatt Portfolio Top Joel Greenblatt Stocks About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. Detailed Analysis of BRADY CORP BRC Guru Analysis BRC Fundamental Analysis ABM INDUSTRIES INC (ABM) is a mid-cap value stock in the Business Services industry. Company Description: ABM Industries Incorporated is a provider of integrated facility, infrastructure, and mobility solutions. |
29086.0 | 2023-11-01 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABM | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-113 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Nucor Corp. (Symbol: NUE) $147.79 $169.25 14.52%
Graco Inc (Symbol: GGG) $74.35 $84.14 13.17%
Flowers Foods, Inc. (Symbol: FLO) $21.93 $24.75 12.86%
ABM Industries, Inc. (Symbol: ABM) $39.34 $44.25 12.48%
Brown & Brown Inc (Symbol: BRO) $69.42 $77.75 12.00%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
Nucor Corp. (Symbol: NUE) 1.38% 14.52% 15.9%
Graco Inc (Symbol: GGG) 1.26% 13.17% 14.43%
Flowers Foods, Inc. (Symbol: FLO) 4.20% 12.86% 17.06%
ABM Industries, Inc. (Symbol: ABM) 2.24% 12.48% 14.72%
Brown & Brown Inc (Symbol: BRO) 0.75% 12.00% 12.75%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
Nucor Corp. (Symbol: NUE) $2 $2.04 2.00%
Graco Inc (Symbol: GGG) $0.84 $0.94 11.90%
Flowers Foods, Inc. (Symbol: FLO) $0.86 $0.9 4.65%
ABM Industries, Inc. (Symbol: ABM) $0.78 $0.88 12.82%
Brown & Brown Inc (Symbol: BRO) $0.412 $0.59 43.20%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on ABM — FREE
Get the latest Zacks research report on BRO — FREE
Dividend Growth Stocks: 25 Aristocrats »
Also see:
Defense Dividend Stocks
3M 13F Filers
Institutional Holders of ISRG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on ABM — FREE Get the latest Zacks research report on BRO — FREE Dividend Growth Stocks: 25 Aristocrats » Also see: Defense Dividend Stocks 3M 13F Filers Institutional Holders of ISRG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Nucor Corp. (Symbol: NUE) $147.79 $169.25 14.52% Graco Inc (Symbol: GGG) $74.35 $84.14 13.17% Flowers Foods, Inc. (Symbol: FLO) $21.93 $24.75 12.86% ABM Industries, Inc. (Symbol: ABM) $39.34 $44.25 12.48% Brown & Brown Inc (Symbol: BRO) $69.42 $77.75 12.00% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Nucor Corp. (Symbol: NUE) 1.38% 14.52% 15.9% Graco Inc (Symbol: GGG) 1.26% 13.17% 14.43% Flowers Foods, Inc. (Symbol: FLO) 4.20% 12.86% 17.06% ABM Industries, Inc. (Symbol: ABM) 2.24% 12.48% 14.72% Brown & Brown Inc (Symbol: BRO) 0.75% 12.00% 12.75% Another consideration with dividend growth stocks is just how much the dividend is growing. | Nucor Corp. (Symbol: NUE) $147.79 $169.25 14.52% Graco Inc (Symbol: GGG) $74.35 $84.14 13.17% Flowers Foods, Inc. (Symbol: FLO) $21.93 $24.75 12.86% ABM Industries, Inc. (Symbol: ABM) $39.34 $44.25 12.48% Brown & Brown Inc (Symbol: BRO) $69.42 $77.75 12.00% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Nucor Corp. (Symbol: NUE) 1.38% 14.52% 15.9% Graco Inc (Symbol: GGG) 1.26% 13.17% 14.43% Flowers Foods, Inc. (Symbol: FLO) 4.20% 12.86% 17.06% ABM Industries, Inc. (Symbol: ABM) 2.24% 12.48% 14.72% Brown & Brown Inc (Symbol: BRO) 0.75% 12.00% 12.75% Another consideration with dividend growth stocks is just how much the dividend is growing. Nucor Corp. (Symbol: NUE) $2 $2.04 2.00% Graco Inc (Symbol: GGG) $0.84 $0.94 11.90% Flowers Foods, Inc. (Symbol: FLO) $0.86 $0.9 4.65% ABM Industries, Inc. (Symbol: ABM) $0.78 $0.88 12.82% Brown & Brown Inc (Symbol: BRO) $0.412 $0.59 43.20% These five stocks are part of our full Dividend Aristocrats List. | Nucor Corp. (Symbol: NUE) $147.79 $169.25 14.52% Graco Inc (Symbol: GGG) $74.35 $84.14 13.17% Flowers Foods, Inc. (Symbol: FLO) $21.93 $24.75 12.86% ABM Industries, Inc. (Symbol: ABM) $39.34 $44.25 12.48% Brown & Brown Inc (Symbol: BRO) $69.42 $77.75 12.00% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Nucor Corp. (Symbol: NUE) 1.38% 14.52% 15.9% Graco Inc (Symbol: GGG) 1.26% 13.17% 14.43% Flowers Foods, Inc. (Symbol: FLO) 4.20% 12.86% 17.06% ABM Industries, Inc. (Symbol: ABM) 2.24% 12.48% 14.72% Brown & Brown Inc (Symbol: BRO) 0.75% 12.00% 12.75% Another consideration with dividend growth stocks is just how much the dividend is growing. Nucor Corp. (Symbol: NUE) $2 $2.04 2.00% Graco Inc (Symbol: GGG) $0.84 $0.94 11.90% Flowers Foods, Inc. (Symbol: FLO) $0.86 $0.9 4.65% ABM Industries, Inc. (Symbol: ABM) $0.78 $0.88 12.82% Brown & Brown Inc (Symbol: BRO) $0.412 $0.59 43.20% These five stocks are part of our full Dividend Aristocrats List. | Nucor Corp. (Symbol: NUE) $147.79 $169.25 14.52% Graco Inc (Symbol: GGG) $74.35 $84.14 13.17% Flowers Foods, Inc. (Symbol: FLO) $21.93 $24.75 12.86% ABM Industries, Inc. (Symbol: ABM) $39.34 $44.25 12.48% Brown & Brown Inc (Symbol: BRO) $69.42 $77.75 12.00% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Nucor Corp. (Symbol: NUE) 1.38% 14.52% 15.9% Graco Inc (Symbol: GGG) 1.26% 13.17% 14.43% Flowers Foods, Inc. (Symbol: FLO) 4.20% 12.86% 17.06% ABM Industries, Inc. (Symbol: ABM) 2.24% 12.48% 14.72% Brown & Brown Inc (Symbol: BRO) 0.75% 12.00% 12.75% Another consideration with dividend growth stocks is just how much the dividend is growing. Nucor Corp. (Symbol: NUE) $2 $2.04 2.00% Graco Inc (Symbol: GGG) $0.84 $0.94 11.90% Flowers Foods, Inc. (Symbol: FLO) $0.86 $0.9 4.65% ABM Industries, Inc. (Symbol: ABM) $0.78 $0.88 12.82% Brown & Brown Inc (Symbol: BRO) $0.412 $0.59 43.20% These five stocks are part of our full Dividend Aristocrats List. |
29087.0 | 2023-10-30 00:00:00 UTC | New Strong Sell Stocks for October 30th | ABM | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-october-30th | nan | nan | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
ABM Industries Incorporated ABM engages in the provision of integrated facility, infrastructure, and mobility solutions. The Zacks Consensus Estimate for its current year earnings has been revised 2.9% downward over the last 60 days.
Alaska Air Group, Inc. ALK is an airline company which provides passenger and cargo air transportation services. The Zacks Consensus Estimate for its current year earnings has been revised 28.2% downward over the last 60 days.
CBRE Group, Inc. CBRE is a commercial real estate services and investment company. The Zacks Consensus Estimate for its current year earnings has been revised 10.7% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report
CBRE Group, Inc. (CBRE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: ABM Industries Incorporated ABM engages in the provision of integrated facility, infrastructure, and mobility solutions. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report CBRE Group, Inc. (CBRE) : Free Stock Analysis Report To read this article on Zacks.com click here. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: ABM Industries Incorporated ABM engages in the provision of integrated facility, infrastructure, and mobility solutions. Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report CBRE Group, Inc. (CBRE) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for its current year earnings has been revised 2.9% downward over the last 60 days. | Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report CBRE Group, Inc. (CBRE) : Free Stock Analysis Report To read this article on Zacks.com click here. Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: ABM Industries Incorporated ABM engages in the provision of integrated facility, infrastructure, and mobility solutions. The Zacks Consensus Estimate for its current year earnings has been revised 2.9% downward over the last 60 days. | Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Alaska Air Group, Inc. (ALK) : Free Stock Analysis Report CBRE Group, Inc. (CBRE) : Free Stock Analysis Report To read this article on Zacks.com click here. Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: ABM Industries Incorporated ABM engages in the provision of integrated facility, infrastructure, and mobility solutions. View the entire Zacks Rank #5 List. |
29088.0 | 2023-10-13 00:00:00 UTC | ABM Makes Bullish Cross Above Critical Moving Average | ABM | https://www.nasdaq.com/articles/abm-makes-bullish-cross-above-critical-moving-average-0 | nan | nan | In trading on Friday, shares of ABM Industries, Inc. (Symbol: ABM) crossed above their 200 day moving average of $44.17, changing hands as high as $44.33 per share. ABM Industries, Inc. shares are currently trading up about 0.8% on the day. The chart below shows the one year performance of ABM shares, versus its 200 day moving average:
Looking at the chart above, ABM's low point in its 52 week range is $37.61 per share, with $49.5796 as the 52 week high point — that compares with a last trade of $44.11.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
Consumer Stocks Hedge Funds Are Selling
Funds Holding TGS
Funds Holding GVLU
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of ABM Industries, Inc. (Symbol: ABM) crossed above their 200 day moving average of $44.17, changing hands as high as $44.33 per share. The chart below shows the one year performance of ABM shares, versus its 200 day moving average: Looking at the chart above, ABM's low point in its 52 week range is $37.61 per share, with $49.5796 as the 52 week high point — that compares with a last trade of $44.11. ABM Industries, Inc. shares are currently trading up about 0.8% on the day. | In trading on Friday, shares of ABM Industries, Inc. (Symbol: ABM) crossed above their 200 day moving average of $44.17, changing hands as high as $44.33 per share. The chart below shows the one year performance of ABM shares, versus its 200 day moving average: Looking at the chart above, ABM's low point in its 52 week range is $37.61 per share, with $49.5796 as the 52 week high point — that compares with a last trade of $44.11. ABM Industries, Inc. shares are currently trading up about 0.8% on the day. | In trading on Friday, shares of ABM Industries, Inc. (Symbol: ABM) crossed above their 200 day moving average of $44.17, changing hands as high as $44.33 per share. The chart below shows the one year performance of ABM shares, versus its 200 day moving average: Looking at the chart above, ABM's low point in its 52 week range is $37.61 per share, with $49.5796 as the 52 week high point — that compares with a last trade of $44.11. ABM Industries, Inc. shares are currently trading up about 0.8% on the day. | In trading on Friday, shares of ABM Industries, Inc. (Symbol: ABM) crossed above their 200 day moving average of $44.17, changing hands as high as $44.33 per share. ABM Industries, Inc. shares are currently trading up about 0.8% on the day. The chart below shows the one year performance of ABM shares, versus its 200 day moving average: Looking at the chart above, ABM's low point in its 52 week range is $37.61 per share, with $49.5796 as the 52 week high point — that compares with a last trade of $44.11. |
29089.0 | 2023-10-02 00:00:00 UTC | Ex-Dividend Reminder: Progressive, ABM Industries and AECOM | ABM | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-progressive-abm-industries-and-aecom | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 10/4/23, Progressive Corp. (Symbol: PGR), ABM Industries, Inc. (Symbol: ABM), and AECOM (Symbol: ACM) will all trade ex-dividend for their respective upcoming dividends. Progressive Corp. will pay its quarterly dividend of $0.10 on 10/13/23, ABM Industries, Inc. will pay its quarterly dividend of $0.22 on 11/6/23, and AECOM will pay its quarterly dividend of $0.18 on 10/20/23. As a percentage of PGR's recent stock price of $138.89, this dividend works out to approximately 0.07%, so look for shares of Progressive Corp. to trade 0.07% lower — all else being equal — when PGR shares open for trading on 10/4/23. Similarly, investors should look for ABM to open 0.55% lower in price and for ACM to open 0.22% lower, all else being equal.
Below are dividend history charts for PGR, ABM, and ACM, showing historical dividends prior to the most recent ones declared.
Progressive Corp. (Symbol: PGR):
ABM Industries, Inc. (Symbol: ABM):
AECOM (Symbol: ACM):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 0.29% for Progressive Corp., 2.21% for ABM Industries, Inc., and 0.87% for AECOM.
In Monday trading, Progressive Corp. shares are currently down about 0.3%, ABM Industries, Inc. shares are off about 0.3%, and AECOM shares are down about 0.5% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
NNBR YTD Return
GSK Dividend History
Regency Centers MACD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If they do continue, the current estimated yields on annualized basis would be 0.29% for Progressive Corp., 2.21% for ABM Industries, Inc., and 0.87% for AECOM. Looking at the universe of stocks we cover at Dividend Channel, on 10/4/23, Progressive Corp. (Symbol: PGR), ABM Industries, Inc. (Symbol: ABM), and AECOM (Symbol: ACM) will all trade ex-dividend for their respective upcoming dividends. Progressive Corp. will pay its quarterly dividend of $0.10 on 10/13/23, ABM Industries, Inc. will pay its quarterly dividend of $0.22 on 11/6/23, and AECOM will pay its quarterly dividend of $0.18 on 10/20/23. | Looking at the universe of stocks we cover at Dividend Channel, on 10/4/23, Progressive Corp. (Symbol: PGR), ABM Industries, Inc. (Symbol: ABM), and AECOM (Symbol: ACM) will all trade ex-dividend for their respective upcoming dividends. Progressive Corp. will pay its quarterly dividend of $0.10 on 10/13/23, ABM Industries, Inc. will pay its quarterly dividend of $0.22 on 11/6/23, and AECOM will pay its quarterly dividend of $0.18 on 10/20/23. Progressive Corp. (Symbol: PGR): ABM Industries, Inc. (Symbol: ABM): AECOM (Symbol: ACM): In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel, on 10/4/23, Progressive Corp. (Symbol: PGR), ABM Industries, Inc. (Symbol: ABM), and AECOM (Symbol: ACM) will all trade ex-dividend for their respective upcoming dividends. Progressive Corp. will pay its quarterly dividend of $0.10 on 10/13/23, ABM Industries, Inc. will pay its quarterly dividend of $0.22 on 11/6/23, and AECOM will pay its quarterly dividend of $0.18 on 10/20/23. Progressive Corp. (Symbol: PGR): ABM Industries, Inc. (Symbol: ABM): AECOM (Symbol: ACM): In general, dividends are not always predictable, following the ups and downs of company profits over time. | If they do continue, the current estimated yields on annualized basis would be 0.29% for Progressive Corp., 2.21% for ABM Industries, Inc., and 0.87% for AECOM. Looking at the universe of stocks we cover at Dividend Channel, on 10/4/23, Progressive Corp. (Symbol: PGR), ABM Industries, Inc. (Symbol: ABM), and AECOM (Symbol: ACM) will all trade ex-dividend for their respective upcoming dividends. Progressive Corp. will pay its quarterly dividend of $0.10 on 10/13/23, ABM Industries, Inc. will pay its quarterly dividend of $0.22 on 11/6/23, and AECOM will pay its quarterly dividend of $0.18 on 10/20/23. |
29090.0 | 2023-09-26 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABM | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-116 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
American States Water Co (Symbol: AWR) $80.75 $93.67 16.00%
National Fuel Gas Co. (Symbol: NFG) $52.61 $60.00 14.05%
ABM Industries, Inc. (Symbol: ABM) $39.44 $44.80 13.59%
Johnson & Johnson (Symbol: JNJ) $160.26 $179.69 12.12%
Pentair PLC (Symbol: PNR) $65.61 $72.73 10.86%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
American States Water Co (Symbol: AWR) 2.13% 16.00% 18.13%
National Fuel Gas Co. (Symbol: NFG) 3.76% 14.05% 17.81%
ABM Industries, Inc. (Symbol: ABM) 2.23% 13.59% 15.82%
Johnson & Johnson (Symbol: JNJ) 2.97% 12.12% 15.09%
Pentair PLC (Symbol: PNR) 1.34% 10.86% 12.2%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
American States Water Co (Symbol: AWR) $1.493 $1.624 8.77%
National Fuel Gas Co. (Symbol: NFG) $1.84 $1.92 4.35%
ABM Industries, Inc. (Symbol: ABM) $0.775 $0.855 10.32%
Johnson & Johnson (Symbol: JNJ) $4.38 $4.64 5.94%
Pentair PLC (Symbol: PNR) $0.83 $0.87 4.82%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on JNJ — FREE
Get the latest Zacks research report on PNR — FREE
Dividend Growth Stocks: 25 Aristocrats »
Also see:
High Yield Baby Bonds
Top Ten Hedge Funds Holding CODE
SND Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | American States Water Co (Symbol: AWR) $80.75 $93.67 16.00% National Fuel Gas Co. (Symbol: NFG) $52.61 $60.00 14.05% ABM Industries, Inc. (Symbol: ABM) $39.44 $44.80 13.59% Johnson & Johnson (Symbol: JNJ) $160.26 $179.69 12.12% Pentair PLC (Symbol: PNR) $65.61 $72.73 10.86% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. American States Water Co (Symbol: AWR) 2.13% 16.00% 18.13% National Fuel Gas Co. (Symbol: NFG) 3.76% 14.05% 17.81% ABM Industries, Inc. (Symbol: ABM) 2.23% 13.59% 15.82% Johnson & Johnson (Symbol: JNJ) 2.97% 12.12% 15.09% Pentair PLC (Symbol: PNR) 1.34% 10.86% 12.2% Another consideration with dividend growth stocks is just how much the dividend is growing. American States Water Co (Symbol: AWR) $1.493 $1.624 8.77% National Fuel Gas Co. (Symbol: NFG) $1.84 $1.92 4.35% ABM Industries, Inc. (Symbol: ABM) $0.775 $0.855 10.32% Johnson & Johnson (Symbol: JNJ) $4.38 $4.64 5.94% Pentair PLC (Symbol: PNR) $0.83 $0.87 4.82% These five stocks are part of our full Dividend Aristocrats List. | American States Water Co (Symbol: AWR) $80.75 $93.67 16.00% National Fuel Gas Co. (Symbol: NFG) $52.61 $60.00 14.05% ABM Industries, Inc. (Symbol: ABM) $39.44 $44.80 13.59% Johnson & Johnson (Symbol: JNJ) $160.26 $179.69 12.12% Pentair PLC (Symbol: PNR) $65.61 $72.73 10.86% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. American States Water Co (Symbol: AWR) 2.13% 16.00% 18.13% National Fuel Gas Co. (Symbol: NFG) 3.76% 14.05% 17.81% ABM Industries, Inc. (Symbol: ABM) 2.23% 13.59% 15.82% Johnson & Johnson (Symbol: JNJ) 2.97% 12.12% 15.09% Pentair PLC (Symbol: PNR) 1.34% 10.86% 12.2% Another consideration with dividend growth stocks is just how much the dividend is growing. American States Water Co (Symbol: AWR) $1.493 $1.624 8.77% National Fuel Gas Co. (Symbol: NFG) $1.84 $1.92 4.35% ABM Industries, Inc. (Symbol: ABM) $0.775 $0.855 10.32% Johnson & Johnson (Symbol: JNJ) $4.38 $4.64 5.94% Pentair PLC (Symbol: PNR) $0.83 $0.87 4.82% These five stocks are part of our full Dividend Aristocrats List. | American States Water Co (Symbol: AWR) $80.75 $93.67 16.00% National Fuel Gas Co. (Symbol: NFG) $52.61 $60.00 14.05% ABM Industries, Inc. (Symbol: ABM) $39.44 $44.80 13.59% Johnson & Johnson (Symbol: JNJ) $160.26 $179.69 12.12% Pentair PLC (Symbol: PNR) $65.61 $72.73 10.86% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. American States Water Co (Symbol: AWR) 2.13% 16.00% 18.13% National Fuel Gas Co. (Symbol: NFG) 3.76% 14.05% 17.81% ABM Industries, Inc. (Symbol: ABM) 2.23% 13.59% 15.82% Johnson & Johnson (Symbol: JNJ) 2.97% 12.12% 15.09% Pentair PLC (Symbol: PNR) 1.34% 10.86% 12.2% Another consideration with dividend growth stocks is just how much the dividend is growing. American States Water Co (Symbol: AWR) $1.493 $1.624 8.77% National Fuel Gas Co. (Symbol: NFG) $1.84 $1.92 4.35% ABM Industries, Inc. (Symbol: ABM) $0.775 $0.855 10.32% Johnson & Johnson (Symbol: JNJ) $4.38 $4.64 5.94% Pentair PLC (Symbol: PNR) $0.83 $0.87 4.82% These five stocks are part of our full Dividend Aristocrats List. | American States Water Co (Symbol: AWR) $80.75 $93.67 16.00% National Fuel Gas Co. (Symbol: NFG) $52.61 $60.00 14.05% ABM Industries, Inc. (Symbol: ABM) $39.44 $44.80 13.59% Johnson & Johnson (Symbol: JNJ) $160.26 $179.69 12.12% Pentair PLC (Symbol: PNR) $65.61 $72.73 10.86% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. American States Water Co (Symbol: AWR) 2.13% 16.00% 18.13% National Fuel Gas Co. (Symbol: NFG) 3.76% 14.05% 17.81% ABM Industries, Inc. (Symbol: ABM) 2.23% 13.59% 15.82% Johnson & Johnson (Symbol: JNJ) 2.97% 12.12% 15.09% Pentair PLC (Symbol: PNR) 1.34% 10.86% 12.2% Another consideration with dividend growth stocks is just how much the dividend is growing. American States Water Co (Symbol: AWR) $1.493 $1.624 8.77% National Fuel Gas Co. (Symbol: NFG) $1.84 $1.92 4.35% ABM Industries, Inc. (Symbol: ABM) $0.775 $0.855 10.32% Johnson & Johnson (Symbol: JNJ) $4.38 $4.64 5.94% Pentair PLC (Symbol: PNR) $0.83 $0.87 4.82% These five stocks are part of our full Dividend Aristocrats List. |
29091.0 | 2023-09-14 00:00:00 UTC | ABM November 17th Options Begin Trading | ABM | https://www.nasdaq.com/articles/abm-november-17th-options-begin-trading | nan | nan | Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABM options chain for the new November 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $40.00 strike price has a current bid of 55 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $40.00, but will also collect the premium, putting the cost basis of the shares at $39.45 (before broker commissions). To an investor already interested in purchasing shares of ABM, that could represent an attractive alternative to paying $41.14/share today.
Because the $40.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.38% return on the cash commitment, or 7.84% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for ABM Industries, Inc., and highlighting in green where the $40.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $45.00 strike price has a current bid of 10 cents. If an investor was to purchase shares of ABM stock at the current price level of $41.14/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $45.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.63% if the stock gets called away at the November 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABM shares really soar, which is why looking at the trailing twelve month trading history for ABM Industries, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing ABM's trailing twelve month trading history, with the $45.00 strike highlighted in red:
Considering the fact that the $45.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.24% boost of extra return to the investor, or 1.39% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $41.14) to be 29%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
TBIO Options Chain
Institutional Holders of WPXP
ETSY YTD Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a chart showing ABM's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABM options chain for the new November 17th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABM's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the November 17th expiration. | Below is a chart showing the trailing twelve month trading history for ABM Industries, Inc., and highlighting in green where the $40.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $45.00 strike price has a current bid of 10 cents. Below is a chart showing ABM's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the November 17th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABM options chain for the new November 17th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABM's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in ABM Industries, Inc. (Symbol: ABM) saw new options begin trading today, for the November 17th expiration. |
29092.0 | 2023-09-09 00:00:00 UTC | ABM Industries (ABM) Declares $0.22 Dividend | ABM | https://www.nasdaq.com/articles/abm-industries-abm-declares-%240.22-dividend-1 | nan | nan | ABM Industries said on September 7, 2023 that its board of directors declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). Previously, the company paid $0.22 per share.
Shares must be purchased before the ex-div date of October 4, 2023 to qualify for the dividend. Shareholders of record as of October 5, 2023 will receive the payment on November 6, 2023.
At the current share price of $39.28 / share, the stock's dividend yield is 2.24%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.92%, the lowest has been 1.42%, and the highest has been 3.62%. The standard deviation of yields is 0.27 (n=235).
The current dividend yield is 1.18 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.25. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
Read the Ultimate Guide to Dividend Harvesting.
The company's 3-Year dividend growth rate is 0.19%, demonstrating that it has increased its dividend over time.
What is the Fund Sentiment?
There are 567 funds or institutions reporting positions in ABM Industries. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 10.23%. Total shares owned by institutions decreased in the last three months by 3.58% to 73,096K shares.
The put/call ratio of ABM is 0.77, indicating a bullish outlook.
Analyst Price Forecast Suggests 47.15% Upside
As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The forecasts range from a low of 50.50 to a high of $68.25. The average price target represents an increase of 47.15% from its latest reported closing price of 39.28.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. The projected annual non-GAAP EPS is 3.74.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,639K shares representing 7.01% ownership of the company. In it's prior filing, the firm reported owning 4,814K shares, representing a decrease of 3.76%. The firm decreased its portfolio allocation in ABM by 11.42% over the last quarter.
SDY - SPDR(R) S&P(R) Dividend ETF holds 3,542K shares representing 5.35% ownership of the company. In it's prior filing, the firm reported owning 3,630K shares, representing a decrease of 2.48%. The firm decreased its portfolio allocation in ABM by 4.21% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,040K shares representing 3.08% ownership of the company. In it's prior filing, the firm reported owning 2,033K shares, representing an increase of 0.33%. The firm decreased its portfolio allocation in ABM by 12.14% over the last quarter.
Macquarie Group holds 1,857K shares representing 2.81% ownership of the company. In it's prior filing, the firm reported owning 1,836K shares, representing an increase of 1.11%. The firm decreased its portfolio allocation in ABM by 0.77% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,707K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 1,730K shares, representing a decrease of 1.36%. The firm decreased its portfolio allocation in ABM by 10.92% over the last quarter.
ABM Industries Background Information
(This description is provided by the company.)
ABM Industries Inc. is a facility management provider in the United States. ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. As of 2013, the company has over 130,000 employees, over 350 offices, and various international locations.
Additional reading:
ABM REPORTS THIRD QUARTER FISCAL 2023 RESULTS
Amended and Restated Bylaws of ABM Industries Incorporated effective June 13, 2023
ABM REPORTS SECOND QUARTER FISCAL 2023 RESULTS
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. ABM Industries said on September 7, 2023 that its board of directors declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). There are 567 funds or institutions reporting positions in ABM Industries. | ABM Industries said on September 7, 2023 that its board of directors declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). There are 567 funds or institutions reporting positions in ABM Industries. Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 10.23%. | ABM Industries said on September 7, 2023 that its board of directors declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). There are 567 funds or institutions reporting positions in ABM Industries. Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 10.23%. | There are 567 funds or institutions reporting positions in ABM Industries. ABM Industries said on September 7, 2023 that its board of directors declared a regular quarterly dividend of $0.22 per share ($0.88 annualized). Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 10.23%. |
29093.0 | 2023-09-09 00:00:00 UTC | UBS Maintains ABM Industries (ABM) Neutral Recommendation | ABM | https://www.nasdaq.com/articles/ubs-maintains-abm-industries-abm-neutral-recommendation | nan | nan | Fintel reports that on September 8, 2023, UBS maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation.
Analyst Price Forecast Suggests 47.15% Upside
As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The forecasts range from a low of 50.50 to a high of $68.25. The average price target represents an increase of 47.15% from its latest reported closing price of 39.28.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. The projected annual non-GAAP EPS is 3.74.
What is the Fund Sentiment?
There are 567 funds or institutions reporting positions in ABM Industries. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 10.23%. Total shares owned by institutions decreased in the last three months by 3.58% to 73,096K shares.
The put/call ratio of ABM is 0.77, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,639K shares representing 7.01% ownership of the company. In it's prior filing, the firm reported owning 4,814K shares, representing a decrease of 3.76%. The firm decreased its portfolio allocation in ABM by 11.42% over the last quarter.
SDY - SPDR(R) S&P(R) Dividend ETF holds 3,542K shares representing 5.35% ownership of the company. In it's prior filing, the firm reported owning 3,630K shares, representing a decrease of 2.48%. The firm decreased its portfolio allocation in ABM by 4.21% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,040K shares representing 3.08% ownership of the company. In it's prior filing, the firm reported owning 2,033K shares, representing an increase of 0.33%. The firm decreased its portfolio allocation in ABM by 12.14% over the last quarter.
Macquarie Group holds 1,857K shares representing 2.81% ownership of the company. In it's prior filing, the firm reported owning 1,836K shares, representing an increase of 1.11%. The firm decreased its portfolio allocation in ABM by 0.77% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,707K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 1,730K shares, representing a decrease of 1.36%. The firm decreased its portfolio allocation in ABM by 10.92% over the last quarter.
ABM Industries Background Information
(This description is provided by the company.)
ABM Industries Inc. is a facility management provider in the United States. ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. As of 2013, the company has over 130,000 employees, over 350 offices, and various international locations.
Additional reading:
ABM REPORTS THIRD QUARTER FISCAL 2023 RESULTS
Amended and Restated Bylaws of ABM Industries Incorporated effective June 13, 2023
ABM REPORTS SECOND QUARTER FISCAL 2023 RESULTS
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. Fintel reports that on September 8, 2023, UBS maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. | Fintel reports that on September 8, 2023, UBS maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. | Fintel reports that on September 8, 2023, UBS maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. | There are 567 funds or institutions reporting positions in ABM Industries. Fintel reports that on September 8, 2023, UBS maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. |
29094.0 | 2023-09-09 00:00:00 UTC | Baird Maintains ABM Industries (ABM) Neutral Recommendation | ABM | https://www.nasdaq.com/articles/baird-maintains-abm-industries-abm-neutral-recommendation | nan | nan | Fintel reports that on September 8, 2023, Baird maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation.
Analyst Price Forecast Suggests 47.15% Upside
As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The forecasts range from a low of 50.50 to a high of $68.25. The average price target represents an increase of 47.15% from its latest reported closing price of 39.28.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. The projected annual non-GAAP EPS is 3.74.
What is the Fund Sentiment?
There are 567 funds or institutions reporting positions in ABM Industries. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to ABM is 0.21%, a decrease of 10.23%. Total shares owned by institutions decreased in the last three months by 3.58% to 73,096K shares.
The put/call ratio of ABM is 0.77, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,639K shares representing 7.01% ownership of the company. In it's prior filing, the firm reported owning 4,814K shares, representing a decrease of 3.76%. The firm decreased its portfolio allocation in ABM by 11.42% over the last quarter.
SDY - SPDR(R) S&P(R) Dividend ETF holds 3,542K shares representing 5.35% ownership of the company. In it's prior filing, the firm reported owning 3,630K shares, representing a decrease of 2.48%. The firm decreased its portfolio allocation in ABM by 4.21% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,040K shares representing 3.08% ownership of the company. In it's prior filing, the firm reported owning 2,033K shares, representing an increase of 0.33%. The firm decreased its portfolio allocation in ABM by 12.14% over the last quarter.
Macquarie Group holds 1,857K shares representing 2.81% ownership of the company. In it's prior filing, the firm reported owning 1,836K shares, representing an increase of 1.11%. The firm decreased its portfolio allocation in ABM by 0.77% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,707K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 1,730K shares, representing a decrease of 1.36%. The firm decreased its portfolio allocation in ABM by 10.92% over the last quarter.
ABM Industries Background Information
(This description is provided by the company.)
ABM Industries Inc. is a facility management provider in the United States. ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. As of 2013, the company has over 130,000 employees, over 350 offices, and various international locations.
Additional reading:
ABM REPORTS THIRD QUARTER FISCAL 2023 RESULTS
Amended and Restated Bylaws of ABM Industries Incorporated effective June 13, 2023
ABM REPORTS SECOND QUARTER FISCAL 2023 RESULTS
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM was founded in 1909 by Morris Rosenberg in San Francisco, California, as a single-person window washing business. Fintel reports that on September 8, 2023, Baird maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. | Fintel reports that on September 8, 2023, Baird maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. | Fintel reports that on September 8, 2023, Baird maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. The projected annual revenue for ABM Industries is 8,212MM, an increase of 2.46%. | There are 567 funds or institutions reporting positions in ABM Industries. Fintel reports that on September 8, 2023, Baird maintained coverage of ABM Industries (NYSE:ABM) with a Neutral recommendation. Analyst Price Forecast Suggests 47.15% Upside As of August 31, 2023, the average one-year price target for ABM Industries is 57.80. |
29095.0 | 2023-09-08 00:00:00 UTC | Should Value Investors Buy ABM Industries (ABM) Stock? | ABM | https://www.nasdaq.com/articles/should-value-investors-buy-abm-industries-abm-stock-1 | nan | nan | While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company to watch right now is ABM Industries (ABM). ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with P/E ratio of 11.89 right now. For comparison, its industry sports an average P/E of 30.53. Over the last 12 months, ABM's Forward P/E has been as high as 13.48 and as low as 10.16, with a median of 12.01.
Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. ABM has a P/S ratio of 0.32. This compares to its industry's average P/S of 0.54.
Finally, investors will want to recognize that ABM has a P/CF ratio of 9.56. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 36.78. Over the past 52 weeks, ABM's P/CF has been as high as 10.75 and as low as 8.05, with a median of 9.18.
Value investors will likely look at more than just these metrics, but the above data helps show that ABM Industries is likely undervalued currently. And when considering the strength of its earnings outlook, ABM sticks out at as one of the market's strongest value stocks.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One company to watch right now is ABM Industries (ABM). ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Over the last 12 months, ABM's Forward P/E has been as high as 13.48 and as low as 10.16, with a median of 12.01. | Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. One company to watch right now is ABM Industries (ABM). ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. | One company to watch right now is ABM Industries (ABM). Click to get this free report ABM Industries Incorporated (ABM) : Free Stock Analysis Report To read this article on Zacks.com click here. ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. | One company to watch right now is ABM Industries (ABM). ABM has a P/S ratio of 0.32. ABM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. |
29096.0 | 2023-09-08 00:00:00 UTC | ABM Industries (ABM) Q3 Earnings Miss Estimates, Revenues Beat | ABM | https://www.nasdaq.com/articles/abm-industries-abm-q3-earnings-miss-estimates-revenues-beat | nan | nan | ABM Industries Inc. ABM reported mixed third-quarter fiscal 2023 results wherein earnings missed the Zacks Consensus Estimate while revenues beat the same.
Adjusted earnings (considering 68 cents from non-recurring items) came in at 79 cents per share, which missed the consensus estimate by 10.2% and decreased 16% from last fiscal year’s quarterly figure.
Total revenues of $2.03 billion beat the consensus mark by a slight margin but improved 3.4% from the last fiscal year’s quarterly figure. The upside was backed by solid segmental performance, strength from new accounts which came online late last year and the acquisition of RavenVolt. Quarterly revenue growth included 2.5% organic growth and a 0.9% upside from acquisitions.
ABM Industries Incorporated Price, Consensus and EPS Surprise
ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote
Segment-Wise Revenues
The Business & Industry segment’s revenues decreased 1.2% from the last fiscal year’s quarterly figure to $1.02 billion, thus matching our estimates.
Revenues from the Manufacturing & Distribution segment rose 6.6% to $381.9 million, beating our estimate by 2%. The Aviation segment’s revenues rose 16.9% from the last fiscal year’s quarterly figure to $238 million and surpassed our estimate by 9.7%.
Technical Solutions and Education segments’ revenues increased 6% and 5.6% from the prior-year fiscal quarter’s levels to $167.9 million and $219.1 million, respectively. Revenues from the Education segment beat our estimate by 4%.
Operating Results
Adjusted EBITDA came in at $125.3 million, decreasing marginally from the prior-year period. Adjusted EBITDA margin was 6.4% compared with 6.6% reported in the prior-year period.
Operating expenses increased 4.1% from the year-ago figure to $1.77 billion. Selling, general and administrative expenses declined 34.3% from the year-ago level to $104.3 million.
Balance Sheet & Cash Flow
ABM Industries exited third-quarter fiscal 2023 with cash and cash equivalents of $97.7 million compared with $71.2 million at the end of the prior fiscal quarter. Long-term debt was $1.29 billion compared with $1.4 billion at the end of the prior fiscal quarter.
Net cash provided by operating activities totaled $149.1 million for the reported quarter. Free cash flow came in at $138.3 million.
2023 Guidance
For fiscal 2023, ABM Industries expects adjusted earnings per share to be in the range of $3.40-$3.50, which is narrower than the previous guidance of earnings per share of $3.40-$3.60. The Zacks Consensus Estimate of earnings of $3.51 per share lies above the guided range. Adjusted EBITDA margin is anticipated to be between 6.5% and 6.8%. Interest expense is expected to be at around $80 million.
ABM currently holds Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Here are a few stocks from the broader Business Services sector, which have performed well in their recent earnings release:
Automatic Data ADP reported better-than-expected fourth-quarter fiscal 2023 results. Adjusted earnings per share of $1.89 (excluding 1 cent from non-recurring items) beat the Zacks Consensus Estimate by 3.3% and grew 26% from the year-ago fiscal quarter’s figure. Total revenues of $4.47 billion beat the consensus estimate by 1.8% and improved 8.5% from the year-ago fiscal quarter’s reading on a reported basis and 9% on an organic constant-currency basis.
TransUnion TRU reported impressive second-quarter 2023 results wherein earnings and revenues beat the Zacks Consensus Estimate. Quarterly adjusted earnings of 86 cents per share (adjusting 58 cents from non-recurring items) surpassed the consensus mark by 3.6% but decreased 12.2% year over year. Total revenues of $968 million beat the consensus mark by 1% and increased 2.1% year over year on a reported basis. Revenues were up 3% on a constant-currency basis, mainly driven by strength in the international markets.
Gartner IT reported better-than-expected second-quarter 2023 results. Adjusted earnings per share (excluding 37 cents from non-recurring items) of $2.85 beat the Zacks Consensus Estimate by 14.9% but matched the year-ago reported figure. Revenues of $1.5 billion beat the consensus estimate by 1% and improved 9.2% year over year on a reported basis and 10% on a foreign-currency-neutral basis. Total contract value was $4.6 billion, up 8.9% year over year on a foreign-currency-neutral basis.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
Gartner, Inc. (IT) : Free Stock Analysis Report
TransUnion (TRU) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABM Industries Inc. ABM reported mixed third-quarter fiscal 2023 results wherein earnings missed the Zacks Consensus Estimate while revenues beat the same. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Segment-Wise Revenues The Business & Industry segment’s revenues decreased 1.2% from the last fiscal year’s quarterly figure to $1.02 billion, thus matching our estimates. Balance Sheet & Cash Flow ABM Industries exited third-quarter fiscal 2023 with cash and cash equivalents of $97.7 million compared with $71.2 million at the end of the prior fiscal quarter. | ABM Industries Inc. ABM reported mixed third-quarter fiscal 2023 results wherein earnings missed the Zacks Consensus Estimate while revenues beat the same. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Segment-Wise Revenues The Business & Industry segment’s revenues decreased 1.2% from the last fiscal year’s quarterly figure to $1.02 billion, thus matching our estimates. Click to get this free report Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Gartner, Inc. (IT) : Free Stock Analysis Report TransUnion (TRU) : Free Stock Analysis Report To read this article on Zacks.com click here. | ABM Industries Inc. ABM reported mixed third-quarter fiscal 2023 results wherein earnings missed the Zacks Consensus Estimate while revenues beat the same. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Segment-Wise Revenues The Business & Industry segment’s revenues decreased 1.2% from the last fiscal year’s quarterly figure to $1.02 billion, thus matching our estimates. Click to get this free report Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report ABM Industries Incorporated (ABM) : Free Stock Analysis Report Gartner, Inc. (IT) : Free Stock Analysis Report TransUnion (TRU) : Free Stock Analysis Report To read this article on Zacks.com click here. | ABM Industries Inc. ABM reported mixed third-quarter fiscal 2023 results wherein earnings missed the Zacks Consensus Estimate while revenues beat the same. ABM Industries Incorporated Price, Consensus and EPS Surprise ABM Industries Incorporated price-consensus-eps-surprise-chart | ABM Industries Incorporated Quote Segment-Wise Revenues The Business & Industry segment’s revenues decreased 1.2% from the last fiscal year’s quarterly figure to $1.02 billion, thus matching our estimates. Balance Sheet & Cash Flow ABM Industries exited third-quarter fiscal 2023 with cash and cash equivalents of $97.7 million compared with $71.2 million at the end of the prior fiscal quarter. |
29097.0 | 2023-09-08 00:00:00 UTC | Why ABM Industries Wasn't a Winning Stock This Week | ABM | https://www.nasdaq.com/articles/why-abm-industries-wasnt-a-winning-stock-this-week | nan | nan | What happened
Industrial maintenance company ABM Industries (NYSE: ABM) wasn't looking too solid this week. Over that period, its share price fell by 14%, according to data compiled by S&P Global Market Intelligence, on the back of fiscal 2023 third-quarter results that didn't entirely meet expectations.
So what
For the period, which ended July 31, ABM earned slightly under $2.03 billion in revenue, up 3% year over year. However, non-GAAP (adjusted) net income slipped to a bit under $53 million ($0.79 per share) from a profit of over $63 million in the year-ago period.
While that top-line figure was essentially in line with the average estimate, the adjusted net income number was not. Collectively, prognosticators following ABM stock were anticipating that the company would net $0.89 per share.
"Strong growth in our Aviation, Education and Manufacturing & Distribution segments was partially offset by delayed project starts and lower bundled energy solutions activity within our Technical Solutions segment," said ABM CEO Scott Salmirs in explaining the quarter's performance. "Additionally, market conditions remained soft for our janitorial service line in Business & Industry."
On the plus side, the Dividend King declared that its next quarterly payout of $0.22 per share will be distributed on Nov. 6 to investors of record as of Oct. 5.
Now what
ABM also narrowed its profitability guidance for its fiscal 2023. It now expects adjusted net income will land in the range of $3.40 per share to $3.50 per share. That range, however, falls short of the average analyst estimate of $3.52.
10 stocks we like better than Abm Industries
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abm Industries wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 5, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "Strong growth in our Aviation, Education and Manufacturing & Distribution segments was partially offset by delayed project starts and lower bundled energy solutions activity within our Technical Solutions segment," said ABM CEO Scott Salmirs in explaining the quarter's performance. What happened Industrial maintenance company ABM Industries (NYSE: ABM) wasn't looking too solid this week. So what For the period, which ended July 31, ABM earned slightly under $2.03 billion in revenue, up 3% year over year. | What happened Industrial maintenance company ABM Industries (NYSE: ABM) wasn't looking too solid this week. So what For the period, which ended July 31, ABM earned slightly under $2.03 billion in revenue, up 3% year over year. Collectively, prognosticators following ABM stock were anticipating that the company would net $0.89 per share. | Collectively, prognosticators following ABM stock were anticipating that the company would net $0.89 per share. 10 stocks we like better than Abm Industries When our analyst team has a stock tip, it can pay to listen. What happened Industrial maintenance company ABM Industries (NYSE: ABM) wasn't looking too solid this week. | 10 stocks we like better than Abm Industries When our analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Abm Industries wasn't one of them! What happened Industrial maintenance company ABM Industries (NYSE: ABM) wasn't looking too solid this week. |
29098.0 | 2023-09-07 00:00:00 UTC | ABM Industries (ABM) Reports Q3 Earnings: What Key Metrics Have to Say | ABM | https://www.nasdaq.com/articles/abm-industries-abm-reports-q3-earnings%3A-what-key-metrics-have-to-say | nan | nan | ABM Industries (ABM) reported $2.03 billion in revenue for the quarter ended July 2023, representing a year-over-year increase of 3.4%. EPS of $0.79 for the same period compares to $0.94 a year ago.
The reported revenue represents a surprise of +0.39% over the Zacks Consensus Estimate of $2.02 billion. With the consensus EPS estimate being $0.88, the EPS surprise was -10.23%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Business & Industry: $1.02 billion versus $1.02 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.2% change.
Revenues- Aviation: $238 million versus the two-analyst average estimate of $220.50 million. The reported number represents a year-over-year change of +17%.
Revenues- Education: $219.10 million versus the two-analyst average estimate of $213.28 million. The reported number represents a year-over-year change of +5.6%.
Revenues- Manufacturing & Distribution: $381.90 million versus $376.19 million estimated by two analysts on average.
Revenues- Technical Solutions: $167.90 million compared to the $187.18 million average estimate based on two analysts. The reported number represents a change of +6% year over year.
Operating profit- Business & Industry: $78.90 million compared to the $74.87 million average estimate based on two analysts.
Operating profit- Aviation: $11.70 million versus the two-analyst average estimate of $9.58 million.
Operating profit (loss)- Manufacturing & Distribution: $38.10 million versus the two-analyst average estimate of $37.67 million.
Operating profit- Technical Solutions: $11.40 million versus $11.51 million estimated by two analysts on average.
Operating profit- Education: $15.90 million versus $11.81 million estimated by two analysts on average.
View all Key Company Metrics for ABM Industries here>>>
Shares of ABM Industries have returned -3.5% over the past month versus the Zacks S&P 500 composite's -0.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABM Industries Incorporated (ABM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ABM Industries have returned -3.5% over the past month versus the Zacks S&P 500 composite's -0.1% change. ABM Industries (ABM) reported $2.03 billion in revenue for the quarter ended July 2023, representing a year-over-year increase of 3.4%. Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Business & Industry: $1.02 billion versus $1.02 billion estimated by two analysts on average. | Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Business & Industry: $1.02 billion versus $1.02 billion estimated by two analysts on average. ABM Industries (ABM) reported $2.03 billion in revenue for the quarter ended July 2023, representing a year-over-year increase of 3.4%. View all Key Company Metrics for ABM Industries here>>> | Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Business & Industry: $1.02 billion versus $1.02 billion estimated by two analysts on average. ABM Industries (ABM) reported $2.03 billion in revenue for the quarter ended July 2023, representing a year-over-year increase of 3.4%. View all Key Company Metrics for ABM Industries here>>> | Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Business & Industry: $1.02 billion versus $1.02 billion estimated by two analysts on average. ABM Industries (ABM) reported $2.03 billion in revenue for the quarter ended July 2023, representing a year-over-year increase of 3.4%. View all Key Company Metrics for ABM Industries here>>> |
29099.0 | 2023-09-07 00:00:00 UTC | Implied SMDV Analyst Target Price: $69 | ABM | https://www.nasdaq.com/articles/implied-smdv-analyst-target-price%3A-%2469 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Russell 2000 Dividend Growers ETF (Symbol: SMDV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $68.54 per unit.
With SMDV trading at a recent price near $59.01 per unit, that means that analysts see 16.15% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SMDV's underlying holdings with notable upside to their analyst target prices are ABM Industries, Inc. (Symbol: ABM), Ensign Group Inc (Symbol: ENSG), and Glacier Bancorp, Inc. (Symbol: GBCI). Although ABM has traded at a recent price of $44.81/share, the average analyst target is 22.74% higher at $55.00/share. Similarly, ENSG has 17.65% upside from the recent share price of $95.41 if the average analyst target price of $112.25/share is reached, and analysts on average are expecting GBCI to reach a target price of $34.00/share, which is 16.80% above the recent price of $29.11. Below is a twelve month price history chart comparing the stock performance of ABM, ENSG, and GBCI:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
ProShares Russell 2000 Dividend Growers ETF SMDV $59.01 $68.54 16.15%
ABM Industries, Inc. ABM $44.81 $55.00 22.74%
Ensign Group Inc ENSG $95.41 $112.25 17.65%
Glacier Bancorp, Inc. GBCI $29.11 $34.00 16.80%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
CDx3 Weekly Preferred Stock Newsletter
Funds Holding DFIN
Funds Holding TRVG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ProShares Russell 2000 Dividend Growers ETF SMDV $59.01 $68.54 16.15% ABM Industries, Inc. ABM $44.81 $55.00 22.74% Ensign Group Inc ENSG $95.41 $112.25 17.65% Glacier Bancorp, Inc. GBCI $29.11 $34.00 16.80% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SMDV's underlying holdings with notable upside to their analyst target prices are ABM Industries, Inc. (Symbol: ABM), Ensign Group Inc (Symbol: ENSG), and Glacier Bancorp, Inc. (Symbol: GBCI). Although ABM has traded at a recent price of $44.81/share, the average analyst target is 22.74% higher at $55.00/share. | Three of SMDV's underlying holdings with notable upside to their analyst target prices are ABM Industries, Inc. (Symbol: ABM), Ensign Group Inc (Symbol: ENSG), and Glacier Bancorp, Inc. (Symbol: GBCI). ProShares Russell 2000 Dividend Growers ETF SMDV $59.01 $68.54 16.15% ABM Industries, Inc. ABM $44.81 $55.00 22.74% Ensign Group Inc ENSG $95.41 $112.25 17.65% Glacier Bancorp, Inc. GBCI $29.11 $34.00 16.80% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Although ABM has traded at a recent price of $44.81/share, the average analyst target is 22.74% higher at $55.00/share. | Three of SMDV's underlying holdings with notable upside to their analyst target prices are ABM Industries, Inc. (Symbol: ABM), Ensign Group Inc (Symbol: ENSG), and Glacier Bancorp, Inc. (Symbol: GBCI). Although ABM has traded at a recent price of $44.81/share, the average analyst target is 22.74% higher at $55.00/share. Below is a twelve month price history chart comparing the stock performance of ABM, ENSG, and GBCI: Below is a summary table of the current analyst target prices discussed above: | Although ABM has traded at a recent price of $44.81/share, the average analyst target is 22.74% higher at $55.00/share. ProShares Russell 2000 Dividend Growers ETF SMDV $59.01 $68.54 16.15% ABM Industries, Inc. ABM $44.81 $55.00 22.74% Ensign Group Inc ENSG $95.41 $112.25 17.65% Glacier Bancorp, Inc. GBCI $29.11 $34.00 16.80% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SMDV's underlying holdings with notable upside to their analyst target prices are ABM Industries, Inc. (Symbol: ABM), Ensign Group Inc (Symbol: ENSG), and Glacier Bancorp, Inc. (Symbol: GBCI). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.